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Abstract 
This thesis investigates the quantification of two scintigraphic biomarkers used for the diagnosis of 
dementia with Lewy bodies (DLB): 123I-FP-CIT (123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-
iodophenyl) nortropane), commonly known as DaTSCAN™, and cardiac 123I-MIBG (123I-
metaiodobenzylguanidine).   Accurate quantification is critical as we increasingly move towards 
diagnosis at the earlier mild cognitive impairment (MCI) stage, where more subtle changes from 
normality are expected.  A range of novel approaches have been examined to overcome technical 
limitations that have previously been barriers to accurate quantification.  Uniquely, this has been 
studied in cohorts of highly characterised dementia and MCI subjects as well as older adults with 
normal cognition recruited as age matched controls. The subject studies have been complemented by 
work using advanced anthropomorphic phantoms. Throughout, the innovative methods have been 
compared with the established ones. Results are presented in detail and clinical and research relevance 
is discussed together with proposals for optimal usage.  Briefly, the key findings are: 
FP-CIT key findings 
• Specific binding ratio values (SBR) for FP-CIT images calculated by different software packages 
are systematically different, although give similar diagnostic accuracy. 
• Striatal uptake does not decrease with age in healthy older adults, as previously reported, 
indicating potential misdiagnosis if age correction is applied.  
• Absolute quantification separates normal and abnormal subjects less well than relative-
quantification with SBR. 
• Advanced FP-CIT reconstruction methods using SPECT-CT and collimator modelling improve 
the accuracy of activity concentration measurements in a phantom. 
• Advanced FP-CIT reconstruction methods affect relative quantification with SBR, but not 
clinical interpretation. 
Cardiac MIBG key findings 
• Different methods of planar MIBG analysis are operator dependent and give systematically 
different results – recommendations are provided for an optimal method. 
• Establishing a normal threshold is critical. This thesis shows that previously published values 
may not be valid in a UK population and proposes a suitable alternative. 
• Images obtained soon after injection give similar accuracy as those obtained at 3.5 hours (the 
standard delayed method), and the latter scans could be omitted in the majority of cases. 
• Planar cardiac MIBG semi-quantification is significantly dependent on subject size.  Using 
SPECT-CT gives greater separation between normal and abnormal scans than planar.   
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In summary, an in-depth and comprehensive study of technical aspects of Nuclear Medicine biomarker 
quantification using 123I labelled radiopharmaceuticals for the diagnosis of Lewy body disease is 
presented in this thesis. This provides a solid foundation for clinical and research application of these 
techniques in both early and established disease. 
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Abbreviations and nomenclature 
Term Description 
123I Iodine-123; radionuclide used to label both radiopharmaceuticals included in 
this thesis 
123I-FP-CIT 
123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane; 
ioflupane 
123I-MIBG 123I-metaiodobenzylguanidine 
99mTc Technetium-99m; most common radionuclide used in nuclear medicine 
ACE Addenbrooke’s cognitive examination; used for identifying cognitive 
impairment 
ACSC Attenuation and scatter correction 
AD Alzheimer’s disease (the dementia stage is usually implied) 
AF Atrial fibrillation 
Benamer Author of well-known FP-CIT visual ratings scale developed for PD 
BMI Body mass index 
BRASS Hermes software for brain scan quantification, including FP-CIT SBR analysis 
CAD Coronary artery disease 
Cardiac MIBG Throughout this thesis, the term “cardiac MIBG” is used to refer to the cardiac 
sympathetic imaging technique using 123I-MIBG 
CDnorm Normalised count density; quantity analogous to SUV, used in this thesis for 
cardiac MIBG absolute quantification 
CoV Coefficient of variation; measurement of spread of data or noise in dataset 
CSPECT Coronal SPECT images, summed to give image similar to planar scan 
CSPECT-CT Summed coronal SPECT images, with CT ACSC applied 
DaTQUANT Software for performing SBR analysis, manufactured by GE Healthcare 
DaTSCAN™ GE Healthcare’s tradename for the 
123I-FP-CIT radiopharmaceutical; commonly 
used in clinical practice to refer to the scan itself 
DLB Dementia with Lewy bodies 
EANM European Association of Nuclear Medicine 
ENC-DAT EANM multicentre project acquiring FP-CIT scans of healthy controls 
FBP Filtered back projection; commonly used SPECT reconstruction method 
FCM Full (Monte Carlo) collimator model 
FP-CIT Throughout this thesis, the term “FP-CIT” is used to refer to the dopaminergic 
imaging technique using 123I-FP-CIT 
Hermes Hermes Medical Solutions Ltd; manufacturer of nuclear medicine image 
reconstruction and processing software used at NuTH 
HMR Heart to mediastinum ratio; H/M also used in the literature 
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HMR cut-off Threshold value, below which HMRs are considered abnormal 
HybridRecon Hermes software for reconstructing SPECT images 
Intevo Siemens hybrid gamma camera with SPECT-CT functionality 
kBq/ml Unit of activity concentration in phantom or tissue 
LBM Lean body mass; alternative normalisation method to patient weight 
LEHR Low energy high resolution; refers to collimator properties 
LewyPro Newcastle study into the use of FP-CIT in MCI patients 
MBq 10
6 Becquerels - unit of radioactivity; used to specify radiopharmaceutical 
activities administered to patients 
mCi 10-3 Curies - unit of radioactivity; used in USA.  1 mCi = 37 MBq 
MCI-AD Mild cognitive impairment due to Alzheimer’s disease 
MCI-LB Mild cognitive impairment with Lewy bodies 
MCRR_CT Reconstruction protocol used for FP-CIT images incorporating full Monte Carlo 
model of collimator interactions, resolution recovery and CT ACSC; 
MCRR_uniform Reconstruction protocol used for FP-CIT images incorporating full Monte Carlo 
model of collimator interactions, resolution recovery and uniform ACSC; 
MDS-UPDRS Movement disorders society unified PD ratings scale; used to quantify 
parkinsonian features 
MEGP Medium energy general purpose; refers to collimator properties 
MELP Medium energy low penetration; refers to collimator properties 
MI Myocardial infarction 
MIDAS Newcastle pilot study into the use of cardiac MIBG in a typical NHS setting 
MLEM Maximum likelihood expectation maximisation; iterative reconstruction 
method 
MMSE Mini mental state examination; used for identifying cognitive impairment 
MRI Magnetic resonance imaging, a functional and anatomical imaging technique 
mSv 10-3 Sieverts – unit of effective radiation dose 
NHS National Health Service – public funded healthcare provider in the UK 
NIA-AA National Institute on Aging and the Alzheimer’s Association (US public bodies) 
NICE 
National Institute for Clinical Excellence, UK public body that provides guidance 
on  evidence based healthcare 
NuTH Newcastle upon Tyne Hospitals NHS Foundation Trust 
OSEM Ordered subsets expectation maximisation; fast implementation of MLEM 
OSEM_RRACSC Reconstruction protocol used for FP-CIT images analysed with BRASS 
incorporating resolution recovery and uniform ACSC 
PD Parkinson’s disease 
PDD Parkinson’s disease dementia 
PET Positron emission tomography, a radionuclide imaging technique 
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PPMI Parkinson’s progression markers initiative; multicentre PD study, from which 
the DaTQUANT healthy control database is taken 
PSF Point spread function; describes blurring of point source due to finite 
resolution 
PubMed Database of scientific literature related to medicine 
QPS Quantitative perfusion SPECT 
QRISK2 Online tool used in NHS for estimating 10 year risk of cardiovascular event 
REM Rapid eye movement, as in REM sleep behaviour disorder 
ROC Receiver operating curve; analysis used to determine accuracy of a test 
RR Resolution recovery; geometric correction for collimator resolution using PSF 
RR_CT Reconstruction protocol used for FP-CIT images incorporating resolution 
recovery and CT ACSC 
RR_uniform Reconstruction protocol used for FP-CIT images incorporating resolution 
recovery and uniform ACSC; same as OSEM_RRACSC 
RVI Royal Victoria Infirmary; NuTH site and location of nuclear medicine 
department where study patients were scanned 
SBR Specific binding ratio; striatal to background ratio also used in literature 
SNM Society of Nuclear Medicine (US body) 
SNR Signal to noise ratio 
Southampton 
method 
Resolution-independent method for calculating SBR using large box-like striatal 
VOIs to capture all counts attributed to striata 
SPECT Single photon emission computed tomography 
SPECT-CT Hybrid imaging technique combining SPECT and x-ray computed tomography 
Subset Refers to dividing raw projections in OSEM method into multiple groups of 
fewer projections per iteration to speed up convergence 
SUPErB Newcastle study into the use of FP-CIT and cardiac MIBG in MCI patients, with 
older adults with normal cognition recruited as controls 
SUV Standardised uptake values, used for absolute quantification of tracer uptake 
SUVmax SUV of maximum voxel in VOI 
SUVmean Mean SUV in VOI 
SUVpeak Mean SUV of maximum cm3 within VOI 
SUV-SPECT Technique for determining standardised uptake values from SPECT or SPECT-CT 
images 
Symbia Siemens gamma camera model (no CT) 
TEW Triple energy window; empirical scatter correction method 
VoD Tracer volume of distribution within the body 
VOI Volume of interest; volume on SPECT image used for quantification 
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Chapter 1: Introduction 
Lewy body disease is one of the most common causes of neurodegeneration and cognitive decline, 
second only to Alzheimer’s disease.  There are two nuclear medicine scans that have been shown to 
be useful in the detection of neurodegeneration at the relatively late dementia stages of the disease: 
the 123I-FP-CIT scan (123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane) 
(DaTSCAN™) and the cardiac 123I-MIBG scan (123I-metaiodobenzylguanidine).  Both scans are indicated 
as biomarkers in the 2017 consensus criteria for the diagnosis and management of dementia with 
Lewy bodies (DLB) [1], reflecting the extensive evidence base in the literature for their use at the 
dementia stage.  However, they have both been much less frequently studied in the early stages of 
Lewy body disease.    
Evidence from pathology studies suggests that Lewy bodies are present in the cardiac nerves at an 
early stage in the disease, and this can occur prior to brain involvement [2, 3].  Cardiac MIBG therefore 
has the potential to be the more sensitive test for distinguishing Lewy body disease from Alzheimer’s 
disease at an early stage.  However, the current standard methods for cardiac MIBG analysis are more 
basic than FP-CIT and could be subject to more technical inaccuracies.  If these are not addressed, a 
potentially valuable biomarker test for early DLB diagnosis might not be used to its full potential.   
Both scans have technical limitations that suggest that, whilst very accurate in distinguishing between 
DLB cases and other neurodegenerative conditions at the dementia stage, they may not be ideal for 
detecting early neurodegenerative change using current methods.  Neither scan is routinely corrected 
for attenuation or scatter, and the radionuclide used, iodine-123 (123I), poses further challenges due 
to its high energy emissions that reduce image contrast and complicate accurate quantification.  In 
addition, the interpretation of quantification data is limited by the availability of reliable data from 
age-matched controls with similar co-morbidities to the clinical population. 
In this doctoral fellowship project we sought to address these issues in a practical manner, using 
techniques that could easily be introduced into routine NHS practice, as well as more advanced 
methodology that could be implemented in a state-of-the-art centre of excellence setting, where 
more complex techniques for research and clinical use are appropriate.  Throughout the thesis these 
standard techniques are compared with the more complex ones to evaluate their potential benefit.    
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We used both advanced anthropomorphic phantom data and patient data from joint Newcastle 
University and Newcastle Hospitals clinical research studies in Lewy body disease.  These were the 
MIDAS study on the use of cardiac MIBG for DLB diagnosis in a typical UK population, which recruited 
48 patients with dementia, the LewyPro study on the use of FP-CIT in 76 people with mild cognitive 
impairment, and the SUPErB study, which expands and extends LewyPro to include cardiac MIBG, 
recruiting 100 MCI patients and 31 age-matched controls.   
An important feature of these studies is the recruitment of cohorts of highly characterised dementia 
and MCI subjects, with diagnoses confirmed by a panel of expert NHS Consultants.  This approach has 
significant advantages over the more common approach in nuclear medicine, often used in peer 
reviewed publications, of retrospectively reviewing the scan data of patients referred to the service 
as part of clinical care.  The clinical diagnoses of patients referred for a scan are intrinsically linked to 
the results of the scans and not independent of them as they are in our research studies.  Our approach 
makes it possible to assess the accuracy of the scans without this bias.   
Another important feature of the SUPErB study is the inclusion of a relatively large sample of 31 older 
adults with normal cognition recruited as age matched controls, all of whom are over the age of 60.  
The scans of these individuals were used to set normal thresholds with our scanning techniques that 
are appropriate for the study population and to investigate whether FP-CIT and cardiac MIBG uptake 
measurements decline in healthy ageing.  It is common in nuclear medicine imaging studies to use 
patients with normal scan results to generate normal databases retrospectively; our approach is 
independent of the scan result and avoids possible bias, allowing the full range of image appearances 
in healthy older adults to be assessed.   The control data was also used to investigate and optimise 
image reconstruction protocols, particularly for cardiac MIBG SPECT-CT, which is a novel technique.   
The overall objective of the project is the optimisation of acquisition, processing and interpretation 
methods for two nuclear medicine biomarkers in order to minimise variability and maximise accuracy 
for clinical and research use in both established and early Lewy body disease. 
Structure of thesis 
Chapter 2 provides background information on diagnosing dementia and mild cognitive impairment, 
outlines the current status of FP-CIT and cardiac MIBG imaging for DLB diagnosis and introduces the 
research studies at Newcastle University used in this thesis.  Chapter 3 consists of an overview of 
methods for 123I quantification in nuclear medicine imaging and provides more detail on current 
quantitative methods for FP-CIT and cardiac MIBG image analysis used in the literature. 
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Chapters 4 and 5 consist of work done towards the beginning of the fellowship (and in some cases as 
pilot work for funding applications).  This work explores standard FP-CIT and cardiac MIBG methods 
and develops the nuclear medicine imaging protocols to be used within the SUPErB study. 
Chapter 6 compares visual rating of FP-CIT scans with standard and more complex methods of uptake 
quantification, including absolute quantification with SUVs (standardised uptake values).  The test-
retest repeatability of each method is assessed using follow up scans in healthy controls. 
In chapter 7, planar cardiac MIBG analysis methods are covered in more detail, using data from the 
MIDAS and SUPErB studies to assess repeatability and accuracy of visual and quantitative methods, 
the effect of imaging at 20 minutes post MIBG administration instead of at 3.5 hours and whether 
normal cardiac uptake thresholds from the literature are suitable for use in a UK population with co-
morbidities. 
Chapter 8 focuses on more advanced tomographic methods of cardiac MIBG quantification, using 
SPECT and SPECT-CT with corrections for attenuation and scatter.  The effect of patient size on 
apparent uptake is assessed with phantom data and with the SUPErB controls, for both planar and 
advanced image reconstruction methods.  The diagnostic accuracy and the separation of normal and 
abnormal scans into clusters is compared for planar, SPECT-CT relative quantification and SPECT-CT 
absolute quantification.  The uniformity pattern of MIBG uptake within the myocardium is assessed 
for controls and dementia patients, as a feasibility study to see if this might be useful for diagnosing 
Lewy body disease in patients with global uptake within the normal range. 
Chapter 9 uses the scan data for the controls with normal cognition to explore ageing effects for both 
FP-CIT and cardiac MIBG.  Multivariate analysis using linear mixed effects models is performed to 
determine whether there is an association between uptake and ageing in adults with normal cognition 
between 60 and 90 years of age. 
The final chapter summarises the main findings of the thesis and evaluates whether or not it provides 
evidence that applying advanced image reconstruction and quantification methods to 123I-FP-CIT and 
cardiac 123I-MIBG scans gives rise to an improvement in the accuracy of the diagnosis of Lewy body 
disease at the mild cognitive impairment stage.  The strengths and limitations of the project are 
discussed here as well as future directions.
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Chapter 2: Clinical background 
This thesis focusses on the application of nuclear medicine imaging techniques to the diagnosis of Lewy 
body disease at the mild cognitive impairment stage.  In this chapter an overview of the 
neurodegenerative causes of cognitive impairment and how they are diagnosed is given, focussing on 
Lewy body disease and Alzheimer’s disease since they are the clinical groups included in this thesis.  
An introduction is given to two nuclear medicine imaging biomarker tests included in the international 
DLB consortium criteria [1] for the diagnosis of dementia with Lewy bodies: FP-CIT and cardiac MIBG 
and the evidence base for each reviewed, including autopsy validation studies.  An overview is then 
given of the three clinical studies in Lewy body disease at Newcastle University from which data has 
been used in this thesis: MIDAS, LewyPro and SUPErB. 
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2.1 Dementia and mild cognitive impairment 
2.1.1 Causes of dementia 
Dementia is a clinical syndrome of cognitive impairment caused by brain diseases [4]. It presents one 
of the biggest health and social care challenges of the 21st century [5]. In 2014 there were estimated 
to be 850,000 people living with dementia in the UK [5] and over 47 million worldwide [6]. It is expected 
that by 2021 there will be more than a million people living with dementia in the UK [5]. Dementia has 
now become the biggest cause of death in the UK [7] with cases projected to double by 2050 [8].   
Dementia is not a disease in itself, but rather an umbrella term for a syndrome.  The symptoms 
associated with dementia, including problems with memory, cognition and language, can be caused 
by various neurodegenerative diseases of the brain [9], which include Alzheimer’s disease, dementia 
with Lewy bodies (the clinical focus of this work), vascular dementia, fronto-temporal dementia and 
many others1.  The neurodegenerative diseases are all progressive, so get worse over time and 
eventually lead to death.  Although medication can be used to alleviate some of the symptoms, there 
are currently no drugs available that can stop the progression of any of the neurodegenerative diseases 
causing dementia.   
Alzheimer’s disease (AD) is the most common illness causing dementia, affecting approximately two 
thirds of people with dementia [9].  In AD, abnormal structures made from amyloid and tau proteins 
build up in the brain, damaging the nerves and leading to loss of brain tissue.  As the hippocampus is 
generally affected early on in AD, memory problems are often one of the earliest symptoms. However, 
the specific symptoms an individual experiences vary widely and are thought to depend on the part of 
the brain affected (see Diagnosing Dementia, below).   After Alzheimer’s disease, vascular dementia 
and Lewy body disease (comprising dementia with Lewy Bodies and Parkinson’s disease dementia) are 
the most common causes of dementia.  Vascular dementia (VaD) is caused by problems with the blood 
supply to the brain, often due to strokes or chronic small vessel disease [10].  Since any part of the 
brain can be damaged by a vascular event, the symptoms vary and memory loss is not necessarily an 
early feature in VaD [11].  
Dementia with Lewy Bodies (DLB) is caused by abnormal alpha-synuclein protein structures (Lewy 
bodies) that damage neurons in the brain, and elsewhere in the nervous system, including the 
sympathetic nerves to the heart.  DLB is characterised by fluctuations in cognition, motor features of 
Parkinsonism, REM sleep behaviour disorder and complex visual hallucinations (see section on 
Diagnosing Dementia below).  Dementia with Lewy bodies (DLB) is the second most common form of 
                                                          
1 Less commonly, dementia can be caused by reversible conditions such as space occupying lesions or can be 
drug-induced.   
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neurodegenerative dementia after Alzheimer’s disease, accounting for 5-10% of clinically diagnosed 
cases [12, 13].  Accurate diagnosis is important for clinical management, prognosis, and carer wellbeing 
[14-16], but initial misdiagnosis outside the specialist setting is common [1, 13, 17].  Schneider et al. 
found that about 15% of dementia cases at autopsy have Lewy bodies in the brain [18], further 
evidence that many people with DLB or mixed dementia are being misdiagnosed during life.   
Parkinson’s disease (PD) is also caused by Lewy body pathology and PD patients often go on to develop 
dementia, termed Parkinson’s disease dementia (PDD) [19].  These disorders are often grouped 
together as Lewy body dementia or Lewy body disease, and are thought of as a spectrum of essentially 
the same disease process.  DLB and PDD are common and account for 15-20% of all neurodegenerative 
dementia cases [12].  DLB can be difficult to diagnose, particularly in the early stages, because the 
symptoms often overlap with AD.  Early and accurate diagnosis is important for all people with 
dementia so that they can access relevant care, support and treatment services and plan for the future.  
Diagnosing DLB at an early stage is especially important as DLB patients can have severe, sometimes 
fatal, reactions to neuroleptic drugs that might be given if the disease is not recognised [20, 21],  and 
they experience more debilitating symptoms and give rise to more carer stress than other forms of 
dementia [15, 22, 23].   
Accurate early diagnosis of the neurodegenerative diseases leading to dementia is essential for 
research studies, particularly in studies looking to understand the disease pathogenesis, develop or 
test treatments. 
2.1.2 Diagnosing dementia  
Dementia is usually diagnosed following a referral to a specialist memory clinic, where interviews and 
tests of memory and cognitive function take place.  The National Institute on Aging and the Alzheimer’s 
Association, recommend that dementia should be diagnosed if the person’s cognitive problems 
represent a decline from previous levels of function and cause significant interference with normal 
living [24].  Delirium or a major psychiatric illness must be excluded and the impairment must include 
two or more of the following [24]: 
• Short-term memory problems 
• Impaired reasoning and ability to perform complex tasks 
• Impaired visuospatial ability – e.g. not recognising common objects 
• Language problems – e.g. word finding difficulties 
• Changes in personality or behaviour. 
If the decline in ability is not judged to be a significant barrier to normal day to day function, Mild 
Cognitive Impairment (MCI) would be diagnosed rather than dementia (see section 2.1.3 below). 
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The particular disease causing the dementia can be challenging to diagnose.  The symptoms of AD, VaD 
and DLB can overlap significantly and autopsy studies show that it is not uncommon to have more than 
one disease present [25].  The only definitive way to diagnose the specific disease causing dementia is 
by examining the brain at autopsy.  However, there are different clinical criteria for the diagnosis of 
the major causes of dementia based on a combination of symptoms and tests that have been shown 
to have good accuracy.  These are devised by international working parties of experts and are revised 
from time to time to take new knowledge into account.  The most recent criteria for DLB diagnosis 
published in 2017 by the international DLB consortium [19] are summarised in Table 1 alongside the 
current National Institute on Aging and the Alzheimer’s Association criteria for AD diagnosis in Table  
for comparison (AD being the most likely differential diagnosis for DLB) [24].   At least one of the core 
features of fluctuations, visual hallucinations, parkinsonism and REM sleep behaviour disorder must 
be present for probable DLB to be diagnosed; at least two if no positive biomarker evidence is available.  
Possible DLB may be diagnosed if only one core feature is present and there is no indicative biomarker 
evidence or if at least one biomarker is positive in the absence of core features (see Table 1).  The 
indicative biomarkers may therefore contribute towards both possible and probable DLB diagnoses, 
but cannot be used to diagnose probable DLB alone.  Supportive clinical features and biomarkers 
include autonomic dysfunction, postural instability, apathy and normal medial temporal lobes on CT 
or MRI.  These features are often present in DLB but are not recommended to be relied on for diagnosis 
due to low specificity.   
Table 1: Fourth DLB consortium consensus clinical criteria for diagnosing dementia with Lewy bodies [1] 
Probable DLB Possible DLB 
CENTRAL FEATURE: 
Progressive cognitive decline that interferes with normal functioning. 
Memory impairment may not occur at an early stage but usually occurs as the disease progresses. 
Either: 
Two or more core clinical features (and any 
number of suggestive features) 
Or: 
One core feature and one or more indicative 
biomarkers 
Any number of supportive features or 
biomarkers 
Either: 
One core feature with no indicative biomarkers 
Or: 
One or more indicative biomarkers but no core 
features 
 
Any number of supportive features or 
biomarkers 
CORE CLINICAL FEATURES 
• Fluctuating cognition, attention and alertness 
• Recurrent visual hallucinations 
• Spontaneous features of parkinsonism 
• REM sleep behaviour disorder 
INDICATIVE BIOMARKERS 
• Reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET 
• Abnormal (low uptake) 123iodine-MIBG myocardial scintigraphy 
• Polysomnographic confirmation of REM sleep behaviour disorder 
 
8 
 
In the AD diagnostic criteria, AD is diagnosed as the probable cause of dementia if the main symptom 
is related to memory, language, spatial awareness or impaired reasoning and no other causes are 
identified.  A diagnosis of possible, rather than probable AD is made if symptoms were of sudden onset 
or it is not certain that they are progressive. 
Table 2: NIA-AA clinical criteria for diagnosing Alzheimer's disease [24] . 
Probable AD Possible AD 
Meets general criteria for dementia  Atypical course: 
Meets criteria for probable AD except 
there is either sudden onset or 
uncertainty regarding progression 
 
Gradual onset of symptoms Mixed dementia: 
Meets all criteria for probable AD except 
that there is evidence of other disease 
such as DLB and / or cerebrovascular 
disease 
 
Worsening cognition 
 
 
Most prominent symptom is one of the following: 
• Impaired learning and recall 
• Language difficulties 
• Impaired spatial cognition 
• Impaired reasoning and judgement 
 
 
Does not have evidence of 
• Cerebrovascular disease 
• Features of other dementias including DLB 
• Another neurological disease 
• Use of medication affecting cognition 
 
 
2.1.3 Diagnosing mild cognitive impairment 
As discussed above, a diagnosis of mild cognitive impairment is made if a patient is experiencing 
problems with cognition in two or more domains, but these are not severe enough to impact their day 
to day function.  MCI can be caused by the same disease processes that lead to dementia and in most 
cases patients will go on to develop dementia at a later stage.  These cases are also known as 
prodromal dementias, though in the case of dementia with Lewy bodies there are other types of 
prodromal presentation, e.g. psychiatric onset [26].  In this thesis MCI is the only type of prodromal 
dementia syndrome considered.  Although it often precedes a dementia diagnosis, MCI is non-specific 
and can be caused by other disorders such as depression, so it is not certain that someone labelled as 
having MCI will go on to develop dementia.  Clinical trials of disease modifying drugs for dementia due 
to Alzheimer’s disease have suggested that to be effective any intervention would need to be delivered 
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at the very early stages of the disease, making prodromal dementia extremely important to diagnose 
and characterise [17, 27, 28].  Clinical studies on patients with mild cognitive impairment with Lewy 
bodies (MCI-LB) will be needed to test potential new treatments for DLB and so early accurate 
diagnosis will be crucial for patient selection.  Imaging biomarkers will play an important role in both 
early diagnosis and in monitoring response to treatment [28]. 
Currently there are published consensus guidelines for identifying people with MCI due to Alzheimer’s 
disease (MCI-AD) but not yet for MCI-LB - although such guidelines are expected to be published by 
the DLB consortium imminently.  Several authors have put forward the view that further work is 
needed on the characterisation of the various presentations of prodromal DLB [17, 26-34], including 
the investigation of the utility of various biomarker tests available for DLB in the early stages.  
Biomarker utility in MCI-LB is the topic of the LewyPro and SUPERB studies at Newcastle University 
(see below), which this PhD on image analysis integrates with.   
2.2 Nuclear medicine imaging techniques for Lewy body disease 
123I-FP-CIT (dopaminergic imaging of the striatum) and cardiac 123I-MIBG imaging (sympathetic imaging 
of the myocardium) are both established biomarker techniques for distinguishing between DLB and 
AD, but neither has been thoroughly evaluated for prodromal diagnosis [35].  The evidence base for 
the use of these radiopharmaceuticals in dementia diagnosis was reviewed by searching on PubMed 
for original articles containing the following terms: (“MIBG” OR "metaiodobenzylguanidine" OR “FP-
CIT” OR “123I-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) nortropane)” OR 
“DaTSCAN”) AND ("lewy" OR "dementia").  This returned 253 entries in March 2017 increasing to 343 
in June 2019, showing the current interest in this topic.  None of the articles retrieved in March 2017 
focussed the use of FP-CIT or MIBG for diagnosis at the MCI stage (excluding case reports), but by June 
2019 five such articles had been published [36-40], including the Newcastle report on the LewyPro 
study [37].  
A brief review of the clinical evidence base for FP-CIT and cardiac MIBG and the autopsy validation 
studies carried out for each biomarker is given below.  Standard image processing and analysis 
methods will be introduced in Chapter 3. 
2.2.1 FP-CIT (DaTSCAN) imaging 
123I-FP-CIT imaging demonstrates the density of dopamine transporter in neurons in the basal ganglia, 
with reduced striatal uptake in both PD and DLB and normal uptake in AD [41].  Typical patterns of 
uptake can be seen in Figure 1.   Images are usually displayed on a relative colour scale, with the 
maximum voxel shown as white and all other voxels assigned based on their percentages relative to 
maximum (Figure 1).  This means that the background colour scaling is used to assess for global loss of 
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uptake in the striata, with the background appearing to increase when striatal uptake is globally 
reduced.  Other displays may be used, and the potential advantages and disadvantages of the use of 
an absolute uptake scale is discussed in Chapter 6. 
       
Figure 1: Left: normal FP-CIT scan showing the classic “comma” appearance.  Middle: abnormal scan showing severe loss of 
dopaminergic function in the putamen bilaterally and more moderate loss in the caudate nuclei (the classic “dot” appearance).  
Right: mild reduction in global uptake affecting the caudate and putamen, identified by the raised background appearance.   
FP-CIT is well established in the UK for distinguishing between probable DLB and AD [42-48] and is a 
biomarker in the international consensus criteria for DLB diagnosis [19]. A recent pooled analysis of 
four clinical trials found a sensitivity of 92% and specificity of 84%, based on visual analysis [49].  The 
sensitivity is likely to be much lower in MCI-LB as neurodegeneration is likely to be at an earlier stage 
and in some cases pathology may not (yet) be present in the dopaminergic system.  Indeed, in the 
LewyPro study into prodromal DLB (see below) we found that 54% of MCI-LB subjects had positive FP-
CIT scans [37].  
2.2.2 Cardiac MIBG imaging 
Cardiac 123I-metaiodobenzylguanidine (MIBG) sympathetic innervation imaging is now included as an 
indicative biomarker in the fourth DLB consensus criteria, alongside 123I-FP-CIT SPECT [1] and was 
subsequently recommended in the 2018 UK National Institute for Clinical Excellence (NICE) guideline 
NG97 for dementia diagnosis and management [50], to be considered when 123I-FP-CIT SPECT is not 
available.  FP-CIT is more widely used than MIBG in clinical settings in Europe although a reported 
sensitivity of 89% shows that some patients with DLB have normal FP-CIT findings [49], which has been 
confirmed by autopsy studies on patients scanned during life [48].  The NICE guideline NG97 advises 
clinicians not to rule out a diagnosis of DLB based solely on normal FP-CIT or cardiac MIBG imaging 
[50]. 
Cardiac MIBG imaging demonstrates the integrity of neurons in the sympathetic nervous system, 
including the myocardium.  Sympathetic denervation occurs in DLB (and PD) and results in low cardiac 
MIBG uptake [51] as demonstrated in Figure 2.   
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Figure 2: Left: Normal planar cardiac MIBG image.  The heart is outlined with a red circle and the mediastinum background 
region in green.  Note the overlap between heart and lung.    Right: Abnormal cardiac MIBG scan, with reduced uptake seen 
in the heart. 
Cardiac MIBG is widely used in Japan in the diagnosis of dementia with Lewy bodies, and to some 
extent in other European countries [51-57], but is not routinely established in the UK.  The majority of 
published studies on cardiac MIBG for distinguishing between AD and DLB were single centre studies 
carried out in Japan, and showed very high sensitivities and specificities of over 90% [54, 55, 58-60].  
However most excluded cardiac conditions, which can also cause reduced uptake and therefore affect 
the specificity.  A meta-analysis of these studies determined a pooled sensitivity in detecting DLB of 
98% and specificity of 94% [61].  However, the largest multicentre trial of cardiac MIBG scintigraphy in 
DLB to date (133 DLB and non-DLB dementia patients scanned in Japanese centres) reported a 
sensitivity and specificity of 69% and 89% respectively [53].  This used ROC (receiver operating curve) 
analysis to give optimal separation between the groups, rather than using an independent normal 
cardiac uptake threshold.  With diagnostic revisions after three year follow up of 65 of the subjects, 
these results have been updated to 77% and 97% [62], although the optimal cardiac uptake cut-off 
between DLB and non-DLB was updated based on re-analysis of this subgroup.  Such findings led to 
the inclusion of MIBG imaging in the 2017 consensus criteria for DLB as a biomarker alongside FP-CIT 
imaging [1].  
Cardiac MIBG scintigraphy is also used for the estimation of risk of sudden cardiac death in heart failure 
patients and predicting those who could benefit from an implantable cardiac defibrillator (ICD) [63, 64] 
and this is currently the principal application in Europe and the US [65].  Cardiac MIBG may also be 
used to distinguish between Parkinson’s disease (PD) and other parkinsonian syndromes such as multi-
system atrophy and progressive supranuclear palsy, in which the sympathetic nervous system is not 
affected [66]. 
2.2.3 Comparison between FP-CIT and cardiac MIBG 
There have been few published studies comparing FP-CIT and cardiac MIBG directly, even in 
established DLB.  Tiraboschi et al. [67] used visual image assessment in their study comparing cardiac 
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MIBG and FP-CIT for DLB diagnosis, with HMR analysis as a secondary method.  This was the first 
prospective study comparing the two biomarkers in DLB.  Their cardiac MIBG results in 30 DLB patients 
and 29 non-DLB show 100% specificity for both visual and HMR techniques with 97% sensitivity.  123I-
FP-CIT had a sensitivity of 90 and specificity of just 76%, lower than seen in the literature [67].   
However, prior to this, a smaller Italian study in 31 patients found the same high sensitivity (90%) and 
specificity (91%) for both techniques [68].  Our study at Newcastle University (see section 2.3.1 below), 
published during this doctoral fellowship, reported a sensitivity and specificity of 71% and 81% for 
cardiac MIBG and 88% and 75% for FP-CIT [69] – our results were therefore similar to Tiraboschi et al. 
for FP-CIT but much lower for cardiac MIBG.  The first Japanese study to compare both scans in 76 DLB 
and 57 AD patients found the sensitivity and specificity of differentiating DLB from AD were 72% and 
94% for cardiac MIBG and 88% and 89% for FP-CIT, with slightly better diagnostic accuracy for FP-CIT 
[70].   
Although the above points towards FP-CIT being slightly more sensitive in established DLB, there is 
some limited evidence from pathology studies that in MCI-LB cardiac MIBG may be a more sensitive 
biomarker than FP-CIT.  Pathology studies in Lewy body disease have shown degeneration of cardiac 
sympathetic neurons prior to dopaminergic neurons in the basal ganglia [71, 72]. Furthermore, 
previous longitudinal studies have shown that some subjects with normal appearances on FP-CIT 
imaging were diagnosed as having probable DLB after follow up [73-75], and that follow up FP-CIT 
imaging in these patients with normal scans may become abnormal over time [76].  However, a recent 
review article on imaging in the diagnosis of prodromal dementia with Lewy bodies [77] found that 
dopaminergic deficits have a high specificity for Lewy body disease at the pre-dementia stage, although 
longitudinal follow up is lacking, whereas for cardiac sympathetic denervation it remains to be 
determined whether imaging abnormalities precede DLB [77]. 
2.2.4 Autopsy validation of FP-CIT and cardiac MIBG 
A recent systematic review by Sonni et al. [35] looked at the evidence base for both FP-CIT and MIBG 
for the differential diagnosis between AD and DLB.  They found that for both biomarkers, whilst there 
is good evidence of ability to distinguish between AD and DLB, autopsy validation is limited and no 
studies have yet performed autopsy validation of both biomarkers in the same group of patients [35]. 
Confirmation of disease subtype at autopsy is important to support the validity of these scans and is 
limited in both cases, but stronger in FP-CIT than in cardiac MIBG. 
Walker et al. [78] showed that in eight patients with DLB and 12 with other dementias the sensitivity 
of FP-CIT with respect to neuropathological confirmation was 88% and specificity 100%, with abnormal 
scans defined as those with quantification results more than two standard deviations below the mean 
of controls.  Colloby et al. [79] also correlated quantitative FP-CIT uptake with neuropathology and 
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found that image uptake was associated with dopaminergic neuronal density in the substantia nigra, 
but not the presence of alpha-synuclein. 
Two studies have validated visual rating of FP-CIT scans, common in clinical practice, with autopsy 
findings.  Jung et al. [80] performed autopsy validation of FP-CIT in 18 patients with dementia, including 
12 who had DLB. The sensitivity and specificity of abnormal FP-CIT SPECT by visual rating for predicting 
Lewy body disease were 92% and 83% respectively.  The largest autopsy validation study to date, by 
Thomas et al. [48], included 33 patients with DLB and 22 with Alzheimer disease who underwent FP-
CIT scanning as part of a research study and donated brain tissue on death. FP-CIT was found to have 
a sensitivity of 80% and specificity of 92% with respect to autopsy findings.  There were three DLB 
cases (10%) who met pathologic criteria for Lewy body disease but had normal FP-CIT imaging. 
There have been several autopsy studies from Orimo and colleagues reporting on the degeneration of 
the cardiac sympathetic nervous system in people who had DLB, as well as in asymptomatic individuals 
[2, 3, 71].  Beach et al. showed that alpha-synuclein pathology is found throughout the sympathetic 
nervous system at autopsy in patients with Lewy body disease and is predominant in the sympathetic 
ganglia [81], which suggests that cardiac sympathetic innervation imaging should be an effective 
diagnostic tool.    
There is only one autopsy study on patients who had cardiac MIBG scanning in life, including 15 DLB 
patients, published by the same group as the Japanese studies above [82].  This is the only direct 
evidence to link reduced cardiac MIBG uptake and loss of sympathetic cardiac neurons [82].   Of the 
15 patients confirmed to meet the pathological criteria for DLB, cardiac MIBG uptake was found to be 
decreased in 13 cases (sensitivity 87%), with no decrease of MIBG uptake observed in two of the DLB 
cases with confirmed pathology in the brain.  Of these two cases, one had moderate cardiac 
sympathetic denervation at autopsy, two years following the scan, and one had only mild denervation. 
Both the cardiac MIBG autopsy study of Takahashi et al. and the FP-CIT studies of Thomas et al. and 
Jung et al. show that a normal scan result does not rule out a diagnosis of DLB, suggesting it is possible 
to have significant Lewy body pathology without dopaminergic or sympathetic denervation.  
2.3 Radionuclide imaging studies in DLB and MCI-LB at Newcastle University 
There are three studies completed or currently recruiting subjects for cardiac MIBG and / or FP-CIT 
studies in Newcastle in order to assess the utility of imaging as a diagnostic tool: MIDAS, LewyPro and 
SUPErB.  All subjects in these studies agreed to their data being used for subsequent studies within 
Newcastle University when their consent to take part was first obtained.  The images and the clinical 
diagnoses from these studies were therefore available for use in this doctoral fellowship.  The imaging 
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protocols used in the studies are described in more detail in the main body of thesis.  The information 
below is included to give a broader clinical overview of the studies. 
2.3.1 MIDAS study 
The MIDAS study (123I-MIBG in dementia with Lewy bodies as a marker for sympathetic denervation) 
is a single centre pilot study at Newcastle University, with the aim of determining whether cardiac 
MIBG is a useful tool in typical subjects presenting for dementia assessment in the NHS [83]. MIDAS 
also aimed to assess more difficult cases of possible DLB and to compare MIBG with FP-CIT.  In most 
published studies patients with even mild cardiac disease were excluded because heart failure and 
cardiovascular disease can cause abnormal cardiac MIBG uptake and give rise to confounding results.   
This means that the positive results seen in the literature may not translate to a typical elderly UK 
population, where the prevalence of cardiovascular disease and heart failure is high.  In this study 
inclusion criteria have been deliberately kept as broad as possible and patients with mild 
cardiovascular disease are not excluded. 
The MIDAS study aimed to recruit and scan a total of 90 subjects with dementia – 30 with probable 
DLB according to the consensus criteria [19], 30 with probable or possible AD according to the revised 
NIA-AA criteria [24] and a further 15 subjects with possible DLB and 15 with probable DLB who have 
negative FP-CIT results.   Seventeen DLB patients completed the protocol, 16 AD patients and 6 
additional FP-CIT negative DLB.  All subjects underwent MIBG and FP-CIT imaging at baseline (if not 
already done), as well as clinical and neuropsychometric assessment.    The cardiac MIBG scans were 
carried out with SPECT, but the SPECT-CT scanner was not yet installed when the study started, so CT 
data for attenuation correction is not available.  
2.3.2 LewyPro study 
LewyPro was an NIHR Biomedical Research Unit study at Newcastle and was the first prospective 
assessment of subjects with MCI-LB [37, 84].  This study was a predecessor to SUPErB (see below) and 
carried out by the same principal investigator.  The methodology was similar to SUPErB, but with some 
features, such as cardiac MIBG scanning, not included.  LewyPro closed in 2016, but subjects continue 
to be followed up and many have agreed to enter the SUPErB study.   
The team recruited patients presenting for assessment at NHS memory clinics with mild cognitive 
impairment, rather than with dementia.   The clinical assessment and cognitive tests were used to 
judge whether the subjects had probable or possible MCI with Lewy bodies (MCI-LB), or probable MCI 
due to AD (MCI-AD).   Of the 90 patients recruited, 75 completed the assessments and scans. Of these 
33 were judged to have probable MCI due to Lewy body disease, 15 possible MCI due to Lewy body 
disease and 27 had probable MCI due to AD.  We found that 54% of patients with MCI-LB had an 
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abnormal FP-CIT scan, based on visual assessment of the scans by an experienced panel reporters, a 
significantly lower sensitivity than seen in dementia cohorts.  The specificity was 89%, which is 
comparable to results in dementia (see section 2.2 above). 
2.3.3 SUPErB study 
SUPErB (Scintigraphy Utility in Prodromal dEmentia with Lewy Bodies) is an extension of the LewyPro 
study with a larger cohort of 100 subjects with MCI and 30 age matched controls, which is ongoing at 
the time of writing.  It is a single centre prospective cohort observational study of people over 60 years 
of age recruited from memory clinics with symptoms not sufficient for a dementia diagnosis, or 
recruited as volunteers with normal cognition.   MCI subjects have baseline MIBG imaging, FP-CIT and 
high resolution hippocampal MRI, an in-depth clinical and neuropsychometric assessment and then 
annual review for up to four years.   At annual review the clinical assessments are repeated and the 
diagnoses reviewed.  The control volunteers undertake the same detailed assessments as patients 
presenting with MCI, so they are thoroughly evaluated as having normal cognition. 
A key feature of the SUPErB study for this thesis is that the imaging protocols include SPECT-CT for 
both FP-CIT and cardiac MIBG, which was not the case for MIDAS and LewyPro.  This enables the full 
benefits of quantitative imaging with CT based scatter and attenuation correction to be studied in this 
patient and control cohort and the results compared the standard methods that do not use SPECT-CT.  
After consenting to participate, subjects have a baseline assessment, consisting of five sessions in 
which they complete the tests outlined below: 
1) Consent and neurocognitive assessment consisting of the following items 
a. Addenbrooke’s Cognitive Examination  
b. Standard MMSE  
c. Graded Naming Test  
d. Rey AVLT  
e. Trail Making Test  
f. FAS  
g. Neuropsychiatric Inventory (NPI)  
h. Epworth sleepiness scale  
i. Visual Hallucinations Scale (VHI)  
j. Geriatric Depression Scale  
k. Questionnaire for Symptoms Suggestive of Lewy Body Disease  
l. National Adult Reading Test  
m. Digit Symbol Substitution tasks  
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2) A diagnostic interview, medical examination and neuropsychiatric assessment including 
medication review, an assessment of olfactory function, height, weight, pulse, lying and 
standing blood pressure, blood sample. Measurement of supine and standing heart rate 
variability (HRV) and ECG for MCI patients only. 
3) Cardiac MIBG scan  
4) FP-CIT scan  
5) 3T MRI scan and EEG; optional lumbar puncture. 
MCI diagnoses in SUPErB  
A diagnosis of either possible or probable MCI-LB or probable MCI-AD will be given following review 
of the assessments by a panel of experienced old-age psychiatrists, following the international DLB 
consortium criteria given in Table 1 above, except that polysomnography is not included as a biomarker 
in the study.  To summarise, patients with two or more core features will be classed as probable MCI-
LB, even if their FP-CIT and cardiac MIBG biomarker tests are normal.  Patients with one core feature 
will be classed as possible MCI-LB if their scans are normal and probable MCI-LB if one or both scans 
are abnormal.  Patients with no core clinical features are classified as probable MCI-LB if one or both 
scans are abnormal and MCI-AD if both scans are normal.   In the SUPErB study an abnormal FP-CIT 
scan is determined by a consensus panel of five raters and an abnormal cardiac MIBG scan is defined 
as planar HMR result lower than two standard deviations below the mean of the controls.  A cut-off at 
two standard deviations below the mean of normal subjects is a standard method throughout 
radionuclide imaging, used by the manufacturers of FP-CIT software for example and in the autopsy 
studies above [78, 79]. 
In this thesis we are assessing the imaging biomarkers, which makes using the scan results for diagnosis 
problematic.  One approach would be to use the core clinical features only, resulting in the same 
clinical groupings throughout the thesis.  However, we chose to include either FP-CIT or cardiac MIBG 
results for diagnosis, depending on which scan was under evaluation, with the aim of increasing 
diagnostic certainty.  So for the chapters assessing FP-CIT methods using the SUPErB MCI patients we 
use the cardiac MIBG result as part of the diagnostic criteria and for the chapters assessing MIBG 
methods we use the FP-CIT result.   Possible MCI-LB subjects are excluded in both scenarios to increase 
diagnostic certainty. The clinical symptoms at one year follow up assessment are used for diagnosis of 
the SUPErB subjects in this thesis, resulting in 59 MCI patients and 31 controls with follow up 
completed in January 2019 being considered for inclusion.  Flow charts depicting the decision making 
processes leading to the clinical groupings for SUPErB MCI patients are shown in Figure 3 for FP-CIT 
assessment (i.e. using cardiac MIBG results) and in Figure 4 for cardiac MIBG assessment.  The resultant 
groups consist of 27 probable MCI-LB and 18 MCI-AD patients to use in the FP-CIT chapters and 28 
probable MCI-LB and 18 MCI-AD patients to use in the MIBG chapters. 
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Figure 3: Decision flow chart for clinical groupings of SUPErB MCI subjects for the FP-CIT chapters in this thesis, based on core 
clinical features at 1 year follow up and MIBG result at baseline. 
 
Figure 4: Decision flow chart for clinical groupings of SUPErB MCI subjects for the cardiac MIBG chapters in this thesis, based 
on core clinical features at 1 year follow up and FP-CIT result at baseline. Two of the cases did not have MIBG imaging so are 
of course excluded. 
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Chapter 3: Technical background 
Recent developments in nuclear medicine quantification have the potential to improve the diagnostic 
accuracy of FP-CIT and MIBG for dementia diagnosis, maximising the value of the acquired scan data. 
More accurate quantification has the potential to improve diagnosis for DLB, both in routine practice 
and in clinical research - particularly in early disease. This thesis implements and assesses such 
improved quantification methods, which include corrections for signal lost due to scatter and 
attenuation and for the effect of high energy gamma photons that penetrate through the collimator. 
In this chapter the fundamental underlying issues related to 123I image quantification are discussed, 
and the specific issues in FP-CIT and cardiac MIBG quantification addressed in this thesis are 
introduced.  
 
  
19 
 
 Overview 
Nuclear medicine images are considerably degraded by photon scatter and attenuation and so do not 
inherently provide an accurate measure of tracer uptake within a subject.  For example, signal from 
the centre of the brain is subject to 70% more attenuation than the cortex and corrections for 
attenuation and scatter have a significant effect on the appearance of 99mTc perfusion brain scans [85].  
Conventional nuclear medicine imaging relies on visual detection of characteristic patterns of uptake 
and so does not require quantification.  However, for nuclear medicine scans to truly realise their 
potential as imaging biomarkers, quantitative techniques are required and corrections for image 
degradation are essential for these to be as accurate as possible.  
Lack of the ability to measure the absolute uptake of a radiotracer has meant that traditionally ratios 
between the counts in the organ of interest and counts in a background region are used for semi-
quantification [86]. This is the case for standard analysis of both FP-CIT and cardiac MIBG scans, where 
the striatum and myocardium respectively are compared to a background region.  Absolute 
measurement of activity concentration has in recent years become possible due to advances in 
attenuation and scatter correction and SPECT reconstruction methods, which all contribute to 
providing a more accurate representation of the activity distribution within a subject, if careful 
calibration methods are used [87, 88].   A particular enabler for these advances has been the ability to 
measure attenuation and scattering properties with a simultaneously acquired CT scan (SPECT-CT 
scanning) rather than relying on unrealistic assumptions about these properties [89].    
123I radionuclides emit a principle gamma photon at 159 keV, of a similar order of magnitude as the 
99mTc photopeak at 141 keV, but with additional high energy emissions between 440 and 784 keV (3% 
of total emissions) that make accurate quantification even more challenging.  The advances discussed 
in this chapter aim to improve the accuracy of semi-quantification of 123I images and also enable true 
absolute uptake quantification after normalising for patient size and injected activity. The 
improvements in semi-quantification and the potential benefits of absolute quantification for cardiac 
MIBG and FP-CIT will be evaluated in this thesis.  In 2018 a quantitative SPECT meeting was held by the 
Institute of Physics and Engineering in Medicine, at which the author presented some of the work 
discussed in this thesis.  The overall feeling of the delegates was quantitative SPECT imaging is ready 
to be implemented for widespread clinical use, as a subsequent review article by the organisers 
demonstrates [88]. 
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 Radionuclide imaging (nuclear medicine)  
3.2.1 Introduction 
Nuclear medicine is a functional imaging technique using radioactive tracers to obtain information 
about physiological function.  The aim is to visualise or quantify the distribution of uptake of a 
radiopharmaceutical within an organ of interest to aid in the diagnosis and staging of disease or 
response to treatment.  Typically, radiopharmaceuticals are labelled with technetium-99m (99mTc), 
which emits a gamma photon of 141 keV energy, with a half-life of 6 hours.  However, both the 
techniques used in this thesis, FP-CIT and cardiac MIBG are labelled with iodine-123 (123I), which has a 
principal gamma emission at 159 keV and half-life of 13.2 hours.   
The radiopharmaceutical is administered via intravenous injection and allowed to distribute within the 
body and be taken up by organs of interest, before being imaged using a gamma camera (Figure 5).   
 
 
Figure 5: Left: Siemens Intevo SPECT-CT gamma camera at the Royal Victoria Infirmary.  Right: Schematic diagram of a gamma 
camera detector head [90]  
 
The main components of the gamma camera design used in this thesis are the parallel hole collimator, 
sodium iodide (NaI) scintillation crystal, photomultiplier tubes and processing circuits (Figure 6).  The 
collimator is a lead grid of parallel holes designed to allow only photons incident within a small angle 
of acceptance to pass through to the scintillation crystal2.  Gamma photons incident from oblique 
angles (the vast majority of the total emissions) are absorbed by the collimator septa.  Without the 
collimator, a meaningful image could not be formed as the path of the photons would be unknown.  
                                                          
2 Other collimator designs, such as high sensitivity pinhole collimators are available, as are novel designs of 
gamma camera that do not use scintillation detectors.  These are not used in our centre and consideration of 
them is beyond the scope of this work. 
CT bore 
Gamma camera head 
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Gamma photons that reach the scintillation crystal interact via the photoelectric effect and emit 
thousands of visible photons, which are then detected as photoelectrons and amplified by an array of 
photomultiplier tubes.  The relative signal detected by each photomultiplier tube is used to determine 
the likely position of the interaction within the crystal, and the overall magnitude of the signal 
determines the energy of the gamma photon that caused the interaction.  An image is formed from 
many thousands of detected gamma photons, or “counts”, each assigned to a pixel within an image 
matrix.  This process is subject to stochastic uncertainty, which gives rise to uncertainties in both spatial 
localisation and energy resolution.   
Due to absorption and scatter within the patient, many photons originally emitted in a perpendicular 
direction to the gamma camera fail to reach the detector (Figure 6), resulting in a loss of signal.  
Attenuation causes structures located deeper within the body to appear less active than those nearer 
the surface, with the signal reduction following an exponential relationship within a uniform 
attenuating medium. 
 
 
Figure 6: Illustration of possible photon tragetories, adapted from [91].  The blue arrow depicts the ideal scenario.  The black 
arrows represent attenuation due to absorption and scattering.  The red arrow depicts a scattered photon originating from 
the centre of the source that will be detected as if it came from the edge. 
 
It is also possible for photons not originally emitted perpendicularly to the collimator to undergo 
Compton scattering within the patient, resulting in the scattered photon reaching the crystal and being 
detected in the wrong location (Figure 6).  Photons lose energy via Compton scattering, so the amount 
of scatter detected is minimised by only accepting photons within a certain energy window around the 
photopeak, typically ± 10%.  The photopeak energy is broadened due to statistical uncertainty, with 
most 159 keV 123I photons distributed between 140 and 170 keV (see 123I spectra in Figure 13, section 
5.3.4).    The width of the energy window is set to obtain a balance between accepting as many primary 
photopeak photons as possible (to maximise sensitivity) and rejecting as many scattered photons as 
possible.  However, even photons that have scattered by 90 degrees, as shown in Figure 6, may still 
carry enough energy to be detected within a ±10% photopeak window [92], which means that the 
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detection of a significant proportion of scattered photons is unavoidable.  Scatter causes an increase 
in incorrectly positioned background counts, reducing image contrast.  
The probability of these processes occurring is patient-specific, as it depends on the composition and 
amount of tissue between the source and the detector.  Accurate compensation for attenuation and 
scatter improves image quality and is essential for quantification of tracer distribution [92, 93].  A 
recent review by Ljungberg concludes that the most important factors that affect SPECT quantification 
and require compensation for accurate results are attenuation, scatter and poor collimator resolution 
[94]. Common methods for performing these compensations within tomographic SPECT imaging are 
described below. 
3.2.2 SPECT imaging and reconstruction 
Images obtained with the gamma camera detector in a static position over the patient are called planar 
images.  Planar images are a simple method for visualising the three dimensional activity distribution 
in the patient as two dimensional projections.  However, they are inherently subject to attenuation 
and scatter, with deeper structures more affected, and this cannot be accurately corrected for.  
Nevertheless they are often used in nuclear medicine, including for cardiac MIBG imaging. 
The summation of activity from overlying structures into a two dimensional projection results in a 
significant loss of contrast, making planar imaging particularly unsuitable for brain imaging.  This is 
resolved by looking at the activity distribution within a slice through the brain using single photon 
emission computed tomography (SPECT).  SPECT allows more accurate visualisation and quantification 
of tracer uptake and is used for both brain and torso imaging.  SPECT images are reconstructed from a 
set of multiple planar images taken at different angles as the detector rotates around the patient, 
typically 120 or 128 views in total for brain imaging.  These raw planar images are called projections 
and are used to estimate the activity at each point within the field of view.  The simplest method to do 
this is via back projection of the signal from each projection, which is illustrated in Figure 7 for a 
simplified scenario of just four orthogonal projections.   
In simple back projection, the raw signal is projected back over the whole field of view, which leads to 
blurring of structures and star artefacts from the overlapping projections (Figure 7).   To correct for 
this blurring, a ramp filter is applied in frequency space, to supress low spatial frequencies (which 
correspond to large structures).  High spatial frequencies (corresponding to small structures) are also 
supressed to reduce image noise, typically with an additional Butterworth filter.  The resultant 
technique is called filtered back projection and has been widely used in nuclear medicine for decades.   
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Figure 7: Left: Illustration of gamma camera detector rotating around patient, acquiring projections.  Right: Simple back 
projection of acquired projections to form image estimate.  The radial blurring is corrected by a filter in FBP, which reduces 
the “star artefact”.  This simplified example shows four projections – typically 64 to 128 are used to build up a much more 
accurate image estimate. 
 
An alternative method is iterative reconstruction, where an initial image estimate is refined and 
updated via a series of comparisons between the raw projections and the estimated projections that 
would give rise to the estimated image as shown in Figure 8.  The forward projection step (shown 
outlined in red in Figure 8) is a model of the acquisition process, and can incorporate effects such as 
attenuation and scatter and poor collimator resolution [91] (see section 5.3).  The better the forward 
projection step model, the closer the resultant image estimation is to the true activity distribution.  
However, artefacts can be introduced if the assumptions used are incorrect.   The ability to compensate 
for scatter and attenuation makes the iterative method much more suitable for quantification than 
filtered back projection.   
 
Figure 8: Overview of iterative reconstruction process, adapted from [91] 
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There are different algorithmic approaches to implementing the iterative method illustrated in Figure 
8, all of which have different ways of implementing the key step (shown in blue) of comparing 
estimated and measured projections in order to converge on a solution that represents the true 
activity distribution.   In the 1990s Gilland et al. used phantom studies to show that iterative 
reconstruction using the maximum likelihood expectation maximisation algorithm (MLEM) gave 
quantitative accuracy comparable to FBP for 123I imaging with the benefit of less noisy images [95].  
However, MLEM is computationally demanding and long reconstruction times prevented adoption for 
clinical use.  A variation of the MLEM algorithm, ordered subsets expectation maximisation (OSEM) 
was developed by Hudson et al. to speed up the iterative process by including only a subset of the 
projections in each iteration [96], resulting in more rapid convergence to the final estimate.  The 
combination of OSEM and modern processing speeds means iterative reconstruction is now commonly 
used in routine nuclear medicine imaging, including for FP-CIT SPECT [97].  
However, a disadvantage of OSEM is that it is not clear when adequate convergence is achieved, and 
the algorithm may continue updating the estimate with only small improvements in activity 
distribution at the cost of high frequency noise being introduced [90].  In clinical practice it is not 
feasible to optimise individual images so a fixed number of iterations is generally used to avoid 
amplification of noise, with the number of iterations and subsets tailored to each type of scan.  
However, convergence rates are likely to depend on the individual patient activity distribution, with 
Dickson et al. showing that for 123I striatal phantom scans different numbers of iterations were required 
for different uptake scenarios, and high striatal uptake images did not converge [98].  Nevertheless, 
the authors concluded that OSEM was more suitable for FP-CIT quantification than FBP because 
corrections, such as attenuation and scatter correction, can be incorporated.    
Filtered back projection remains widely used in clinical practice and the adoption of iterative methods 
is still far from universal.  The key advantage of iterative methods is that they support the incorporation 
of attenuation and scatter correction and collimator resolution modelling.  The benefit of OSEM 
without image corrections is unproven and implementation in centres without access to advanced 
image correction methods could be unhelpful.  Changing the reconstruction method from FBP to OSEM 
is not straightforward as it requires medical physics support for optimisation and a period of retraining 
for reporters, since the visual appearance of the images is affected.  In this thesis the OSEM method 
with corrections for resolution, scatter and attenuation for visual rating of FP-CIT images is compared 
with the Newcastle upon Tyne Hospitals (NuTH) standard method of filtered back projection.  OSEM is 
then used for FP-CIT throughout the thesis, rather than the local departmental FBP method.   For 
cardiac MIBG SPECT, OSEM with corrections for resolution, scatter and attenuation is used throughout 
thesis, except in section 8.4 on regional cardiac innervation, where FBP is used instead due to concerns 
about possible artefacts introduced by the resolution recovery model.   
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 Factors affecting quantification of 123I uptake in radionuclide imaging 
3.3.1 Attenuation 
The current “gold standard” method for attenuation correction makes use of transmission scans to 
provide an attenuation map, using a CT scan acquired immediately after SPECT on a hybrid SPECT-CT 
scanner [89].  This method has been available since SPECT-CT scanners were introduced in 1999 [99].  
The SPECT scan is performed first and the patient couch then moves through to the CT gantry, located 
behind the gamma camera head (see photograph of SPECT-CT scanner in Figure 5).  The CT scan 
provides patient specific attenuation maps for attenuation correction via the iterative reconstruction 
algorithm and also an anatomical image that can be used for localisation.  As the gamma photopeak 
varies depending on the radionuclide used, and generally the CT energies are lower, the measured CT 
transmission is not a true reflection of the attenuation properties at the gamma photon energy of 
interest.  A look up table based on empirical data is used to modify the attenuation coefficients [99, 
100].  
An alternative method that does not require a SPECT-CT scanner is the uniform, or “Chang” method, 
where a patient contour is automatically defined on an initial estimate of the reconstructed image, 
and all the tissue inside the contour is assumed to be the density of water for the purposes of the 
attenuation map [101].  Uniform attenuation correction is often used in brain imaging and has been 
shown to be of similar accuracy to CT methods for both 99mTc perfusion scans [85] and for 123I-FP-CIT 
dopaminergic imaging [102].  The assumption of uniform density is adequate for brain tissue and the 
issue of potential mis-registration between SPECT and CT due to patient motion is avoided.  The 
uniform method also requires no additional radiation dose to the patient. 
However, SPECT-CT is required for the attenuation correction of torso SPECT images because the 
uniform density assumption is inappropriate [100].  The CT image provides a detailed map of 
attenuation coefficients throughout the patient, which is used for attenuation correction and can also 
be used for Monte Carlo simulation of scatter within the imaged volume. 
3.3.2 Scatter 
In this context, scatter refers to photons that are detected within the photopeak but attributed to the 
wrong position, as depicted by the red arrow in Figure 6.  Photons that scatter out of the field of view 
or are detected outside the energy window contribute to attenuation rather than detected scatter.  
Photons can undergo a single Compton scattering event of up to 90 degrees and still be detected in 
the photopeak energy window [92], demonstrating the importance of scatter correction.  A simple 
method for correcting for scatter within the photopeak, the triple energy window method (TEW), 
involves setting narrow energy windows just either side of the photopeak and using the signal in these 
windows to estimate the amount of signal due to scatter within the photopeak [91].  The scatter 
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fraction is estimated by interpolating between the signal in the upper and lower scatter windows as 
illustrated in Figure 9.   The counts attributed to scatter within the photopeak are then subtracted from 
the total.   
 
 
Figure 9: Illustration of the triple energy window scatter estimation technique [91] 
 
A fundamental problem with the TEW method is that the spatial distribution of scatter is energy 
dependent, with the photopeak window more likely to contain photons deflected by smaller angles 
than the lower energy window [92].  The windows are kept narrow to minimise this effect.  A further 
disadvantage of scatter window subtraction methods is that the projection data are noisy due to the 
necessity for narrow scatter windows, and subtraction of a noisy estimate may result in negative pixels 
within the projections [92].  Papanastasiou et al. state that the use of TEW scatter correction for cardiac 
123I imaging provides a semi-quantitative assessment, based on results in a phantom [103].  Lagerburg 
et al. investigated scatter window subtraction methods using an image quality phantom with different 
123I source to background ratios [104] and found that scatter correction was effective for low energy 
collimators but made quantification less accurate with medium energy collimators. However, Inoue et 
al. found that the triple energy window could not correct for 123I scatter in patients using low energy 
high resolution collimators [105].   Collimator choice for 123I imaging in relation to scatter and septal 
penetration is discussed in section 5.3.4. 
An alternative approach to scatter window estimations is to simulate the scatter within the patient 
using Monte Carlo methods. Full estimation of scatter for an individual patient was traditionally 
considered too computationally demanding to be practical [92]. However, recent work in optimising 
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Monte Carlo methods has demonstrated that it is feasible to compute scatter estimates in sufficient 
time to be practical for inclusion in image reconstruction [93, 106, 107].  Shcherbinin evaluated one 
such algorithm showing accuracy to with 5% in a phantom for 123I using SPECT-CT [108].  Robinson et 
al. have shown that the triple energy window is less accurate than Monte Carlo methods of scatter 
correction [109].  Scatter window techniques, such as TEW, will not be investigated further in this 
thesis as the literature shows both theoretical and empirical evidence that they are sub-optimal.  
Monte Carlo methods are not widely adopted in clinical practice, but show promise and are supported 
by evidence from the literature.  Monte Carlo methods are supported within the reconstruction 
software used in NuTH (see below) and are used throughout this thesis.   
3.3.3 Resolution and partial volume effect  
The resolution of nuclear medicine images is inherently limited by the uncertainty in localisation of the 
gamma photon interaction in the scintillation crystal.  A further major factor affecting resolution is  the 
collimator geometry (Figure 10) with longer, narrower holes providing better resolution but reduced 
sensitivity [110].  Geometric resolution, Rcoll is defined based on the physical dimensions of the 
collimator of hole length, l, hole width, d, and the distance of the source, b: 
𝑅𝑅𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝑑𝑑(𝑙𝑙 + 𝑏𝑏) 𝑙𝑙⁄   
 
Figure 10: Illustration of the dependence of collimator resolution on geometric properties of hole length and width and source 
distance [110].  The resolution can be improved by moving the source closer or selecting a collimator with narrower and longer 
collimator holes, the latter of which is at the expense of reduced sensitivity. 
Table 3 gives the properties of the two collimators used in this thesis, the Siemens low energy high 
resolution (LEHR) collimator and medium energy low penetration (MELP) (Siemens Healthcare, 
Munich, Germany).  The holes in the MELP collimators have lead septal walls that are 7 times as thick 
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as the LEHR, which minimise septal penetration (see next section).  Medium energy general purpose 
collimators are used in some centres, and have similar properties to the MELP collimators below. 
 
Table 3: Geometrical properties of the Siemens LEHR and MELP collimators used in this thesis. 
Collimator LEHR MELP 
Hole Shape Hexagonal Hexagonal 
Number of Holes 148,000 14,000 
Hole Length 24.05 mm 40.64 mm 
Septal Thickness 0.16 mm 1.14 mm 
Hole Diameter 1.11 mm 2.94 mm 
Geometric Resolution 
at 10 cm 
6.4 mm 10.8 mm 
 
The point spread function (PSF) is the probability function describing the spatial distribution of counts 
detected from a point source [91].  The measured activity distribution is the convolution of the true 
activity distribution and the point spread function, so in principle the true activity distribution can be 
recovered by de-convolution (Figure 11).  The PSF is depth dependent, due to collimator geometry, 
with higher resolution achieved closer to the detector.  As gamma camera collimators have known 
dimensions of hole length, hole diameter and septal thickness, the acceptance angle of photons can 
be determined.  As the distance of the collimator from the centre of rotation is known iterative 
reconstruction algorithms can model the point spread function, with the width of the function 
increasing with distance from the detector.  This technique is known as resolution recovery (RR).   
 
 
Figure 11: Illustration of blurring of structures and loss of peak signal due to the partial volume effect [91] 
The partial volume effect refers to the loss of signal in a voxel of interest due to limited resolution and 
finite voxel size [110].  This effect is reduced by improving resolution using resolution recovery 
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modelling.  In objects much larger than the full-width half maximum of the PSF (approximately 
equivalent to the collimator geometric resolution) the centre will reflect true uptake, provided the 
voxel size is adequately small, and the edges will be blurred.  The impact of the partial volume effect 
is greater for small structures, where even the maximum voxel is underestimated.  In this thesis, this 
has particular relevance to FP-CIT imaging of the striata, which are only around 11 cm3 in volume [111], 
with maximum dimension around 10 mm.  The resolution of MELP collimators at a distance of 10 cm 
is 10.8 mm, making MELP collimators unsuitable for resolving striatal anatomy, especially at a typical 
imaging distance of 15 cm. In FP-CIT imaging, low energy high resolution collimators are used, despite 
the effects of septal penetration (see next section), because high resolution is more important for 
diagnosis than accurate quantification.  It is important to be able to resolve the striata and distinguish 
between the caudate and putamen.  LEHR collimators are recommended by GE Healthcare and the 
European and SNM guidelines [112, 113].   
3.3.4 Septal penetration and collimator choice 
The decay scheme of 123I is complex (Figure 12) with a predominant emission at 159 keV (97% 
probability) and several higher energy emissions of lower probability.   
 
Figure 12: Adapted from http://www.nucleide.org/DDEP_WG/Nuclides/I-123_tables.pdf 
Although the higher energies represent a lower proportion of emissions, due to septal penetration and 
subsequent loss of energy in the detector they can cause a considerable increase in down scatter into 
the photopeak window.  Measurements of 123I energy spectra obtained at our centre with low energy 
collimators and medium energy collimators (with properties in Table 3) are shown in Figure 13.  The 
reduction in scatter due to septal penetration is clear by examining the area just above the photopeak.   
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Figure 13: 123I energy spectra acquired by the author with LEHR and MELP collimators for a point source (top) and cylindrical 
phantom (bottom). Peaks: 1= iodine k-edge, 2= compton scatter peak, 3 = photopeak at 159 keV, 4-6 = high energy emissions 
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Macey et al. advised the use of medium energy collimators for 123I imaging to reduce septal penetration 
in the 1980s (for all imaging applications) and this is reiterated by several authors [114] including 
Dobbeleir et al. [115] and Fletcher et al. [116].  Inoue et al. demonstrated that uptake ratios in an 
image quality phantom are lower with LEHR [117] and that septal penetration is low with medium 
energy collimators and of no clinical significance [118]. 
In cardiac MIBG imaging resolution is less critical as the heart is a larger structure than the striata, so 
quantification is less susceptible to the partial volume effect.  Cardiac MIBG studies are usually 
quantified by the heart-to-mediastinum ratio (H/M ratio, or HMR) calculated from regions of interest 
placed on anterior planar images [51].  The HMR is affected by acquisition parameters, most notably 
the collimator used [119].  Low energy collimators give lower HMRs than medium energy collimators 
for the reasons discussed above [120] [121].  The difference in image appearance between medium 
energy and low energy collimators is shown in Figure 14 for torso phantom images acquired in our 
centre. Figure 15 shows a clinical example, where the increase in background scatter with low energy 
collimators is clear. 
 
LEHR collimator MELP collimator 
 
 
 
 
 
 
 
 
Figure 14: Torso phantom 123I images acquired by the author using LEHR and MELP collimators.  The bottom row shows the 
phantom covered with attenuating material.  The reduction in downscatter from high energy photons with MELP is clear from 
the reduced background signal outside the phantom. 
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Image with LEHR collimator 
HMR = 1.77 (below MELP normal range) 
Image with MELP collimator 
HMR = 2.79 (within normal range) 
Figure 15: Planar cardiac MIBG image from the MIDAS study with incorrect low energy collimator (left) and correct medium 
energy collimator (right).   
 
3.3.5 Quantitative SPECT reconstruction algorithms used in this thesis 
All SPECT reconstructions in this thesis are performed with HybridRecon software (Hermes Medical 
Solutions, Stockholm, Sweden).  The HybridRecon reconstruction algorithm uses the OSEM method 
discussed above, allowing image corrections to be applied during the iterative process.  This includes 
the implementation of attenuation correction and Monte Carlo scatter correction [122].  The Monte 
Carlo simulator tracks the path of simulated scattered photons to the detector as part of the forward 
projection step discussed above.  The algorithm supports either a uniform or CT attenuation map, used 
for both attenuation and scatter correction [123].   Depth-dependent resolution recovery is 
implemented in the algorithm, using the collimator geometry specified by the user to define the point 
spread functions.  This has been validated for myocardial perfusion imaging with 99mTc but not for 123I 
[123].  However, resolution recovery is recommended by Hermes for 123I-FP-CIT reconstruction, as well 
as uniform scatter and attenuation correction, and is used throughout this thesis. 
Septal penetration is not modelled in the standard algorithms used in this thesis – only the 159 keV 123I 
photopeak is taken into account.  However, a more advanced Monte Carlo algorithm incorporating 
septal penetration and subsequent scatter of high energy emissions for LEHR collimators has been 
developed [124, 125] and was accessed under a research agreement with Hermes.  This algorithm is 
called full collimator modelling and is applied to FP-CIT imaging in chapter 6.  Hermes have not 
implemented the full collimator model algorithm for 123I imaging with medium energy collimators, as 
septal penetration is already minimised, as shown in the energy spectra in Figure 13 above. 
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 Relative and absolute quantification 
Until relatively recently, SPECT was not thought to be a fully quantitative imaging modality, unlike PET 
[86].  Quantification of activity in organs of interest has traditionally been estimated by comparison 
with a reference region assumed to contain non-specific uptake.  Specific binding ratios in FP-CIT and 
heart to mediastinum ratios are both examples of this method, known as semi-quantification (see FP-
CIT and cardiac MIBG sections below), which continues to be used for most radionuclide imaging 
applications.  However, the reliance on a background region and the assumption that this represents 
non-specific uptake introduces uncertainty – the regions used are often noisy due to low count density 
and there may be issues with image registration and uniformity of signal.  These background regions 
may also be affected by disease, for example atrophy may cause reduced signal, or may vary between 
patients due to fluctuations in physiological uptake.  It may also be difficult to ensure there is no 
element of specific uptake contained within the background region. 
Absolute quantification of the activity concentration within a volume of interest (VOI) is therefore 
attractive because it removes the reliance on the background region.  A calibration factor is used to 
convert between reconstructed image counts and activity concentration in kBq/ml; this is obtained 
using a phantom containing measured activity concentration. Accurate quantification relies on a 
reconstruction method that is able to model the factors that cause image degradation and loss of signal 
– gamma ray attenuation, scatter, and the finite resolution of the system, which leads to substantial 
partial volume effects.  For 99mTc, absolute quantification has been shown to be accurate to within 10% 
in a multicentre phantom setting [126], but this has not been explored for 123I, which is more complex 
to quantify.  In the case of 123I, septal penetration of high energy emissions also affects quantification, 
for low energy collimators but is less important for medium energy [104].   The absolute activity 
concentration also depends on the tracer volume of distribution, which is related to patient size, so 
some form of normalisation is necessary.  The simplest way to normalise the images is to use patient 
weight, but this may be an oversimplification.  
Crucially, software must be available for performing the absolute uptake calculations.  Lack of suitable 
methods for attenuation and scatter correction has traditionally been a barrier to absolute 
quantification methods being developed for nuclear medicine, but in recent years several 
manufacturers have released software supporting SUV (standardised uptake value) calculations, 
including within HybridRecon (Hermes Medical Solutions), the image reconstruction software used in 
this thesis.  SUV is a dimensionless quantity defined as the observed activity concentration within a 
volume of interest, normalised to the administered activity and patient weight (as a surrogate for 
tracer volume of distribution).   
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𝑆𝑆𝑆𝑆𝑆𝑆 =  𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐 (𝑘𝑘𝐵𝐵𝑞𝑞 𝑚𝑚𝑙𝑙⁄ )
𝐴𝐴𝑑𝑑𝑚𝑚𝐴𝐴𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑑𝑑 𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (𝑀𝑀𝐵𝐵𝑞𝑞) 𝑃𝑃𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴 𝑤𝑤𝑐𝑐𝐴𝐴𝑤𝑤ℎ𝐴𝐴 (𝑘𝑘𝑤𝑤)⁄  
SUV values are calculated for each voxel, allowing images to be displayed using an absolute SUV scale 
rather than the standard relative scale.  SUV has been used in PET imaging for many years and been 
shown to be useful in a wide range of clinical settings, despite issues regarding the normalisation 
method [88, 127, 128].   
SUV information for a volume of interest can be reported in a number of ways.  The SUV of the 
maximum voxel within a volume of interest, SUVmax is the simplest technique and commonly used in 
PET imaging, but can be an unreliable marker due to statistical noise [129-131] and will not be used in 
this thesis.  SUVmean is the mean SUV within a volume of interest. SUVpeak is defined as the SUVmean of 
the most active 1cm3 cubic volume within a given volume of interest.    
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 123I-FP-CIT image analysis overview 
FP-CIT studies are often reported using visual analysis alone, although a 2015 Cochrane review 
concluded that semi-quantitative measures alone may be more accurate than both visual ratings and 
clinical diagnoses [132].  In DLB there is often a more uniform reduction in striatal uptake, rather than 
the predominantly putaminal loss seen in PD [133, 134]. This “balanced loss” is more difficult to 
recognise visually, because images are scaled to the maximum pixel, which may account for some of 
the scans reported as normal in DLB patients.    
FP-CIT semi-quantification usually involves calculating the specific binding ratio, SBR, from the mean 
counts per voxel (CPV) in striatal and background volumes of interest: 
𝑆𝑆𝐵𝐵𝑅𝑅 =  𝐶𝐶𝑃𝑃𝑆𝑆𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 − 𝐶𝐶𝑃𝑃𝑆𝑆𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑏𝑏𝑠𝑠𝑐𝑐𝑏𝑏𝑏𝑏𝑠𝑠𝑐𝑐𝑠𝑠𝑏𝑏𝑏𝑏
𝐶𝐶𝑃𝑃𝑆𝑆𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑏𝑏𝑠𝑠𝑐𝑐𝑏𝑏𝑏𝑏𝑠𝑠𝑐𝑐𝑠𝑠𝑏𝑏𝑏𝑏
 
Here the count density in the background volume is assumed to be representative of the non-specific 
binding in the striatal volume.  The SBR is often referred to as the striatal to background ratio but this 
is not strictly accurate as it is only the specific binding in the striatal region that is used in the 
calculation. 
As an adjunct to clinical reporting, semi-quantification with SBR has been shown to reduce equivocal 
reporting of 123I-FP-CIT studies in clinical practice [135] and increase repeatability [136] and reporter 
confidence [137] with a small increase in diagnostic accuracy reported for DLB patients [138].  
However, a recent large single centre study comparing visual interpretation with semi-quantification 
in 382 patients in a movement disorders setting concluded that visual read alone was at least as 
accurate as semi-quantification [139].    However, changes in PD may be more obvious visually than in 
DLB, and in early Lewy body disease changes could be more subtle and benefit from quantification.  
The introduction of sophisticated fully automated commercial 123I-FP-CIT software packages [111, 135, 
140-142], combined with greater awareness in the nuclear medicine community of “balanced loss” of 
dopaminergic function, particularly in DLB, has led to increased interest in quantification for FP-CIT 
imaging [137].  Balanced loss can be challenging for the non-expert to identify visually as images are 
scaled to maximum uptake rather than to a predefined absolute uptake level; low specific binding ratio 
(SBR) values for striata with otherwise normal appearance are therefore useful for identifying global 
loss of uptake.  Z scores, defined as the number of standard deviations the subject SBR is away from 
the mean SBR of a database of healthy control subjects, are often used to help show how normal or 
abnormal an SBR value is, with a Z score below -2 typically raising concern for an abnormal scan. 
There is a wide range of SBR calculation methods available for identifying reduced striatal uptake, 
ranging from automated 3D image registration methods to simple yet repeatable manual programs.  
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The Southampton method uses large volumes of interest encompassing counts from the entire striata 
to minimise partial volume effects [143, 144], whereas most other methods calculate count density in 
a volume of interest registered to the striata [144].  The accuracy of these two approaches are similar, 
although a study from Japan, where the Southampton method has been adopted for clinical use, 
suggested GE Healthcare’s automated method (DaTQUANT) was slightly more accurate [145].  A recent 
large multicentre comparison of standard SBR methods (striatal-sized VOIs) and the Southampton 
method concluded that the standard method is slightly more accurate for single centre use and the 
Southampton method for multicentre [146].  However, the SBR method used was an in-house method 
so it is not certain that these results would apply with commercially available software packages.    
Crespo et al. showed that correction for the partial volume effect using a freely available method, 
BasGan, improves quantification [147, 148].  However, there are no CE marked commercially available 
software packages with PVE correction implemented, so it is not available in clinical practice.  Recent 
interesting results from Japan suggest that SBR accuracy improves when corrections for low signal 
ventricle contribution are corrected for [149-151], however this is outside of the scope of this thesis. 
Regardless of the quantification method used to calculate the SBR, the results are subject to reported 
variation due to age and sex [152, 153] as well as technical factors [154-156] including variations in 
sensitivity and resolution between gamma camera models, SPECT reconstruction method, use of 
attenuation and scatter correction and the partial volume effect.  Substantial variation between 
centres was demonstrated by a recent multicentre phantom study [157].  This means a normal range 
for striatal uptake is only usually valid if acquired in the same centre as the scan being analysed.  It is 
challenging for an individual centre to acquire scans of sufficient normal subjects for confident 
application of semi-quantitative analysis, so visual reporting has remained common in clinical centres. 
The European ENC-DAT project has produced a multicentre normal database of control subjects by 
accounting for the differences between gamma cameras via phantom calibration data [158].  Hermes 
have used the data to provide normal ranges within their BRASS software [159, 160], which is assessed 
in Chapter 4.    We assess the benefits of a normal range developed with local controls in Chapter 4 
and 6. 
Lange et al. showed that both CT-based AC and uniform AC had minimal impact on the interpretation 
of FP-CIT scans, both on visual analysis, where no difference was seen and on quantification where 
diagnostic accuracy was not improved significantly [102]. A small retrospective study by Lapa et al. also 
showed no difference in diagnostic accuracy in thirty patients with suspected PD [161].  Warwick et al. 
showed SPECT-CT to be effective in a striatal phantom study but not in patients undergoing FP-CIT 
scanning [162].  However, some authors have found evidence of an improvement in relative 
quantification of FP-CIT scans when SPECT-CT is used for image registration, rather than attenuation 
correction. Maebatake et al. found that in phantom studies a volume of interest defined on registered 
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CT images [163]; however the study failed to investigate CT attenuation correction and instead used 
the uniform method.  Yokoyama found similar results for clinical studies reconstructed with uniform 
corrections and registered to a template using the CT data [164].  It is unclear why these publications 
did not consider CT attenuation correction.  The benefit of CT attenuation correction for MCI-LB 
diagnosis will be evaluated in Chapter 6. 
  
38 
 
 Cardiac 123I-MIBG image analysis overview 
Despite the technical advantages of medium energy collimators, low energy collimators continue to 
be used in publications and in clinical practice.  The European Association of Nuclear Medicine 
guidelines for standardisation of cardiac MIBG imaging state that the “extensive availability of low 
energy, high-resolution (LEHR) parallel-hole collimators determine their common use for 123I studies” 
but recommend that medium energy collimators be used for cardiac MIBG if practical [165].   Medium 
energy collimators have limited use for other studies as 99mTc radionuclides are imaged using low 
energy collimators; it may therefore be difficult for a small nuclear medicine department to justify the 
additional cost.    Collimator choice for cardiac MIBG imaging is considered further in Chapter 5, as part 
of a literature review of clinical protocols. 
Calibration of HMRs between gamma cameras to overcome collimator effects using a phantom has 
been shown to be feasible [166] and was implemented in a Japanese multicentre study [53].  More 
recently, a European calibration study was published that included results for the gamma cameras at 
the Newcastle Royal Victoria Infirmary used for the cardiac MIBG studies discussed in this thesis [167].  
This is discussed in more detail in Chapter 5.   
Several authors have commented on the need to standardise cardiac MIBG image acquisition and 
processing parameters in order for cardiac uptake thresholds to be applicable between centres, e.g. 
[167-172].  A method to correct for differences in image acquisition parameters between centres 
(predominantly caused by different gamma camera and collimator models) has been developed by 
Nakajima et al. [166] was used in the multicentre study mentioned above [53, 62].  However centres 
outside Japan still tend to publish results generated using local acquisition parameters and local normal 
uptake thresholds [67, 68], omitting information known to affect apparent cardiac uptake such as 
gamma camera model and collimator type, which limits the generalisability of the results.  In addition, 
there is currently no generally accepted method for processing and interpreting the images.  Okuda et 
al. have developed a semi-automated image analysis method [173], used in the multicentre study [53], 
but outside Japan there remains a variety of methods in use for interpreting planar cardiac MIBG 
images for Lewy body disease, including visual analysis and semi-quantification.  These issues are 
discussed in a review article by Chen et. al., where it is noted that further studies comparing the 
accuracy and repeatability of different analysis methods are required [120].  To our knowledge only 
two studies utilising visual assessment of cardiac MIBG images in Lewy body disease have been 
published [67, 174], neither directly comparing the accuracy of visual and semi-quantitative methods 
using statistical analysis, and thus there is a need for further work to clarify how the performance of 
visual rating compares with semi-quantitative analysis.    This will be covered in Chapter 7. 
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The phantom calibration procedure is useful in reducing camera-specific factors, but the HMR 
calculated from planar images is also affected by patient specific factors such as the amount of non-
cardiac uptake overlying the myocardium, scattered radiation from the liver and lungs and the degree 
of scatter and attenuation due to differences in body habitus [170].   This is discussed further in Chapter 
8.  The variation in HMR means planar analysis may not be a robust method for quantifying small 
reductions in innervation that may be seen in prodromal cases – the magnitude of the variation may 
mask any true difference between MCI-LB and other subjects.   
Although planar imaging is used as standard throughout the literature, use of SPECT has the potential 
to improve DLB diagnosis by increasing contrast between the heart and background.  SPECT-CT could 
lead to further improvements by reducing the effects of scatter and attenuation, potentially allowing 
more subtle reductions in uptake to be identified.  Tomographic imaging may allow identification of 
regional areas of low uptake due to heart disease which may improve specificity in a population with 
a high prevalence of coronary arterial disease.  The additional benefit of SPECT MIBG imaging over 
planar imaging for DLB has not been fully evaluated in the literature, but regional assessment of 
denervation is used routinely in heart failure imaging [175-177] and is beginning to be used for Lewy 
Body diseases [56].  Alvi et al. have shown that HMR results from a dedicated SPECT cardiac camera 
correlate with planar HMR [178].  SPECT has been shown to improve the sensitivity of PD diagnosis 
primarily by reducing the number of false negative scans caused by non-cardiac uptake in the heart 
region [179].  However, corrections for scatter and attenuation were not evaluated in this study and 
could bring further improvements.  The use of the mediastinum as a reference region has been 
questioned, with studies coming to different conclusions about its validity [169, 180-182].  This will be 
explored in Chapter 8 and 9.   
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Chapter 4: Development of imaging methods for 
research studies: FP-CIT 
The work presented in this chapter deals with establishing an optimised standard method to use in the 
SUPErB study for quantitative and visual analysis of FP-CIT scans.  123I-FP-CIT scans of normal clinical 
patients, control subjects, MCI and dementia subjects recruited and scanned locally are used to explore 
a range of technical aspects related to DaTQUANT and BRASS and to determine which is the most 
appropriate to use for research studies using FP-CIT, in particular the SUPErB study. 
We show that BRASS and DaTQUANT give similar results and outline our reasons for selecting BRASS 
for the SUPErB study.  Concerns over age-correction are uncovered, to be investigated further later in 
the thesis.   MCI subject scans and phantom studies are used to show that the effects of acquiring 
images with a smaller pixel size and applying zoom and reorientation during image reconstruction have 
little impact on BRASS quantification results but may affect DaTQUANT results. 
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 Comparison and validation of two commercial 123I-FP-CIT software packages  
4.1.1 Introduction 
The 123I-FP-CIT radiopharmaceutical is patented by GE Healthcare (Chalfont, UK) and sold under the 
brand name DaTSCAN.  GE Healthcare have released a software package for semi-quantification, 
DaTQUANT, which calculates SBRs and compares the results to a normal database.  Similar 
functionality is available in the FP-CIT module within the BRASS brain analysis software produced by 
Hermes Medical Solutions (Stockholm, Sweden).  Both programs perform an image registration 
between the subject FP-CIT image and a normal template generated from over 100 control scans.  They 
then apply fixed volumes of interest to the striata and the occipital background region in order to 
calculate SBRs.  These values are expressed relative to the control database via Z scores, which indicate 
how the subject result compares to age-matched controls in terms of number of standard deviations 
from the control mean.  Example output from DaTQUANT (v1.01) and BRASS (v2.5) for the same normal 
scan is given in Figure 16. 
Despite the apparent similarity between DaTQUANT and BRASS there are several technical and 
practical differences between them, which are listed in Appendix A.   These include different 
approaches to image registration, the use of different normal databases, whether corrections for the 
camera used are applied and whether the images are reconstructed within the program or externally.  
BRASS has several technical advantages over DaTQUANT but DaTQUANT is quicker and easier to use, 
and produces results in a useful graphical form.  Both apply age correction factors to the Z score output, 
although this can be removed or modified in BRASS, boosting the results in old age to compensate for 
a reduction in normal SBR values with age.  In this thesis the default age corrected results are used, 
unless otherwise specified. 
Objectives 
• To acquire striatal phantom scan data for known striatal and background activity 
concentrations and produce a camera correction factor for BRASS.   
• To validate the two software packages using FP-CIT scans from clinical patients unlikely to have 
Lewy body disease – average age corrected Z scores should be close to zero 
• To compare SBR and age corrected Z score results given by each package 
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Figure 16: Results screens for DaTQUANT (top) and BRASS (bottom) for the same subject with normal uptake. 
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4.1.2 Methods 
The software packages are compared here using data from clinical studies rather than true healthy 
control subjects because such control data was not yet available at the time the initial comparison was 
made (autumn 2016).  Fifteen anonymised patients with normal scans were selected from an RVI 
clinical audit of FP-CIT scans.  These patients had been referred for suspected PD or DLB but had had 
a normal FP-CIT scan report and at least three years follow up post-scan, confirming that there was no 
indication that any of them had Lewy body disease.  Patient records were accessed by NHS staff 
forming part of the clinical care team, and not by the author, to conform to clinical governance 
guidelines and protect patient confidentiality.  Whole striatum, caudate and putamen SBRs and Z 
scores were calculated with BRASS (after camera calibration – see below) and with DaTQUANT.   
Acquisition parameters 
All individuals included in this thesis were scanned three to six hours following a bolus intravenous 
injection of 185 MBq of 123I-FP-CIT (DaTSCAN, GE Healthcare, UK) using a dual headed gamma camera  
fitted with low energy high resolution (LEHR) parallel hole collimators. 120 x 25 second views over a 
360° orbit were acquired on a 128×128 matrix with a zoom of 1.23x giving a pixel size 3.9mm × 3.9mm.  
BRASS: camera calibration 
BRASS applies a camera correction factor to the SBR results, which is calculated by Hermes using scans 
of a striatal phantom of six different known SBRs.  The known ratios are compared to the uncorrected 
SBRs given by BRASS for these scans3.  We obtained the required image data using an anthropomorphic 
striatal phantom (RSD Radiology Support Devices, Long Beach, CA, USA), which consists of a perspex 
brain shell with fillable caudate, putamen and background compartments inserted into a skull model 
for scanning (Figure 17).  
The phantom was filled with 123I activity in the striatal and background sections – with the right 
striatum more concentrated than left, giving activity ratios of approximately 7:1 and 5:1.  The exact 
ratios were verified later using striatal and background samples measured in a gamma counter. The 
phantom was imaged three times with increased background activity concentration each time to 
obtain scans with six different known striatal to background activity ratios (approx. 7:1, 5:1, 3.5:1 and 
2.5:1, 1.7:1 and 1.2:1).    
  
                                                          
3 The calibration factor is intended to correct for differences between camera models that can introduce small 
systematic differences in SBR.  The ENC-DAT normal database scans come from a range of different camera 
models with all results corrected using this phantom technique.  A similar calibration must therefore be applied 
to our image data to be consistent with the normal database.   
44 
 
     
 
 
Figure 17: Striatal phantom used for FP-CIT quantification work.  The images show the brain shell and assembled phantom 
being scanned and an example transaxial phantom image analysed in BRASS  
 
The uncorrected SBRs given by BRASS were recorded for each of these known ratios by running the 
software on the reconstructed phantom images.   The performance of the system can be evaluated by 
calculating the gradient of a linear fit of the BRASS SBRs against the known activity ratios.  This gradient 
is always less than 1 due to count losses from partial volume effect and any residual losses due to 
attenuation and scatter.   For our camera the gradient was 0.46 (see Figure 18).  The gradient for the 
reference camera model used in the normal database is 0.42. These results were used by Hermes to 
produce a camera specific calibration factor applied to adjust the SBR values within the BRASS software 
so that they would be the same as those given by the reference gamma camera.  The factor obtained 
was 0.9265 and was supplied via an updated system file that BRASS refers to when displaying SBRs.  
Both the uncorrected and corrected SBRs can be viewed in the software.  The factor is multiplicative 
so a correction factor of less than one corrects for SBRs given by our camera model (Siemens Intevo) 
being higher than the reference camera. 
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Figure 18: BRASS specific ratios (SBR -1) against activity ratios measured with a gamma counter, showing a linear fit with 
gradient 0.46. 
BRASS: normal patient processing 
The raw patient data was reconstructed within Hermes HybridRecon Neurology, using iterative 
reconstruction with resolution recovery, uniform attenuation correction and Monte Carlo scatter 
correction (OSEM_RRACSC).  Reconstruction parameters specified by Hermes (Figure 19) were used so 
that the BRASS normal database results, derived from images reconstructed with the same 
parameters, would be valid. These parameters were also used for the phantom acquisitions discussed 
above.  The resultant images were processed with BRASS and the SBR results and age corrected Z 
scores for the left and right whole striatum, caudate and putamen were recorded.  The mean SBR and 
mean Z score for each region was calculated.   This work led to the detection of a software error, 
affecting multiple centres and causing BRASS Z scores to be underestimated by around 1 standard 
deviation, which was subsequently rectified by the manufacturer. 
DaTQUANT: camera calibration 
DaTQUANT does not have a camera correction feature as the study that the normal database scans 
were taken (PPMI – Parkinson’s Progression Markers Initiative) used multiple cameras but did not take 
differences between them into account.   
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Figure 19: BRASS reconstruction parameters for FP-CIT scans 
DaTQUANT: normal patient processing 
The raw FP-CIT data was imported into DaTQUANT and reconstructed using iterative reconstruction 
(OSEM) with no attenuation correction4 with the parameters shown in Figure 20.  This is one of the 
four reconstruction options recommended by GE (OSEM with and without AC and FBP with and 
without AC).  The PPMI healthy control database has been reconstructed with each of these sets of 
parameters and the database matching the reconstruction settings chosen for the input image is 
automatically selected.   SBR results and age corrected Z scores for the left and right whole striatum, 
caudate and putamen were recorded for each patient.  The mean SBR and mean Z score for each region 
was calculated.   
                                                          
4 Uniform (Chang) attenuation was found to be unreliable in DaTQUANT with the default threshold applied, 
leading to discontinuities between transverse slices.  AC was therefore not used with DaTQUANT. 
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Figure 20: DaTQUANT reconstruction parameters 
 
Direct comparison between DaTQUANT and BRASS SBRs 
Because of the different standard reconstruction parameters used by DaTQUANT and BRASS it is not 
possible to use the above data to determine whether there are any technical differences between the 
SBR calculation methods of the two software packages.  To compare BRASS and DaTQUANT SBRs 
directly, the OSEM_RRACSC reconstructed images used for BRASS were exported from the Hermes 
system and imported into DaTQUANT.  DaTQUANT accepts externally reconstructed images for SBR 
calculation but cannot give a Z score as the reconstruction parameters are different from the 
DaTQUANT normal database.   If the two programmes are comparable there should be no significant 
difference between the BRASS SBR results without camera correction applied and the DaTQUANT SBR 
results for the same input images.   
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4.1.3 Results and discussion 
One patient was excluded from analysis because there was significant atrophy in the background 
region, giving a much higher SBR than the other normal subjects on DaTQUANT, with Z score showing 
this was more than 4 standard deviations above the database mean (Figure 21).  The SBR was not high 
for BRASS, even though the region placement was similar.  The discrepancy was investigated and 
followed up with Hermes, who confirmed that BRASS compensates for lower than average voxel values 
in the background VOI, to avoid this artificial increase in SBR.  This seems sensible, but as it is not 
mentioned in the extensive manual it is somewhat misleading.  Expert users will recognise that 
atrophic background regions could lead to overestimated uptake, and if they are unaware of this 
compensation they may discard results that are fine or mentally adjust them without needing to.  We 
found it is possible to indirectly tell when this compensation has occurred as the results can be 
presented with the number of voxels in the VOI alongside the SBR result.  A typical value for the 
background is 8000 voxels and in this case less than 7000 were included. 
 
Figure 21: DaTQUANT output for the excluded normal patient with low signal in the occipital background region. 
 
The average SBRs and Z scores for the right and left whole striatum, caudate and putamen regions for 
the remaining 14 patients are given in Table 4 for BRASS and DaTQUANT.  The SBR results are much 
higher for BRASS than DaTQUANT, due to the different image reconstruction methods used for each 
software package.  Attenuation and scatter corrections are applied to the BRASS input images but not 
for the images reconstructed within DaTQUANT, which is a likely reason for the SBRs to be higher with 
BRASS.  However, the Z scores are also quite different and this cannot explained by differences in 
reconstruction parameters as Z scores are based on comparing the images with a normal database 
reconstructed with the exact same parameters.  The average Z scores for the normal subjects analysed 
with BRASS are close to zero (0.08), as expected. The Z scores for DaTQUANT were higher than 
expected, 0.65 standard deviations higher than the mean of the normal database.   
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The Z scores for DaTQUANT and BRASS are shown against patient age in Figure 22. GE Healthcare was 
contacted to discuss the higher than average Z score with DaTQUANT but no clear reason was 
identified.  The technical specialist commented that it is possible to see very high SBRs in normal 
subjects and that this can skew Z score results since a normal distribution is assumed. 
 
Table 4: Mean normal patient SBR and Z score results for BRASS and DaTQUANT 
  BRASS DaTQUANT 
 Mean SBR Mean Z score Mean SBR Mean Z score 
Right striatum 3.2 0.1 2.2 0.72 
Left striatum 3.19 0.07 2.21 0.57 
Average striatum 3.2 0.08 2.2 0.65 
Right caudate 3.33 0.14 2.51 0.79 
Left caudate  3.4 0.16 2.49 0.62 
Right putamen 3.06 0.05 2.09 0.66 
Left putamen 2.97 -0.04 2.04 0.51 
 
 
 
Figure 22: Z scores for the 15 patients for BRASS and DaTQUANT.  The patient with the very high result with DaTQUANT result 
(Z score > 4 SD, shown in blue) was excluded from analysis.  The results for BRASS are equally distributed around zero (with 
the correct calibration applied).  Most of the DaTQUANT results are above zero. 
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Direct comparison between DaTQUANT and BRASS SBRs 
The average SBR results for the 14 patients reconstructed with Hermes OSEM_RRACSC and processed 
on both BRASS and DaTQUANT are given in Table 5.  The difference between the mean SBR and the p-
value for a paired t-test between the results are also given.  The plot in Figure 23 shows that DaTQUANT 
SBRs are higher than BRASS for all 14 patients. Ideally a comparison in a larger dataset containing 
normal and abnormal studies would be done.  This is covered later in section 6.2. 
 
Table 5: Difference in SBR results between BRASS and DaTQUANT 
Mean DaTQUANT 
SBR 
Mean BRASS SBR (no 
camera correction) 
Mean diff BRASS - 
DaTQUANT 
p-value (paired t-test 
for difference) 
3.29 2.84 -0.49 (15%) <0.001 
 
 
 
Figure 23: Direct comparison between DaTQUANT and BRASS SBR values for the same input images, indicating a systematic 
difference between the packages in the way SBR values are calculated. 
 
DaTQUANT gives significantly higher SBR values than BRASS for the exact same input images.  The 
mean difference is 0.52 (15% higher with DaTQUANT).  This shows that there is a difference in the 
method the two packages use to produce SBR results, which is likely due to differences in image 
registration, differences in the volume of interest template applied to the scans or a combination of 
factors.  However, this difference in SBR does not explain the difference in Z scores seen above because 
each normal database has been reconstructed and processed in the same way as the input images.  
The difference in Z score is more likely linked to differences in the normal databases, which could be 
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caused by population differences, camera differences, lack of camera correction, or differences in age 
correction.  These potential factors are discussed in Appendix B. 
4.1.4 Conclusions 
In this section two commercial software packages were explored using phantom and normal patient 
data. Initial work discovered an error in camera correction for BRASS which was corrected for all 
subsequent analysis. We found a difference in Z scores between the two packages – the impact of this 
difference will be considered in the next sections on research subjects with well-characterised MCI and 
dementia diagnoses. 
Based on this initial validation and comparison, BRASS is the package of choice.  BRASS gives Z scores 
close to zero for normal patients as expected and has several technical advantages over DaTQUANT.  
The practical effect of the differences will be explored further in the following sections.   
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 Comparison between BRASS and DaTQUANT in a large MCI research cohort 
4.2.1 Introduction 
The previous section showed some theoretical and practical differences between BRASS and 
DaTQUANT for FP-CIT quantification.  In this section we aim to compare DaTQUANT and BRASS age 
corrected Z scores in a large MCI dataset from the LewyPro study consisting of approximately 50% 
normal and 50% abnormal scans.  We will compare the sensitivity and specificity of each quantification 
method with consensus binary visual assessment (normal/abnormal), using follow up consensus 
clinical diagnoses as the gold standard. 
4.2.2 Methods 
Seventy-seven FP-CIT scans of subjects with mild cognitive impairment were taken from the Newcastle 
LewyPro study (see Chapter 2 for LewyPro study details).  The raw scan data was processed and 
analysed with DaTQUANT and BRASS using the methods introduced in the previous section.  The 
average Z score results were calculated for the whole striatum and compared between DaTQUANT and 
BRASS.  The caudate and putamen results were not compared as the boundary between these 
structures is rather arbitrary on FP-CIT images and there are likely to be differences between the two 
VOI templates.  The overall SBR was thought to be more meaningful, particularly as it is known that in 
DLB loss of signal is more uniform than in PD. 
Clear abnormal or normal cases could have quite different Z scores but still be interpreted in the same 
way, but borderline cases with similar absolute numerical differences could be reported differently.  
For example, if DaTQUANT gave a Z score of +2 and BRASS +1, both would be reported as normal 
despite the large difference, but if the scores were -1 and -2 respectively this would make a difference.  
The Z scores were therefore compared for individual patients to assess the clinical impact of any 
difference between DaTQUANT and BRASS Z scores. Scans with both whole striatum Z scores above -
0.5 on both programs are regarded as clearly normal, at least one striatum below -2 on both programs 
as clearly abnormal and all scans in between as low normal/borderline. 
Consensus binary visual assessment had been carried out for the LewyPro study in 2014 by a panel of 
five raters, using images reconstructed with filtered back projection without attenuation or scatter 
correction.  The consensus visual results were compared to BRASS and DaTQUANT results based on 
whole striatum Z scores.  For each method the sensitivity (percentage of LB cases with abnormal scans), 
specificity (percentage of non-LB cases with normal scans) and accuracy (percentage of results in 
keeping with clinical diagnosis) were calculated.  This was done with the three year follow-up diagnoses 
of the subjects taken as the gold standard.  Note that at the time this analysis was done (2017) most 
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subjects still had an MCI rather than dementia diagnosis, with eighteen having gone on to develop 
dementia. 
4.2.3 Results and discussion 
One subject with very low uptake was excluded because the study did not spatially register to the 
template correctly on DaTQUANT.   Two subjects were later excluded from the study as they did not 
fulfil the requirement for MCI. The Z scores for the remaining 74 scans are on average higher for 
DaTQUANT than BRASS, by 0.43 SD (paired t-test p <0.001).  However, the results are very variable, 
with the DaTQUANT result ranging from 0.77 SD lower to 1.93 SD higher than BRASS (Figure 24).  
Although slightly smaller, the difference between BRASS and DaTQUANT is probably in keeping with 
the results seen for the normal patient scans above, given that lower Z scores are likely to show a 
smaller absolute difference and the fact that LewyPro subjects are older on average than the RVI 
normal patients so may have lower SBRs even if normal.  
 
 
Figure 24: Bland-Altman plot of differences in Z score between BRASS and DaTQUANT for subjects with mild cognitive 
impairment from the LewyPro study. Right striatum shown in blue; left striatum red. 
 
Around half of the subject scans (54%) were clear cut normal or abnormal (26/74 clear normal with Z 
scores over -0.5 and 14/74 clear abnormal with one or both Z scores lower than -2 on both BRASS and 
DaTQUANT).   The other 34 subjects had low end of normal to possibly abnormal Z scores between -2 
and -0.5.  Of these “borderline” cases, 13 have similar scores on both BRASS and DaTQUANT (both 
striata within 0.5 SD), 21 are lower with BRASS by at least 0.5 SD on at least one striatum. None are 
more than 0.5 SD lower with DaTQUANT.   However, there were only four cases where the Z scores 
were greater than -2 for both striata with one package and less than -2 for at least one striatum with 
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the other package –i.e. different clinical interpretation with a -2SD cut-off. In one of these four cases 
the quantification results were very similar but the DaTQUANT result was just below -2 and BRASS just 
above (-2.18 vs -1.97).  In the other three cases the BRASS results were significantly lower than 
DaTQUANT.   If a Z score of -2 was being used as the cut-off, as is often the case, the outcome would 
have been the same for the majority (95%) of the scans. 
The sensitivity of both BRASS and DaTQUANT is lower than for consensus visual reporting, but 
specificity is higher (Table 6).  Overall accuracy is lower, but it is important to note that quantification 
is used as an aid to visual reporting rather than as a stand-alone diagnostic tool.   
 
Table 6: Sensitivity and specificity for visual, DaTQUANT and BRASS analysis for subjects with mild cognitive impairment. 
 
Visual 
reporting 
DaTQUANT BRASS 
Sensitivity 52% 31% 31% 
Specificity 88% 100% 92% 
Accuracy 64% 55% 52% 
 
 
4.2.4 Conclusion 
In this dataset of 74 scans in MCI subjects the average Z score was 0.43 SD higher with DaTQUANT than 
BRASS.  However, DaTQUANT and BRASS have similar low sensitivities and high specificities for 
diagnosis of early LB disease, with respect to the consensus clinical MCI diagnosis.  Visual reporting 
with filtered back projection was more sensitive but less specific.  However, it should be noted that 
most of the LewyPro subjects do not yet have validated dementia diagnoses, so it is not possible to 
use these results to compare the diagnostic performance of BRASS and DaTQUANT in early disease, 
only to provide further evidence of a difference between the packages.  A comparison using subjects 
with known dementia diagnosis is required for this and this will be carried out in the next section. 
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 Comparison between DaTQUANT and BRASS in healthy ageing and dementia 
4.3.1 Introduction 
In the previous section we confirmed that DaTQUANT gave higher Z scores than BRASS in a large cohort 
of MCI subjects.  In this section we compare the performance of the two packages in dementia using 
research subjects with firm consensus dementia diagnoses and introduce controls with normal 
cognition from the SUPErB study to compare with the patient data analysed in section 4.1. 
Objectives 
• To compare DaTQUANT and BRASS age corrected Z scores in subjects from the MIDAS study 
with firm consensus dementia diagnoses 
• To compare quantification with consensus binary visual assessment (normal/abnormal) via the 
sensitivity and specificity with respect to clinical diagnosis 
• To explore whether a fixed SBR threshold could be more accurate than age-corrected Z score 
for DLB diagnosis  
• To process a subset of healthy control subjects from the SUPErB study and compare with the 
normal RVI patient results in section 4.1 
 
4.3.2 Methods 
Patient selection 
Patients with confirmed dementia diagnoses of probable DLB or probable AD were taken from the 
MIDAS and LewyPro studies.  Although LewyPro is an MCI study, patients who had converted to 
dementia (based on August 2017 records) were included if they did not continue into the SUPErB study.  
This is to avoid overlap with future analysis of SUPErB subjects.  The six MIDAS DLB cases recruited 
specifically because they had normal FP-CIT scans were of course excluded and a further three MIDAS 
patients were excluded – one because of uncertain diagnosis (possible DLB), one because of lack of 
raw image data due to being scanned in another hospital and one because a non-Siemens camera was 
used.  One LewyPro subject was excluded because of image registration problems due to low uptake 
and two because of possible rather than probable DLB diagnosis.  The first sixteen controls recruited 
to the SUPErB study were analysed.  These older adults with normal cognition had undergone the same 
rigorous clinical and psychiatric tests as the SUPErB MCI subjects, with normal results – see section 
2.3.3 for further details.  Of these 16 controls one could not be used because of low signal in the brain 
background region in the occipital lobe, possibly due to atrophy.    The final dataset of DLB, AD and 
controls is summarised in Table 7. 
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Table 7: MIDAS, LewyPro (subset converted to dementia) and SUPErB subjects included in comparison 
 DLB AD Controls 
MIDAS 16 17 0 
LewyPro 13 5 0 
SUPErB 0 0 15 
Totals 29 22 15 
 
The SBRs and Z scores were calculated for each dementia subject with DaTQUANT and BRASS, using 
the methods detailed above.  Assigning a Z score of -2 or below as abnormal, the sensitivity, specificity 
and accuracy of BRASS and DaTQUANT for diagnosing DLB in patients with dementia was calculated, 
using the consensus dementia diagnosis as the gold standard.  The control data was also analysed with 
DaTQUANT and BRASS and used to set local normal SBR cut-offs of 2 standard deviations below the 
control mean. ROC analysis was carried out using SPSS to give the areas under the curve for BRASS and 
DaTQUANT and the sensitivity and specificity for DLB diagnosis for the optimal SBR cut-offs.  Controls 
were not included in the ROC analysis. 
Comparison of local normal patients, SUPErB study controls and PPMI database controls 
The 15 SUPErB control subject SBR results were compared to the local normal patients and to the PPMI 
healthy control database (subjects over 60 only).  Unpaired t-tests were used to test for difference.  
Results were also compared with the BRASS normal database indirectly via Z scores as the BRASS 
normal database SBRs are not provided to the user.  The SBRs were not age corrected so a comparison 
between the ages of the different control groups was made. 
4.3.3 Results 
The sensitivity and specificity for DLB diagnosis based on Z scores (designating scores less than -2 as 
abnormal) for BRASS and DaTQUANT is given in Table 8.  The sensitivity and specificity based on control 
SBR cut-offs of two standard deviations below the mean of the SUPErB controls is given in Table 9.  The 
results show similar low sensitivity and high specificity for BRASS and DaTQUANT for both the Z score 
(normal database) and local SUPErB control cut-offs.   
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Table 8: FP-CIT sensitivity and specificity for DLB diagnosis in dementia with BRASS and DaTQUANT based on Z score results 
 BRASS  DaTQUANT  
 Right Left Right Left 
Cut-off (Z score) -2 -2 -2 -2 
True positives 17 17 16 16 
False positives 12 12 13 13 
True negatives 22 21 22 22 
False negatives 0 1 0 0 
Sensitivity 59% 59% 55% 55% 
Specificity 100% 95% 100% 100% 
Accuracy 76% 75% 75% 75% 
 
Table 9: FP-CIT sensitivity and specificity for DLB diagnosis with BRASS and DaTQUANT based on SUPErB control data 
 BRASS  DaTQUANT  
 Right Left Right Left 
Cut-off (mean-2SD) 2.2 2.1 1.4 1.3 
True positives 18 17 18 16 
False positives 11 12 11 13 
True negatives 21 21 21 20 
False negatives 1 1 1 2 
Sensitivity 62% 59% 62% 55% 
Specificity 95% 95% 95% 91% 
Accuracy 76% 75% 76% 71% 
 
ROC analysis of the dementia cases (Figure 25; Table 10) shows the highest area under the curve is 
given for the right striatum analysed with DaTQUANT – although the confidence intervals are very wide 
so this is not statistically significant.  The optimal SBR cut-off for the right striatum analysed with 
DaTQUANT is 1.46 giving a sensitivity of 73% and specificity of 91%.  This is an improvement compared 
to both the Z score results and the results using a cut-off based on the control data.  The right striatum 
results are more accurate than the left striatum with both programs, which is probably a chance result 
for this dataset rather than because of a systematic error in the way the programs calculate SBR. 
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Figure 25: ROC curves for BRASS and DaTQUANT showing higher area under the curve for the right striatum 
 
Table 10: Area under the ROC curves - accuracy comparison 
Test Result Variable(s) Area Std. 
Errora 
Asymptotic 95% 
Confidence Interval 
Cut-
off 
Sens. Spec. 
Lower 
Bound 
Upper Bound    
BRASS_RtStriatum_SBR 0.868 0.050 0.769 0.966 2.51 83% 82% 
BRASS_LtStriatum_SBR 0.793 0.063 0.670 0.916 2.70 83% 64% 
DaTQUANT_RtStriatum_SBR 0.872 0.050 0.774 0.971 1.46 73% 91% 
DaTQUANT_LtStriatum_SBR 0.777 0.066 0.648 0.907 1.15 55% 100% 
 
For this dataset, slightly higher accuracy (although not statistically significant) was seen using a fixed 
SBR cut-off derived from ROC analysis, which was lower than the cut-off found from the control data 
(mean-2SD).  However, that cut-off would need to be applied and tested in an independent cohort of 
dementia subjects before we could conclude that a cut-off based on ROC analysis of dementia subjects 
has higher diagnostic accuracy than a cut-off based on control data.  Furthermore, the results based 
on control data (either local or database) all have very high specificity, higher than that with the ROC 
cut-off.  This is more important than high sensitivity particularly given that it is known that DLB patients 
can have normal looking FP-CIT scans [48]. 
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Comparison of local normal patients and SUPErB controls 
There was a large difference in the mean age of the local normal patients (65 years) and the SUPErB 
controls (73 years, Table 11) with the latter being 8 years older on average (p < 0.001).  This is because 
around half the local normal patients are between 55 and 60 whereas the SUPErB controls are all over 
60.  In hindsight, it could be argued that patients under 60 should not have been included in this 
comparison, but this would have reduced local normal patient numbers significantly.  SBRs for the 
SUPErB controls are lower than for the local normal patients with DaTQUANT (p <0.001, Table 11).  Z 
scores are also significantly lower for the SUPErB controls (p <0.001).   
 
Table 11: Mean whole striatum SBRs with DaTQUANT, Z score with respect to PPMI database (if applicable) and mean age for 
the PPMI controls, SUPErB controls and local normal patients. 
 
PPMI controls over 60  SUPErB controls Local normal patients 
n 40 15 14 
Mean SBR 1.8 1.7 2.1 
z score n/a -0.3 0.6 
Mean age 67.4 72.7 64.8 
 
With BRASS, SBRs and age corrected Z scores are again significantly lower for the SUPErB controls than 
the local normal patients (Table 12).  Given that there is no downward trend in SBR with age in either 
group it is likely that age correction is not necessary in older adults and is actually having a negative 
effect on the results.  However, it would not make sense to use either the BRASS or the DaTQUANT 
normal database without age correction as it covers such a wide age range, and indeed this is not even 
an option with DaTQUANT.  Age correction is discussed in more detail in section 9.1.   
 
Table 12: Mean whole striatum SBRs with BRASS, Z score with respect to ENC-DAT database and mean age for SUPErB controls 
and local normal patients.  Note that ENC-DAT database data is not available. 
 
SUPErB controls Local normal patients p-value (t-test) 
n 15 14 n/a 
Mean SBR 2.67 3.15 <0.001 
z score -0.77 -0.01 <0.001 
Mean age 72.7 64.8 <0.001 
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Figure 26: PPMI controls, SUPErB controls and local normal patient SBRs (left) and Z scores for SUPErB and local normal (right) 
calculated with DaTQUANT and plotted against age. 
 
Figure 27: SUPErB and local normal patient SBRs with camera correction (left) and age corrected Z scores (right) calculated 
with BRASS and plotted against age. 
 
The SBRs of local normal patients and SUPErB controls differed even though both groups were scanned 
in the same department.  The results are higher (i.e. “more normal”) for the patients than the SUPErB 
controls, so inclusion of patients with Lewy body disease is unlikely to be the cause.  It is likely that a 
bias was introduced in the local normal group during the audit by selecting patients based on normal 
scan report rather than clinical diagnosis, potentially excluding subtle changes that are within normal 
limits.   
 
1
1.2
1.4
1.6
1.8
2
2.2
2.4
2.6
2.8
50 60 70 80 90
SB
R 
(D
aT
Q
UA
NT
, w
ho
le
 st
ria
tu
m
)
Age (years)
PPMI (DaTQUANT) SUPERB controls
RVI normals
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
2.5
50 60 70 80 90
Z 
sc
or
e 
(D
aT
Q
UA
NT
, w
ho
le
 st
ria
tu
m
)
Age (years)
SUPERB controls Local normals
1
1.5
2
2.5
3
3.5
4
4.5
50 60 70 80 90
SB
R 
(B
RA
SS
, w
ho
le
 st
ria
tu
m
)
Age (years)
SUPERB controls RVI normals
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
2.5
50 60 70 80 90
Z 
sc
or
e 
(B
RA
SS
, w
ho
le
 st
ria
tu
m
)
Age (years)
61 
 
4.3.4 Conclusion 
The accuracy of BRASS and DaTQUANT is very similar.  In this dataset it did not make a significant 
difference whether interpretation of the results is based on Z scores relative to large multicentre 
healthy control databases (age-corrected) or relative to local SUPErB control data (without age 
correction).   There is no downward trend in SBR with age in either the normal patient dataset (aged 
over 55 years) or the SUPErB control dataset (over 60 years).  In this dataset a lower cut-off based on 
ROC analysis gave higher overall accuracy results, but lower specificity. 
The local normal patients have higher SBRs and age-corrected Z scores than the SUPErB controls with 
both BRASS and DaTQUANT.  A good option for future studies, based on this evidence, would be to use 
BRASS SBRs with a local cut-off based on age-matched controls.  The full set of SUPErB control scans 
could be used to set this cut-off (not all had been recruited at the time of writing so this was not a 
practical option for the study itself). 
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 Effects of reorientation and pixel size on quantification with BRASS 
The purpose of this piece of work was to assess whether reorientation, image cropping, zoom and pixel 
size have a significant effect on BRASS quantification results.  These factors were investigated because 
the use of these parameters at NuTH differs from the recommendations for use with BRASS.  
FP-CIT scans from LewyPro subjects were used to show that reorientation and post-processing zoom 
applied during reconstruction both have a small statistically significant effect on BRASS quantification 
results, but that these are both clinically insignificant and furthermore act in opposite directions.  This 
work is detailed in Appendix C. 
We used a striatal phantom to investigate the effect of changing pixel size, via the application of 
hardware zoom.  We also acquired a series of repeat scans with no changes in zoom to assess random 
variation.  Full details are given in Appendix D. The data showed that changing the zoom has no more 
effect on BRASS quantification results than simply repeating the scan with the phantom repositioned, 
which suggests that the variation is random and could be due to slight changes in the input image.  This 
work showed that we could continue to use the same pixel sizes for clinical scans and for research 
scans to be processed with BRASS. 
  
63 
 
 
Chapter 5: Development of imaging methods for 
research studies: cardiac MIBG  
This chapter deals with establishing methods for planar cardiac 123I-MIBG imaging to use in the MIDAS 
and SUPErB research studies.   
In section 5.1 a systematic review of imaging protocols used in studies applying cardiac MIBG imaging 
to dementia diagnosis is presented, including the administered activities, collimator and imaging time 
point.  A cardiac MIBG imaging protocol was set up for research studies at Newcastle, based on 
guidelines and evidence from this literature review.   
In section 5.2 a method for calibrating cardiac uptake results with a phantom to correct for imaging 
hardware factors is presented.  This method was applied to the scanners to be used in our research 
studies so that normal threshold heart to mediastinum ratio cut-off values from Japan could be applied 
to our data. 
In section 5.3 the administered activity used in our research studies is explored in more detail.  
Phantom studies with different imaging times and retrospective evaluation of counting statistics from 
research studies are used to show that the combination of 111 MBq activity and 10 minutes imaging 
time used in our research protocol gives adequate image quality.  
64 
 
 Cardiac 123I-MIBG planar imaging protocol review  
5.1.1 Introduction 
Very few cardiac MIBG scans were carried out at NuTH for the diagnosis of DLB prior to the start of our 
research studies since the FP-CIT scan, recommended in NICE dementia guidelines, was usually 
requested.  We were aware that the majority of clinical and research use of cardiac MIBG for this 
purpose was in Japan, with some research studies from Europe published, and that the activities 
administered, collimators and time points for imaging varied.  We were not aware of any centres in 
the UK carrying out cardiac MIBG to distinguish between AD and DLB.  We therefore reviewed the 
imaging protocols used in the literature in order to implement an evidence-based protocol for research 
studies.  As well as determining the best way to acquire the images, an additional aim of the review 
was to determine an HMR cut-off value to use for interpreting results. 
5.1.2 Methods 
A PubMed search was carried out applying the same search terms used by Treglia et al. in their 2012 
review, which covered articles published before May 2010. (Search ("mibg" OR 
"metaiodobenzylguanidine")) AND ("lewy" OR "dementia")).  This brought up 132 results on PubMed 
on 20/4/15.  The abstracts of each article were reviewed and the 16 original articles evaluating the use 
of cardiac MIBG for differentiating between DLB and AD or other dementia were selected and 
retrieved.   These are listed in Appendix E.  Each study is listed alongside the country or origin, the 
number of patients included, the activity administered and acquisition duration of the planar image, 
the delay between injection and imaging, the collimators used (MEGP – medium energy general 
purpose; LEHR - low energy high resolution; LEGP - low energy general purpose) and the heart to 
mediastinum ratio (HMR) applied as a cut off value for distinguishing between DLB and AD.  The cut-
off values were determined by ROC analysis in most cases.  The sensitivity and specificity were 
recorded if part of the study design.
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5.1.3 Results and discussion 
Although most studies published on the use of cardiac MIBG in dementia diagnosis were carried out in 
Japan (10/16), there have been some recent studies in Europe, including a moderate sized 
retrospective patient study conducted in France in 2015 with 45 patients with Lewy body disease and 
19 without that reported a sensitivity of 82% and specificity of 89% [56].  Most studies are small in 
sample size (<30 DLB patients), retrospective in nature with clinical patient scans used, and report very 
high sensitivity and specificity.  The Japanese studies all administered a dose of 111 MBq (except Oide 
et al. who admnistered 148 MBq [183]).   In the European studies the administered activity range was 
broad: 74 MBq in Belgium [59], 111 MBq in Italy [68, 184], a 148-296 MBq weight based protocol in 
France and 370 MBq in Spain.   
The EANM Cardiovascular Committee guidelines state typical activities range between 111 MBq and 
370 MBq and do not recommend a specific activity as “solid evidence documenting superior results 
with certain activities is not available” [165].  In the USA the FDA approved dose is 370 MBq, 
significantly higher than in Japan [65, 185].  The UK ARSAC guidance also suggests 370 MBq for 
sympathetic innervation imaging of the heart (procedure code 123I-117-136).  Although these levels 
sound precise, they originate from activity measured in millicuries, where 1 mCi = 37 MBq.  The average 
effective dose associated with the administration of 111 MBq (3 mCi) of MIBG is 1.4 mSv, with 185 
MBq (5 mCi) and 370 MBq (10 mCi) of course giving higher effective doses of 2.4 mSv and 4.8 mSv.  
These higher doses would seem unnecessary if the same information can be obtained with 111 MBq.   
It is of interest to note that even though the Japanese centres use a lower activity than the standard 
NuTH clinical protocol (370 MBq), many also use a shorter imaging duration of five or even two 
minutes.  Even taking the greater sensitivity of the low energy collimators used in many of these studies 
into account, the count density will be reduced by several fold compared to the NuTH protocol.  It 
therefore seems that the higher activity of 370 MBq is unlikely to be necessary and the decision was 
taken to move to an activity of 111 MBq for our research protocols, keeping a 10 minute image 
duration.   The validity of this approach is considered further in section 5.3, using phantom and MIDAS 
clinical data to assess counting statistics. 
The vast majority of published cardiac MIBG studies in dementia have used low energy high resolution 
collimators, including the European studies conducted after the EANM guidance on standardisation to 
medium energy were published [165].  However, the most recent article by Yoshita et al., a large 
multicentre study carried out in Japan, presents a cut off value determined for MEGP collimators [53].  
Not all the centres in the study used MEGP collimators, but all camera and collimator combinations 
were calibrated with a phantom to enable HMR results for non-MEGP collimators to be scaled to the 
equivalent of MEGP values.  MEGP was chosen as the reference collimator because calibration work 
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carried out by Nakajima et al. showed that this collimator gave heart to mediastinum ratios in phantom 
studies that were both higher than those obtained with low energy collimators and closest to the true 
values [166, 186].   This was later confirmed for our centre using the phantom method, which is 
outlined in the next section.  As discussed in Chapter 3, collimators designed for medium energy 
gamma ray imaging give better image quality (and higher heart to mediastinum ratios) than those 
designed for low energies because of the reduction in septal penetration of the higher energy 123I 
photons, which reduces image contrast.  The main argument against using them in the MIDAS study is 
that most previous studies have used LEHR, and we would want to apply HMRs derived in those 
studies.  However all camera and collimator combinations are expected to give slightly different ratios, 
hence the need for the large calibration exercise in Japan, so it would not necessarily be valid to apply 
a value from another study.   The more accurate HMR results obtained with medium energy collimators 
may lead to more accurate diagnosis, and the wider HMR range could give finer grained distinctions, 
which may allow subtle changes in early disease to be detected more easily than with low energy 
collimators.  We therefore chose to continue using MELP collimators for cardiac MIBG research studies, 
despite the majority of publications using LEHR. 
A wide range of HMR cut-off values were reported in the literature, likely due to the different 
collimators used.  Since the Japanese multicentre study [53] is the largest body of data, and reports a 
value for medium energy collimators, we will use the value of 2.1 obtained via ROC analysis as our 
initial cut-off, adjusted via phantom calibration if necessary (see next section). 
Since this review was conducted, publications of note include a prospective Italian multicentre study 
comparing cardiac MIBG and FP-CIT in dementia diagnosis [67] and a three year follow up paper 
reporting on around half the patients from the Japanese multicentre study [62].  The Italian study, by 
Tiraboschi et al. included 30 DLB patients, 16 AD and 13 FTD from five Italian centres and reported 93% 
sensitivity and 100% specificity [67].  At first glance this would suggest that the multicentre aspect does 
not reduce accuracy, but in fact the patients were scanned in only two nuclear medicine centres, both 
with the same model gamma camera and collimators (model not stated).  The follow up to the 
Japanese multicentre study [62] assessed 65 of the original 133 patients and found a higher sensitivity 
and specifcity in this subset (sensitivity 77%, specificity 97%; 69% and 89% respectively for the orignal 
study).  However, there was still considerably more overlap between the HMRs in the AD and DLB 
groups than was seen in earlier single centre Japanese studies reporting almost perfect accuracy.  It is 
not clear how much of this is due to the inclusion of different centres and how much to differences in 
inclusion criteria and sample selection.  Importantly, in both the original and follow up study, the early 
image obtained at 20-30 minutes post injection gave similar results to the delayed image at 3-4 hours 
post injection (area under the ROC curve 0.90 for early and 0.92 for delayed).  We therefore included 
67 
 
an early image at 20 minutes post-injection to our research protocol to allow comparison with the 
standard 3-4 hour results at the end of the study.  This is explored further in section 7.3. 
5.1.4 Conclusion 
We determined the optimum cardiac MIBG imaging protocol for the MIDAS and SUPErB research 
studies based on a literature review.  Key parameters of the protocol are given in Table 13. 
Table 13: Settings used in the research cardiac MIBG protocol at Newcastle upon Tyne Hospitals 
Factor Specification in NuTH protocol 
Thyroid blockade 170mg potassium iodate, 1 hour before injection and 8 hours later 
Administered activity 111 MBq ±10% 
Interval post injection 20 minutes (early) and 3-4 hours (delayed) 
Mode Planar; anterior chest 
Collimator MELP  
Patient positioning Feet first supine, detector as close to chest as possible 
Energy Window 20% centred on 159 keV 
Matrix size 128 x 128 
Zoom None 
Acquisition duration 10 minutes 
HMR cut-off 2.1 (taken from Japanese multicentre study) 
 
In the next section we outline the method for calibrating our camera using the same method as the 
Japanese multicentre study [53], so that we can either apply the 2.10 cut-off ratio obtained in said 
study or correct it for our camera if necessary. 
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 Phantom calibration for HMR normalisation between centres 
5.2.1 Introduction 
Calibration of HMRs between gamma cameras using a phantom has been shown to be feasible [166] 
and was implemented in a Japanese multicentre study [53].  Before starting cardiac 123I-MIBG imaging 
at our centre we calibrated our gamma cameras, with help from colleagues in Japan and the 
Netherlands.  We used the method developed by Nakajima et al. [166, 168, 186] which allowed us to 
check whether it is valid to use the HMR cut-off of 2.1 from the multicentre DLB study by Yoshita et al. 
[53, 62] for our research studies.  The calibration results for our Siemens gamma cameras with MELP 
collimators were later included in the 2017 European multicentre calibration paper by Verschure et al. 
[167] alongside 26 centres in the Netherlands, Belgium and Austria.   
The calibration method uses a phantom with heart, liver, lung and background sections filled with 123I 
solution [166].  The relative thickness of the different cavities determines their relative activities on 
planar imaging (Figure 28).  The phantom used in the European project was designed to give a true 
heart to mediastinum ratio of 2.60 when scanned in one orientation and 3.60 when turned over and 
scanned from the other side.  These known values are compared with the values measured on planar 
images in order to determine a calibration coefficient.  The calibration coefficient is simply the slope 
of the linear fit between the measured and true HMRs.  An additional data point of (1,1) is included in 
the fit since the measured ratio would be 1 if there were no difference between the heart and 
mediastinum counts.  However, the method is complicated slightly by the decision to standardise to a 
medium energy general purpose collimator, rather than to the true HMR values.  This was taken so 
that centres using MEGP collimators, commonly used in Japan, would not need to apply a correction 
factor in order to use the published multi-centre threshold value of 2.1 [53].  At NuTH we use Siemens 
MELP collimators, which have similar properties to MEGP. 
 
Figure 28: Photograph of planar calibration phantom used in Japan and diagram of the structure [187].  The cavities are filled 
with uniform 123I solution through a single filling port and the depth of each compartment gives rise to the known ratios.  The 
phantom used in the European study is a light-weight version using water-filled slices instead of solid PMMA plates. 
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5.2.2 Methods 
Phantom calibration scans were acquired on the Siemens Intevo and Siemens Symbia gamma cameras 
at the Royal Victoria Infirmary, Newcastle upon Tyne Hospitals.  Example phantom images and HMR 
region placement are shown in Figure 29.   
 
Figure 29: Phantom images for the Siemens Intevo, showing the 2.5 HMR side (left) and 3.6 HMR side (right). The ROI 
placement for HMR measurement is shown. 
 
5.2.3 Results 
The measured HMRs for each detector with medium energy low penetration (MELP) collimators are 
given in Table 14.  Plots used for calibration are shown in Figure 30 and the calibration factor results 
in Table 15.  The calibration was independently verified by Prof. Nakajima from Kanazawa University, 
Japan. 
Table 14: True and measured HMR values for phantom scanned on Siemens Symbia and Siemens Intevo gamma cameras 
 Symbia detector 1 Symbia detector 2 Intevo detector 1 Intevo detector 2 
True HMR 2.50 2.69 2.68 2.70 2.72 
True HMR 3.60 3.32 3.31 3.35 3.37 
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Figure 30: Plots used to determine calibration coefficients between measured and true HMRs. 
 
Table 15: Calibration coefficients determined from phantom calibration for our cameras compared to the Japanese and 
European average values for MELP collimators. 
 Newcastle MELP average (Europe) MELP average (Japan) 
Intevo 0.996 
0.895 0.950 
Symbia 0.985 
 
The results indicate that our scanners with MELP collimators give values close to the true HMR, 
however, in Japan data was standardised to MEGP collimators, which give HMR values that are slightly 
lower.  To compare our results to Japan an adjustment is therefore required.  The Yoshita multicentre 
study adjusted the HMRs from each centre so that data could be pooled and used with the same 
normal HMR cut-off.  However, we chose to adjust externally derived HMR cut-off values so that they 
are applicable to our data.  The equation provided by Verschure et al. can be rearranged for this 
purpose to give: 
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𝐿𝐿𝑐𝑐𝐴𝐴𝑐𝑐𝑙𝑙 𝐴𝐴𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐 = 1 + (𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝑑𝑑𝑐𝑐𝑐𝑐𝑑𝑑𝐴𝐴𝐴𝐴𝑐𝑐𝑑𝑑 𝐴𝐴𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐 − 1) ×  𝐿𝐿𝑐𝑐𝐴𝐴𝑐𝑐𝑙𝑙 𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴
𝑆𝑆𝐴𝐴𝑐𝑐𝑐𝑐𝑑𝑑𝑐𝑐𝑐𝑐𝑑𝑑𝐴𝐴𝐴𝐴𝑐𝑐𝑑𝑑 𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴  
The mean value for the calibration coefficient for cameras with MEGP collimators in Japan was found 
to be 0.88; this value is taken as the standardised coefficient.   
If we were to adapt the cut-off of 2.1 found by Yoshita et al. [53] using the Japanese coeffificent of 
0.88 and local coefficient of 1.00 we would obtain a local cut-off of 2.25 for use with our Siemens 
Intevo: 
𝐿𝐿𝑐𝑐𝐴𝐴𝑐𝑐𝑙𝑙 𝐴𝐴𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐 = 1 + (2.1 − 1) ×  1.000.88  = 1 + (1.1 ×  1.14) = 1 + (1.25) = 2.25 
Similarly, the HMR cut-off for our Siemens Symbia is very similar at 2.24 allowing the cameras to be 
used interchangeably in practice.   For comparison, the average LEHR collimator coefficient is 0.55 
[188] so the cut-off converted for use with LEHR collimators would be lower at 1.69. 
 
5.2.4 Discussion 
The HMR values obtained with the phantom for our setup show good agreement with the true values 
(a slight over estimation for the 2.5 ratio and underestimation for 3.6), resulting in high calibration 
coefficients of 1.00 and 0.99 (to two decimal places).  The two Siemens scanners to be used in the 
MIDAS and SUPErB study show very close agreement with each other.   Phantom calibration with 
respect to the Japanese MEGP standard, using published calibration coefficients 0.88 resulted in a 
slight increase in the Japanese cut-offs being required for use with our scanners of around 7%. 
It was much later discovered, through extensive email communication with Prof. Nakajima, of 
Kanazawa Univeristy, Japan, that Siemens medium energy general purpose (MEGP) collimators in 
Japan appear to have similar properties to Siemens medium energy low penetration (MELP) 
collimators in Europe, and therefore similar calibration coefficients.  The observed differences 
between our calibration factors and those in the multi-centre study were found to be within the range 
of observed differences with a range of phantoms used in Japan and Europe, which are assumed to be 
partly due to variation in phantom manufacturing.  We therefore decided to apply the multicentre cut-
off without adjustment.  However the above calibration method is still required if a different collimator 
or camera combination were to be used, for example to compare results with another centre using 
LEHR collimators. 
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5.2.5 Conclusion 
The similarity between the imaging setup at the Royal Victoria Infirmary and the standard setup in 
Japan, both of which use medium energy collimators, means we can apply HMR cut-offs from Japan 
directly without the need for correction.  The cut-offs from the multicentre study are 2.10 for both 
early and delayed images [53]. 
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 Is 111 MBq an appropriate activity for cardiac MIBG imaging? 
5.3.1 Introduction 
All subjects in the SUPErB study receive an intravenous injection of 111 MBq ± 10 % of 123I-MIBG, the 
activity set out in the research protocol, which is approved by the Sponsor (Newcastle upon Tyne 
Hospitals) and by the UK Administration of Radioactive Substances Advisory committee (ARSAC). The 
activity of 111 MBq planned for this study (and used for the MIDAS study) is in keeping with the activity 
used in Japan, where most published DLB research studies have been carried out [53, 166, 188, 189].   
Our review of the literature in section 5.1 suggested this lower activity would be adequate, but here 
we wanted to test this retrospectively using data from the MIDAS study. 
In theory the HMR should not be sensitive to changes in cardiac count density due to factors such as a 
lower dose, extravasation (tissuing) or shortened scan time. This is because it is a ratio and any increase 
in image count density should affect both the heart and mediastinum equally.  However, the signal to 
noise ratio (SNR) in a region of interest depends on the total counts and so will be affected.  The SNR 
is proportional to the square root of the total counts, as image counting statistics follow a Poisson 
distribution.  This means increasing the administered activity or image duration by a factor of 4, for 
example, will only improve the SNR by a factor of 2.  Noise clearly increases the uncertainty in the 
measured count density, and therefore uncertainty in HMR.  
In this section we use an anthropomorphic chest phantom to investigate whether increasing or 
decreasing the acquisition time affects the appearance of cardiac MIBG images and whether the HMR 
is significantly affected.  A phantom is useful for this as images are acquired under controlled 
conditions, without the influence of other confounding variables unavoidable in patient studies.  The 
results will let us know whether it is valid to compare results obtained with higher activities with those 
from our studies. 
We examine the mediastinal counts from patients scanned as part of the MIDAS study to see whether 
these give acceptable counting statistics (<2% uncertainty), and from this infer the minimum injected 
activity required for a 10 minute image. 
5.3.2 Methods 
Phantom study 
Images were acquired with the RSD torso phantom (Radiology Support Devices Ltd, Long Beach, CA, 
USA), with fillable heart, lung, liver and background compartments (Figure 31).  The phantom was filled 
with 123I solution, with the activity concentration in each compartment intended to give the same count 
densities as observed in clinical studies.  The phantom was scanned using the same planar acquisition 
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protocol as for MIDAS and SUPErB, i.e. the same gamma camera with MELP collimators, an energy 
window of 159 keV ± 10%, matrix size of 128 x 128 and no zoom. 
    
Figure 31: anthropomorphic torso phantom, with heart insert filled with 123I solution coloured with blue food dye. 
Further scans with twice, half and quarter the acquisition time were taken, without repositioning the 
phantom.  These four images were then summed in various combinations to give images with a wide 
range of count densities, equivalent to 10 minute clinical images with injected activities between 28 
MBq and 333 MBq, or alternatively 111 MBq with acquisition times between 2.5 and 30 minutes.  Each 
image was used only once in each combination. 
A freehand cardiac region of interest and rectangular mediastinum region were defined (Figure 32), 
and the same regions applied to all phantom images.  The cardiac and mediastinal mean count 
densities were recorded and the heart to mediastinum ratios calculated.  The percentage difference 
between the HMR was calculated relative to the standard phantom image, with counts equivalent to 
a patient administered 111 MBq and scanned for 10 minutes at 3.5 hours after injection. 
 
 
Figure 32: The standard count phantom image, with regions of interest. 
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Review of MIDAS patient HMR uncertainty 
The mediastinal region of interest data used to calculate HMR values for MIDAS patients for our 
previous publications [83, 190] was used to calculate the mean number of counts in the 48 pixel region, 
and the 25th percentile.  These patients were all administered 111 MBq ±10% and scanned for 10 
minutes 3-4 hours after injection. The uncertainty associated with the measurement of mediastinum 
count density was calculated from SNR, expressed as a percentage: 
𝑆𝑆𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝐴𝐴𝑐𝑐𝐴𝐴𝐴𝐴 (%) =  √𝑐𝑐
𝑐𝑐
 × 100 
where n is the total number of counts in the mediastinal region of interest (ROI).  The uncertainty 
associated with the cardiac ROI was calculated twice: once assuming the same count density as the 
mediastinum (i.e. no cardiac uptake, HMR = 1) and once assuming twice the count density (HMR = 2).  
The larger number of pixels in the 6 cm diameter circular cardiac region compared to the 4x3 cm 
mediastinum region (113 vs 48) was taken into account. 
The typical mediastinum and cardiac uncertainties were combined in quadrature to give an estimate 
of the percentage uncertainty for HMR, for cases of both no cardiac uptake and borderline-normal 
uptake.  The minimum administered activity required to give HMR estimates of within 2% uncertainty 
was calculated for the different scenarios. 
 
5.3.3 Results 
Phantom study 
The nine resultant images of increasing count density are shown in Figure 33.  The increase in image 
quality due to reduced noise is apparent, particularly for the images of less than 111 MBq equivalent 
counts.  The count densities in the heart and mediastinum regions and the HMRs for each of the images 
are given in Table 16. The HMR for the standard 10 minute / 111 MBq image was 2.77.   
HMRs for the other images ranged between 2.79 and 2.87, which corresponds to an increase in HMR 
of between 0.4% and 3.4% relative to the standard image.  There was no relationship between count 
density and HMR. 
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Figure 33: Phantom images acquired with count densities equivalent to ten minutes scans with between 28 and 333 MBq 
administered activity or equivalent to acquisition times between 2.5 and 30 minutes with 111 MBq administered activity. 
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Table 16: HMRs for the nine phantom images above. 
Equivalent 
image 
duration  
Equivalent 
activity  
Relative 
count 
density 
Heart 
mean 
count 
density 
Mediastinum 
mean count 
density 
HMR % difference 
relative to 
10 mins / 
111 MBq 
2.5 min 28 MBq 0.25 99.4 35.0 2.84 2.2% 
5 min 56 MBq 0.5 197.4 70.9 2.79 0.4% 
7.5 min 83 MBq 0.75 296.8 105.9 2.80 1.0% 
10 min 111 MBq 1 392.2 141.4 2.77 n/a 
12.5 min 139 MBq 1.25 491.6 176.4 2.79 0.4% 
15 min 167 MBq 1.5 589.6 212.3 2.78 0.1% 
20 min 222 MBq 2 782.9 272.5 2.87 3.4% 
25 min 278 MBq 2.5 980.3 343.4 2.85 2.8% 
30 min 333 MBq 3 1175.1 413.9 2.84 2.3% 
 
Review of MIDAS patient HMR uncertainty 
The mean counts in the 48 pixel mediastinum ROI was 5926, but there was substantial variation (Figure 
34).  The 25th percentile value was 4867 total counts.  These counts result in an uncertainty in the 
mediastinum count density estimate of 1.3 and 1.4% respectively.  Table 17 shows that the estimated 
error in HMR is around 1.6% for the MIDAS study, suggesting a slightly lower activity than 111 MBq 
could be administered to obtain an uncertainty of within 2% for an average patient.  This is achieved 
with a mediastinal total count of 5000, assuming and HMR value of 1, which requires an activity of 94 
MBq for the average patient.  However, to achieve an uncertainty of within 2% for 75% of the patients 
an activity of 114 MBq is required.  If the administered activity was increased (3.3x) to 370 MBq the 
HMR uncertainty would be around 0.9% (Table 17). 
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Figure 34: Histogram of mediastinum ROI counts for MIDAS patients 
 
Table 17: Estimated uncertainty in mediastinum and heart ROIs and HMR measurement with 111 and 370 MBq 
  Mediastinum 
counts 
Mediastinum 
uncertainty 
Estimated 
heart 
counts 
Heart 
uncertainty 
HMR 
uncertainty 
(111 MBq) 
HMR 
uncertainty 
(370 MBq) 
HMR 
= 1 
Typical 
patient 
5926 1.3% 13964 0.8% 1.6% 0.85% 
25th 
percentile 
4867 1.4% 11469 0.9% 1.7% 0.94% 
HMR 
= 2 
Typical 
patient 
5926 1.3% 27928 0.6% 1.4% 0.78% 
25th 
percentile 
4867 1.4% 22937 0.7% 1.6% 0.86% 
 
5.3.4 Discussion 
Review articles and guidelines on the use of cardiac MIBG discuss the need for standardisation, 
including of the administered activity and image acquisition duration, suggesting that count density 
may affect image interpretation [64, 165, 168, 191, 192].  However, there are few studies evaluating 
the effect of differences in image count density on the heart to mediastinum ratio (HMR). In 2008 
Verberne et al. performed a retrospective multivariate analysis on 290 heart failure patients from a 
European multicentre cardiac MIBG study, where large differences in acquisition protocols between 
the centres were present [193].  They found that acquisition duration had a small but significant effect 
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on HMR.  However, as the administered activities ranged from 72 to 370 MBq, we would expect that 
this would have had more of an impact on count density - but administered activity was actually not 
reported as a significant variable, nor does it seem to have been combined with acquisition duration 
to give a single variable.   Over 90% of patients were imaged with low energy collimators so the findings 
may not be replicated with medium energy collimators, due to reduced septal penetration. 
Our results suggest that the heart to mediastinum ratio is not affected by count density within the 
typical clinical ranges of 111 MBq to 370 MBq seen in the literature.  This is encouraging for multicentre 
studies and for meta-analysis.  Other factors, such as collimator choice, delay between injection and 
imaging and patient factors are likely to be the cause of significant variation between HMR values 
reported in the literature.   Our results with MIDAS patients confirm that 111 MBq is an appropriate 
activity for 10 minute delayed images, given HMR uncertainties of within 2%.  The ARSAC administered 
activity of 370 MBq gives over three times the effective radiation dose, but reduces the uncertainty by 
less than half. 
For the SUPErB study, the results confirm that we do not need to correct for the exact amount of 
administered activity for planar imaging, or be concerned if some of the activity appears to have 
tissued.  In the event that the scan needs to be terminated early, due to scanner fault or patient being 
unwell, the images can still be used. 
5.3.5 Conclusion 
An administered activity of 111 MBq with a 10 minute acquisition duration results in acceptable image 
quality and counting statistics, with 370 MBq unlikely to give clinically significant improvements. 
Although visual image quality and ease of region placement is affected by the administered activity 
and image duration, the heart to mediastinum ratio does not appear to be.  Variation in image count 
density alone should not be a barrier to comparison between individual scans and between centres. 
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Chapter 6: 123I-FP-CIT image reconstruction and 
analysis 
This chapter focusses on advanced methods for reconstructing and analysing FP-CIT images, comparing 
them to the standard BRASS quantification methods implemented for use in the SUPErB study in 
chapter 4.   In section 6.1 the accuracy of visual rating of FP-CIT scans by a panel of experts with access 
to BRASS results is compared with the accuracy of the quantification alone.  In section 6.2 we explore 
whether absolute quantification of striatal uptake via SUV-SPECT offers any advantages over the 
standard relative SBR method.  In section 6.3 we use striatal phantom scans to compare the standard 
reconstruction method with more advanced methods using CT attenuation map and Monte Carlo 
modelling.  In section 6.4 these advanced reconstruction methods are applied to MCI subjects from 
the SUPErB study to evaluate whether they improve accuracy.  In section 6.5 we assess FP-CIT test-
retest variation using control subjects rescanned after one year and discuss the implications for clinical 
reporting of change in SBR.  The results presented in this chapter are then summarised in section 6.6. 
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 Comparison between visual rating and BRASS SBR results in SUPErB MCI cohort 
6.1.1 Introduction 
In previous Newcastle University studies using 123I-FP-CIT, images were reconstructed with filtered 
back projection, as this was the technique in clinical use at the time.  In the past few years iterative 
reconstruction has been become more widespread outside of research settings due to improved 
computer processing speed and the ability to incorporate corrections for attenuation, scatter and 
depth dependent resolution.  As discussed in Chapter 4, it was decided that for the SUPErB study the 
same reconstruction method required for BRASS image quantification would be used for visual ratings.     
In this section we compare the diagnostic accuracy of the consensus expert panel approach using the 
new reconstruction method with BRASS quantification alone.  Two sets of “stand-alone” BRASS 
quantification results are compared with the panel ratings, one with the standard ENC-DAT database 
and age correction and one relative to a database of 31 age-matched SUPErB controls, without age 
correction. 
6.1.2 Methods 
Modified ratings scale 
123I-FP-CIT was first developed as a radioactive ligand for visualising reduced striatal uptake in 
Parkinson’s disease (PD) due to dopaminergic neuron loss.  In PD, neurons projecting to the putamen 
are often lost before those projecting to the caudate, resulting in a characteristic “full-stop” 
appearance on transverse slices of an FP-CIT scan, compared to a “comma” appearance in healthy 
individuals or those with essential tremor (ET). Visual assessment can be used for distinguishing 
between PD and ET because of these characteristic patterns.  Benamer et al. [194] established a FP-
CIT rating scale for PD ranging from normal (Stage 0) to virtually no uptake (Stage 3), as illustrated in 
Figure 35:  
Stage 0 (normal) Stage 1 (unilateral 
putaminal reduction ) 
Stage 2 (bilateral 
putaminal reduction) 
Stage 3 (virtually 
absent uptake) 
    
Figure 35: Visual rating scale used by Benamer et al. [194]  Stage 0 – normal uptake, Stage 1 – asymmetric uptake with marked 
reduction in putamen uptake on one side, Stage 2 – activity confined to caudate nuclei bilaterally, Stage 3- virtually absent 
uptake bilaterally.  The images are examples from Newcastle studies. 
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As FP-CIT came to be used for the diagnosis of dementia with Lewy bodies (DLB) it became apparent 
that this pattern of neuronal loss over time did not occur for all patients.  O’Brien et al. [44] showed 
that the loss tended to occur at a more uniform rate in both the caudate and putamen in DLB compared 
to PD, leading to a “balanced loss” appearance on imaging.  The rating scale introduced by Benamer 
does not take mild global reduction into account, so these scans are difficult to categorise.  We sought 
to extend this simple and easy-to-use rating scale to make it suitable for use for DLB diagnosis.  We 
added two categories to describe mild and moderate global striatal reduction and a further category 
for any other abnormal/atypical pattern (Figure 36).  For the purposes of dichotomising scans into 
normal or abnormal groups, a rating of 4 (mild global reduction) counts as normal and 5 (moderate 
global reduction) counts as abnormal.  Scans falling into the “other” category 6 were discussed on a 
case by case basis.   The full modified scale is shown in Table 18. 
 
4 (mild global loss) 5 (moderate global loss) 6 (other) 
   
Figure 36: Additional categories added to the FP-CIT visual ratings scale to account for balanced loss and atypical appearances. 
 
This rating scale was validated using scan data from a Newcastle University study funded by the 
Medical Research Council in early 2000s, using patients for which autopsy confirmed diagnoses had 
been obtained. In particular, it was confirmed that a rating of 4 frequently occurred in non-DLB subjects 
and so should be regarded as normal. This is published, alongside a further semi-quantitative ratings 
scale, in our 2018 publication [195]. 
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Table 18: Modified rating scale for FP-CIT adopted for DLB.  Categories 0 and 4 are considered normal, 1,2,3,5 abnormal (i.e. 
in keeping with Lewy body disease) and 6 is for cases that do not fit any category. 
Modified 
rating 
Description Normal / 
Abnormal 
0 
Normal (tracer uptake bilaterally in putamen and caudate nuclei and 
largely symmetric). 
Normal 
1 
Asymmetric uptake with normal or almost normal putamen activity in 
one hemisphere and with a more marked reduction in the 
contralateral putamen. 
Abnormal 
2 
Significant bilateral reduction in putamen uptake with activity 
confined to the caudate nuclei. 
Abnormal 
3 
Virtually absent uptake bilaterally affecting both putamen and 
caudate nuclei. 
Abnormal 
4 Very mild or equivocal global striatal reduction in uptake  Normal 
5 Significant global striatal reduction in uptake  Abnormal 
6 Other atypical pattern of uptake. 
Panel to 
discuss  
 
 
Consensus ratings panel 
The consensus panel consisted of a group of five raters experienced at reviewing FP-CIT images: myself, 
Alan Thomas (Professor of old-age psychiatry), Jim Lloyd (Consultant Clinical Scientist), Paul Donaghy 
(Old-age Psychiatrist) and George Petrides (Consultant Radiologist).  The panel members were sent 
sets of anonymized images to review in a randomised order by an independent member of the team 
(Sean Colloby), with the standard BRASS quantification results for each case (SBR and age-corrected Z 
scores).  The ratings were collated by Dr. Colloby, who checked for agreement and discrepancies.  Cases 
where 4 or 5 raters had assigned the same category were not discussed further.  The remaining cases 
were discussed at a meeting of all the panel members, still fully blinded, and a consensus reached.  For 
example, if two raters had rated a scan as category 3 and three as category 5 the case would be 
discussed and a consensus of either 3 or 5 agreed upon.  A binary normal/abnormal consensus opinion 
was reached for each case for the purposes of diagnostic accuracy calculation.  Cases with a consensus 
score of 6 were discussed on an individual basis and were deemed abnormal if the pattern, although 
atypical, was thought to be in keeping with Lewy body disease.  If infarct was suspected, MRI images 
were reviewed retrospectively and the subject excluded if confirmed. 
FBP vs iterative image reconstruction  
Changing the reconstruction method has a considerable effect on the appearance of the images, with 
the background appearing brighter with FBP than with OSEM_RRACSC.  The background scaling is often 
used to help decide whether there is global loss of dopaminergic function, so this change is not trivial 
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and background levels that would indicate reduced striatal uptake with FBP often look normal with 
OSEM_RRACSC to reporters unused to the wider dynamic range covered by the same colour scale.  To 
aid reporters used to reviewing FBP images a document was produced containing instructions and a 
set of training/reference images reconstructed with both methods.  Some example images from this 
document reconstructed with FBP and OSEM_RRACSC are shown in Figure 37, with tips for assessing 
the images using the appearance of the background in Table 19. 
Given the increasing use of quantification for routine clinical FP-CIT reporting, the panel decided that 
the raters for the SUPErB study should have access to the BRASS quantification results when reviewing 
the images individually and at consensus panel meetings.  This would then reflect clinical practice for 
the majority of centres, in the UK at least, making the results as generalisable as possible.  For similar 
reasons, the standard BRASS output with age corrected Z scores relative to the ENC-DAT database was 
used, despite the concerns with age correction models discussed in chapter 4.   The role of 
quantification was discussed amongst the panel and it was agreed to review the images visually first 
and then use the quantification to identify cases of reduced striatal uptake that might otherwise be 
missed, as well as to assist with uncertain cases.  Panel members used their professional judgement in 
cases where visual assessment and semi-quantification did not agree. 
 
Figure 37: Normal scan (top) and abnormal scan with global striatal reduction (bottom) reconstructed with filtered back 
projection and the new iterative reconstruction method.  The total counts in the images is around 3 times as high with the 
corrections, which has a corresponding effect on the colour scale, which is referenced to the maximum voxel value. 
Filtered back projection OSEM_RRACSC 
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Table 19: Background appearance with the FBP reconstruction method compared to the new iterative OSEM_RRACSC method. 
Background Inferred 
striatal 
uptake 
Background Appearance/Colour 
FBP reconstruction 
Background Appearance/Colour 
OSEM_RRSCAC reconstruction 
Normal Normal 
uptake 
Mostly uniform with green or black 
background 
Mostly uniform dark green or black 
background 
Very mild 
increase 
Very mild / 
equivocal loss 
Some speckling with 
predominantly green/black 
background but with blue/purple 
colour coming through. 
Mostly uniform dark to light green 
or black background, with tiny 
specs of blue/purple 
Mild 
increase 
Mild loss Speckling with a mixture of 
blue/purple and green/black 
Dark to light green or black 
background, with specs of 
blue/purple especially around the 
striata 
Moderate 
increase 
Moderate 
loss 
Little Green/black remaining with 
predominantly purple colour 
Mixed green / blue background 
Marked 
increase 
Severe loss Extensive areas of purple with 
pink/yellow foci 
Mixed green / blue background 
with specs of pink coming through 
 
Subjects 
All the SUPErB cases, including the 31 controls with normal cognition, were rated by the panel, but 
only the MCI cases were used to calculate diagnostic accuracy.  As discussed in section 2.3.3, the MCI 
cases included in this thesis are those with a one year follow up diagnosis of probable MCI-LB or 
probable MCI-AD only.   
One MCI-AD case rated as category 6 - other was excluded because on review of the MRI brain scan 
obtained as part of the study there was clear evidence of significant areas of infarct in the left striatum, 
which corresponded to the abnormal side on quantification (Figure 38). Exclusion of this case results 
in a probable MCI-LB group of 27 and a probable MCI-AD group of 16 (Table 20). 
   
Figure 38: The probable MCI-AD case that was rated as “other” (category 6) by the panel.  On review of the MRI head it was 
seen that there was evidence of infarcts in the left striatum, accounting for the reduced uptake.  This case was excluded from 
analysis. 
Right 
SBR Z score 
Left 
SBR Z score 
2.42 -1.07 1.62 -2.78 
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Table 20: Ages of the healthy older adults, MCI-LB and MCI-AD patients. 
 Number included Mean age (± SD) 
Healthy older adults 31 74.1 (± 7.6) 
Probable MCI-LB 27 73.0 (± 7.2) 
Probable MCI-AD 16 77.5 (± 7.7) 
 
Diagnostic accuracy 
The 31 SUPErB controls were used to calculate SUPErB SBR cut-offs for BRASS so that quantification 
without age correction could be assessed.  The SUPErB cut-offs were taken as two standard deviations 
below the mean, the same method as implemented within BRASS using the factory database.  The 
standard BRASS Z scores with respect to the ENC-DAT database with age-correction were also 
assessed.  Sensitivity, specificity and overall accuracy was calculated for the visual ratings method and 
for BRASS quantification, using MCI subjects only.  The results were reported with binomial confidence 
intervals.   
6.1.3 Results 
Plots of the SBR quantification results for the controls, probable MCI-AD and probable MCI-LB cases 
are shown in Figure 39.  The control and probable MCI-AD groups are similar.  The probable MCI-LB 
cases show a wide range of uptake values, with no clear distinction into normal and abnormal groups. 
 
 
Figure 39: Plots of SBR for the control, MCI-AD and probable MCI-LB groups.  The plot on the left shows the SBR for the whole 
striatum and the right the SBR for the putaminal sub-region.  The excluded asymmetric MCI-AD case is not shown. 
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Diagnostic accuracy 
SBR cut-offs for BRASS (without age correction) using SUPErB controls are shown in Table 21.  There 
were no discrepancies between the standard ENC-DAT BRASS results and the results with respect to 
local controls – all cases with age corrected Z scores below -2 also had SBRs below the local cut-off and 
vice versa.  The sensitivity, specificity and overall accuracy of visual rating and quantification are given 
in Table 22. 
 
Table 21: Local SBR cut-offs derived using SUPErB age matched controls. 
 
Right 
striatum 
SBR 
Left 
striatum 
SBR 
Right 
caudate 
SBR 
Left 
caudate 
SBR 
Right 
putamen 
SBR 
Left 
putamen 
SBR 
Control mean 2.67 2.68 2.79 2.85 2.53 2.49 
Standard deviation 0.28 0.29 0.31 0.31 0.28 0.31 
Local cut-off 2.10 2.10 2.18 2.24 1.96 1.87 
 
Table 22: Sensitivity, specificity and accuracy of visual rating and BRASS quantification for diagnosing Lewy body disease in 
MCI subjects 
 
Method Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Accuracy 
(95% CI) 
Visual  Consensus panel with access 
to BRASS (ENC-DAT results) 
13/27 
48% 
(29 to 68%) 
14/16 
88% 
(62 to 98%) 
27/43 
63% 
(47 to 77%) 
BRASS (ENC-
DAT) 
ENC-DAT database with age 
correction 
12/27 
44% 
(25 to 65%) 
16/16 
100% 
(79 to 100%) 
28/43 
65% 
(49 to 79%) 
BRASS 
(SUPErB)  
SUPErB age matched 
controls 
12/27 
44% 
(25 to 65%) 
16/16 
100% 
(79 to 100%) 
28/43 
65% 
(49 to 79%) 
 
Controls with normal cognition 
Two cognitively normal controls were rated as abnormal, both with normal MR head results (part of 
the study inclusion criteria).  These cases are shown alongside their quantification results in Figure 40.  
The first case, aged 73 years, has normal quantification in all regions but was thought to be abnormal 
because of a rather asymmetric appearance, with the left putamen never reaching normal “brightness” 
on any of the image slices.  The second case, aged 63, had quantification results towards the bottom 
of the BRASS ENC-DAT database normal range, corrected for age and signs of blue speckling in the 
background, indicating a global reduction in striatal uptake.  The image was rated as showing balanced 
loss (category 5). 
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Figure 40: The two control subjects with FP-CIT scans rated as abnormal by the panel.  The first case was rated as 
asymmetric (category 1) and the second as showing significant global striatal loss (category 5). 
Age 
at 
scan 
BRASS 
Registration 
ok? 
Right 
striatum  
Left 
striatum 
Right 
caudate 
Left 
caudate  
Right 
putamen  
Left 
putamen 
 
73 y 2.63  
(-0.81) 
2.77  
(-0.58) 
2.70  
(-0.85) 
2.97  
(-0.45) 
2.57  
(-0.70) 
2.54 
(-0.68) 
Age 
at 
scan 
BRASS 
Registration 
ok? 
Right 
striatum  
Left 
striatum 
Right 
caudate 
Left 
caudate  
Right 
putamen  
Left 
putamen 
 
63 Y 2.23  
(-1.89) 
2.28  
(-1.88) 
2.35  
(-1.78) 
2.35 
(-1.93) 
2.09 
(-1.91) 
2.19 
(-1.68) 
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6.1.4 Discussion 
Visual assessment supported by quantification shows excellent specificity for Lewy body disease 
diagnosis in MCI, with none of the AD cases showing low uptake on quantification and only 2/16 (12%) 
rated as abnormal by the panel.  The specificity is in keeping with the LewyPro study result of 89% 
given in our previous publication, which used FBP and DaTQUANT quantification [37].  Some of the 
LewyPro subjects had another scan as part of SUPErB, and are included here, so there is some overlap 
of cases.  The visual rating sensitivity of 48%, however, is lower than the 61% for LewyPro (95% CI 42.5 
to 77.4%), although the confidence intervals do overlap.  If this is a real difference it may have been 
caused by the change in reconstruction protocol, with the OSEM_RRSCAC used in SUPErB tending to 
appear more “normal”. 
The specificity with quantification alone was 100% but the sensitivity slightly lower than visual rating 
as one MCI-LB case rated as abnormal had completely normal quantification.  In general, concordance 
between quantification and visual rating was high.  The only other cases with disagreement are two 
MCI-AD cases rated as normal on quantification and abnormal on visual rating.  One shows the left 
putamen SBR reduced relative to the right, but still well within normal limits (Z= -1.22 left; -0.54 right).  
The other also shows asymmetry between the left and right striatum (Z= -0.62 left; -1.24 right).  These 
cases suggest that it may be useful to quantify asymmetry using BRASS in future, a feature previously 
thought to give rise to too many false positive results. 
There was 100% concordance between the BRASS results using the ENC-DAT database and the BRASS 
results interpreted using the SUPErB control SBR cut-offs.  This suggests that an age-matched local 
database has no clear advantage over the standard age-corrected factory database, at least in this age 
group.  This is reassuring for other centres for whom it is likely not to be feasible to produce a local 
database.  However, a limitation of this analysis is that there was no assessment without any use of 
quantification for the SUPErB cases, and we did not attempt to quantify the subjective degree to which 
the panel members were influenced by the BRASS results.  In the relatively young control case (63 
years)  rated as showing significantly reduced global striatal uptake, the age correction will have made 
the Z scores lower than they would have been for an older person, which likely contributed to the 
assessment as abnormal.     
The distribution of the SBRs of the MCI-LB cases shown on the plots in Figure 39 shows that there is 
no clear cut-off between normal and abnormal that would give higher accuracy.  There is a significant 
overlap with both the control and the AD groups, which suggests that many of these cases either do 
not have Lewy body disease affecting the substantia nigra, or not sufficient to affect dopaminergic 
function.  Some may be misdiagnosed and not have Lewy body disease at all, but this seems less likely 
in this probable group who have at least two core symptoms of Lewy body disease, or one core 
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symptom and an abnormal cardiac MIBG scan.  As part of the SUPErB study the patients are being 
followed up, including with repeat FP-CT scanning.  This is outside the scope of this thesis but will 
provide valuable information in future. 
6.1.5 Conclusion 
The sensitivity of visual assessment of FP-CIT scans by a consensus panel of raters with access to BRASS 
quantification was 48% and specificity 88%.  The sensitivity and specificity of BRASS quantification 
alone was 44% and 100%.  The overall accuracy of the visual ratings method and quantification alone 
was very similar.  Long term follow up will help to clarify the status of the cases assumed to be early 
Lewy body disease with normal imaging, as well as that of the three cases where there was discordance 
between the panel and BRASS quantification. 
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 Absolute quantification of FP-CIT striatal uptake in MCI patients 
6.2.1 Introduction 
Traditionally, use of relative scaling to the maximum voxel in the image has meant that the appearance 
of the brain background surrounding the striata has needed to be used as a surrogate for overall striatal 
uptake (see the previous section).  As discussed in Chapter 3, quantifying striatal uptake by determining 
the normalised absolute activity concentration in each striatum, rather than an uptake ratio, could in 
principle more closely reflect true uptake, as it removes the dependence on a low count and potentially 
variable background reference region in the cortex.  Standardised uptake values are calculated for each 
voxel, allowing images to be displayed using an absolute SUV scale rather than the standard relative 
scale.   
SUV information for a volume of interest can be reported using SUVmax, SUVpeak or SUVmean.   In FP-CIT 
imaging, SUVmax and SUVpeak have the advantage of being operator independent, but the disadvantage 
of being insensitive to putaminal only losses, as the highest count density is normally located in the 
caudate.  SUVmax is subject to noise as it is derived from a single voxel, so is not used in this thesis.  
SUVmean is the mean SUV within the volume of interest, so SUVmean within a striatal volume is more 
representative of the overall striatal uptake than SUVpeak.  However it is highly dependent on the 
accuracy of the striatal volume of interest. 
Ideally, SUVmean would be defined using accurate striatal reference regions, with the SUV images 
registered to a template, similar to the methods used by BRASS to determine SBR.  However, BRASS 
does not currently support absolute quantification so does not report SUVs.  We therefore developed 
an alternative method for determining striatal SUVmean without the need for accurate striatal VOIs, 
based on the Southampton method [144], described in more detail in the methods.  We also calculated 
SBRs with the Southampton method so SUV could be compared with SBR directly. 
SUV-SPECT is a novel technique, with few publications on FP-CIT so far found in the literature.  Two 
retrospective patient studies from Japan have recently been published, comparing SUV with SBR in 77 
and 52 patients, and concluding that accuracy is actually lower with SUV than with SBR [196, 197].  
Both studies used CT attenuation correction, however scatter correction was not performed in one of 
the studies [197] and the method not stated in the other [196].  There are no publications on the use 
of FP-CIT SUV-SPECT in mild cognitive impairment. 
In this section we reconstruct SUPErB FP-CIT image data to obtain SUVmean and SUVpeak results in 
controls and MCI patients.  As with SBR, the controls are used to set normal thresholds and the MCI 
cases for estimating accuracy for diagnosing MCI-LB.    We aim to compare the accuracy of SUVmean, 
SUVpeak and SBR calculated with the Southampton method, assess whether SUV normalisation based 
on body weight is effective and explore the potential for use of an absolute scale for visual assessment. 
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6.2.2 Methods 
Activity concentration calibration 
A calibration factor to convert reconstructed count density into activity concentration was determined 
by scanning a uniform phantom filled with a known activity, as shown in Figure 41.  The activity, volume 
and assay time are input into the Hermes calculation tool (Figure 42).  The resultant calibration factor 
is then added to the reconstruction protocol for patient scans.  Scan reconstructed with the calibration 
factor applied, but no other changes, are displayed within Hermes HybridViewer in units of kBq/ml.  If 
the patient weight and administered activity are entered during reconstruction images may be 
displayed in either kBq/ml or in units of SUV. 
 
Figure 41: Illustration of steps required for deriving an activity calibration factor. 
 
Figure 42: Example screenshot of uniform phantom activity concentration calibration too, with the activity in the phantom, 
solution volume and assay times specified.  There was no residue left in the syringe (to 1 d.p.). 
93 
 
Striatal SUVmean calculation method 
The Southampton method was developed to calculate SBR, but can be adapted for SUV simply by 
removing the normalisation to the background.  The method still requires a background VOI however, 
as this is used for determining the non-specific uptake in large striatal VOIs.  
Briefly, the method attempts to avoid count losses due to the partial volume effect when selecting 
striatal regions of interest, by using large fixed regions to account for all the counts in the image that 
are given by radioactivity in the striata.  Because a much larger volume than the actual size of the 
striata is used, the true volume of each striatum is assumed to be fixed at 11.2 ml, which is the volume 
used in the anthropomorphic striatal phantom referenced in the paper.   
In the original Southampton method, large fixed sized regions of interest are placed manually over a 
summed transverse slice image, containing a fixed number of slices around the striatal maximum.   We 
modified the method to use volumes of interest, which were defined on the ENC-DAT template based 
on the dimensions specified by Tossici-Bolt et al. [144] and then registered to the striatal phantom and 
patient scans.  This removed much of the operator variation as striatal VOIs rarely needed adjusting.  
The BRASS occipital background VOIs from the template were used as the background VOI. 
 
Figure 43: Diagram showing size in mm of large striatal regions of interest used in the original version of the Southampton 
method. 
The striatal SUVmean is determined on SUV-SPECT images as follows.  The signal in the large striatal VOI, 
SUVtotal, is attributed to the specific binding in the striatum, plus non-specific background.  The non-
specific background level is determined from the background VOI, and subtracted from the large 
striatal VOI. The volume of the large VOI, VVOI, must be known so that the non-specific background can 
be calculated correctly.  The remaining signal is the summed SUV for the whole striatum. In order to 
determine the SUVmean the total is divided by the assumed striatal volume, Vstriatum of 11.2 ml.  If SBR is 
required this can be simply calculated by dividing the resultant SUVmean_striatum by the SUVmean_background. 
𝑆𝑆𝑆𝑆𝑆𝑆𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 𝑆𝑆𝑆𝑆𝑆𝑆𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐 − (𝑆𝑆𝑆𝑆𝑆𝑆𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑏𝑏𝑠𝑠𝑐𝑐𝑏𝑏𝑏𝑏𝑠𝑠𝑐𝑐𝑠𝑠𝑏𝑏𝑏𝑏 ∗ 𝑆𝑆𝑉𝑉𝑉𝑉𝑉𝑉)𝑆𝑆𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠  
𝑆𝑆𝐵𝐵𝑅𝑅 =  𝑆𝑆𝑆𝑆𝑆𝑆𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑆𝑆𝑆𝑆𝑆𝑆𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑏𝑏𝑠𝑠𝑐𝑐𝑏𝑏𝑏𝑏𝑠𝑠𝑐𝑐𝑠𝑠𝑏𝑏𝑏𝑏
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Subjects 
Three of the 31 controls included in section 6.1 had to be excluded from absolute quantification due 
to incomplete records of injected activity.  Twenty-eight healthy older adults were therefore processed 
using the Southampton method to give SBR, SUVmean and SUVpeak normal ranges.  These were calculated 
at two standard deviations below the mean, the same method used in BRASS and DaTQUANT software. 
Fifteen of the 16 MCI-AD cases and 24 of 27 the probable MCI-LB cases from section 6.1 were included 
in the comparison between AD and LB groups and for the diagnostic accuracy calculations.  Two cases 
were excluded due to incomplete injected activity records and two due to being scanned clinically 
within another NHS Trust. 
SUV processing 
Subject image data was reconstructed to give FP-CIT images displayed in units of SUV.  The same FP-
CIT OSEM protocol as used for SBR was applied (OSEM_RRACSC: 16 iterations and 4 subsets; resolution 
recovery, uniform scatter and attenuation correction).  The images were reoriented to standard planes 
within HybridRecon after reconstruction to assist with VOI placement.  The reconstructed images were 
registered to the ENC-DAT normal template, which had had the BRASS striatal VOIs removed and 
replaced by the Southampton striatal VOIs (Figure 44). The occipital background used in BRASS was 
used as the background in the Southampton method.  The template VOIs were transferred to the 
subject scan after rigid registration and the VOI statistics exported as an xml file.  SUVmean values for 
the right and left striata were calculated within a spreadsheet following the method outlined above.  
SBRs obtained with the Southampton method were also calculated, by dividing striatal and background 
SUVmean.  SUVpeak was recorded for each striatum.   
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Figure 44: ENC-DAT template used in BRASS with Southampton VOIs added (bottom row), registered to a patient scan (top). 
The two SUVpeak cube VOIs are seen in the caudate nuclei on the patient scan. 
Evaluation of SUV normalisation methods 
The normalisation method used in SUV calculation was assessed by plotting striatal SUVmean and SUVpeak 
for the controls against background SUVmean.  Background SUVmean values should be similar for all 
controls, and striatal uptake should not depend on the background if normalisation is appropriate.  Any 
residual relationship between background levels and striatal uptake is indicative of a potential 
problem. 
Display of images with absolute SUV scale 
Example control and MCI-LB subjects were displayed with the SUV scale applied, as a preliminary 
assessment of whether absolute scaling could be suitable for visual reporting and worthy of further 
evaluation in future. 
6.2.3 Results 
Normal thresholds 
The mean, standard deviation, coefficient of variation and normal threshold cut-offs obtained from 
the 28 controls are shown in Table 23. 
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Table 23: SBR and SUV values for controls with normal threshold values (mean-2SD).   
 Southampton SBR Southampton SUVmean SUVpeak 
 Right Left Right Left Right Left 
Mean 5.88 5.74 8.15 7.95 6.35 6.43 
SD 0.66 0.73 1.17 1.21 0.72 0.82 
CoV 11% 13% 14% 15% 11% 13% 
Threshold 4.56 4.27 5.81 5.54 4.90 4.79 
 
MCI results compared with controls 
Plots of SBR, SUVmean and SUVpeak obtained with the Southampton method are shown in Figure 45, with 
both the right and left striata included.  The SBR results with BRASS are also shown for comparison.  
There are two slight outlier control subjects for SUVmean (one high, one low), which are not seen with 
SBR.  These subjects have likely contributed to the slightly higher coefficient of variation with SUVmean.  
The high outlier is much more obvious with SUVpeak and was excluded from the normal range.  Visually, 
the SUVmean plot appears to show less of a distinction between MCI-LB and the other groups than the 
SBR plot - calculated with either the Southampton method or BRASS.  SUVpeak shows even less distinct 
groups. 
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Figure 45: Whole striatum SBR, SUVmean and SUVpeak for controls, MCI-AD and MCI-LB calculated with the Southampton 
method.  Both left and right striata are included.  BRASS SBR is also shown for comparison (bottom left).  The outliers are for 
the right and left striata of the same control, who was excluded from the SUVpeak normal cut-off. 
 
Diagnostic accuracy in MCI-LB 
The diagnostic accuracy figures for the SBR and SUV methods are given in Table 24.  These are 
calculated using the lower of the two striatal values for each MCI patient.  SUVmean gives the same 100% 
specificity as SBR with both BRASS and Southampton method.  The sensitivity however is lower than 
BRASS SBR for both SUVmean and Southampton method SBR due to only 7/24 MCI-LB cases falling below 
the control normal threshold.  However, the 95% binomial confidence intervals are wide due to low 
sample sizes and none of the results for any method are significantly different from any other. 
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Table 24: Sensitivity, specificity and overall accuracy for MCI-LB diagnosis for SBR calculated with BRASS and Southampton 
methods, SUVmean caclulated with Southampton method and SUVpeak. 
 
Sensitivity (95% CI) 
Specificity 
(95% CI) 
Accuracy 
(95% CI) 
BRASS SBR  10/24  
42% (22 to 63%) 
15/15 
100% (78 to 100%) 
25/39 
64% (47 to 78%) 
Southampton SBR  7/24  
29% (12 to 51%) 
15/15 
100% (78 to 100%) 
22/39 
56% (40 to 72%) 
SUVmean  7/24  
29% (12 to 51%) 
15/15 
100% (78 to 100%) 
22/39 
56% (40 to 72%) 
SUVpeak  6/24  
25% (10 to 47%) 
13/15 
87% (60 to 98%) 
19/39 
49% (32 to 65%)  
 
Evaluation of SUV normalisation methods 
The coefficient of variation in background mean SUV was 19%.  Plots of striatal SUVmean, SUVpeak, 
Southampton method SBR and BRASS SBR against background SUVmean are shown in Figure 46 with 
slopes, p-values and R2 data in Table 25.  Striatal SUV shows a positive relationship with background 
SUV, particularly for SUVpeak, which is highly correlated with background SUVmean (p <0.001).  The SBR 
with the Southampton method shows a negative relationship with background SUV (p <0.001).  There 
is no significant relationship between BRASS SBR and background SUV. 
Table 25: Slopes for linear fits to SUVmean background for each parameter with associated p-values for difference from zero. 
The estimated percentage variation explained by background SUV is given. 
 SUVmean SUVpeak SBR 
(Southampton) 
SBR (BRASS) 
Slope 2.82 4.49 -1.45 -0.23 
p-value for slope <0.001 <0.001 <0.001 0.09 
R2 34% 87% 23% 9% 
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Figure 46: Striatal SUVmean and SUVpeak plotted against background SUVmean (top), showing a positive correlation.  The 
correlation between SBR and background signal is less obvious. 
 
Display of images with absolute SUV scale 
Figure 47 shows examples of SUPErB images displayed using the standard relative scale and the 
absolute SUV scale.  The abnormal MCI-LB images can be identified with the relative scale by examining 
the background appearance, but with the SUV scale the loss of striatal uptake is immediately apparent.  
However, variation in the appearance of images due to the background variation seen above may limit 
the utility of the scale.  Figure 48 shows three control examples with different background SUV levels 
displayed with the absolute scale, showing different striatal appearances. 
R² = 0.3364
0.00
2.00
4.00
6.00
8.00
10.00
12.00
1.00 1.20 1.40 1.60 1.80
SU
Vm
ea
n 
(S
ou
th
am
pt
on
)
Background mean SUV
R² = 0.8717
0
2
4
6
8
10
12
1.00 1.20 1.40 1.60 1.80
SU
Vp
ea
k 
Background mean SUV
R² = 0.2345
0.00
2.00
4.00
6.00
8.00
10.00
12.00
1.00 1.20 1.40 1.60 1.80
SB
R 
(S
ou
th
am
pt
on
)
Background mean SUV
R² = 0.09
0
0.5
1
1.5
2
2.5
3
3.5
4
1.00 1.20 1.40 1.60 1.80
SB
R 
(B
RA
SS
)
Background mean SUV
100 
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Figure 47: A normal control and two abnormal MCI-LB scans displayed with the standard relative display used in clinical 
practice for visual reporting (left) where the images are scaled relative to the maximum voxel and displayed using an absolute 
scale (right) relative to a maximum SUV of 8. 
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 Example 1:  
SUVpeak = 9.2 
SUVmean background = 1.93 
Example 2: 
SUVpeak = 6.1 
SUVmean background = 1.55 
Example 3: 
SUVpeak = 5.8 
SUVmeanbackground = 1.12 
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Figure 48: Control images with differences in SUV showing quite dramatic differences in image appearance.  The images are 
scaled to a maximum SUV of 12 in the top row and 8 in the bottom row.  The background SUV appears linked to the striatal 
appearance in the first two examples. 
 
6.2.4 Discussion 
In this dataset of MCI patients, the accuracy of SUVmean and SUVpeak were both lower than BRASS SBR, 
although not significantly so.  At first glance this appears to be in line with the Japanese studies 
comparing SUV and SBR in dementia, which found slightly lower diagnostic accuracy with SUV, using 
ROC analysis [196, 197].  However, in our dataset, SUV and SBR calculated with the Southampton 
method both gave the same results, both lower than BRASS SBR.  This suggests that the Southampton 
method, or more likely its implementation here using image registration, may not be ideal for obtaining 
volumes of interest for either SBR or SUV.  This will be explored further with phantom studies in the 
next section.  We would have liked to have used absolute quantification values from BRASS, to enable 
more meaningful comparison with BRASS SBR to be made, but this is not currently supported.  It is 
hoped that this could be made available for research use in future.  We assessed SUVmean using the 
Southampton method as a proof-of-concept, with the possibility of requesting modifications to BRASS 
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in future to support SUV-SPECT without the reliance on a background region, if SUVmean seems a 
promising parameter. 
While we cannot disregard SUVmean as a useful metric, the evidence here suggests that we should reject 
SUVpeak.  The SUVpeak accuracy results were even lower than for SUVmean, with some extreme outliers in 
the controls and possible outliers in other categories.  A common pattern of dopaminergic loss is for 
the putamina to appear reduced compared to the caudate (Figure 49), which can lead to visually 
abnormal scans with normal SUVpeak values.  This was suspected to be a limitation of SUVpeak from the 
outset, but as SUVpeak values are output by the software alongside SUVmean this seemed a good 
opportunity to confirm or refute our assumptions.  The SUVpeak results in controls were also highly 
dependent on background SUV levels, suggesting they cannot be an accurate reflection of 
dopaminergic function.   
   
Figure 49: Left: visually abnormal MCI-LB scan with SBR, SUVmean and SUVpeak all within normal limits.  Right: visually abnormal 
MCI-LB scan with abnormal SBR and SUVmean but right SUVpeak (in caudate) within normal limits. 
 
Display of images with a relative scale has the techical disadvantage of being dependent on a single 
voxel (the maximum), which means the background appearance images is inherently quite uncertain, 
particularly in cases of low striatal uptake.  The absolute scale could therefore offer advantages for 
visual ratings.   In Glasgow, the SUV scale has been compared to the standard relative scale and raters 
were found to be more accurate when using it (data presented at BNMS conference 2017 by Dr. Colin 
Brown).  However, a different reconstruction method (FBP) was used for the relative scale so the 
images were not compared like-for-like and the results may not hold using the more sophisticated 
reconstruction methods used for visual ratings in SUPErB.  This has not been explored further as part 
of this thesis due to the considerable time required from raters but does appear to warrant further 
investigation in future. 
Data from our controls suggests that there is a wide variation in normal image appearances when 
scaled to an absolute SUV scale, more so than seen with a relative scale.  This may reduce the specificity 
of such a scale in practice.  The variation appears to be related to the background SUV demonstrated 
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above.  Variation in background SUV may be due to factors such as incorrect recording of activity, assay 
times or patient weight, normal physiological variation in the amount of FP-CIT crossing the blood-
brain barrier or imperfect normalisation to tracer volume of distribution using the patient weight 
method.   
A potential limitation of accuracy of the reconstruction used in this work was that we used uniform 
attenuation and scatter correction, rather than CT based methods.  This was so that the results were 
more comparable with BRASS SBRs from the previous section and also more generalisable to other 
centres.   The impact on kBq/ml accuracy will be investigated in the next section using the striatal 
phantom filled with known activity concentrations. 
6.2.5 Conclusion 
The accuracy of striatal SUVmean and SBR calculated with the Southampton method are similar.  
However, both appear less accurate than SBR calculated with BRASS.  We hope to be able to evaluate 
SUVmean calculated with BRASS at a later date following software modifications.  Visual rating using the 
absolute SUV scale appears promising and worth future evaluation, although the specificity may be 
limited by substantial normal variation in SUV, which appears to be related to the weight-based 
normalisation method. 
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 Advanced FP-CIT reconstruction methods: a phantom study 
6.3.1 Introduction 
As previously discussed, there are potential benefits to be gained from absolute quantification, which 
requires both accurate measurement of activity concentration and appropriate normalisation to 
patient size.  Accuracy can be difficult to assess in patient studies as both these factors are combined, 
but the results in the previous section suggest the accuracy of striatal SUV may be limited by the 
normalisation step.   In this section we consider the accuracy of kBq/ml quantification in a phantom 
study where normalisation to give SUV is not required. 
So far in this thesis the method used for 123I-FP-CIT reconstruction has not taken into account the effect 
of septal penetration of high energy photons through the collimator.  Towards the end of this 
fellowship a more advanced reconstruction algorithm became available within Hermes HybridRecon 
for Siemens LEHR collimators, which Hermes term full collimator modelling (FCM).  The FCM algorithm 
corrects for the septal penetration of high energy emissions, as described in Chapter 3.  Use of the 
FCM reconstruction to correct for septal penetration and collimator scatter has the potential to 
improve the accuracy of FP-CIT quantification with LEHR collimators, whilst maintaining high 
resolution.  Hermes use the label “MCRR_ACSC” for the reconstructed images, with MC indicating that 
the full Monte Carlo collimator model has been used.  Note that Monte Carlo simulation is also used 
in the standard reconstruction used in previous sections, to estimate the scatter occurring within the 
patient - in the new MCRR version it is also used to model the interactions with the collimator. 
Both the standard and the full Monte Carlo reconstructions can be used with either uniform 
attenuation and scatter correction, where the head is modelled as water, or with CT (measured) 
attenuation and scatter correction, where the attenuation coefficients to apply are determined from 
the CT scan.   CT ACSC should in theory give a more accurate reconstructed image than ACSC with the 
uniform assumption.  However, most centres, including Newcastle Hospitals, do not perform SPECT-
CT imaging for FP-CIT routinely.  Some authors have shown CT attenuation correction to be no more 
accurate than uniform correction for FP-CIT [102, 162, 198], but it should be noted that the 
reconstruction method were different from those considered here.   CT was added to the SPECT 
protocol for SUPErB so that it could be compared with uniform correction with these advanced 
reconstruction methods, and recommendations made for clinical practice and future research studies. 
Hermes recommend that a higher number of iterations is used for 123I SUV-SPECT than is recommended 
for BRASS: 4 iterations and 30 subsets (equivalent to 120 overall iterations).  The protocol 
recommended for SBR calculation with BRASS uses 16 iterations and 4 subsets (equivalent to 64 overall 
iterations).  The differences between the methods with 120 and 64 iterations was explored in the 
phantom with recommendations for clinical scans made. 
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In this section SPECT images were obtained by scanning a phantom filled with a range of different 
known activities, chosen to cover the range of SBRs encountered in clinical practice.  The aim of this 
work was to determine the accuracy of SBR and activity concentration measurement on SPECT images 
generated from the acquired phantom data using a range of different reconstruction methods.  Images 
reconstructed with our standard reconstruction protocol were compared with a range of advanced 
methods combining CT attenuation and scatter correction and Monte Carlo collimator modelling, as 
described below. 
6.3.2 Methods  
Reconstruction methods 
The reconstruction methods used in this section are summarised in Table 26.  Apart from the changes 
in ACSC method and the use of FCM, the reconstruction parameters recommended by Hermes for FP-
CIT scans to be analysed with BRASS were used, i.e. 16 iterations with 4 subsets and a 0.7cm Gaussian 
post-filter for smoothing.   As all reconstructions here use OSEM with some form of ACSC this was 
removed from the name for clarity.   The reconstruction labelled RR_uniform in this section is therefore 
exactly the same as the standard reconstruction referred to as OSEM_RRACSC elsewhere this thesis.  
All four reconstructions described here were also calculated with the increased number of iterations 
(4 iterations 30 subsets) recommended by Hermes for SUV-SPECT.   
 
Table 26: Description of the four reconstruction methods used in this section. 
 Attenuation map Patient scatter 
correction 
Collimator model 
RR_uniform (standard 
method) 
 
Uniform density of 
water assumed 
MC simulation based 
on uniform density 
Gaussian depth 
dependent resolution 
recovery model, no 
correction for septal 
penetration 
RR_CT 
 
Measured densities 
(CT) 
MC simulation based 
on measured 
densities 
Gaussian depth 
dependent resolution 
recovery model, no 
correction for septal 
penetration 
MCRR_uniform 
 
Uniform density of 
water assumed 
MC simulation based 
on uniform density 
Gaussian RR + Full 
Monte Carlo 
collimator model 
MCRR_CT 
 
Measured densities 
(CT) 
MC simulation based 
on measured 
densities 
Gaussian RR + Full 
Monte Carlo 
collimator model 
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Striatal phantoms 
The raw planar data from the striatal phantom acquisitions described in section 4.1 were used to 
reconstruct sets of transaxial slices with each of the different reconstruction methods – this slice data 
was then input into BRASS to determine SBR values for each method.   
To recap, the striatal phantom (RSD Radiology Support Devices, Long Beach, CA, USA) consists of plastic 
striatal compartments that are filled with 123I solution, which sit within a brain background filled with 
more dilute solution (see Figure 17, section 6.1.2 for illustrations).  The exact activity concentrations 
in the phantoms are determined using aliquots from each compartment measured in a sample 
counter.   The images were reconstructed with each of the reconstructions in Table 26, with both sets 
of iterations.  The measured SBRs and activity concentrations, are given in Table 27 and Table 28.  
Different activity concentrations are used for the right and left striata so that two SBRs could be 
acquired in the same scan.  SBR is calculated as follows: 
𝑆𝑆𝐵𝐵𝑅𝑅 =  𝑘𝑘𝐵𝐵𝑞𝑞/𝑚𝑚𝑙𝑙𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 − 𝑘𝑘𝐵𝐵𝑞𝑞/𝑚𝑚𝑙𝑙𝑏𝑏𝑠𝑠𝑐𝑐𝑏𝑏𝑏𝑏𝑠𝑠𝑐𝑐𝑠𝑠𝑏𝑏𝑏𝑏
𝑘𝑘𝐵𝐵𝑞𝑞/𝑚𝑚𝑙𝑙𝑏𝑏𝑠𝑠𝑐𝑐𝑏𝑏𝑏𝑏𝑠𝑠𝑐𝑐𝑠𝑠𝑏𝑏𝑏𝑏  
The left and right striatal compartments are filled with solutions of different activity concentration to 
obtain two independent measurements per scan.   The SBR values in the phantom are altered between 
scans by leaving the striatal compartments unchanged and increasing the background concentration 
by adding more 123I activity.  This phantom method was developed for calibrating SBR values obtained 
with different gamma cameras [158] and is here extended to activity concentration.   The background 
was increased twice, resulting in three different configurations and six SBR values per phantom 
imaging session.  For the absolute striatal compartment measurements, only the first two 
configurations were used as the final increase in background concentration resulted in very low SBRs. 
A second set of phantom images acquired on a separate occasion with different activity concentrations 
and SBRs was used to increase the number of striatal activity concentrations sampled.  These sets of 
images are referred to as session A and session B. 
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Table 27: SBRs for the striatal phantoms, measured using a sample counter 
 Right striatum 
SBR 
Left striatum 
SBR 
Session A Background 1 5.82 4.56 
Session A Background 2 2.37 1.75 
Session A Background 3 0.70 0.39 
Session B Background 1 13.7 8.71 
Session B Background 2 5.61 3.36 
Session B Background 3 2.07 0.91 
 
Table 28: Measured phantom activity concentrations for background and striatal compartments.  The third configuration with 
the background increased again was not used for kBq/ml measurements as the striatal to background ratios were so low.  
  Session A 
Activity concentration 
kBq/ml 
Session B 
Activity concentration 
kBq/ml 
Configuration 1 Background 5.58 3.34 
Right striatum 38.0 49.2 
Left striatum 31.0 32.4 
Configuration 2 
(increased 
background) 
Background 8.89 5.96 
Right striatum 30.0 39.4 
Left striatum 24.5 26.0 
 
Calibration factor 
The calibration factor used in section 6.2 to convert between image count density and activity 
concentration was recalculated with all the reconstruction protocols described above.  This was to 
determine if there were differences between protocols that would be likely to affect apparent uptake.   
The calibration factors are similar for different number of iterations and between RR and MCRR.  Use 
of CT ACSC instead of uniform gives higher apparent activity concentrations (by around 5-6%).  
However in this section the same cps/MBq calibration factor was used throughout, to make it more 
straightforward to compare methods. 
Calculating SBRs and activity concentration on phantom images 
SBRs were calculated within BRASS and by using the Southampton method.  Activity concentrations 
were calculated using the Southampton method only.   The Southampton method, described in section 
6.2, estimates striatal kBq/ml via registration of the phantom to the template (Figure 50) and 
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assumption of a fixed 11.2 ml striatal volume.  The background activity concentration was estimated 
from the mean kBq/ml in the occipital VOI shown in Figure 50.  As discussed in section 6.2, striatal 
activity concentration cannot be measured within BRASS directly because an additional scaling factor 
is applied.  SUVpeak was not investigated using the striatal phantom as it is only output for SUV data, 
not kBq/ml.     
 
 
Figure 50: Southampton method VOIs registered to the striatal phantom.  The occipital VOIs had to be resized because the 
template was slightly big for the phantom. 
 
Effectiveness of ACSC methods 
A second background measurement was taken using a 6cm diameter spherical VOI placed more 
centrally within the phantom (Figure 51).  The occipital and central background measurements were 
compared as an assessment of attenuation and scatter correction. 
 
Figure 51: Additional background VOI used to compare mean kBq/ml with occipital background obtained from the 
Southampton method processing. 
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6.3.3 Results 
Differences between number of iterations 
There was very little difference between results obtained with 16 iterations and 4 subsets (BRASS 
reconstruction) and those obtained with 4 iterations and 30 subsets.  All results from now on refer to 
the BRASS protocol of 16 iterations and 4 subsets. 
BRASS SBR differences between reconstruction methods 
All reconstruction methods gave BRASS SBRs that were much lower than the measured values (around 
50-70%), which is expected due to the partial volume effect [111, 199].  Images reconstructed with CT 
ACSC give lower SBRs than with uniform ACSC, much more so than expected from the small differences 
in calibration factor.   
A plot of the BRASS SBRs against measured SBR for each reconstruction method is shown in Figure 52, 
with the percentage differences between BRASS and measured SBR, and between RR_unform and 
other methods in Figure 53.  The highest SBRs, and therefore the closest to measured values, are given 
by the MCRR_uniform method, although these are still around half the measure values.  There is more 
discrepancy between the reconstruction methods at low and borderline values than for high SBRs.  
There is about a 50% difference between reconstruction methods in the clinically relevant mid range 
(BRASS SBRs of around 1.5 to 3), but very little difference for high uptake. 
  
Figure 52: BRASS SBR against measured SBR for the four reconstruction methods over the full phantom SBR range (left) and 
restricted to a more clinically relevant range (right). 
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Figure 53: The percentage difference between BRASS SBR and measured SBR for all reconstruction methods (left) and between 
standard RR_Uniform and other methods (right). 
 
Southampton method SBR differences between reconstruction methods 
Plots of Southampton SBRs in the striatal phantoms against known values are shown in Figure 54.  Both 
RR and MCRR methods with uniform attenuation and scatter correction appear to overestimate SBR, 
particularly at high SBR, but with CT corrections SBR is underestimated at all SBR values suggesting a 
systematic error.  In the clinically relevant range (measured SBR of around 5) the RR_uniform 
reconstruction gives reasonably accurate SBRs.  
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Figure 54: Plots of Southampton SBR results in striatal phantom against measured SBR for all four reconstruction methods.  
The line of identity is shown in green.   
 
Activity concentration differences between reconstruction methods 
Although the calibration factors obtained with the uniform phantom were similar to within 10% for 
the various reconstruction methods, the background activity concentrations in the striatal phantom 
images were much higher with CT ACSC than with uniform ACSC.  The reconstructions using the full 
Monte Carlo collimator model (MCRR) also gave higher values for background activity concentration 
than the basic Gaussian collimator model (RR).  Figure 55 shows the difference in background activity 
concentration, striatal activity concentration and SBR for each of the methods.  It is demonstrated that 
although CT ACSC gives higher results than uniform ACSC for both background and striatal activity 
concentration, the difference between the methods is less for the striata.  This results in CT ACSC SBRs 
that are lower, and less accurate, than those obtained on uniform ACSC images, as seen on the plots 
in Figure 54 above.  Higher background with CT ACSC results in lower SBR. 
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Figure 55: Background activity concentration (top), striatal activity concentration (middle) and BRASS SBR (bottom) for the 
different reconstruction methods.  The MCRR_CT reconstruction gives the background result closest to the measured activity 
concentration of 5.58 kBq/ml.  The true activity concentrations and SBRs are noted on the plots. 
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Table 29 shows the percentage difference in activity concentration for the advanced reconstruction 
methods compared to the RR_Uniform method.  The background activity concentration differences 
for each reconstruction are shown for the phantom scanned on two separate occasions with different 
activity concentrations, alongside the striatal activity concentration differences.  All the methods give 
higher activity concentrations than RR_Uniform, but the percentage differences are very variable.  
Table 29: Percentage difference in activity concentration between standard RR_Uniform and other reconstruction methods. 
  Background Right striatum Left striatum 
Session A RR_CT 42% 21% 12% 
MCRR_uniform 9% 18% 19% 
MCRR_CT 55% 41% 34% 
Session B RR_CT 93% 91% 81% 
MCRR_uniform 8% 11% 7% 
MCRR_CT 107% 110% 99% 
 
Effectiveness of attenuation and scatter correction 
The difference between the occipital background at the edge of the brain (i.e. the background VOI 
used in the Southampton method) and a 6 cm spherical background VOI placed more centrally is shown 
in Table 30 for uniform and CT ACSC methods.  The activity concentration for the central VOI is higher 
than the occipital VOI, with the difference more marked for uniform ACSC, indicating possible 
overcompensation for attenuation and scatter.  This may contribute to the SBR differences between 
uniform and CT methods. 
Table 30: Percentage difference between occipital background activity concentration in the phantom and spherical VOI placed 
more centrally with different reconstruction methods. 
 Session A (5.58 kBq/ml) Session B (3.34 kBq/ml) 
 RR MCRR RR MCRR 
 Uniform CT Uniform CT Uniform CT Uniform CT 
Occipital-central -0.46 -0.13 -0.61 -0.22 -0.64 -0.16 -0.82 -0.20 
Percentage difference -13% -3% -15% -4% -30% -5% -33% -6% 
 
Accuracy of striatal activity concentration with the Southampton method 
Plots of striatal activity concentration for the Southampton method are shown in Figure 56.  Both 
RR_uniform and MCRR_CT methods give noisy estimates of striatal activity concentration compared 
to the SBR results above. The correlation is better with CT ACSC, but there is still low agreement with 
the measured values, with values underestimated by a factor of 2-3.  
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Figure 56: Plots of Southampton striatal activity concentration results in phantom against measured activity concentration 
for RR_Uniform (left) and MCRR_CT (right).  The line of identity is shown in green.   
 
6.3.4 Discussion 
The reconstruction method had a greater impact on both SBRs and striatal activity concentrations than 
was expected from the calibration factor differences.  The calibration factor is obtained using a uniform 
phantom so it seems likely that this is linked to differences in geometry.   
CT ACSC gave higher activity concentration results than uniform correction in the occipital background 
region.  Striatal values were also higher with CT ACSC than with uniform corrections, but there was less 
of a difference.  This results in lower (and therefore less accurate) SBRs for CT ACSC than uniform.  It 
is not clear why this is the case, but the difference between the occipital and central background VOIs 
with uniform correction suggests that attenuation and scatter correction differences may contribute 
to the differences between CT and uniform SBR.  The effect of the different reconstruction methods 
on clinical SBR and diagnostic accuracy will be investigated in the next section. 
The large differences between reconstruction methods at lower SBRs suggest that problems with 
image registration at lower relative striatal activity may have introduced uncertainty.  The phantom 
“brain” is smaller than the BRASS template, so the background VOIs are closer to the edge of the 
“brain” than they would be in patients, which may have contributed to random error.  The original 
paper on calibrating gamma cameras with a striatal phantom [158] uses the Southampton method 
with a larger background VOI and reports a random error of 14%, but does not discuss uncertainty at 
low SBRs.  Dickson et al. [156] noted that different activity distributions in FP-CIT phantom images may 
require different numbers of iterations to achieve convergence.  This may explain the wide variation 
in the phantom striatal activity concentration measurements and suggests that it would have been 
preferable to alter striatal activity concentration and keep background concentration constant.  This is 
difficult to achieve in practice. 
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Estimating striatal uptake with the Southampton method using background reference regions appears 
to introduce uncertainty.  If BRASS is modified in future it would be useful to see whether kBq/ml 
values measured directly give more accurate results. 
Accurate measurement of kBq/ml values is a pre-requisite for clinical quantification with SUV-SPECT, 
but this alone is not sufficient to ensure accuracy of absolute quantification as there are other factors 
that affect SUVs.  Work presented in the previous section using control SUV images showed that in 
practice there remain considerable obstacles to implementation due to issues with normalisation.  
6.3.5 Conclusion 
Advanced reconstructions methods appear to provide accurate activity concentration results, judging 
by the background measurements.  Estimates of background activity concentration in the phantom 
are higher and more accurate with CT attenuation and scatter correction with Monte Carlo collimator 
modelling (MCRR_CT) than with uniform attenuation and scatter correction.  However, SBRs are 
actually lower and therefore less accurate with MCRR_CT, because of the higher background.   The use 
of advanced reconstruction methods for relative quantification in clinical images will be explored for 
SUPErB patients in the next section. 
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 Can SBR using advanced FP-CIT reconstruction methods improve early diagnosis? 
6.4.1 Introduction 
The iterative reconstruction method used for clinical FP-CIT images so far in this thesis, OSEM with 
resolution recovery and uniform attenuation and scatter correction (RR_uniform), is already advanced 
compared to the uncorrected OSEM and FBP methods still used clinically in some departments.  The 
Society of Nuclear Medicine FP-CIT guidelines state that “Iterative reconstruction is preferred, but 
filtered back projection may be used” [112] and the European Association of Nuclear Medicine also 
lists both FBP and iterative reconstruction as options [113].  Both recommend attenuation correction, 
either with uniform method or CT but neither discuss additional image corrections, including scatter 
correction, which Hutton states is as essential for accurate quantification as attenuation correction 
[92].    However, these guidelines were published in 2011 and 2009 respectively, before more advanced 
image corrections became routinely available.   
Most centres, including Newcastle Hospitals, do not perform SPECT-CT imaging for FP-CIT routinely.  
Some authors have shown CT attenuation correction to be no more accurate than uniform correction 
for FP-CIT [102, 162, 198], but it should be noted that the reconstruction methods were different from 
those considered here.   In the previous section more advanced FP-CIT reconstruction methods using 
CT ACSC and Monte Carlo collimator modelling were introduced.  CT was added to the SPECT protocol 
for SUPErB so that it could be compared with uniform correction with these advanced reconstruction 
methods, and recommendations made for clinical practice and future research studies. 
In this section we compare SUPErB subjects images reconstructed with our standard protocol with 
those using the full collimator model, both with and without CT attenuation and scatter correction.  
The aim is to assess the differences between SBRs for each method and to evaluate the impact of using 
advanced methods on diagnostic accuracy in MCI. 
6.4.2 Methods  
Reconstruction methods 
The four reconstruction methods used in this section are the same as those used in the phantom study 
in the previous section:  RR_Uniform, RR_CT, MCRR_Uniform and MCRR_CT.   The SUV-SPECT 
reconstruction parameters, with 4 iterations and 30 subsets are not included in this section as the 
phantom data showed little difference between the two.   
For consistency, the same initial cropping of the raw data was used for each reconstruction, and no 
image reorientation was performed, so that the input images into BRASS would all have the same 
geometry.  When reconstructing the CT ACSC images, the SPECT-CT alignment was checked and 
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adjusted if necessary.  The same shifts were applied to the RR_CT as to the MCRR_CT to remove 
additional sources of variation. 
SUPErB subjects 
The 31 healthy older adults were processed to give reconstruction-specific normal ranges, since the 
BRASS ENC-DAT database is only valid for the RR_Uniform reconstruction.  We calculated the 
coefficient of variation of the control SBRs for each reconstruction.   
Fifteen of the 16 MCI-AD cases and 25 of 27 the probable MCI-LB cases from section 6.1 were included 
in the comparison between AD and LB groups and for the diagnostic accuracy calculations.  The MCI-
AD case was excluded because no CT was acquired due to a scanner fault.  The 2 MCI-LB scans obtained 
at other centres were excluded as the scanner was a different model and no CT was acquired.  All the 
SUPErB MCI patients, including 11 less certain possible MCI-LB cases were included to assess any 
systematic differences between reconstruction methods, but only the probable cases were included 
in the diagnostic accuracy calculation.  
SBRs and Z scores 
SBRs were calculated using BRASS, with the camera correction feature turned off as this has been set 
up for the standard reconstruction method.  BRASS Z scores were not used for the same reason, so age 
correction was not applied.  However, the controls were age matched to the MCI subjects (see section 
6.1.2).   SBRs were recorded for the left and right whole striatum and caudate and putamen sub-
regions.                                                                           
Systematic differences between the SBRs with each reconstruction method were assessed using Bland-
Altman plots, with paired t-tests used to check for a significant difference, after checking for normality 
with histograms.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
The mean and standard deviation of the 31 controls was calculated for each of the four reconstruction 
methods.  This data was used to calculate Z scores for the MCI subjects, where Z = (subject mean – 
control mean)/ control SD.  The Z scores were used for sensitivity and specificity calculations, with a 
cut-off of -2.  Note that this gives the same result as using 2 SD below the control mean as a cut-off, 
but makes the presentation of results more in keeping with standard BRASS output, and makes it easier 
to compare the reconstruction methods if there is a systematic difference in SBR.  Any difference in 
accuracy between reconstruction methods was assessed via ROC analysis using the SigmaPlot 
statistical software package.  Sensitivity, specificity and overall accuracy were calculated twice: once 
using just the whole striatum Z scores and one using z scores for all regions, with the scan being classed 
as abnormal if any Z score falls below -2.  The former approach should be less dependent on mis-
registration errors, but the latter more sensitive to any early changes in uptake predominantly 
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affecting the putamina.  Typically, subregions are used in clinical practice as they are available in BRASS 
and DaTQUANT. 
6.4.3 Results 
SBR differences between reconstruction methods  
The patient results show a systematic difference between the standard RR_uniform reconstruction 
and the same reconstruction using measured (CT) ACSC, with the RR_CT being 14% lower on average 
(Table 31).  The full Monte Carlo model acted in the opposite direction, being 15% higher on average 
with uniform ACSC.  These two effects cancel each other out when comparing the standard 
reconstruction with the most complex MCRR_CT reconstruction.  A comparison between two CT 
reconstructions with and without the full Monte Carlo collimator model also shows an increase in SBR 
with the model applied.  The Bland-Altman plots (Figure 57) reveal that the difference between 
uniform and CT ACSC does not depend on SBR.  However, the difference between reconstructions with 
and without the full collimator model increases with SBR, suggesting that this model could increase 
diagnostic accuracy.  However, Table 32 shows that the percentage difference in SBR between the 
MCI-AD and probable MCI-LB groups is the same for all the reconstruction methods.  The coefficient 
of variation based on control data is also the same.  The plots in Figure 58 show that the variation 
within both MCI-AD and MCI-LB data is much greater than the difference in mean SBR between the 
groups. 
Table 31: Difference in SBR between the standard and more complex reconstruction methods, and between the two CT ACSC 
methods with and without full MC collimator model. 
 
RR_uniform 
vs RR_CT 
RR_uniform vs 
MCRR_Uniform 
RR_uniform vs 
MCRR_CT 
RR_CT vs MCRR_CT 
Mean 
difference (%) 
-0.31  
(-14%) 
0.34  
(+15%) 
0.02  
(+1%) 
0.34 
(+18%) 
P value (paired 
t-test) 
<0.001 <0.001 0.07 <0.001 
 
Table 32: Differences in mean SBR between MCI-AD and probable MCI-LB groups for each of the reconstructions. SBRs are for 
the whole striatum. 
SBR 
differences 
RR_Uniform RR_CT MCRR_Uniform MCRR_CT 
MCI-AD mean 2.41 2.11 2.80 2.49 
Prob MCI-LB 
mean 
2.10 1.80 2.40 2.11 
Difference -0.31 -0.31 -0.40 -0.38 
% difference -13% -15% -14% -15% 
CoV (controls) 11% 12% 11% 12% 
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Figure 57: Bland-Altman plots showing the difference between the reconstruction methods using data for all MCI patients 
Diagnostic accuracy 
The normal cut-offs from the control dataset are given in Table 33 for each reconstruction.  The cut-
offs for the different reconstructions are in keeping with the phantom and MCI patient results.   
Table 33: Mean control SBR and associated normal cut-off values for each region for the four reconstruction methods 
Reconstruction 
method 
Right 
striatum 
SBR 
Left 
striatum 
SBR 
Right 
caudate 
SBR 
Left 
caudate 
SBR 
Right 
putamen 
SBR 
Left 
putamen 
SBR 
RR_Uniform 
Mean 
Cut-off 
2.33 
1.84 
2.34 
1.84 
2.44 
1.89 
2.50 
1.94 
2.21 
1.73 
2.17 
1.65 
RR_CT 
Mean 
Cut-off 
2.05 
1.57 
2.02 
1.49 
2.16 
1.61 
2.16 
1.60 
1.93 
1.47 
1.87 
1.30 
MCRR_Uniform 
Mean 
Cut-off 
2.64 
2.08 
2.63 
2.06 
2.80 
2.17 
2.74 
2.17 
2.46 
1.88 
2.46 
1.85 
MCRR_CT 
Mean 
Cut-off 
2.40 
1.86 
2.37 
1.78 
2.57 
1.92 
2.49 
1.87 
2.22 
1.72 
2.24 
1.61 
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Figure 58:  SBRs for the MCI-AD and MCI-LB groups for each reconstruction method, with the mean SBRs shown as red 
horizontal lines for each group. 
The diagnostic accuracy is similar for all reconstruction methods, with only three discrepancies among 
the four methods (Table 34).  The use of smaller caudate and putamen regions does not appear to 
improve accuracy.   Note that the sensitivity values are slightly lower than in section 6.1 because the 
two abnormal MCI-LB scans acquired at other centres were excluded.  The areas under the ROC curves 
are the same for all methods with p-values between 0.22 and 0.98 (Figure 59,Table 35). 
 
Table 34: Left: diagnostic accuracy based on whole striatum Z scores for each of the four reconstruction methods. Right 
diagnostic accuracy based on the minimum of striatum, caudate and putamen scores. 
 
Sensitivity Specificity Accuracy 
 
 Sensitivity Specificity Accuracy 
RR_Uniform 10/25 
40% 
15/15 
100% 
25/40 
63% 
 RR_Uniform 10/25 40% 
15/15 
100% 
25/40 
63% 
RR_CT 9/25 
36% 
14/15 
93% 
23/40 
58% 
 RR_CT 9/25 36% 
14/15 
93% 
23/40 
58% 
MCRR_Uniform 9/25 
36% 
15/15 
100% 
24/40 
60% 
 MCRR_Uniform 10/25 40% 
15/15 
100% 
25/40 
63% 
MCRR_CT 10/25 
40% 
15/15 
100% 
25/40 
63% 
 MCRR_CT 10/25 40% 
14/15 
93% 
24/40 
60% 
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Figure 59: ROC curves for the four reconstruction methods for whole striatum SBR 
Table 35: Differences between the area under the ROC curve for each reconstruction method, showing no statistically 
significant differences. 
Pair RR_uniform, 
RR_CT 
RR_uniform, 
MCRR_uniform 
RR_uniform, 
MCRR_CT 
RR_CT, 
MCRR_uniform 
RR_CT, 
MCRR_CT 
MCRR_uniform, 
MCRR_CT 
Area 
Difference -0.02 0.00 0.00 0.02 0.02 0.01 
Standard 
Error 0.04 0.02 0.04 0.04 0.02 0.04 
95% 
Confidence 
Interval 
-0.10 to 
0.06 -0.05 to 0.04 
-0.08 to 
0.08 -0.07 to 0.10 
-0.01 to 
0.06 -0.08 to 0.09 
ChiSquare, 
DF = 1 0.22 0.03 0.00 0.13 1.49 0.02 
P Value 0.64 0.86 0.95 0.72 0.22 0.88 
 
6.4.4 Discussion 
The Bland-Altman plots with MCI data showed that CT attenuation and scatter correction gives 
systematically lower SBRs than standard uniform correction, which is what we saw with the phantom 
data in the previous section.  The phantom results suggest that the SBR difference is predominantly 
due to higher background counts with CT ACSC than with uniform ACSC, possibly due to overcorrection 
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with the uniform method.  Warwick et al. noted similar SBR differences in 14 patients reconstructed 
with uniform and CTAC, and suggested that small sub-voxel mis-registrations between SPECT and CT 
may be the cause of lower SBR with CTAC [162].  However it seems unlikely that this would give rise to 
systematically lower SBRs; random differences seem more likely.  We manually registered the SPECT 
and CT data if it was necessary, although this can only correct for mis-registrations that are apparent 
on the pre-reconstruction QC tool provided by Hermes.   
As the difference between SBR with CT and SBR with uniform ACSC is similar over the whole uptake 
range it is not expected to affect diagnostic accuracy, which did indeed seem to be the case.  There 
was actually slightly lower sensitivity and specificity with CT than with uniform corrections so these 
results do not support a change to CT ACSC.   However we are limited by the small sample sizes 
recruited into SUPErB thus far, making it impossible to detect small differences in accuracy with 
certainty.  Interestingly, one of the MCI-AD cases rated as abnormal due to asymmetry in section 6.1 
that had normal quantification with the RR_uniform method does show abnormal right caudate uptake 
with both the CT methods. This reduces the specificity of the CT methods, but should not necessarily 
be regarded as poor performance as the scan does appear abnormal.    
The difference between the standard RR_uniform reconstruction and that with the full Monte Carlo 
collimator model applied was of note as SBRs were greater with the full collimator model.  We would 
expect that scatter into the background region may be being effectively suppressed with this method, 
leading to the increased SBRs.  However with the phantom we saw that the background activity was 
actually higher with MCRR reconstructions than with RR.  The striatal activity was even higher, leading 
to increased SBRs.   As the difference between MCRR and RR increases with SBR, we might expect an 
improvement in the separation between normal and abnormal scans with the full collimator model.  
However the histograms in Figure 60 show that this is not the case, with the MCI subjects showing 
approximately normal distributions, with no division between normal and abnormal.  The diagnostic 
accuracy results (and ROC analysis) also showed no evidence of improved accuracy with the full Monte 
Carlo collimator model applied.  A limitation is that the standard reconstruction parameters of 16 
iterations and 4 subsets (equivalent to 64 iterations), which is recommended for FP-CIT reconstruction 
with RR_Uniform may not be optimised for use with the full Monte Carlo collimator model as it is 
possible that convergence occurs after a different number of iterations.  We chose to keep all 
parameters the same, other than the use of the full Monte Carlo model, so that comparisons could be 
made.  In addition, there were not significant differences seen between reconstructions with 64 and 
120 equivalent iterations in the phantom work. 
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Figure 60: Histograms of standard reconstruction SBRs and full Monte Carlo collimator model, for uniform ACSC.  
By coincidence, the effect of the CT ACSC and the full Monte Carlo collimator model act in opposite 
directions, so there is very little difference at all between the standard RR_Uniform reconstruction 
method and that with all the advanced corrections applied. 
The much greater differences between reconstruction methods at lower SBRs seen in the phantom in 
the previous section are not reflected in the patient Bland-Altman plots in Figure 57.  This suggests 
that problems with phantom image registration at lower relative striatal activity may have introduced 
uncertainty.  The phantom “brain” is smaller than the BRASS template, so the background VOIs are 
closer to the edge of the “brain” than in patients, which may have contributed to random error.   
Clearly, the fact that so many MCI-LB cases do not have abnormal dopaminergic function based on the 
FP-CIT scans makes it difficult to assess reconstruction methods.  We are confident these scans are 
normal as they are within normal limits on both quantification and visual assessment, so the low 
sensitivities do not reflect the accuracy of the reconstruction methods.  As shown in section 6.1 for the 
RR_uniform reconstruction, there is good agreement between expert visual assessment and 
quantification.  We assume that if these subjects with normal FP-CIT scans do have Lewy body disease 
then the disease is not affecting the striatum and may be found in the neocortex, for example.    
It is any change in interpretation of the borderline cases that is of interest, and which we do not see 
much of in this dataset.  We can therefore assume that any increase in the quantitative accuracy of 
reconstructions with the use of CT ACSC or the application of the full collimator model does not have 
a clinically significant effect on SBR interpretation.  The FCM could be applied as an additional 
reconstruction using the uniform ACSC assumption for further assessment as it does not inconvenience 
the patient and does not appear to reduce accuracy; however reconstruction times are currently still 
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quite long with this method (about 10 minutes) as Hermes have not yet implemented it with GPU 
processing.  It currently is not supported by BRASS so can only be used with a local normal database. 
Given the differences between SBRs with the full collimator model implemented, it is clearly important 
for users not to attempt to analyse FCM data with BRASS using the ENC-DAT database, as this was 
reconstructed with the RR_uniform method, so results are likely to be too high.  Because of this clinical 
risk, the full collimator model has not yet been released for HybridRecon Neurology and these results 
were obtained under a research agreement with Hermes.  In our dataset, if MCRR_uniform results are 
interpreted using Z scores from controls reconstructed with RR_uniform, two of the 10 probable MCI-
LB cases with abnormal results (20%) would be interpreted as normal.   
6.4.5 Conclusions 
The use of CT attenuation and scatter correction reduces SBR with respect to uniform correction, but 
does not have a significant impact on diagnostic accuracy.  The use of the full Monte Carlo collimator 
model increases SBR, with the difference between SBR values with and without FCM applied increasing 
with SBR.  However this also does not appear to have a significant impact on the interpretation of 
clinical SBR results in this dataset.  In clinical practice we would not recommend CT ACSC as this 
increases the radiation dose and scan time with no demonstrable benefit.  The FCM method with 
uniform ACSC could continue to be used for research as in theory the greater SBR difference at higher 
SBRs could make the method more accurate, and if so this could perhaps be demonstrated with a 
larger study of borderline cases with clinical follow-up.  Currently there does not seem to be strong 
evidence for centres using the standard BRASS reconstruction method to switch to the full collimator 
model. 
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 Test-retest variation of FP-CIT SBR and SUV in healthy older adults  
6.5.1 Introduction 
The assessment of longitudinal change in dopaminergic function via repeat FP-CIT scanning is an 
important part of the SUPErB study with the aim of assessing the rate of dopaminergic loss in early 
Lewy body disease.  Around half of the participants with clinical diagnoses of MCI with Lewy bodies 
had normal FP-CIT scans at baseline.  All SUPErB patients and controls have been invited to return for 
a repeat scan one year after the baseline scan, and we are in the process of arranging further follow 
up scans.  Given the considerable inter-subject variation, a subject with uptake at the top of the normal 
range could drop considerably and still be within normal limits at follow up.  The change in uptake of 
an individual over time may therefore be a useful biomarker for Lewy body disease, although this will 
depend on the test-retest variation in the scanning technique.      
In our adults with normal cognitions, we would not expect more than a 1.5% drop in the year between 
baseline and follow up, since the rates of decline in the literature for healthy controls are between 3% 
and 14% per decade [200].  This anticipated lack of true change in uptake means that the baseline and 
follow up scans in older adults with normal cognition can be used to give an estimate of FP-CIT test-
retest variation.  This is a measure of how different we might expect the uptake measurement to be 
due to physiological and technical sources of variation if the scan was repeated.  This is something that 
is not often included in research studies with FP-CIT, possibly due to the considerable cost of the scan 
and the additional radiation dose to the participants.   
An early publication by Booij et al. studied six healthy women aged 51 to 70 years, rescanning after 3-
6 weeks [201].  The test-retest variability in SBR was 7% and intraclass correlation coefficient (ICC) 
0.95, indicating excellent repeatability.  Matsuoka et al. studied 8 healthy young men rescanned 
between 1 and 4 weeks, with FP-CIT scans registered to MRI images [202].  The test-retest variation 
was 6% for the whole striatum, with ICC 0.95 [202].   However, Tsuchida performed repeat scans after 
one week on 10 healthy controls aged between 25 and 70 years, reporting a higher test-retest 
variability of 11% and intraclass correlation coefficient (ICC) of only 0.59 for the whole striatum [203].  
Differing protocols and analysis methods for striatal uptake make it difficult to compare between 
studies. 
The most relevant study was carried out at Newcastle University in 2005, where Colloby et al. found 
test-retest variation of around 10% between repeat scans of 15 healthy older adults scanned a year 
apart, and ICC of around 0.7, indicating reasonable repeatability over a 1 year time gap [204].  The 
scans were acquired, reconstructed and analysed differently from the SUPErB study, so may not reflect 
the repeatability of methods used in this thesis. We were unable to reanalyse this data with current 
methods as the raw data had not been archived so the images could not be reprocessed.  We have 
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found no other studies of test-retest repeatability over a longer time scale that would help to inform 
the expected random variation in SBR that may occur in follow up scans in patients suspected of having 
Lewy body disease.  Jacobson Mo et al. studied baseline and repeat FP-CIT at three and five years in 
16 healthy controls as part of a longitudinal Swedish Parkinson’s disease study [205, 206].  The mean 
age at baseline was 69.5 ± 7.0 years and there was no significant difference in mean uptake at follow 
up compared to baseline, with “a varying pattern for both a relative decline and a relative increase” in 
FP-CIT uptake [206].  The aim of this study was to assess age related changes, so test-retest 
repeatability analysis was not carried out, however the lack of change in uptake is encouraging.  To our 
knowledge, there have been no other previous studies with repeat FP-CIT scans in healthy subjects 
with similar time gaps (a few years), no studies using state of the art automated quantification 
methods such as BRASS or DaTQUANT and no studies assessing the repeatability of absolute striatal 
uptake (SUV-SPECT).   Although absolute quantification with SUVmean at baseline appeared less 
accurate than SBR with BRASS, SUV may have a role for follow up studies in the same patient since 
accurate normalisation will be less important. 
The test-retest analysis covered in this section was carried out towards the end of the doctoral 
fellowship, when 27 of the 31 healthy older adults had consented to and undergone a repeat FP-CIT 
scan.  The aim of this work was to compare SBR, SUV and visual assessment in a group of cognitively 
normal subjects scanned at one year interval. This provides a surrogate measure of the test-retest 
repeatability which is important in assessing disease progression in studies in patients.  Possible 
reasons for test-retest variation, such as operator variability were explored. 
6.5.2 Methods 
Subjects 
The SUPErB cohort of healthy older adults was used for this analysis, with 27 individuals with repeat 
scans included in this section.  Seven of the repeat scans had not yet been rated by the panel, so 20 
scans were included to assess the concordance between baseline and repeat visual assessment.  The 
repeat scans were carried out between 355 and 490 days after the baseline scan (mean 390 days ± 35). 
FP-CIT imaging 
The standard acquisition and reconstruction methods outlined in section 6.1 were used. Briefly, 
subjects were administered 185 MBq FP-CIT and scanned 3-6 hours after injection on a Siemens 
gamma camera fitted with LEHR collimators.  Images were reconstructed with 16 iterations and 4 
subsets, with uniform attenuation and scatter correction and resolution recovery applied.   
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Visual ratings 
Visual ratings at baseline and follow up were assigned independently of one another, using the 
consensus panel approach outlined in section 6.1. 
Consistency of processing for semi-quantification 
As semi-quantification is a routine part of the SUPErB study, the baseline and repeat studies were 
reconstructed and processed independently of one another, and not necessarily by the same operator.  
It was noted that several baseline and repeat scans had quite different BRASS quantification results, 
more extreme changes than expected from the literature.  In section 4.4 we showed that BRASS was 
insensitive to reorientation of the same scan, but repeat scans were not investigated as they were not 
available at the time.  We therefore investigated whether reprocessing of these scans would give more 
consistent results (Appendix F).  Careful reprocessing of baseline and repeat scans by the same 
operator did not result in more consistent SBR values, so the original data is used in this section. 
Quantification of striatal uptake 
Semi-quantification was carried out with BRASS using the ENC-DAT database normal range, with 
camera correction and age correction applied.  SUVmean and SUVpeak results were obtained using the 
Southampton method, as outlined in section 6.2.   As SBRs calculated using the Southampton method 
use the same volumes of interest as those required for absolute quantification, the repeatability of 
semi-quantification with the Southampton method was also tested.  
Analysis 
Between-subject variation was assessed with the coefficient of variation, calculated using the baseline 
scan results.  Test-retest variation was calculated from the baseline and repeat scan for each individual.  
Variation was defined as the mean absolute change in uptake parameter, expressed as a percentage.  
Bland-Altman plots of the differences between repeat and baseline imaging were produced for each 
uptake parameter.  The overall mean difference between baseline and repeat imaging was calculated, 
and paired t-tests used to check for significance, assuming a normal distribution for striatal uptake. 
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6.5.4 Results 
Visual ratings 
Of the 20 controls rated so far, 2 were rated as abnormal at baseline and normal on repeat scanning 
(Table 36).  None were rated as normal on baseline and abnormal on repeat.  There was 75% 
agreement between baseline and repeat results at the scoring level, 90% if only the binary ratings were 
considered.  The scans for the two patients with abnormal ratings at baseline are shown in Figure 61.  
All BRASS quantification results are within normal limits, as defined Z scores greater than -2 relative to 
the ENC-DAT database, with age correction.  The subject with borderline-abnormal values is relatively 
young (64 years) so the Z scores are lower than they would be for the same SBR in an older volunteer. 
Table 36: Baseline and repeat scan consensus panel ratings for 20 of the controls. 
Baseline score Baseline binary rating Repeat score Repeat binary rating 
0 Normal 0 Normal 
4 Normal 0 Normal 
0 Normal 0 Normal 
1 Abnormal 4 Normal 
0 Normal 0 Normal 
0 Normal 0 Normal 
0 Normal 0 Normal 
0 Normal 0 Normal 
4 Normal 4 Normal 
5 Abnormal 0 Normal 
0 Normal 0 Normal 
0 Normal 0 Normal 
0 Normal 0 Normal 
0 Normal 0 Normal 
4 Normal 0 Normal 
4 Normal 0 Normal 
0 Normal 0 Normal 
0 Normal 0 Normal 
0 Normal 0 Normal 
0 Normal 0 Normal 
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Figure 61: Baseline and repeat scans for the controls rated abnormal at baseline and within normal limits on repeat. 
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Absolute mean change between baseline and repeat 
Our results show no drop in the mean striatal uptake of the control cohort between baseline and one 
year repeat (Table 37), although there is actually a suggestion of slightly increased quantification 
results on average for all parameters except SUVpeak.  However these relationships are not statistically 
significant when correcting for multiple comparisons. 
Table 37: The average change in uptake between baseline and repeat, expressed in absolute terms and as a percentage.  
Paired t-tests were used to assess for significance. 
 
 
Right 
striatum 
Left 
striatum 
Right 
caudate  
Left 
caudate  
Right 
putamen  
Left 
putamen  
BRASS SBR Mean 
SBR diff 
0.15 
(+5%) 
0.06 
(+2%) 
0.14 
(+5%) 
0.13 
(+4%) 
0.15 
(+6%) 
0.07 
(+3%) 
p-value 0.06 0.24 0.11 0.12 0.07 0.34 
Southampton 
SBR 
 
Mean 
SBR diff 
0.36 
(+6%) 
0.31 
(+5%) 
n/a n/a n/a n/a 
p-value 0.04 0.04 n/a n/a n/a n/a 
SUVmean Mean 
SBR diff 
0.29 
(+4%) 
0.17 
(+2%) 
n/a n/a n/a n/a 
p-value 0.15 0.34 n/a n/a n/a n/a 
SUVpeak 
 
Mean 
SBR diff 
0.02 (0%) -0.20 (-
3%) 
n/a n/a n/a n/a 
p-value 0.89 0.08 n/a n/a n/a n/a 
 
Intra-subject repeatability (baseline) 
The baseline coefficient of variation results are shown in Table 38 and indicate variation of around ± 
12% for most methods, with slightly higher variation for SUVmean. 
Table 38: Coefficient of variation (SD / mean) striatal uptake results for each method taken between all subjects at baseline. 
 
Right 
striatum 
Left 
striatum 
Right 
caudate  
Left 
caudate  
Right 
putamen  
Left 
putamen  
BRASS SBR 11.4% 12.0% 11.6% 12.2% 12.5% 13.0% 
Southampton 
SBR 
11.0% 12.2% n/a n/a n/a n/a 
SUVmean 14.1% 14.9% n/a n/a n/a n/a 
SUVpeak 11.7% 12.6% n/a n/a n/a n/a 
 
Intra-subject variation (baseline and repeat) 
The mean absolute intra-subject variation expressed as a percentage of baseline and repeat, with 
standard deviation is shown in Table 39.  The greatest drop and greatest increase in striatal uptake 
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between baseline and repeat for each method is also shown.  For SBR methods, the variation between 
baseline and repeat is very similar to the inter-subject variation at baseline in Table 38.  For SUV 
methods, the variation between baseline and repeat for individuals is lower than the variation 
between subjects. Bland-Altman plots showing variation in striatal uptake between baseline and 
repeat are shown in Figure 62. 
Table 39: Intra-subject variation for each of the methods assessed.  The mean percentage absolute difference between 
baseline and repeat scans is presented with SD.  The most extreme negative and positive changes are also shown. 
 
 Right 
striatum 
Left 
striatum 
Right 
caudate  
Left 
caudate  
Right 
putamen  
Left 
putamen  
BRASS SBR Mean % 
difference 
± SD 
11.5% ± 8.7 
% 
11.0% ± 
8.6% 
12.8% 
±8.6% 
10.6% ± 
9.1% 
12.7% ± 
9.6% 
11.8% ± 
7.0% 
% 
difference 
range 
-26.6% to 
32.8% 
-23.5% 
to 32.7% 
-32.9% 
to 
33.0% 
-25.9% 
to 
35.2% 
-34.4% to 
32.8% 
-18.9% to 
29.7% 
Southampton 
method SBR 
Mean % 
difference 
± SD 
12.2% ± 
8.6% 
10.5% ± 
7.4% 
n/a n/a n/a n/a 
% 
difference 
range 
-32.8 to 
32.3% 
-25.7 to 
22.9% 
n/a n/a n/a n/a 
Southampton 
method 
SUVmean 
Mean % 
difference 
± SD 
9.3% ± 
10.7% 
8.2% ± 
10.0% 
n/a n/a n/a n/a 
% 
difference 
range 
-18.3% to 
53.0% 
-18.4% 
to 50.6% 
n/a n/a n/a n/a 
SUVpeak Mean % 
difference 
± SD 
5.6% ± 5.8% 6.0% ± 5.8% 
n/a n/a n/a n/a 
% 
difference 
range 
-19.1% to 
19.3% 
-20.9% 
to 8.8% 
n/a n/a n/a n/a 
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Figure 62: Bland-Altman plots for change in striatal uptake measures between baseline and repeat 
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6.5.5 Discussion 
Our results for SBR intra-subject variation of around 12% are in keeping with those of Colloby et al. 
who also rescanned after a year and found around 9-10% variation.  The variation between baseline 
and repeat is similar to the inter-subject variation at baseline, suggesting that physiological 
fluctuations and technical variation between baseline and repeat scanning is similar to the variation 
between individuals. 
The fact that the FP-CIT scans of two healthy older adults were rated as abnormal at baseline but 
normal on repeat strongly suggests that these subjects do have normal dopaminergic function and 
that scans in normal patients are therefore likely to occasionally show similar borderline-abnormal 
appearances.  Care should be taken not to over-report such scans, which was also the conclusion of 
our publication on FP-CIT ratings methods with autopsy validation [195], where mild balanced 
reduction in striatal uptake was often reported in subjects without Lewy body disease at autopsy.   
Both control subjects rated as abnormal had baseline quantification results within normal limits, 
although these did improve on repeat.   The concordance between baseline and repeat ratings 
categories was 75%, 90% if only the binary categorisation of normal/abnormal is used.  This reflects 
the fact that it is often difficult to decide between for example, the mild and significant balanced loss 
categories.  A limitation is that due to the time involved in ratings, so far we have not repeated ratings 
on the same scans, so we do not yet have a measure of intra-rater reliability in controls or patients.  
However it is likely that we would see similar concordance in repeat rating of the baseline cohort just 
by chance as the display of the images introduces variation. 
One outcome of this variation could be the presence of unusually high SBR values in a few subjects, 
skewing the results.  The histogram in Figure 63 suggests that the distribution of BRASS SBR values is 
predominantly normal, with a tail towards the high end.  Outliers may actually reduce the normal range 
SBR cut-off values used with BRASS by increasing the standard deviation.  It may therefore be useful 
in future work to devise a probability based approach to classifying quantification results, or a machine 
learning approach based on the image features rather than quantification. 
Our results of fairly substantial random variation in SBR with both BRASS and Southampton method, 
including some cases of greater than 20% apparent change, have important implications for the 
interpretation of repeat studies in patients. Clearly a drop in uptake of less than 10% in a patient follow 
up scan should not be considered significant and the results here would suggest that at least a 20% 
change is needed to be confident that the results are likely to represent a real decline in function. 
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Figure 63: Histogram of BRASS SBR results, with left and right whole striatum and baseline and repeat data included 
 
Our SUV results are interesting because, unlike with SBR, the variation between baseline and repeat 
scans was lower than the variation between subjects.  As the variation between subjects is higher than 
for SBR, absolute quantification is less likely to be useful than semi-quantification for cross-sectional 
studies, which is what we saw in the previous section.  However, the better reproducibility between 
baseline and repeat may make absolute quantification more suitable for longitudinal studies than 
semi-quantification.  The issues that we assume give rise to differences in SUV between people, such 
as correcting for tracer volume of distribution and differences in uptake outside the brain cancel out 
for baseline and repeat in the same individual.   It will be interesting to see whether this is reflected in 
the SUPErB MCI-LB patients when all the follow up scans are completed.  
6.5.6 Conclusion 
The coefficient of variation in BRASS SBR among control subjects at baseline of 12% is similar to the 
average variation between baseline and repeat scans of 12 ± 9%.  Changes in SBR of less than 10% 
between baseline and repeat are therefore negligible and changes of up to 20% are also likely to be 
within normal variation.  This should be kept in mind when reporting both baseline and follow-up 
scans.  The variation in absolute striatal uptake between subjects is relatively high for SUVmean at 
around 15%, but only around 9% between baseline and repeat suggesting SUV may be useful for 
longitudinal studies.   
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 Summary of chapter 6 
In section 6.1 we compared visual rating of the SUPErB scans at baseline by a consensus panel of 
experts with standard BRASS quantification, using the one year clinical diagnoses (including MIBG 
results) as the gold standard.  We compared the sensitivity and specificity of expert visual rating with 
BRASS quantification alone, showing that the accuracy of both methods was very similar.  This has 
implications for efficiency in future large studies, as the consensus panel method requires considerable 
time and effort.  Longer term follow up of the MCI cases will help to establish which method was 
correct for the few discrepancies between the panel and the quantification results alone.   We showed 
that the default method of age correction in BRASS gave the same accuracy as results using a database 
made up of age-matched SUPErB control subjects, suggesting that the benefits of a bespoke centre-
specific normal range are limited. 
The absolute quantification results in MCI presented in section 6.2 showed than the accuracy of 
SUVmean with the Southampton method for diagnosing Lewy body disease was the same as the accuracy 
of relative quantification with SBR using the Southampton method, suggesting absolute quantification 
of striatal uptake is not beneficial.  However, images presented with an absolute SUV scale may assist 
in visual reporting, as the striata can be assessed without reference to the background appearance.  
However, the variation in appearance of controls with this scale was quite large, suggesting that the 
method may not be very specific in practice.  Full assessment of the SUV scale images by a blinded 
panel would be needed to confirm. 
Sections 6.3 compared the standard RR_uniform reconstruction method with more advanced 
methods: CT attenuation and scatter correction and Monte Carlo modelling of septal penetration of 
high energy gamma photons.  We found that the combination of CT ACSC and full collimator modelling 
gave background activity concentration results in a striatal phantom that were very close to the true 
value.  However, striatal activity concentration results appeared more uncertain, and phantom SBRs 
were actually further from the true values with CT ACSC applied than without.  In the comparison of 
these methods for patient SBRs in section 6.4 we confirmed that CT ACSC reduced SBR, but found that 
the full collimator model increased SBR compared to the standard reconstruction.  However this did 
not result in improved diagnostic accuracy.  We concluded that CT ACSC is not beneficial for relative 
quantification with SBR but that the full collimator model may be and should continue to be assessed 
in future studies. 
In section 6.5 we assessed the test-retest variation in FP-CIT imaging, using baseline and one year 
repeat scans in the SUPErB controls.  We found that at baseline, the variation measured by the 
coefficient of variation of SBR measurements was 12%.  The mean absolute variation between baseline 
and repeat scans was also 12%, with some subjects showing larger changes in SBR of 20-30%.  We also 
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saw that with visual reporting, two control subjects were rated abnormal at baseline and normal on 
repeat.  The clinical implications of these results are that care should be taken not to over-call scans 
and that SBR changes of less than 20% on follow up scans are likely to be within normal physiological 
or technical variation.  With SUVmean we saw slightly higher baseline variation, but lower test-retest 
variation, suggesting that absolute quantification may have a role in the assessment of longitudinal 
change. 
In summary, we have shown that the quantification method selected for the SUPErB study, which uses 
BRASS SBRs with default age correction calculated on images reconstructed with the RR_uniform 
iterative reconstruction method, is not outperformed by any of the advanced reconstruction and 
analysis techniques assessed in this chapter. 
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Chapter 7: Planar cardiac 123I-MIBG imaging for 
the diagnosis of Lewy body disease 
This chapter focusses on the use of planar cardiac 123I-MIBG imaging for the diagnosis of Lewy body 
disease and the changes that can be made to potentially increase accuracy or make the procedure 
more practical.  In section 7.1 processing methods for calculating the heart-to-mediastinum ratio are 
assessed and compared with visual assessment, with recommendations made for clinical practice.  In 
section 7.2 the normal-abnormal HMR cut-off value that should be used in a UK population is 
considered in detail, comparing results from the SUPErB study with published data for Japanese 
populations.  In section 7.3 early imaging at 20 minutes after tracer administration is explored to see 
whether it can replace delayed imaging at 4 hours without affecting the sensitivity or specificity of the 
test. 
Content from sections 7.1 and 7.3 was published in Nuclear Medicine Communications in January 2019 
[190]. Content from section 7.2 has recently been accepted in August 2019 for publication in the 
Journal of Nuclear Cardiology, where it will be published alongside an editorial by Prof K. Nakajima, 
Kanazawa University, Japan.  
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7.1 Analysis methods for planar cardiac 123I-MIBG scintigraphy in DLB 
7.1.1 Introduction 
As discussed in Chapter 3, there is a variety of methods used in the literature for interpreting planar 
cardiac MIBG images for Lewy body disease, including visual analysis and semi-quantification.  In this 
section we compare planar cardiac MIBG analysis methods for discriminating between DLB and 
Alzheimer’s disease (AD) using dementia and healthy control subjects recruited and scanned locally as 
part of the MIDAS and SUPErB studies.  
We compare visual assessment with various semi-quantitative analysis methods, including the one 
used by Nakajima et al. [166], made possible by participating in a European multicentre phantom 
calibration exercise [167] allowing us to apply the HMR cut-off of Komatsu et al. [53, 62] of 2.20 for 
delayed images.  The overall aim is to determine the optimal method for processing and interpreting 
planar cardiac MIBG images for DLB diagnosis in routine clinical practice and research studies. This is 
achieved by considering the variation between operators and raters for each method as well as the 
accuracies given by ROC analysis.  This work was published in Nuclear Medicine Communications in 
January 2019 [190]. 
7.1.2 Methods 
Subjects 
Dementia subjects were recruited as part of the Newcastle University MIDAS study into the use of 
cardiac MIBG in a representative UK population [83].  Thirty-two of the 33 patients included in our 
previous publication [83] were included in this analysis: 15 with probable AD and 17 with probable DLB 
(one AD subject was excluded here because the early image was not available). Diagnoses were made 
by an expert panel of three old-age psychiatrists blinded to scan results, based on clinical assessment 
and applying standard research criteria [1]. This consensus panel method has previously been validated 
against autopsy and is accepted by regulatory authorities as the clinical gold standard for living patients 
[43, 207].  Sixteen older adults with normal cognition were taken from the SUPErB study.   
Image acquisition 
Subjects were administered 111 MBq 123I-MIBG via slow intravenous injection.  Potassium iodate 
tablets (170mg) were given before and after injection for thyroid blockade.  Ten minute anterior planar 
images were acquired at 20 minutes (“early”) and 4 hours (± 30 minutes, “delayed”).  Analysis here 
uses delayed images only; early images and the relationship between the two time points is covered 
in section 7.3.  Images were acquired on a Siemens Symbia T series or Siemens Symbia Intevo gamma 
camera with medium energy low penetration (MELP) collimators and processed on a Hermes 
workstation.  The energy window was 159 keV ± 10%, matrix size was 128 x 128 and no zoom was 
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applied.  The same settings were applied when participating in the European phantom calibration 
study [167].  This calibration showed that the HMR cut-off published by Komatsu et al. [53, 62] of 2.20 
is appropriate for use with our Siemens cameras with MELP collimators (personal communication, 
Prof. K. Nakajima, Kanazawa University, Japan) – see sections 5.2 and 7.2 for more detail. 
Visual rating 
Images were anonymised and rated blind to diagnosis on a 4 point scale: definitely abnormal, probably 
abnormal, probably normal or definitely normal.  Seven individuals experienced in nuclear medicine 
reporting (two consultant radiologists and five nuclear medicine physicists) were recruited as raters.  
The raters were provided with a set of reference images for each category. The modal (most frequent) 
rating was taken as the consensus result.  The results were dichotomised into normal or abnormal 
ratings for the accuracy study and comparison with HMR.  
Heart-to-mediastinum ratio processing 
Nine operators experienced in processing nuclear medicine studies took part in this part of the study 
(six nuclear medicine physicists and three nuclear medicine technologists).  Five of the physicists also 
rated the images visually (see above).  This was carried out in a randomised order and before the 
quantitative results were generated to avoid bias.  Operators were provided with comprehensive 
instructions including example images showing region placement.   
We used four different cardiac region placement methods: freehand regions delineated manually 
around the myocardium and fixed circular regions of 6, 7 and 8 cm in diameter placed over the centre 
of the visible myocardium.  Smaller regions were not tested because the ventricular cavity apparent 
on some images would lead to an under sampling of counts.  A fixed sized rectangular mediastinum 
region of 4 cm x 3 cm was placed between the apices of the lungs, in an area containing only 
background counts.  The mediastinum region size was chosen to be consistent in shape and position 
within the mediastinum with Okuda et al. [208] but simplified by using a fixed sized region placed 
manually.  The size is small enough not to be subject to interference from the lungs and large enough 
to give a reasonable sample of background counts.   Since there is little variability uptake throughout 
the mediastinum we did not investigate mediastinum region size or placement, or automate 
placement.  The same mediastinum region was used with all four cardiac ROIs for HMR calculation.  
The heart and mediastinum values were exported and all HMR values were calculated by the author 
using a macro to minimise typographical errors.  An example image with manual and circular cardiac 
ROIs and resulting HMR values is shown in Figure 64. 
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Figure 64: Example normal uptake cardiac MIBG image with HMR values for freehand, 6 cm and 8 cm circular cardiac regions. 
7.1.3 Analysis 
Difference in HMR between cardiac region methods 
The effect of region drawing method on HMR was tested using a generalised linear model ANOVA 
analysis applying the Greenhouse-Geisser method for conditions where sphericity cannot be assumed 
(SPSS Statistics v23.0.0.3 (IBM Corporation)). A p-value of <0.05 was taken to indicate a significant 
dependence of HMR on region method.   
Difference in inter-operator variability between cardiac region methods 
The average coefficient of variation (CoV) was taken as a measure of variability with which to compare 
the region drawing methods. The CoV was calculated for each subject using the result for each of the 
nine operators and these CoV values were averaged to give the mean.  This was repeated for each 
region method and time point.  Paired t-tests were used to test for differences in coefficient of 
variation.   
Difference in accuracy between cardiac region methods 
The HMR value for each subject was taken as the mean of nine operators and these mean values used 
for comparing cardiac region methods.  SigmaPlot v.13 (SystStat Software, San Jose, CA) was used to 
generate ROC curves including all subjects for each method by varying the normal/abnormal cut-off, 
using the consensus diagnoses (with the DLB, AD and control subject diagnoses dichotomised as either 
DLB or non-DLB) as the gold standard.  SigmaPlot output was used to check for significant differences 
between the area under the ROC curves. This allows a comparison of overall accuracy of each HMR 
method to be made.  The best method was selected based on the area under the curve (accuracy), 
difference between mean DLB and non-DLB HMRs and the average CoV between operators 
determined above. 
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The HMR values for the DLB and non-DLB subjects obtained with the method identified as optimal 
were used to determine the sensitivity and specificity for this method.  This was done within SigmaPlot 
by applying the optimal cut-off given by the ROC analysis.    
Comparison between visual rating and HMR analysis 
The sensitivity and specificity for early and delayed consensus visual ratings were calculated from the 
true and false positive and negative results, using the consensus clinical diagnoses as the gold standard.  
As above, sensitivity and specificity results were calculated with the DLB, AD and control subject 
diagnoses dichotomised as either DLB or non-DLB. 
To assess agreement between raters, the intraclass correlation coefficient was calculated using SPSS 
for all subjects.  The concordance between early and delayed ratings was calculated as well as the 
number of control images rated as abnormal. 
7.1.4 Results 
Subject characteristics 
The age, sex, MMSE and ACE scores and MDS-UPDRS scores [209] for all subjects are given in Table 40.  
As expected, there were significantly higher levels of Parkinsonism in the DLB group but otherwise the 
dementia groups were well matched for age and cognition.  The control and AD subjects taken as a 
single non-DLB group were well matched for age and gender mix with the DLB group. 
 
Table 40: Clinical characteristics of the AD, DLB and healthy control groups.  In this study we grouped the AD and control 
subjects together to form a single group of “non-DLB” subjects that would be expected to have normal scan appearances. 
 Subjects 
(no. 
female) 
Mean age 
(min – max) 
Mean MDS-
UPDRS score 
(min – max) 
Mean MMSE 
(min – max) 
Mean ACE 
total (min – 
max) 
Alzheimer’s Disease 15 (4) 76.2 (62 – 85) 5.0 (0 – 27) 22.0 (12 – 26) 64.8 (23 – 85)  
DLB 17 (2) 77.5 (60 – 89) 33.4 (2 – 89) 21.8 (14 – 27) 66.0 (34 – 87) 
Healthy controls 16 (6) 72.3 (61 – 86) 5.4 (0 – 16) 28.6 (26 – 30) 93.6 (85 – 99) 
p-value AD vs DLB  0.31 0.63 <0.001 0.95 0.83 
p-value non-DLB vs DLB 0.09 0.17 <0.001 n/a n/a 
 
Effect of cardiac region method on HMR 
The HMR values averaged over the nine operators for each processing method are shown in Table 41. 
The ANOVA repeated measures test demonstrated a significant difference in HMR values between the 
four region drawing methods (F=7.196, p=0.006).  Pairwise comparisons showed the largest 
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differences were between the 6cm and freehand regions and the 6 cm and 8 cm regions.  For fixed 
circular regions, HMRs tend to decrease with increasing region size, as expected (Table 41).    
 
Table 41: Mean and standard deviation of HMR values over all subjects calculated with freehand and circular cardiac regions 
on early and delayed images.  The p-values test for significant differences between early and delayed HMR with each method, 
using paired t-tests. 
Region method Mean early HMR 
(SD) 
Mean delayed 
HMR (SD) 
p-value 
Freehand 2.22 (0.55) 2.19 (0.66) 0.37 
6cm circle 2.32 (0.60) 2.31 (0.74) 0.70 
7cm circle 2.26 (0.57) 2.25 (0.69) 0.74 
8cm circle 2.19 (0.53) 2.18 (0.64) 0.67 
 
Difference in inter-operator variability between cardiac region methods 
The fixed sized circular methods have a lower average coefficient of variation (CoV), than the freehand 
method (Table 42, p <0.001).  There was no significant difference in variation between any two fixed 
circle HMR methods (p values between 0.14 and 0.84).  
 
Table 42: Average coefficients of variation for each region drawing method used for HMR calculation.  All subjects are included. 
 Region method 
Freehand 6 cm 7 cm 8 cm 
CoV  5.7% 4.3% 4.2% 4.2% 
 
Display of ROIs superimposed for all operators showed closer agreement between operators with the 
circular regions than with the freehand region, although this was not analysed using statistical testing 
as region overlap data was not available.  An example image with normal uptake and example image 
with reduced uptake is shown in Figure 65 with freehand regions and 6 cm circular regions for all 
operators displayed.  Operators reported that the 7 and 8 cm circular regions were difficult to place 
on some images without including non-cardiac uptake, for example in the lung or liver. 
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Figure 65: Top: example normal cardiac MIBG image (top row) and abnormal image (bottom row) processed by multiple 
operators with freehand and 6cm circular regions.  
Difference in sensitivity, specificity and accuracy between cardiac region methods 
ROC curves and AUC results are shown in Figure 66, with 95% confidence intervals given in Table 43.   
AUCs were very similar for all methods and there were no statistically significant differences in 
accuracy between any of the region drawing methods (p-values ranging between 0.23 and 1.00).   
 
Figure 66: ROC curves for all cardiac region methods tested. 
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Table 43: ROC cure areas and 95% confidence intervals for all cardiac regions tested. 
 
 
 
 
 
The optimal cut-offs for each method were applied to the HMR values for the DLB and non-DLB groups.  
This gave sensitivities for distinguishing between DLB and non-DLB subjects ranging between 65% and 
71% for the different region methods.  The specificity with the optimal cut-offs applied was 100% for 
all methods.  The results for the 6cm circle region HMR on delayed images were 71% sensitivity (95% 
binomial confidence interval: 44% to 90%) and 100% specificity (89% to 100%) using the optimal cut-
off of 1.66.  The overall accuracy of this method was 90% (77% to 97%).  Table 44 shows the difference 
in mean HMR for the DLB and non-DLB groups for each method, with 95% confidence intervals around 
the means.  The difference between mean HMRs is highest for the 6cm method but the 95% confidence 
intervals suggest this is not statistically significant. 
 
Table 44: Difference in mean HMR between DLB and non-DLB groups for the HMR methods tested, with 95% confidence 
intervals around the mean HMR values given in brackets 
Region method Mean HMR DLB 
(95% CI) 
Mean HMR non-DLB 
(95% CI) 
Difference 
Freehand 1.63 (1.28 to 1.98)  2.50 (2.35 to 2.65)  0.87 
6cm circle 1.69 (1.28 to 2.10) 2.64 (2.48 to 2.81) 0.95 
7cm circle 1.68 (1.30 to 2.06)  2.56 (2.41 to 2.72)  0.88 
8cm circle 1.65 (1.31 to 2.00) 2.47 (2.32 to 2.61) 0.82 
 
 
Comparison between visual rating and HMR analysis 
The agreement between visual raters was very good (intraclass correlation coefficient of 0.98.  Overall, 
accuracy was lower for visual rating (73%) than for HMR analysis (90%), due to the lower specificity 
(Table 45). 
 
 Freehand 6cm circle 7cm circle 8cm 
circle 
ROC curve area 0.83 0.82 0.82 0.83 
95% confidence 
interval 
0.68 to 0.98 0.67 to 0.98 0.67 to 0.98 0.68 to 0.98 
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Table 45: Sensitivity, specificity and accuracy for distinguishing between DLB and non-DLB subjects using consensus visual 
rating, with binomial 95% confidence intervals. 
 Sensitivity Specificity Accuracy 
Result 76%  71%  73%  
95% confidence interval 50% to 93% 52% to 86% 58% to 85% 
 
The overall concordance between consensus visual rating and mean HMR using the 6cm circle method 
for the controls was 13/16 (81%).  Overall the concordance between the 6cm circle HMR method and 
visual rating for all subjects was 38/48 (79%). 
7.1.5 Discussion 
Effect of cardiac region method on HMR 
We have demonstrated that the region drawing method had a significant impact on HMR values and 
that ROI methods should not be used interchangeably – the appropriate cut-off depends on the 
processing method.  In this dataset, the 6cm circle HMR results were significantly higher than the 
freehand results, likely due to the freehand regions of interest being larger on average and so including 
more non-specific background counts.   
A fixed sized region minimises variation between operators processing the same patient, but could in 
theory lead to inaccuracies for individual patients.  The size of the visible myocardium varies between 
patients, as does the size of the ventricular cavity, often visible on images as a “cold” area with low 
counts.   However our results show very similar accuracy for all methods suggesting that this effect is 
minimal.  Given the higher variation between operators for freehand region HMRs and no benefit in 
accuracy, we recommend that fixed sized circular regions be used over freehand. 
The 8cm circle method gave the lowest inter-operator variability.  However, the difference in both 
accuracy and variability between the 8cm and 6cm circle method is very small and not statistically 
significant.  Furthermore, slightly smaller ROIs are less likely to be influenced by non-cardiac uptake in 
the liver, lungs or bowel and at the same time less likely to include background counts surrounding the 
LV.  Our study supports the use of the 6cm fixed circle method used in several previous publications, 
and we therefore suggest that this be adopted as standard. 
Accuracy of visual rating compared with HMR analysis 
In our study, consensus visual rating with binary outcome (i.e. probable/definite normal vs 
probable/definite abnormal) performed less well than using an HMR cut-off, with a lower specificity 
for detecting DLB and two of the 16 control subjects rated as probably abnormal.  Tiraboschi et al. [67] 
used binary (normal / abnormal) visual image assessment (consensus of three raters) as their primary 
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analysis method in their study comparing cardiac MIBG and FP-CIT for DLB diagnosis, with HMR 
analysis as a secondary method.  In contrast to our study, their results show 100% specificity for both 
visual and HMR techniques (95% confidence interval 88-100%).  The sensitivity is slightly higher for the 
HMR method than visual consensus (97% vs 93%) but the confidence intervals overlap considerably 
and the authors state the results were similar [67].  We found that extending our normal categorisation 
to include the “probably abnormal” category improved specificity without having a large impact on 
sensitivity, suggesting that any level of cardiac uptake above background is likely normal. However 
such a system may not be useful in detecting early disease, where we might expect to see subtly 
reduced uptake. 
Although the heart-to-mediastinum ratio is intended to be objective, it may be affected by the amount 
of lung and liver uptake and proximity to the heart.  In publications using HMR results, visual inspection 
of images for confounding factors potentially affecting HMR is not typically mentioned.  The presence 
of lung uptake on MIBG scans is normal and is due to uptake by pulmonary endothelial cells [210, 211].  
Reduced lung uptake has been reported in Lewy body disease [212] and has been linked to treatment 
with L-dopa leading to an increase in plasma homocysteine levels [213].   Reduced lung uptake in DLB 
due to medication could potentially exaggerate the difference in HMR between DLB and non-DLB 
groups, due to reduced scatter from the lungs into the cardiac ROI in those taking L-dopa.  However, 
although ours is a small sample, we found no evidence of a relationship between L-dopa dose and lung 
uptake for DLB patients (Figure 67).   
 
 
Figure 67: Cardiac uptake plotted against lung uptake for the patients and controls analysed in this section. 
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We recommend HMR analysis be used as the primary method of assessment for planar cardiac MIBG 
images for DLB diagnosis, rather than visual rating.  However the visual appearance of the study should 
still be taken into account, particularly in borderline cases where extra-cardiac uptake could give 
confounding results.   
Use of an HMR cut-off from a published multicentre study  
The results of a recent study at our centre [83] suggest that the threshold of 2.20 taken from the 
Japanese multicentre follow-up study [62] is too high, as several patients with clear Alzheimer’s disease 
and without clinical signs suggestive of Lewy body disease have HMR values below this cut-off using 
the same 6cm circle method.  Similarly, the lowest control HMR value is 2.16 (6cm circle method on 
delayed images).  The optimal cut-off for this dataset calculated using ROC analysis was only 1.66, 
giving 71% sensitivity and 100% specificity.   With the prior cut-off of 2.20 applied the sensitivity would 
remain 71% but specificity drop to 87%, due to three AD subjects and one control subject becoming 
false positives.   The appropriate HMR cut-off to use in a UK population is covered in section 7.2. 
7.1.6 Conclusion 
HMR values depend on the method used to draw the cardiac region, with the smallest region (6cm 
diameter) giving the highest values.  Accuracy is similar for all HMR methods but inter-operator 
variation lower for fixed sized ROI methods than freehand.  Visual rating specificity is lower than HMR 
methods so HMR should be used as the primary reporting method, provided an appropriate cut-off for 
the gamma camera(s) used has been established.    
Given that all fixed sized region HMR methods give similar results, we recommend using a 6cm 
diameter circular region for research studies; this is in keeping with published methods and may 
reduce the effect of non-cardiac uptake compared to larger ROIs.  The sensitivity and specificity of the 
6cm ROI method on delayed images with optimal cut-off of 1.66 were 71% and 100%.  
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7.2  Are cardiac 123I-MIBG normal uptake values population-specific? 
7.2.1 Background 
Although planar cardiac MIBG imaging is straightforward technically to implement in any hospital with 
a nuclear medicine service, the interpretation of cardiac uptake depends critically on establishment of 
a normal range, or cut-off for HMR values.  In section 7.1 we saw that, provided that an appropriate 
normal HMR cut-off is used, HMR analysis is more accurate than visual rating [190].  The HMR normal 
range will depend on: 
• Acquisition factors, including the camera and collimator 
• Processing factors, such as region placement 
• Population specific factors, for example obesity and heart disease 
We addressed processing factors in the previous section and in our corresponding publication [190], 
with a standardised 6 cm circular cardiac ROI recommended.  We previously discussed the effects of 
camera calibration and population specific factors as being potential barriers to comparison of data 
between centres [83, 190] and now address these here using images from older adults from a typical 
UK older population to generate a normal range. 
The phantom calibration method applied in the previous section can only adjust for technical factors, 
for example collimator difference, not for population differences.  If typical true HMR results vary 
between populations phantom calibration will not be sufficient, and measurements of local controls 
will be required.  In the MIDAS study we found that when we applied a normal HMR cut-off derived 
from Japanese studies to our dementia patients it seemed much too high, with several Alzheimer’s 
disease patients falling into the abnormal category [83].   
In this section we aim to: 
• Establish, for the first time, a normal HMR cut-off based on older adults without cognitive 
impairment in a typical UK population 
• Compare the diagnostic accuracy of this UK cut-off for detecting Lewy body disease in a cohort 
of dementia patients to that of calibrated cut-off values from the literature. 
7.2.2 Methods 
Phantom calibration 
Before starting cardiac 123I-MIBG imaging at our centre, a calibration check on our gamma cameras was 
performed with help from colleagues in Japan and the Netherlands, using a planar phantom, as 
described in section 5.2.  This calibration procedure revealed that the performance of our Siemens 
cameras fitted with medium energy low penetration (MELP) collimators was very similar to that of 
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typical medium energy collimators in Japan (personal communication, Prof. K. Nakajima, Kanazawa 
University, Japan).  The HMR cut-offs of 2.1 published by Yoshita et al. have recently been recalculated 
by Komatsu et al. as part of a three year follow-up study [53, 62].  The updated cut-off values of 2.51 
for early images and 2.20 for delayed images are used in this section.   
Subjects 
Older controls without cognitive impairment: 
Thirty-one individuals aged over 60 years with normal cognition were recruited as part of the SUPErB 
study.   Volunteers were excluded if they presented with cognitive impairment, major cerebrovascular 
disease on MRI brain imaging, Class II or worse heart failure according to the New York Heart 
Association classification, had had a myocardial infarction in the previous year, were taking labetalol 
or were unlikely to be able to tolerate imaging.  Subjects were not excluded if they had risk factors for 
cardiac disease, such as a history of smoking, raised blood pressure or Type 2 diabetes because we 
aimed to recruit typical older adults with normal cognition.  Diabetes has been shown to be associated 
with reduced cardiac MIBG uptake in a small proportion of patients with clinical autonomic neuropathy 
[214] but similar to healthy controls in another study of patients with impaired glucose tolerance [215].  
In our clinical studies in Lewy body disease we aim to assess cardiac MIBG in a “real-world” setting, 
where diabetes and risk factors for cardiac disease are extremely common.  However, a detailed 
medical history including assessment of cardiac risk factors was taken. 
Older people with dementia: 
Seventeen patients meeting the clinical criteria for probable dementia with Lewy bodies and 15 
meeting criteria for dementia due to Alzheimer’s disease were taken from the MIDAS study.  Briefly, 
patients had their dementia diagnoses confirmed by an expert panel of old-age psychiatrists.  They 
were categorised as having probable DLB if two or more of the core consensus criteria for DLB [1] 
(fluctuations, visual hallucinations, REM sleep behaviour disorder and parkinsonism) were present, and 
AD if none of these were present.  The same broad general inclusion criteria as discussed above for 
the controls were applied to ensure the patients were typical of the local population. 
Image acquisition and processing 
Ten minute anterior planar images were acquired at 20 minutes (early) and at 4 hours (± 30 minutes) 
after injection (delayed) as described in section 7.1. 
All images were processed on a Hermes workstation (Hermes Medical Ltd, Stockholm).  Planar images 
were analysed to obtain the heart to mediastinum ratio (HMR) using a 6 cm circular ROI placed over 
the left ventricle and 4 x 3 cm rectangular ROI between the lungs in the mediastinum, as described in 
our previous publication [190].  Images were processed by the author.  Normal ranges based on control 
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images were taken to be two standard deviations below the mean value and were calculated 
separately for early and delayed images. 
7.2.3 Results 
Control and patient demographics 
Of the 31 controls recruited, 2 were excluded due to their image appearance (see below).  The 
remaining 29 people included were aged between 62 and 94 years (mean 75.2).  Most were male 
(22/29) and white (28/29).  Body mass indices (BMI) ranged from 22 to 38 kg/m2, with the mean value 
of 27.2 in the overweight category.  The demographics for the controls and patients are summarised 
in Table 46 alongside incidence of cardiovascular risk factors such as smoking. 
Table 46: Demographics summary for the 29 controls, 17 DLB and 15 AD patients included in the study.  More data is available 
for the controls as they are from a different study (SUPErB). 
 Controls DLB AD 
Age (Mean ± SD) 
Range 
75.2 ± 8.3  
62 to 94 years 
77.5 ± 8.0 
60 to 89 years 
76.2 ± 6.8 
62 to 85 years 
Sex 7 female (24 %) 
22 male (76 %) 
2 female (12 %) 
15 male (88 %) 
4 female (27 %) 
11 male (73 %) 
BMI (kg/m2) 
Mean ± SD 
Range 
 
27.8 ± 4.2 
21.6 to 37.8 
 
Not measured 
 
Not measured 
Ethnicity 28 white (97 %) 
1 Asian (3 %) 
Not recorded Not recorded 
Smoking 13 never smoked (45 %) 
13 ex-smokers (45 %) 
2 current smokers (7 %) 
1 not recorded (3 %) 
 
Not measured 
 
Not measured 
Diabetes 0 Type I (0 %) 
3 Type II (10 %) 
Not recorded Not recorded 
Systolic blood 
pressure 
Mean ± SD 
Range 
 
140.5 ± 17.8 
112 to 173 
Not recorded Not recorded 
On blood pressure 
medication 
8 (28 %) 4 (24%) 5 (33%) 
Raised cholesterol 
documented 
11 (34 %)  Not recorded Not recorded 
Documented 
cardiac history 
 
 
Previous MI and AF:  
1 (3 %) 
Angina: 1 (3 %) 
ECG changes: 1 (3 %) 
 
Previous MI: 2 (12%) Previous MI: 3 (20%) 
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Control HMR results 
Of the 31 older adults with normal cognition recruited, one had a markedly abnormal appearance on 
early and delayed cardiac MIBG imaging and one had an abnormal appearance on delayed imaging.  
The HMRs were also clearly reduced for these patients, shown as empty symbols on the plot in Figure 
68. It is well recognised that occult Lewy body disease (usually termed incidental Lewy body disease) 
is present in many older people [81], which may explain these findings. These two outlying scans were 
therefore excluded from analysis to determine local normal HMR cut-offs.  Figure 68 also shows the 
distribution of early and delayed control HMRs and the change in HMR between early and delayed.   
   
Figure 68: Left: early HMR values (blue triangles) and delayed (orange circles) with means of 2.72 (SD 0.32) and 2.78 (SD 0.46) 
respectively for the 29 included individuals. Excluded individuals are shown as empty symbols. Right: individual change in HMR 
between early (left) and delayed (right) images for each of the 29 controls. 
Eight of the 29 controls had HMR values below the Japanese cut-off of 2.51 on early images and 5/29 
below 2.20 on delayed images.   
Means, standard deviation and normal cut-offs (mean-2SD) derived from the control HMR data are 
shown in Table 47.  The cut-off on the early images is higher due to the lower variation between 
individuals on the early images – the mean HMR is actually lower on the early images than delayed.  
With these cut-offs applied none of the 29 control subjects included were classified as abnormal.  
Table 47: HMR data from healthy control subjects with normal scan appearances 
 
n Mean HMR 
Standard 
deviation 
Control 
normal cut-off 
Early images 29 2.72 0.32 2.07 
Delayed images 29 2.78 0.46 1.86 
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Dementia patient results 
The mean HMR values for the patients with Alzheimer’s disease and those with dementia with Lewy 
bodies from our previous work [83] are given in Table 48 with the control results included for 
comparison.  Figure 69 shows plots of the HMRs for controls, AD patients and DLB patients for early 
and delayed images, with the cut-offs determined from controls shown as red lines and the Japanese 
cut-offs as purple lines.  Three of the AD patients have uptake below the local cut-off (i.e. unexpectedly 
low) on early images and two on delayed.  Six of the DLB patients have uptake above the local cut-off 
on early images, five of which are well above and 1 borderline (HMR = 2.15).  This latter patient’s HMR 
was 1.61, clearly abnormal, on the delayed image.  The other five patients retained a normal HMR on 
the delayed images, and the images appeared normal visually.  The corresponding sensitivity, 
specificity and overall accuracy for DLB vs AD diagnosis using the local cut-offs are given in Table 49, 
alongside the results with the higher cut-offs taken from the Komatsu et al. multicentre follow up study 
[62].  The third row shows the results with the optimal cut-off for this cohort determined via ROC 
analysis [83], which was 1.77 to 1.80 for early images and 1.61 to 1.70 for delayed.   
Table 48: HMR results (mean and standard deviation) for DLB and AD patients. 
 
 Early Delayed 
 
n mean SD mean SD 
DLB 17 1.88 0.71 1.69 0.79 
AD 15 2.47 0.41 2.48 0.41 
Control 29 2.72 0.32 2.78 0.46 
 
   
Figure 69: Heart to mediastinum ratios for controls, Alzheimer's disease and dementia with Lewy bodies patients for early 
images (left) and delayed images (right). The red lines show the local normal cut-off values, the green lines the optimal DLB 
vs AD cut-offs for data from our previous study [83] and the purple lines the calibrated cut-off taken from the Japanese 
multicentre three year follow-up study [62]. 
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Table 49: Sensitivity, specificity and overall accuracy for DLB vs AD differential diagnosis for early and delayed images with 
HMR cut-offs taken from local controls, Japanese multicentre study and ROC analysis of the dementia subject data. 
Cut-off Early Delayed 
Sensitivity Specificity Accuracy Sensitivity Specificity  Accuracy 
Local controls  
(2.07 early; 1.86 delayed) 
65% 80% 72% 71% 87% 78% 
Komatsu et al. (Japan) 
(2.51 early; 2.20 delayed) 
76% 47% 63% 71% 87% 78% 
Optimal (ROC analysis) 
(1.8 early; 1.7 delayed) 
65% 100% 81% 71% 100% 84% 
 
7.2.4 Discussion 
Early and delayed cut-offs 
Eight of the 29 controls included in our study had HMR values below the early image cut-off of 2.51 
from the Japanese follow-up DLB study [62] on early images and five of 29 below 2.20 on delayed 
images, providing strong evidence for lower thresholds for this population.  We note that the value 
from the Japanese normal database (patient-based) gives a normal range of 2.2 to 4.0 for early images 
(mean 3.1) and 2.2 to 4.4 for delayed images (mean 3.3) [188].  These HMR ranges seen in Japanese 
patients without Lewy body disease do not seem to fit our UK population. 
Our cut-offs of 2.07 (early) and 1.86 (delayed) reflect the higher variation in normal delayed HMR 
results compared with early results, rather than a difference in the mean, which is in line with previous 
studies [58, 174, 216].  These results were obtained using Siemens cameras fitted with MELP 
collimators, and as such cannot be directly applied to other centres using other collimators.  Using a 
calibration coefficient of 0.99 for our centre measured via phantom calibration we can apply the 
average coefficients given in the Japanese normal database publication [188] to calculate equivalent 
cut-off thresholds for other cameras using the method of Nakajima et al. [166], assuming similar 
patient populations and the same processing method.  These average coefficients are 0.55 for LEHR, 
0.65 for LEGP and 0.88 for MEGP, so lower cut-offs are required if applying our results to other 
collimators.  These are summarised in Table 50.  Note that these are average values and Verschure et 
al. showed variation of around ±6% (±2 SD) for both low and medium energy collimators in the 
European calibration study [167].  In addition, small differences between the phantoms used in the 
Japanese and European study may well add to the uncertainty, as well as possible regional differences 
in collimator specification for collimators with the same name (personal communication, Prof. K. 
Nakajima, Kanazawa University, Japan). 
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Table 50: Cut-offs based on our controls adapted to common collimator groups.  These results are only valid for the same 
processing protocol, i.e. 6 cm circular ROI placed over the myocardium, see [190]. 
 
Early cut-off Delayed cut-off 
MELP (Newcastle) 2.1 1.9 
LEHR 1.6 1.5 
LEGP 1.7 1.6 
MEGP 2.0 1.8 
 
For both early and delayed imaging of the patients with dementia slightly higher accuracy could be 
achieved with the optimal ROC cut-off than with the a-priori cut-offs derived from controls, which is 
unsurprising as these are cut-offs tailored to this specific dataset.  For early images, the use of the local 
control cut-off rather than the Japanese cut-off (2.07 vs 2.51) resulted in two fewer DLB patients being 
correctly assigned as abnormal; one of whom had a less equivocal HMR on delayed imaging.  The 
specificity was greatly increased with the local cut-off as only seven AD patients had early HMRs above 
the Japanese cut-off of 2.51.  However with delayed imaging, the sensitivity and specificity was the 
same with both the local and Japanese cut-offs (1.86 vs 2.20) as there were five DLB patients with 
clearly normal looking scans (lowest HMR = 2.39) and there were no AD patients falling between the 
two cut-offs.  It is worth noting however that five control subjects have HMR values between the two 
thresholds, suggesting our local values are more appropriate. We note that, due to possible differences 
in phantom structure due to manufacturing tolerances, it is possible that the Japanese thresholds 
calibrated for our camera could be slightly higher or lower (personal communication, Prof. K. Nakajima, 
Kanazawa University, Japan). 
Comparison with other studies 
In the multicentre study and its three year follow up, Yoshita et al. used ROC analysis to produce 
thresholds giving optimal separation between the groups, rather than using an independent normal 
cardiac uptake threshold [53].  However, we note that the Japanese normal database gives similar cut-
offs of 2.2 for both early and delayed images. With diagnostic revisions after three year follow up of 
65 of the subjects, the sensitivity and specificity for DLB diagnosis have improved from 69% and 89% 
respectively to 77% and 97% [62].   
At our centre we focus on the use of cardiac MIBG imaging for the diagnosis of Lewy body disease.  
However, as well as the differential diagnosis of Lewy body disease from other conditions [35, 51, 217], 
cardiac MIBG scintigraphy is also used for the estimation of risk of sudden cardiac death in heart failure 
patients and predicting those who could benefit from  an implantable cardiac defibrillator (ICD) [63, 
64] and this is currently the principal application in Europe and the US [65].  The largest study of healthy 
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controls recruited to a cardiac MIBG research study (n=94) was that of Jacobsen et al. [218] carried out 
as part of the ADMIRE heart failure study [63].  The controls were aged between 29 to 82 years (mean 
58.5 ± 10.6 years, with BMI between 20.4 and 44.3 (mean 28.7 ± 5.1).  These individuals were carefully 
screened to exclude coronary heart disease or Type 1 or 2 diabetes, making them healthier on average 
than the typical population.  Although a substantial proportion (39/94) were aged over 60 years, the 
inclusion requirement of having an annual cardiac risk of less than 10% would further increase the 
difference in health between these individuals and a typical elderly population.  We regard the 
inclusion of adults with diabetes and coronary risk factors as a strength of our study in relation to the 
diagnosis of Lewy body disease, rather than a weakness. In recruiting older adults that, aside from 
having no cognitive impairment, are similar in general health to that of the general population we are 
determining a true normal range.   However, despite this, the controls from the US ADMIRE study have 
lower HMR values on average than those from our study, even accounting for the different collimator.   
Using LEHR collimators their result was 1.78 ± 0.22, which would correspond to normal cut-off of 1.34 
with LEHR (two standard deviations below the mean of 1.78).  This cut-off converts to around 1.6 with 
our camera with MELP (determined using average coefficients of 0.55 for LEHR collimators [219] and 
the measured coefficient of 0.99 for our camera).  One possible reason for the lower HMRs in the 
United States may be differences in the method used to delineate the cardiac ROI, with a freehand 
method used in the ADMIRE study.  We found previously that this tends to give lower HMR values than 
a 6cm circular region [190].  Interestingly, the a priori cut-off used in the ADMIRE study was much 
higher than subsequently seen in the controls: 1.6 with LEHR collimators, equivalent to around 2.1 for 
our camera with MELP.  The a priori cut-off was determined by pooling the literature on cardiac MIBG 
values in healthy controls (n=202) [220].  This was done without population or camera differences 
being taken into account, which may account for the discrepancy. 
To our knowledge, the only other recent UK study in controls is by Asghar et al. in Manchester, again 
using LEHR collimators and excluding people with any history of diabetes or cardiac disease [216].  In 
14 healthy adults (mean age 54.6 ± 5.4 years, mean BMI 27.0 ± 3.1) they found a mean early HMR of 
1.67 ± 0.13 and delayed 1.73 ± 0.16, which would give cut-offs (mean – two standard deviations) of 
1.41 for both early and delayed images.  This cut-off is equivalent to around 1.7 for our camera with 
MELP collimation and therefore similar to our result for delayed imaging of 1.86.  Since there is thought 
to be little dependence of HMR on age [181, 221] we would expect any differences between our 
controls and this study to be due to the inclusion criteria, as it seems unlikely that there would be large 
differences between the population of Manchester and Newcastle, two post-industrial cities in 
northern England.  The fact that our mean and cut-off values are slightly higher rather than lower than 
the Manchester study, after accounting for camera differences, provides further indirect support of 
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our previous findings that cardiac disease is unlikely to have a big impact on HMR [83], and further 
supports the small body of evidence suggesting HMR is not strongly linked to age.  
Effect of cardiovascular disease on HMR 
It is known that regional cardiac sympathetic denervation assessed with SPECT or PET sympathetic 
imaging is associated with both areas of myocardial infarction (MI) and also with ischaemia in patients 
without previous MI [222-224].  The impact of MI and coronary artery disease (CAD) on global uptake 
assessed via planar cardiac MIBG scintigraphy is not well established, however most studies in healthy 
controls exclude those with CAD.  To our knowledge there are no large studies that evaluate the impact 
of regional sympathetic denervation associated with MI and CAD on planar HMR.  In this study and our 
previous work [83], one control and three AD patients had experienced an MI, all more than 1 year 
prior to scanning.  The control showed clear regional defects on SPECT imaging but borderline-normal 
delayed planar HMR (2.14).  The three AD cases showed defects of varying magnitude and extent on 
SPECT and planar HMRs of 2.99, 2.16 and 2.59.  The numbers are too low to establish a correlation 
between the extent of regional denervation and effect on global HMR but it seems likely that regional 
denervation would have to be widespread for planar HMR to be abnormally low.  Given the variation 
between healthy individuals, it is unlikely that MI and CAD alone would give an abnormal HMR result 
in individual cases.  However it is likely that both the mean and standard deviation of a group of 
subjects would be affected by heart disease, suggesting that differences in the prevalence of 
cardiovascular disease between populations could contribute to differences in HMR cut-offs.  In the 
UK the prevalence of cardiovascular diseases increases with age, with 8% of people between 60 and 
70 years of age and 24% of those over 80 reporting at least one symptom [225].  In England the 
prevalence of coronary heart disease over all ages in 2018 was reported by the National Health Service 
to be 3.1% [226].   Equivalent data for Japan is not published but we note that a large cohort study 
(Akita-Osaka study) showed 0.2% incidence of new coronary heart disease cases in urban Japanese 
men aged between 60 and 69 between 1996 and 2003 [227] suggesting a much lower prevalence in 
this age group than in the UK. 
Effect of obesity on HMR 
Obesity has been linked to decreased apparent cardiac MIBG uptake by two previous studies [181, 
228], and is thought to be due to increased attenuation and scatter in larger individuals, rather than 
to true differences in cardiac uptake.  The ADMIRE control study discussed above [181] had a wide BMI 
range of 20.4 to 44.3 kg/m2 (mean 28.7) and reported a “modest” decrease in HMR with BMI.  This 
was a study into ageing and the incidental finding of a relationship between BMI and HMR was not 
discussed in detail.  Pellegrino et al. reported lower HMRs in patients with BMI>30 (n=10) compared 
to those with BMI<30 (n=35) [228].  This was in heart failure patients and the results have not yet been 
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replicated in healthy controls but do suggest patient size may affect apparent cardiac MIBG uptake.  In 
our study the mean BMI of the controls was 27.8 kg/m2 which is representative of the mean value of 
27.3 for 119,230 men aged 40-69 recruited into the UK biobank study between 2006 and 2010 [229].  
The Manchester study had a similar mean BMI of 27.0.  In contrast, the mean BMI in a Japanese 
longitudinal study of 104,928 individuals was 22.6 in men and 22.9 in women [230].  A relatively higher 
proportion of overweight individuals may therefore contribute to the lower mean HMRs in the UK and 
US compared to Japan.  Future work using attenuation and scatter corrected SPECT imaging may 
provide insight into the contribution of patient size to these population differences in apparent cardiac 
MIBG uptake. 
Limitations 
This study was retrospective in nature, utilising control and patient data recruited to our centre for 
wider Lewy body disease studies.  The inclusion of older adults with a range of cardiac risk factors and 
without detailed cardiac assessment to detect undiagnosed cardiovascular disease makes it difficult to 
determine the impact of cardiac disease on HMR.  Very large samples of older adults with and without 
risk factors for cardiovascular disease could help to determine this, but as seen here, older people 
often have cardiac risk factors, making it impractical to recruit true healthy controls.   As obesity is both 
a risk factor for cardiovascular disease and a potential cause of artefactually reduced HMR this would 
also need to be accounted for.  If it were feasible, a large prospective study in multiple countries 
recruiting cognitively normal older adults typical of the local population and scanning them using the 
same protocol could determine whether HMR is population specific in a more rigorous manner. 
7.2.5 Conclusion 
We determined cardiac 123I-MIBG heart-to-mediastinum ratio cut-off values derived from a group of 
older adults in average health without evidence of cognitive decline for the first time.  After accounting 
for camera differences, these values were lower than the values used in Japan, higher than in a large 
US study but similar to those found in another UK centre.   
Our results suggest that normal cardiac 123I-MIBG heart-to-mediastinum ratio values may be 
population specific, although processing differences cannot be excluded.  Further work is required to 
determine the reasons for these differences, which could include contributions from heart disease, 
obesity and other co-morbid conditions.  This work highlights the importance of deriving HMR cut-offs 
from controls that are representative of the population being studied. 
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7.3 Can we use early phase cardiac MIBG images to diagnose Lewy body disease? 
7.3.1 Introduction 
Many studies using cardiac 123I-MIBG for the assessment of Lewy body disease acquire both early 
images (acquired 15-20 minutes after MIBG administration) and delayed images (3-4 hours after 
administration).  The HMR is usually calculated on the delayed images since these are thought to reflect 
the function of the cardiac sympathetic nerves and early images the distribution of the nerves [217, 
231].  However in the MIDAS study we saw little difference between heart-to-mediastinum ratios 
(HMR) obtained on cardiac MIBG images acquired at 20 minutes post-injection and those acquired at 
around 4 hours after injection [83, 190], suggesting that initial capability for uptake of MIBG by 
sympathetic neurons is impaired at the same time as storage mechanisms.  Autopsy studies report a 
loss of sympathetic nerve fibres in Lewy body disease cases [3, 71], suggesting that cardiac MIBG 
uptake should be reduced on both early and delayed imaging.  This was indeed the case in the only 
study to date to report autopsy findings in patients with cardiac MIBG imaging during life [82], where 
cardiac MIBG uptake was reduced on early images in 91% of Lewy body disease cases and on the 
delayed images in 96%.  
Three recent cardiac MIBG studies in Lewy body disease carried out in Japan by separate groups [174, 
232, 233] have demonstrated no significant difference between diagnostic accuracy of early or delayed 
imaging, suggesting that early images alone may be sufficient.  Acquiring early images alone would 
benefit both patients and clinical departments and would also make the test much more convenient 
than 123I-FP-CIT, which requires a 3-6 hour uptake period before scanning.  This would be particularly 
helpful for patients with more advanced dementia symptoms, who may find a lengthy period spent in 
an unfamiliar environment unsettling.  Even if the delayed image could only be omitted in a subset of 
cases, such a protocol would still be worthwhile. 
Examining the literature on early versus delayed MIBG in dementia and Lewy body disease we found 
two articles that stated early MIBG imaging was more accurate, 13 that stated delayed imaging was 
more accurate and 18 that reported no difference. However, only five of these compared early and 
delayed statistically, four of which showed no significant differences [174, 232-234].  However, Yoshita 
et al. [235] demonstrated that HMR values in Parkinson’s disease were significantly lower on delayed 
images than early images, whereas control HMR values were the opposite and were higher on the 
delayed images.  The differences between early and late HMR were statistically significant.   
In our publications on MIDAS we failed to find evidence for a significant difference between the 
diagnostic accuracy of early and delayed imaging [83, 190]. It is possible that there is a true difference 
in the accuracy of early and delayed imaging but that the MIDAS study dataset is too small for our 
results to reach statistical significance.  The sample size for MIDAS was derived based on the power to 
159 
 
detect a difference in the mean uptake between DLB and AD groups on delayed imaging in a UK 
population - given the large effect size seen in previous MIBG studies in DLB, relatively small numbers 
were predicted to be required for MIDAS.  Several of the subjects included had quite different uptake 
levels on delayed imaging compared to early, although this did not usually affect normal/abnormal 
categorisation with the optimal ROC cut-offs applied [190].  Furthermore, we tended to see greater 
differences in mean HMR between our DLB and non-DLB groups on delayed imaging compared with 
early, which is in keeping with previous studies, including those that demonstrated no statistically 
significant difference in diagnostic accuracy between early and delayed imaging [233, 234].   
The objective of this section is to bring together the MIDAS dementia cases and the SUPErB control 
and MCI cases used in this thesis to give larger clinical groups.  The difference between early and 
delayed HMR are explored for the whole dataset, providing a wide range of cardiac uptake values as 
well as for the individual clinical groups.  Diagnostic accuracy on early and delayed imaging is compared 
in both MCI and dementia, and for combined Lewy body (LB) disease and non-LB groups.   
7.3.2 Methods 
Subjects 
All individuals scanned as part of MIDAS or SUPErB up until January 2018 were used to compare early 
and delayed HMR values, even those subsequently excluded from the main study analyses – unless 
this was because of incorrect cardiac MIBG imaging protocol being followed.   Two MIDAS and two 
SUPErB cases had to be excluded because either the early or the delayed image was inadvertently 
acquired using the wrong collimator. All other cases were included: 40 MIDAS and 86 SUPErB (including 
31 controls), giving 126 data points in total.   
However, to compare HMR between clinical groups and to compare diagnostic accuracy, only a well-
characterised subset of 76 of the 95 cases with neurodegenerative disease was included, so as not to 
reduce the accuracy of gold-standard clinical diagnosis at 1 year follow-up. Patients with less certain 
diagnoses (i.e. possible DLB or possible MCI-LB), or diagnoses that appeared more in keeping with 
neurodegenerative diseases other than Alzheimer’s or Lewy body disease were excluded from this part 
of the analysis.  The 31 controls were also excluded so that specificity would reflect that of clinical 
cases. The patients included therefore have a 1 year follow up consensus diagnosis of either probable 
DLB (prob DLB) or dementia due to Alzheimer’s disease (AD) for MIDAS and either probable MCI with 
Lewy bodies (MCI-LB) or probable MCI due to Alzheimer’s disease (MCI-AD) for SUPErB.  The numbers 
in each group are given in Table 51. 
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Table 51: Number of patients included in the Lewy body disease and Alzheimer’s disease groups for each category 
 
Lewy body disease Alzheimer’s disease 
Mild cognitive impairment 26 18 
Dementia 17 15 
Combined groups 43 33 
 
Comparison between imaging time points 
Images were acquired as described in section 7.1 for both MIDAS and SUPErB.  Early and delayed planar 
cardiac MIBG images were processed to obtain HMR values as described previously, i.e using a 6cm 
circular cardiac region of interest and a 3 x 4 cm rectangular mediastinum region.   Two operators 
processed the images: the author (GR) and Joseph Kane (JPMK) for MIDAS and the author and Jim 
Lloyd (JJL) for SUPErB.  The relationship between early and delayed imaging was assessed using linear 
regression, taking the mean HMR from the two operators for each image.  The mean of two operators 
was taken as previous work on inter-operator repeatability section 7.1 showed variability was low.  
Bland-Altman plots were used to compare the difference between early and delayed images over the 
full HMR range more closely. 
Comparison between mean early and mean delayed HMRs for LB and AD groups 
The dementia and MCI groups were analysed separately and combined into larger Lewy body (LB) and 
Alzheimer’s disease (AD) groups.  The mean HMR values and standard deviation for early and delayed 
images were calculated.  Paired t-tests were used to determine whether a statistically significant 
difference between early and delayed HMR exists.  The mean HMR for the two operators was used. 
Accuracy of early and delayed planar imaging for LB and AD groups 
The 29 healthy controls from SUPErB with normal images were used to derive HMR cut-offs, as 
described in the previous chapter.  The HMR cut-offs were used to assign each scan as normal or 
abnormal.  Sensitivity, specificity and overall accuracy were calculated for each of the clinical groups 
described above.  Since sensitivity and specificity values are expressed as a percentage, binomial 
confidence intervals for proportions were calculated using the “Exact Binomial and Poisson Confidence 
Intervals” online tool available at http://statpages.info/confint.html 
7.3.3 Results 
Comparison between imaging time points 
The plots in Figure 70 show slightly worse agreement between HMRs at early and delayed time points 
than was seen between operators.  This is also reflected in the goodness-of-fit parameters (Table 52), 
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with R2 values of around 85% suggesting around 15% of the variance in delayed HMR is not predicted 
by early HMR.  The goodness-of-fit is very similar for HMRs produced by a single operator (GR) as for 
both operators combined (Table 52; plots not shown).  The Bland-Altman plots in Figure 71 show that 
for normal HMR values (mean early and delayed HMR greater than around 2.0) there is no systematic 
difference between the HMRs on early and delayed imaging.  However abnormal scans (mean early 
and delayed HMR less than around 2.0) are much more likely to have a drop in HMR between early 
and delayed imaging.  The HMR histograms in Figure 72 show a clearer separation of the data into two 
distinct normal and low uptake groups on delayed imaging. 
 
Table 52: Goodness-of-fit parameters for linear regression analysis between early and delayed time points 
Dataset Operators R2 (% explained 
variance) 
Standard error of 
regression (in units of 
HMR) 
MIDAS  GR+JPMK mean 91% 0.21 
GR only 89% 0.23 
SUPErB  GR+JJL mean 83% 0.25 
GR only 84% 0.24 
MIDAS+SUPErB Mean 86% 0.24 
GR only 85% 0.24 
 
 
MIDAS: SUPErB: MIDAS + SUPErB: 
   
Figure 70: Correlation between early and delayed images (mean of both operator HMRs) for the MIDAS and SUPErB datasets 
and for the two studies combined. 
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MIDAS: SUPErB: MIDAS + SUPErB: 
   
Figure 71: Bland-Altman plots of the difference between delayed and early HMR for MIDAS, SUPErB and both datasets.  The 
data point shown as a solid circle is one of the controls excluded from the main analysis as the early image was normal and 
delayed image abnormal. 
 
 
 
 
Figure 72: Histograms for early and delayed HMR for all subjects (top) and for MCI subjects (bottom).  The red categories are 
below the normal cut-offs, orange borderline and green normal. 
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The numbers of cases included in each of the clinical groups is given in Table 53.  Paired t-tests showed 
no significant difference in the group means between early and delayed imaging for controls or AD 
cases (Table 53).  There was however a significant difference for probable DLB cases, with the early 
image HMR higher by 0.19 (16%) on average.  There was no significant difference in mean early and 
delayed HMR for the probable MCI-LB cases from SUPErB.  The lack of difference in this dataset is to 
be expected, given the Bland-Altman plots above, as around half the MCI-LB cases have normal HMRs 
(see below). 
Table 53: Difference between mean HMR on early and delayed images for the different clinical groups. 
 
n Mean 
early 
HMR 
Mean 
delayed 
HMR 
Mean 
difference 
Mean % 
difference 
SD % 
difference 
p-value 
(paired t-
test) 
Controls 29 2.71 2.78 0.07 2% 11% 0.238 
MCI-AD 18 2.35 2.26 -0.10 -5% 14% 0.201 
Prob MCI-LB  26 2.02 1.97 -0.05 -5% 14% 0.382 
AD (MIDAS) 15 2.47 2.48 0.01 1% 7% 0.843 
Prob DLB (MIDAS) 17 1.88 1.69 -0.19 -12% 11% 0.002 
DLB (abnormal only) 12 1.47 1.23 -0.24 -16% 9% <0.001 
DLB+Prob MCI-LB 43 1.97 1.86 -0.10 -8% 13% 0.015 
 
Accuracy of early and delayed planar imaging for LB and non-LB groups 
The categorisation of scans into normal or abnormal groups is given in Table 54 for probable DLB and 
AD (MIDAS) and probable MCI-LB and MCI-AD (SUPErB) with the sensitivities and specificities in Table 
55.  In all but three cases (3/76; 4%) the categorisations are the same on both early and delayed images 
(2 from MIDAS and 1 SUPErB).  One probable DLB case had a borderline-normal HMR on early imaging 
(2.15; cut-off 2.07), which fell to 1.61 on delayed imaging.  One AD dementia case had a borderline-
abnormal early HMR of 2.01, increasing to a clear normal 2.26 on delayed imaging.  From the MCI 
dataset there was only one discrepancy between early and delayed results: an MCI-AD case with an 
early HMR of 2.17, dropping to 1.61 on delayed images.  The images were reviewed and this does 
appear to be a true difference, rather than a collimator or processing error.  As there are only 18 MCI-
AD cases, this discrepancy is the cause of the 5% greater reported specificity for the diagnosis of MCI-
LB on early images (83 vs 78%).  If the datasets are grouped together, the specificity for diagnosing 
Lewy body disease is the same for early and delayed imaging at 82% (95% CI: 65 to 93%).  The overall 
sensitivity is slightly higher for delayed imaging (60% vs 58%) - but this difference is due to just the one 
extra DLB case that fell to below the normal range on delayed imaging.  Although the accuracies are 
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similar, the histograms in Figure 72 suggest there is better separation of abnormal and normal scans 
on delayed imaging. 
Table 54: Early and delayed normal-abnormal categorisation for prob DLB, AD, prob MCI-LB and MCI-AD groups.  
Discrepancies between early and delayed results occur on the positive diagonal and are shown in red font. 
Prob DLB 
Early 
normal 
> 2.10 
abnormal 
< 2.10 
De
la
ye
d 
 
normal  
> 1.86 
5 0 
abnormal  
< 1.86 
1 11 
 
AD 
Early 
normal 
> 2.10 
abnormal 
< 2.10 
De
la
ye
d 
 
normal  
> 1.86 
12 1 
abnormal  
< 1.86 
0 2 
 
Prob MCI-LB 
Early 
normal 
> 2.10 
abnormal 
< 2.10 
De
la
ye
d 
 
normal  
> 1.86 
12 0 
abnormal  
< 1.86 
0 14 
 
MCI-AD 
Early 
normal 
> 2.10 
abnormal 
< 2.10 
De
la
ye
d 
 
normal  
> 1.86 
14 0 
abnormal  
< 1.86 
1 3 
 
 
Table 55: Sensitivity, specificity and overall accuracy figures for the diagnosis of Lewy body disease on early and delayed 
cardiac MIBG imaging, with 95% confidence intervals calculated using the binomial distribution. 
 
Dementia MCI Combined data 
 Early Delayed Early Delayed Early Delayed 
Sensitivity 65% 
(38 to 86 %) 
71% 
(44 to 90 %) 
54% 
(33 to 73 %) 
54% 
(33 to 73 %) 
58% 
(42 to 73 %) 
60% 
(44 to 75 %) 
Specificity 80% 
(52 to 96 %) 
87% 
(60 to 98 %) 
83% 
(59 to 96 %) 
78% 
(52 to 94 %) 
82% 
(65 to 93 %) 
82% 
(65 to 93 %) 
Accuracy 72% 
(53 to 86 %) 
78% 
(60 to 91 %) 
66% 
(50 to 80 %) 
64% 
(48 to 78 %) 
69% 
(58 to 79 %) 
71% 
(59 to 81 %) 
 
7.3.4 Discussion 
Bland-Altman plots of the pooled cardiac MIBG scans carried out for MIDAS and SUPErB revealed a 
difference between early and delayed imaging for low HMR values only, with no apparent difference 
between early and delayed HMR for scans with normal cardiac uptake.   Paired t-tests on well 
characterised subsets of the data confirmed that in healthy controls and AD there was on average no 
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difference between early and delayed HMR, whereas in probable Lewy body disease early HMR was 
significantly higher than delayed HMR, particularly for the DLB cases.  It is likely that the early images 
contain a higher degree of non-specific uptake in the cardiac region, which washes out later and is not 
so apparent on delayed images.  This reduction in non-specific uptake would have more effect when 
the level of specific uptake is low (or zero), which may explain why the DLB patients had lower HMRs 
on delayed images.   The histograms of HMR distribution also suggested a clearer distinction between 
normal uptake and low uptake groups on delayed imaging than on early imaging, for both the 
combined dataset of dementia and MCI patients and the MCI dataset alone.  While this is evidence in 
favour of delayed imaging in principle, a larger separation between LB and non-LB groups does not 
necessarily equate to superior diagnostic accuracy – the accuracy of early imaging may be equivalent 
in practice if the smaller separation between groups is more than adequate.    We see in our dataset 
that the vast majority of scan results do not change between early and delayed, and that those clearly 
abnormal early on do not go on to become normal on delayed imaging.  These results also suggest that 
the exact timing of the early and delayed imaging is not critical, which is useful to know in clinical 
practice as it can be difficult to schedule a patient for an exact timeslot. 
Published papers from Japan [174, 232, 233] have shown no statistically significant difference in the 
area under the ROC curve between early and delayed imaging.  However, this is a questionable 
statistical approach as the objective of these papers was to show that early imaging could be used 
instead of delayed.  They use a null hypothesis of no difference but they have already said they want 
to show that early and delayed imaging give the same results.  So while they showed that there was 
insufficient evidence that delayed imaging has better accuracy than early imaging, this does not prove 
that there is no difference in accuracy.   In my opinion, one of the studies provides weak evidence, 
rather than no evidence, for delayed imaging being more accurate (AUC 0.871 early, 0.893 delayed; p 
= 0.091) [232].  These three studies were quite large with 453, 111 and 192 cases included.  However, 
they were all done retrospectively, on clinical patients attending for diagnostic testing and as such the 
results are likely to have influenced the clinical groupings.  A key strength of our work is that diagnoses 
were made as part of research studies and done entirely independently of cardiac MIBG imaging; 
however a limitation is the relatively small sample size, especially when only the patients with more 
certain diagnoses are included.  Since only a small proportion of cases (3/76, 4%) changed their normal-
abnormal designation between early and delayed imaging we can conclude that the accuracies of early 
and delayed imaging must be similar.  However it is clear from reviewing the 95% confidence intervals 
that this study is not powered to detect clinically important difference in sensitivity or specificity 
between early and delayed imaging even with the MIDAS and SUPErB datasets combined.  A power 
calculation (assuming 80% power and a 5% significance level) suggests that 8338 subjects per group 
would be needed to detect the 2% difference in accuracy seen here!  The very small difference in 
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accuracy is not clinically important, especially in the context of other factors which might contribute 
to larger variations in the MIBG data such as obesity, cardiac disease and physiological fluctuations in 
uptake. 
Taken together, the results in this chapter suggest that we should assume that delayed imaging is likely 
to be slightly more accurate than early imaging, but only by a small percentage - so the majority of the 
time the outcome on the early image will be the same.  The question is then, what range of early HMR 
results can we accept as being definitively normal or abnormal (when requiring a binary result) and 
which range should be regarded as equivocal?   I.e. what are the early HMR upper and lower cut-off 
values that result in delayed HMR values that are statistically likely to be above or below 1.86?  The 
standard error that we found earlier from linear regression can be used to define a confidence interval, 
i.e. a range of values that the delayed HMR is likely to fall within for a given early HMR value.  The 
least-squares best fit relationship between early and delayed HMR for all data is: 
𝐷𝐷𝑐𝑐𝑙𝑙𝑐𝑐𝐴𝐴𝑐𝑐𝑑𝑑 𝐻𝐻𝑀𝑀𝑅𝑅 = (1.1124 ∗ 𝐸𝐸𝑐𝑐𝑐𝑐𝑙𝑙𝐴𝐴 𝐻𝐻𝑀𝑀𝑅𝑅) − 0.3226 
 
The standard error in delayed HMR from the linear fit is 0.286, so a 95% confidence interval, assuming 
a normal distribution, is 1.96*SE, which is ± 0.56 (in units of delayed HMR).  This means that the 
delayed HMR is very likely to fall within ± 0.56 of the value calculated above.  Rearranging, we find that 
the delayed cut-off value of 1.86 is given by an early HMR value of 2.02 (0.7696*1.86 +0.5887). 
𝐸𝐸𝑐𝑐𝑐𝑐𝑙𝑙𝐴𝐴 𝐻𝐻𝑀𝑀𝑅𝑅 = (0.7696 ∗ 𝐷𝐷𝑐𝑐𝑙𝑙𝑐𝑐𝐴𝐴𝑐𝑐𝑑𝑑 𝐻𝐻𝑀𝑀𝑅𝑅) + 0.5887 
 
But other delayed HMRs could also occur when the early HMR is 2.02: 95% of the time we would expect 
the delayed values to fall between 1.30 and 2.42 (1.86 ± 0.56).  If we want to be reasonably confident 
of an early result being normal or abnormal, one approach is to work out what range of early HMRs 
could result in a delayed value of 1.86 with 95% confidence.  The standard error in early HMR (from 
linear regression) is 0.238 so the 95% confidence interval is ± 0.467.  The early value most likely to give 
a delayed value of 1.86 is 2.02.  2.02 ± 0.467 results in a lower limit of 1.55 and upper limit of 2.47 for 
early HMR values.  This means that an early HMR below 1.55 is very likely to be abnormal (<1.86) on 
delayed imaging and any value above 2.47 is likely to be normal.  Applying this method in clinical 
practice, any patient with an early HMR between these values should return for delayed imaging to 
clarify.   In our full dataset of 126 scans scanned with MELP collimators, 20 had early HMRs below 1.55, 
none of which were over 1.86 on delayed imaging.  None of the 67 cases with early HMRs above 2.47 
had abnormal delayed HMRs.   We could therefore have omitted the delayed image in 69% of the cases 
and have still been confident of the results.   In terms of the practicalities of this suggestion, since the 
HMR on the early image is very quick to calculate using our method presented in section 7.1, it would 
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be feasible to inform the patient whether they needed to return within 10 minutes of the early scan 
being completed. 
We note that this method does not take into account the non-linearity seen over the HMR range (i.e. 
that early HMR is likely to be higher than delayed HMR when uptake is low), so one could argue that 
the confidence intervals would be best calculated separately for normal and abnormal HMRs.  This 
would however increase the standard errors and therefore confidence intervals due to the smaller 
sample, making the equivocal range even wider.   An alternative approach could be to assume that any 
case already below the delayed HMR cut-off of 1.86 on early imaging is very likely to remain below 
1.86 on delayed imaging.  There were 12 further cases with early HMR between 1.55 and 1.86 in our 
dataset and all were below 1.86 on delayed imaging.  This means that in total 78% of the delayed scans 
(99/126) could have been omitted with this additional approach.  Of the remaining 27 scans, there 
were five where the early and delayed result differed: three changed from normal on early images 
(>2.10) to abnormal on delayed (<1.86) and 2 changed from abnormal to normal. 
7.3.5 Conclusion 
Sensitivity and specificity values using HMR cut-offs derived from healthy controls are very similar for 
early and delayed imaging, showing that any difference in diagnostic accuracy between the time points 
is very small.  However there is some suggestion from our data that the later imaging could separate 
Lewy body and non-Lewy body groups better than the early imaging; there would be some theoretical 
support for this view as non-specific uptake will wash out later.    
Considering that much of the literature uses delayed imaging and there are evidence-based reasons to 
prefer it, we would recommend that imaging 3-4 hours after injection remains the reference standard.  
However we suggest that in clinical practice centres could omit the delayed image if the early results 
were unequivocal and have provided suggested ranges for this, valid for Siemens gamma cameras with 
medium energy collimators.  In our dataset, 69% of cases would count as non-equivocal on early 
imaging, 78% if the lower limit of the equivocal range was increased to 1.86.  Adopting this approach 
in clinical practice would remove the need for the delayed image in the majority of cases, with 
negligible potential impact on diagnostic accuracy. 
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7.4 Summary of Chapter 7 
In section 7.1 we evaluated the accuracy and reproducibility of a simple method for calculating HMR 
on cardiac MIBG images, suitable for use in both routine clinical practice and research studies.  This 
method gives similar accuracy to a bespoke cardiac region tailored to the patient and better 
reproducibility.  The method has been adopted for HMR calculations in the SUPErB study and is used 
throughout the thesis.  We also confirmed that semi quantification is crucial for cardiac MIBG imaging, 
with visual raters tending to overcall subtle reductions in cardiac uptake, leading to reduced specificity.  
However, HMR analysis is of course only accurate if a suitable cut-off value is available, and currently 
this is a barrier to the technique being used outside research settings, at least in the UK.   
The issue of normal thresholds is discussed in more detail in section 7.2, where we evaluate whether 
it is appropriate to apply HMR cut-off values from the Japanese literature to our UK population.  It was 
seen that HMRs are significantly higher in Japan than in our study and could lead to misdiagnoses if 
applied in the UK.  Potential population specific causes, such as obesity and heart disease, were 
discussed.  The HMR values for controls from the large US ADMIRE-HF study [218] were compared with 
ours and shown to be lower, after correction for collimator differences.  However HMR results for a 
cohort of 14 controls recruited and scanned in Manchester were similar to our results [216].  We 
presented a series of collimator-specific approximate HMR cut-offs based on control data from the 
SUPErB study that could be used by centres not wishing to switch to medium energy collimators. 
Cardiac MIBG imaging using the early phase only could be a good alternative to FP-CIT for people 
whose dementia symptoms make a lengthy procedure challenging.   In our dataset we found that 
delayed images appear to separate patients with normal and abnormal uptake better than early 
images, but overall accuracy was very similar, with only 4% of subjects changing normal/abnormal 
categorisation between early and delayed.  We suggest that, rather than switching to early imaging 
entirely, the delayed imaging could be omitted if the early image is non-equivocal, which was the case 
in 78% of scans in our combined MIDAS and SUPErB dataset.   
In summary, we have provided data, both this chapter and chapter 5, to enable us to propose an 
accurate and practical evidence-based cardiac MIBG protocol for image acquisition and analysis.  This 
protocol could be used in clinical practice and in research studies requiring a binary normal/abnormal 
sympathetic innervation result.  We suggest that patients should be administered 111 MBq and a 
planar anterior image of the chest acquired around 20 minutes later, using medium energy collimators.  
If the HMR, calculated using our 6 cm circle ROI method, is below 1.6 or above 2.5 the patient should 
be informed that the test is complete.  If the HMR at 20 minutes is equivocal the patient should be 
asked to return for a repeat scan to be carried out 3-4 hours after injection.   For research studies 
focussing on cardiac MIBG we recommend that delayed images are acquired for all subjects. 
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Chapter 8: Tomographic cardiac 123I-MIBG 
analysis 
In this chapter we explore more advanced methods for cardiac MIBG imaging using SPECT and SPECT-
CT and assess whether these techniques are likely to improve the diagnosis of Lewy body disease 
compared to standard planar imaging. 
In section 8.1 we use a phantom to demonstrate the effect of attenuation and scatter on apparent 
uptake with planar and tomographic methods.   We investigate whether planar cardiac uptake results 
in control subjects are linked to patient size and explore whether using SPECT-CT to correct for 
attenuation and scatter can improve quantification in the phantom and controls.   In section 8.2 we 
extend these methods to MCI patients from the SUPErB study and compare the diagnostic accuracy of 
planar imaging with both SPECT (without attenuation and scatter correction) and SPECT-CT (with 
corrections). 
In section 8.3 we outline methods for quantifying the absolute uptake of MIBG within the heart, and 
compare the accuracy of these methods to both planar and tomographic HMR methods.  In section 8.4 
we use SPECT imaging to examine the pattern of cardiac MIBG uptake within the myocardium, 
comparing controls with normal cognition to patients from the MIDAS study with either dementia with 
Lewy bodies or Alzheimer’s disease.  In section 8.5 we summarise these results and discuss whether 
there is a role for tomographic cardiac MIBG imaging in the diagnosis of Lewy body disease. 
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8.1 Planar cardiac MIBG HMRs depend on patient size – can SPECT-CT reduce 
dependence? 
8.1.1 Introduction 
Systematic equipment and processing differences in cardiac 123I-MIBG HMRs between centres can be 
accounted for with planar phantom calibration, as described in sections 5.2 and 7.2.  However, patient 
factors affecting HMR values, such as variation in the amount of attenuation and scatter due to patient 
size, cannot be taken into account with this method.  There have been few publications commenting 
on whether patient factors may have a significant impact on diagnostic value of planar cardiac MIBG 
scintigraphy, and to our knowledge none that have explored whether SPECT with CT attenuation 
correction and scatter correction (CT ACSC) would be of benefit.  Although several groups investigating 
the diagnostic accuracy of cardiac 123I-MIBG for the diagnosis of Lewy body disease have acquired 
SPECT data alongside planar, often it is only the planar scans that have been used for analysis with the 
SPECT results not reported [55, 183, 236-238], suggesting the added value of SPECT is unclear.  In 2016 
Odagiri et al. reported that the accuracies of planar and SPECT-CT 123I-MIBG cardiac scintigraphy were 
similar, but did not use the CT data for SPECT image corrections, only for localising the heart [239].  In 
their 2015 multicentre study, Yoshita et al. used SPECT for visual analysis but not for quantification of 
cardiac uptake [53]. 
Obesity has been linked to decreased apparent cardiac MIBG uptake by two previous studies [181, 
228], and is thought to be due to increased attenuation and scatter in larger individuals, rather than 
to true differences in cardiac uptake.  The largest study of healthy controls recruited to a cardiac MIBG 
research study (n=94) was that of Jacobsen et al. [218] carried out as part of the ADMIRE heart failure 
study [63].  The controls were aged between 29 to 82 years (mean 58.5 ± 10.6 years, with a wide BMI 
range of 20.4 to 44.3 kg/m2 (mean 28.7 ± 5.1).  The study reported a “modest” decrease in HMR with 
BMI, however this was a study into ageing and the incidental finding of a relationship between BMI 
and HMR was not discussed in detail.  Pellegrino et al. reported lower HMRs in patients with BMI>30 
(n=10) compared to those with BMI<30 (n=35) [228].  This was in heart failure patients and the results 
have not yet been replicated in healthy controls but do suggest that patient size may affect apparent 
cardiac MIBG uptake.   
In this study we aimed to establish the degree to which planar cardiac 123I-MIBG scintigraphy is affected 
by patient size and whether SPECT with CT ACSC can correct for this.  We investigated this using an 
anthropomorphic chest phantom configured with different amounts of attenuation and a cohort of 
older adults with normal cognition with BMI between 22 and 38 kg/m2. 
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8.1.2 Methods 
Subjects 
Twenty-nine volunteers aged over 60 years with normal cognition were recruited as part of the SUPErB 
study, as described in section 7.2 and elsewhere in this thesis. 
Image acquisition 
Ten minute anterior planar images were acquired at 20 minutes and at 4 hours (± 30 minutes) after 
injection, as described in Chapter 7.  SPECT-CT imaging was carried out immediately after the delayed 
planar image with the subject in the supine position with arms raised if possible.  Only ten of the 
volunteers were able to be scanned with arms raised, the others kept their arms by their sides.  SPECT 
images were acquired over 360 degrees in H mode (detectors oriented parallel to each other) to obtain 
120 projections of 20 seconds using a non-circular autocontoured orbit. The energy window was 159 
keV ± 7.5%, matrix size 64 x 64 and zoom factor 1.64.  Following SPECT imaging, a low dose CT scan 
(130 kV with a quality reference mAs of 13) was acquired for attenuation and scatter correction. 
Image reconstruction 
All images were processed on a Hermes workstation (Hermes Medical Ltd, Stockholm Sweden).    SPECT 
images were processed in Hermes Hybrid Recon Cardiology v1.1.2 using OSEM iterative reconstruction 
with 15 iterations and 3 subsets, with a Butterworth filter of 0.90 cm applied.  Resolution recovery for 
the MELP collimator was applied, with parameters set for the Siemens Intevo gamma camera as 
provided by Hermes: hole diameter 0.294 cm; hole length 4.06 cm; detector intrinsic resolution at 140 
keV 0.38 cm; radius of rotation off-set 4.76 cm.    Two sets of images were reconstructed, both using 
resolution recovery: non-corrected (NC) and CT corrected for attenuation and scatter (ACSC). The 
scatter correction model is based on a Monte Carlo simulation of scatter within the patient [107, 123].  
Full collimator and detector response modelling [125] is not included in this model. 
Phantom image acquisition  
Images were acquired with the RSD torso phantom with fillable heart, lung, liver and background 
compartments (Figure 73).  The original heart insert supplied with the phantom did not give realistic-
looking cardiac MIBG images so was substituted with a simple left ventricle insert manufactured in-
house with fillable myocardial wall and cavity compartments.  The phantom was filled and scanned 
with 123I, using activity concentrations designed to mimic patient studies.  The activities used are given 
in Table 56. The left ventricle insert was imaged alone on the scanner bed without any additional 
attenuation followed by three filled phantom scans with increasing amounts of attenuation: torso 
phantom, torso phantom with solid PMMA chest extension plate and torso phantom with chest plate 
and breasts (plastic shells filled with water) – see Figure 73. 
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The scan parameters were the same as those used for clinical research studies at our centre: MELP 
collimators, auto-contouring, 1.64 zoom, 64 x 64 matrix size.  As with clinical scans, CT was acquired 
so that both attenuation and scatter corrected and non-corrected images could be reconstructed.  
Images were reconstructed using the clinical parameters given above. 
 
   
Figure 73: Anthropomorphic torso phantom (centre), with in-house replacement LV insert (left) and additional PMMA chest 
plate and water filled breasts (right) 
 
Table 56: activity concentrations used in the anthropomorphic torso phantom, selected to give count densities similar to 
healthy control images. 
 
Activity / MBq kBq / ml 
Concentration 
relative to 
background 
LV dose (diluted into 200 ml, 
actual volume ~160 ml) 
27.7 138.7 22 
Background (approx. 8200 ml) 52.6 6.4 1 
Liver (1000 ml) 78.6 78.6 12.2 
Lungs (diluted in 1000 ml 
before filling) 
50.1 50.1 7.8 
 
Image analysis for cardiac uptake 
The images of the torso phantom and the images of the older adult volunteers were analysed in the 
same way.  Anterior planar images were analysed to obtain the heart to mediastinum ratio (HMR) 
using a 6 cm circular ROI placed over the left ventricle and 4 x 3 cm rectangular ROI between the lungs 
in the mediastinum, see [190].  The phantom was not moved from the scanner couch between 
acquisitions, allowing the same regions to be used for all three attenuation configurations.   
The SPECT coronal slices were summed over all 64 slices to give images analogous to planar images. 
We obtained HMRs on these summed images in the same way as for the planar and we term these 
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“coronal SPECT HMRs”.  The summed coronal SPECT-CT technique was included because it should be 
a simple and reproducible way of analysing attenuation and scatter corrected SPECT images, using 
planar analysis methods.  The same regions of interest were used for planar and summed coronal 
SPECT HMRs, with no adjustment between the non-corrected and ACSC SPECT (see Figure 74 for 
example).  This enables a direct assessment of the effects of attenuation and scatter correction to be 
made. 
 
 
Figure 74: Planar image (left) with corresponding summed coronal SPECT slice images without CT ACSC (middle) and with 
corrections (right).  Note the relative reduction in lung uptake and increased heart contrast on the ACSC image. 
 
Volumetric HMRs on clinical and phantom SPECT images were calculated using 6cm diameter spherical 
VOIs placed over the left ventricle and cuboid VOIs over the mediastinum (Figure 75).  The placement 
of VOIs was not modified between the ACSC and non-corrected datasets.   
 
 
Figure 75: Example control SPECT-CT images showing coronal, sagittal and transverse slices centred on the left ventricle, with 
spherical cardiac VOI and rectangular mediastinal VOI shown. 
 
Planar and SPECT HMR data for the controls were plotted against BMI and the slopes and standard 
errors calculated using linear regression.  The standard errors of the slopes were used to calculate t-
statistics to determine whether each relationship between HMR and BMI (for planar or SPECT) was 
significant at the α = 0.05 level.   To compare slopes, normalisation was necessary since average HMRs 
are much higher for SPECT than planar due to increased contrast.  The SPECT slopes and the standard 
errors were scaled to be consistent with planar data by multiplying by the ratio between the mean 
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planar HMR and HMR in question.  The differences between the normalised slopes and their combined 
standard errors were used to determine whether corrections for attenuation and scatter had a 
significant impact on reducing the dependence of HMR on BMI. 
8.1.3 Results 
Torso phantom 
The appearance of the phantom on planar images was significantly affected by additional attenuation, 
whereas this was not the case with the attenuation and scatter corrected SPECT images (Figure 76).  
The HMR on planar imaging was reduced by 20% with the additional PMMA chest plate added and by 
40% with the plate and water filled breasts added (Figure 76 and Figure 77).  The summed coronal 
SPECT images showed an increase in HMR with attenuation, due to lower mediastinum counts – the 
appearance of the images was reasonably preserved.  The SPECT count data, corrected for attenuation 
and scatter, and decay corrected, showed a much lower drop with additional attenuation.   
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Figure 76: The effects of attenuation and scatter on planar and ACSC SPECT images of the torso phantom.  The top row shows 
the planar images, middle row the ACSC summed coronal slices and the bottom row the ACSC SPECT-CT images.  The planar 
and summed coronal SPECT HMRs are calculated using 6 cm circular cardiac ROIs; the ACSC SPECT mean cardiac counts using 
a 6 cm spherical VOI. 
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Figure 77: Phantom heart to mediastinum ratios for the three configurations, calculated from planar images, summed ACSC 
coronal SPECT images and volumetric HMRs from ACSC and non-corrected (NC) SPECT.  Both the planar and non-corrected 
SPECT HMRs decrease with additional attenuating material. 
 
  
Figure 78: Counts in cardiac volume of interest with ACSC and non-corrected SPECT for the heart insert scanned alone and 
with increasing attenuation within the torso phantom. The drop in counts when the insert is scanned within the phantom is 
much less with ACSC applied. 
 
0
1
2
3
4
5
6
7
8
9
Standard phantom Chest plate Chest plate+breasts
HM
R
Planar Summed SPECT slices ACSC SPECT HMR ACSC SPECT HMR NC
0
500
1000
1500
2000
2500
3000
Heart insert alone Standard phantom Chest plate Chest plate+breasts
Ca
rd
ia
c c
ou
nt
s
ACSC SPECT NC SPECT
177 
 
Clinical results 
On planar imaging a negative linear correlation between HMR and BMI is seen (Figure 79), with a slope 
that is significantly different from zero (p <0.01), resulting in a 32% drop in HMR on average between 
BMI of 20 and 35 (Table 57).  In comparison, the drop in HMR over this BMI range with attenuation 
and scatter corrected SPECT was 14% on average for the summed coronal slice method and 16% for 
the volumetric SPECT method (with 6cm diameter spherical VOI).  However, comparison between 
normalised slope values (Table 58) shows no significant difference between planar and either summed 
coronal ACSC SPECT (p =0.11) or volumetric ACSC SPECT (p=0.36). 
Figure 80 shows the plots of HMR or cardiac counts against BMI for the summed coronal SPECT images 
and SPECT volumetric HMR.  These are displayed with the non-corrected data on the left and the ACSC 
data on the right for each method.  The linear fits, and p values for slopes being different from zero for 
planar and SPECT imaging are given in Table 57.  The p-values show that with the summed non-
corrected SPECT coronal slices, there is a significant drop in HMR with BMI but with attenuation and 
scatter correction this is not statistically significant.  However, when comparing the slopes for non-
corrected and ACSC coronal HMR data directly (Table 58) there is no evidence of a statistically 
significant difference.  SPECT volumetric HMR (spherical VOI) data show no significant relationship with 
BMI either with or without ACSC, and have the highest normalised standard errors, possibly due to 
greater uncertainty in cardiac and mediastinum volume of interest placement compared to the other 
2D methods.  The coefficients of variation of the HMR data (independent of any relationship with BMI) 
are also higher for the volumetric SPECT data than for the planar or summed coronal HMRs (Table 57). 
 
 
Figure 79: planar HMR plotted against BMI for the 29 older adults, with linear fit. 
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Figure 80: Summed coronal HMR with and without ACSC (top), SPECT volumetric HMR with and without ACSC (bottom). 
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Table 57: Linear regression between HMR and BMI for planar data and SPECT with and without attenuation and scatter 
correction. 
Quantitative measurement Planar 
HMR 
Summed SPECT coronal 
slices HMR 
Volumetric SPECT HMR 
CT ACSC? n/a Yes No Yes No 
Coefficient of variation  17% 14% 13% 25% 28% 
Linear fit to BMI -0.067*BMI 
+ 4.61 
-0.039*BMI 
+ 4.76 
-0.053*BMI 
+ 4.74 
-0.117*BMI 
+ 12.84 
-0.125*BMI 
+ 12.42 
R2 0.44 0.11 0.28 0.05 0.05 
Normalised slope n/a -0.028 -0.037 -0.034 -0.039 
SE of slope 0.017 0.023 0.017 0.104 0.11 
Normalised SE n/a 0.017 0.015 0.03 0.034 
p-value for non-zero slope <0.01 0.09 <0.01 0.27 0.27 
Predicted drop in value 
between BMI 20 and 35 
3.36 to 2.27 
(-32%) 
3.95 to 3.39 
(-14%) 
3.69 to 2.90 
(-21%) 
10.5 to 8.74 
(-16%) 
9.93 to 8.06 
(-19%) 
 
 
Table 58: Comparison between normalised slopes for planar and SPECT HMR with BMI, and for attenuation and scatter 
corrected SPECT data vs no corrections. 
Comparison Difference in 
normalised 
slopes 
Combined 
normalised 
standard error 
T-statistic P-value 
Planar HMR vs ACSC summed 
coronal HMR 
0.038 0.022 1.60 0.11 
Planar HMR vs ACSC 
volumetric SPECT HMR 
0.032 0.035 0.932 0.36 
Summed coronal: ACSC vs no 
corrections 
0.008 0.022 0.380 0.71 
Volumetric SPECT: ACSC vs no 
corrections 
0.005 0.046 0.104 0.92 
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8.1.4 Discussion 
A strength of our study is the inclusion of both phantom and clinical data.  The phantom data was 
acquired under controlled conditions allowing us to investigate the impact of increasing phantom size 
alone with no other sources of variation.  The clinical data applies image reconstruction in more 
realistic conditions to determine whether the effect holds in practice. 
Our results in the torso phantom show a clear advantage of SPECT-CT 123I imaging with attenuation 
and scatter correction over planar imaging and over SPECT without CT ACSC.  The visual appearance of 
the phantom reconstructed with the planar-equivalent summed ACSC SPECT images was greatly 
improved compared to the standard planar images; this is particularly apparent on the third 
configuration with both the PMMA chest plate and the water filled breast inserts added.  The counts 
within the left ventricle insert showed a much greater reduction with increasing scatter and 
attenuation on the non- corrected images compared to those reconstructed with ACSC.   Given that 
this was an anthropomorphic phantom with realistic dimensions and activity concentrations, the 
results can be assumed to hold in individual patients.   
However, when examining our cohort of 29 older adults with normal cognition, the benefit of ACSC 
SPECT is not as apparent.  Although on average, the relationship between BMI and cardiac uptake was 
less obvious with SPECT imaging than planar, there was no evidence that this was statistically 
significant.  It is clear that there is a significant relationship between planar HMR and body mass index, 
so on average we would expect to see lower HMRs in larger people.  However given the substantial 
variation between subjects (an R2 value of 0.44 suggests that less than half the variation is related to 
BMI), it would not be practical to apply a linear correction to the HMR results based on BMI.  This 
variation seems to be even greater with SPECT volumetric HMRs and there is furthermore no 
statistically significant negative slope between SPECT HMR and BMI, which we would expect for data 
without attenuation and scatter correction if this is the cause of the drop seen in planar imaging.  The 
summed coronal slices do show a drop on the non-corrected images, suggesting that the summation 
of the SPECT slices reduces noise in the data.  We recognise that BMI is more complex than the 
increases in size applied to our phantom study and there is likely to be substantial variation in the 
gamma ray interactions of two people of the same BMI.  The inactive material used for the phantom 
chest plate and breasts is also not representative of active background tissue in patients.  However, 
we cannot exclude the possibility that larger people may on average be more likely to have true 
reductions in cardiac uptake, for example due to underlying coronary artery disease, for which obesity 
is a risk factor. 
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Normal random variation in uptake between individuals may not be the only explanation for our 
findings.  The ACSC summed coronal SPECT images do not appear noisier than the planar images but 
do suggest a drop in HMR with increasing BMI, albeit not statistically significant.   A possible 
explanation is errors in the CT ACSC that are not seen in the phantom scans.  Motion between SPECT 
and CT is a possibility, either due to volunteers moving slightly or internal mis-registration due to free 
breathing (e.g. diaphragm) or lack of cardiac gating.  The images were examined for mis-registration 
during reconstruction, but this will not detect subtle shifts. 
8.1.5 Conclusion 
In an anthropomorphic torso phantom, increasing the size reduces cardiac uptake by 39% on planar 
images and 33% on non-corrected SPECT images but with attenuation and scatter correction applied 
the reduction is only 3%.  Planar cardiac 123I-MIBG images show a significant inverse relationship 
between cardiac uptake ratios and subject BMI.   SPECT images with attenuation and scatter correction 
applied show no statistically significant drop in cardiac uptake with BMI, but there is considerable inter-
subject variation and no statistically significant difference between the slopes of HMR against BMI for 
non-corrected and ACSC SPECT.  It may be possible to reduce variation in future studies by using a 
SPECT-CT protocol that is more acceptable to older patients.  This work suggests that ACSC SPECT does 
have the potential to improve cardiac 123I-MIBG quantification, particularly in borderline planar cases 
but much larger studies would be needed to demonstrate this conclusively. 
  
182 
 
8.2 Does cardiac 123I-MIBG SPECT-CT improve the diagnosis of Lewy body disease?   
8.2.1 Introduction 
Previously we saw that in a phantom, the planar HMR decreased with the addition of attenuating 
material.  Corrections for attenuation and scatter, applied during SPECT reconstruction, reduced these 
effects.  Cardiac MIBG images in controls showed an inverse relationship between planar HMR and 
BMI, indicating that patient size affects HMR. 
In this section we explore whether SPECT with and without CT attenuation and scatter correction 
improves the diagnostic accuracy of cardiac MIBG imaging compared with the standard planar 
technique.  Planar and SPECT control data is used to calculate normal cardiac uptake ranges for all the 
techniques considered.  In this section, the term SPECT refers to reconstructions without attenuation 
and scatter correction, i.e. a technique available on any scanner.  SPECT-CT refers to reconstructions 
with CT based attenuation and scatter correction.  This reconstruction is less widely used in clinical 
practice as it requires use of a SPECT-CT scanner and a small additional CT radiation exposure. 
SPECT data is available for both the MIDAS and SUPErB subjects, but CT data for attenuation and 
scatter correction was only acquired for SUPErB.  In dementia and MCI, we therefore consider whether 
SPECT alone, without CT based image corrections, is of benefit over planar imaging.  In MCI we also 
consider the benefit of SPECT-CT for relative quantification over both SPECT and planar imaging. 
8.2.2 Methods 
Subjects 
The MIDAS and SUPErB subjects included were the same as those in the previous chapters: 29 healthy 
older adults, 28 probable MCI-LB, 18 MCI-AD, 15 DLB (as 2/17 DLB did not have SPECT imaging) and 15 
AD. In addition, the entire SUPErB MCI dataset of 56 scans was used to compare the distribution of 
HMR values over the full range.  The 29 control scans were used to produce normal cut-offs for SPECT 
imaging, analogous to the methods used with planar images in section 7.2.  The MCI and dementia 
cases were used to calculate diagnostic accuracy for SPECT and the MCI alone for SPECT-CT.  One 
probable MCI-LB case was scanned on the wrong collimator but was clearly normal on planar and 
SPECT.  This case was included as normal for the accuracy calculations but excluded from quantitative 
analysis. 
Image acquisition, reconstruction and processing 
SPECT-CT images for the SUPErB MCI dataset were acquired and processed as described for the 
controls in the previous section.    Images were processed to obtain HMRs as described in the previous 
section, with the addition of a thresholded cardiac volume of interest for SPECT-CT (Figure 81), 
introduced to remove the left ventricular cavity and surrounding background from the VOI.  The 
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hypothesis is that a VOI containing fewer non-specific counts may provide better separation between 
normal and abnormal images, and therefore have the potential to improve diagnostic accuracy.  The 
thresholded VOI was generated by masking out all anatomy other than the left ventricle and including 
any voxels containing counts within 50% of the maximum voxel.  The mean number of counts per voxel 
was then taken for comparison with the mediastinum reference VOI, as for the spherical cardiac VOI. 
   
 
Figure 81: Slice data masked and reformatted into cardiac plane for thresholding, with 50% cardiac threshold VOI shown. 
 
SPECT images for the MIDAS dataset were acquired and processed similarly, but without the additional 
attenuation and scatter corrected image reconstructions.  Only the volumetric SPECT HMR method 
was therefore assessed for patients with dementia.  The resultant set of processed images is 
summarised in Table 59 with the names they will be referred to throughout the rest of the section.  As 
SPECT images were acquired after the delayed planar images only, not after the early planar images, 
the early planar HMR will not be used for comparison in this section.  If insufficient cardiac uptake was 
visible for meaningful spherical VOI placement on SPECT images, the CT was used as a guide for SUPErB 
cases and a “best guess” based on lung and liver anatomy was made for the MIDAS cases.  If there was 
insufficient uptake to apply the 50% threshold method, the images were classed as abnormal for the 
purposes of the sensitivity and specificity calculation. 
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Table 59: HMR methods used for each dataset in addition to the standard delayed planar HMR. 
Name Description Controls MCI Dementia 
Planar HMR Delayed planar HMR  X X X 
CSPECT HMR Summed coronal SPECT HMR  X X  
CSPECT-CT HMR Summed coronal SPECT-CT HMR  X X  
SPECT HMR Volumetric SPECT HMR with 
spherical VOI  
X X X 
SPECT-CT HMR Volumetric SPECT-CT HMR with 
spherical VOI  
X X  
SPECT-CT 
HMR50% 
Volumetric SPECT-CT HMR with 
50% threshold cardiac VOI 
X X  
 
Analysis 
The distribution of HMR values for the entire MCI dataset for each of the techniques was plotted using 
histograms, to reveal any differences in separating clusters of scans with different levels of cardiac 
uptake.  The difference in mean HMR between MCI-LB and MCI-AD groups, and between DLB and AD 
groups was calculated for each method, and the standard error of the mean difference used to 
calculate confidence intervals for the difference.  Scatter plots of SPECT HMR against planar HMR were 
produced to illustrate variation.  Dot plots of HMR for each clinical group were produced for each HMR 
method. 
The normal cut-off values for each method were derived from the 29 controls and taken as two 
standard deviations below the mean.  This method of determining a normal range is used throughout 
the thesis and is also used in 123I-FP-CIT commercial software.  The coefficient of variation for each 
method was calculated from the control HMRs.   The MCI results for each processing method were 
dichotomised as normal or abnormal according to the cut-offs and the resulting values used to 
calculate sensitivity, specificity and overall accuracy for each method.  Contingency tables for each 
SPECT method were generated relative to delayed planar imaging.  Percentage concordance between 
methods was calculated.  For SPECT HMR, where MCI and dementia data was available, the datasets 
were assessed separately and as combined Lewy body and Alzheimer’s disease groups.   
8.2.3 Results 
Normal cut-offs from control data 
The mean HMR, standard deviation, coefficient of variation and normal-cut off calculated from the 
controls for each of the methods assessed is shown in Table 60.  
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Table 60: Control mean HMR, SD, coefficient of variation (CoV) and mean-2SD cut-off for the different processing methods 
used 
 Mean Standard 
deviation 
CoV Normal cut-off 
Planar HMR 2.78 0.46 16.5% 1.86 
CSPECT HMR 3.27 0.42 12.8% 2.43 
CSPECT-CT HMR 3.67 0.51 13.9% 2.65 
SPECT HMR 8.95 2.49 27.8% 3.96 
SPECT-CT HMR 9.58 2.35 24.5% 4.87 
SPECT-CT HMR50% 10.69 2.46 23.0% 5.77 
 
HMR distribution for each method 
Figure 82 shows histograms of HMR distribution for the planar and SPECT HMR methods, using the 46 
MCI cases.  Categories below the normal cut-offs in .  
Table 60 are displayed in red, above in green and borderline categories in orange.  Delayed planar 
imaging shows reasonable separation between normal and abnormal uptake.  The CSPECT method, 
where the SPECT slices are summed to give images similar to planar images, shows no clear separation.  
The distributions with CSPECT-CT and SPECT appear similar to planar.  SPECT-CT HMR with both the 
spherical cardiac VOI and the threshold VOI show more distinct normal and abnormal uptake groups.  
The threshold VOI histogram is skewed towards zero because several scans had insufficient uptake for 
threshold analysis. 
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Figure 82: HMR histograms for MCI subjects in SUPErB, showing the degree to which each imaging technique separates normal 
and low uptake. A: planar, B: summed coronal SPECT, C: summed coronal SPECT-CT, D: volumetric SPECT, E: volumetric SPECT-
CT, F: SPECT-CT with cardiac threshold. Categories below the normal cut-offs in Table 60 are displayed in red, above in green 
and borderline categories in orange.   
  
(b) (a) 
(d) (c) 
(e) (f) 
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Difference between AD and LB groups for each method 
Table 61 shows that there is a significant difference between the AD and DLB mean HMR for both 
planar and SPECT imaging, but not between the MCI-AD and MCI-LB groups.  This is expected given the 
high proportion of MCI-LB scans designated as normal for all imaging methods (Figure 84).  The 
difference between AD and DLB for MIDAS is much greater for SPECT than for planar, likely due to the 
increased SPECT contrast for high uptake scans.  However, the dot plots for the MIDAS dataset in Figure 
83 show that for both planar and SPECT HMR there is one AD case below the normal cut-off and 5 DLB 
cases above.  These are the same patients, giving 100% concordance between planar and SPECT HMR 
for the MIDAS dataset. 
Table 61: Differences between mean HMR for probable Lewy body disease and Alzheimer’s disease groups.  In the MIDAS 
dataset mean HMR is significantly lower for DLB compared to AD for both planar and SPECT imaging.  In the SUPErB MCI 
dataset mean HMR appears lower in the Lewy body group but this is not statistically significant.  The largest difference is seen 
for SPECT-CT HMR.  SPECT-CT50% is not included because many low uptake scans could not be analysed with this method. 
 Lewy body 
disease 
Alzheimer’s 
disease 
Difference 
Mean Standard 
deviation 
Mean Standard 
deviation 
Mean 
difference 
(AD-LB) 
95% CI for 
mean 
difference 
p-value 
(unpaired 
t-test) 
De
m
en
tia
 
(M
ID
AS
) 
Planar 
HMR 
1.63 0.77 2.51 0.36 0.88 0.46 to 1.29 <0.001 
SPECT 
HMR 
2.79 2.46 6.39 1.69 3.60 2.05 to 5.14 <0.001 
M
ild
 co
gn
iti
ve
 im
pa
irm
en
t (
SU
PE
rB
) 
Planar 
HMR 
1.98 0.84 2.26 0.56 0.21 -0.12 to 0.68 0.18 
CSPECT 
HMR 
2.25 0.76 2.44 0.59 0.20 -0.21 to 0.58 0.36 
CSPECT-
CT HMR 
2.52 1.14 2.75 0.72 0.27 -0.30 to 0.77 0.40 
SPECT 
HMR 
4.62 3.48 5.34 2.11 0.82 -0.89 to 2.34 0.38 
SPECT-
CT HMR 
5.28 3.81 6.60 2.43 0.92 -0.48 to 3.13 0.16 
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Figure 83: Dot plots for MIDAS for planar HMR (left) and SPECT HMR (right) showing no change in interpretation with SPECT.  
The blue circles are AD patients and the red circles DLB.  The green line shows the normal cut-off – the borderline AD case is 
the same patient and is just below the normal cut-off for both planar and SPECT 
 
Figure 84: SPECT HMR plotted against delayed planar HMR for the MIDAS dementia dataset (left) and SUPErB MCI (right).  
The green lines show where the data points would fall if planar and SPECT HMR were equivalent.  In cases with cardiac uptake 
the SPECT HMR is much higher than the planar due to improved contrast, but when uptake is low there is little contrast with 
background for either method. 
 
Comparison between HMR methods for MCI patients 
Figure 85 shows that the CSPECT method provides little distinction between normal and abnormal 
scans for either the MCI-AD or MCI-LB dataset, which is in keeping with the histogram distributions in 
Figure 82.  Visually there appears to be a better separation between normal and abnormal scans for 
SPECT-CT compared to SPECT and to planar.  The SPECT-CT50% threshold method appears similar to 
SPECT-CT, taking the scans with no visible uptake into account. 
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Figure 85: Dot plots for HMR for MCI-AD and MCI-LB groups.  The MCI-LB group contains many normal uptake scans, and the 
MCI-AD some low uptake scans.  However, the SPECT-CT HMR plot shows a clear division of the data into high and low uptake 
clusters, which is not as obvious for the other methods. The CSPECT methods show no distinction between groups. 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
Pl
an
ar
 H
M
R
MCI-AD Prob MCI-LB
0
0.5
1
1.5
2
2.5
3
3.5
4
CS
PE
CT
 H
M
R
MCI-AD MCI-LB
0.00
2.00
4.00
6.00
8.00
10.00
12.00
SP
EC
T 
 H
M
R
MCI-AD Prob MCI-LB
0.00
1.00
2.00
3.00
4.00
5.00
6.00
CS
PE
CT
-C
T 
HM
R
MCI-AD Prob MCI-LB
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
SP
EC
T-
CT
  H
M
R
MCI-AD Prob MCI-LB
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
SP
EC
T-
CT
  T
hr
es
ho
ld
 H
M
R
MCI-AD Prob MCI-LB
190 
 
Concordance between planar and SPECT techniques 
Concordance between planar HMR and SPECT HMR was 100% for both the MIDAS and SUPErB datasets 
(Table 62).  For the MCI dataset, concordance between planar HMR and SPECT-CT50% HMR was also 
100%.   Concordance between planar HMR and summed coronal SPECT was slightly poorer (89%) both 
with and without attenuation and scatter correction, due to more cases being designated as abnormal 
with CSPECT and CSPECT-CT (Table 63).  Concordance between planar and SPECT-CT HMR was 100% 
for the Lewy body group but 98% overall as one of the MCI-AD cases was below the planar cut-off but 
above the SPECT-CT cut-off. 
Table 62: Contingency table showing perfect concordance between planar and SPECT HMR imaging for the MCI and dementia 
groups. 
 
 
 
 
 
 
 
 
 
 
 
 MCI Dementia 
SPECT 
> 3.96 < 3.96 > 3.96 < 3.96 
LB
 
Pl
an
ar
 
normal  
> 1.86 
11 0 5 0 
abnormal  
< 1.86 
0 15 0 10 
AD
 
normal  
> 1.86 
14 0 14 0 
abnormal  
< 1.86 
0 4 0 1 
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Table 63: Contingency table showing concordance between planar and SPECT imaging in MCI for each SPECT method tested.  
Red figures indicate non-concordance.  The CSPECT methods both designated four additional MCI-AD cases and one additional 
MCI-LB as abnormal.  The only other disagreement was for a single MCI-AD case that was designated abnormal with planar 
HMR but was within the SPECT-CT normal range. 
 CSPECT CSPECT-CT SPECT HMR SPECT-CT 
HMR 
SPECT-CT 
HMR50% 
>2.43 < 2.43 > 2.65 < 2.65 > 3.96 < 3.96 > 4.87 < 4.87 > 5.77 < 5.77 
M
CI
-L
B 
Pl
an
ar
  
> 
1.86 
10 1 10 1 11 0 11 0 11 0 
< 
1.86 
0 15 0 15 0 15 0 15 0 15 
M
CI
-A
D 
> 
1.86 
10 4 10 4 14 0 14 0 14 0 
< 
1.86 
0 4 0 4 0 4 1 3 0 4 
 
Diagnostic accuracy of SPECT techniques compared with planar 
The sensitivity, specificity and overall accuracy for distinguishing between MCI-LB and MCI-AD for each 
of the techniques assessed is given in Table 64.  The specificities are lower for the summed coronal 
SPECT methods and higher for SPECT-CT due to the cases mentioned above.  Overall there is little 
difference in diagnostic accuracy between any of the methods.  Sensitivity is low for all methods due 
to the high proportion of normal scans within the MCI-LB group (as seen in the plots in Figure 85). 
 
Table 64: Diagnostic accuracy with respect to clinical diagnosis for each of the image analysis methods assessed. 
 
 
Planar CSPECT-CT CSPECT SPECT HMR SPECT-CT 
HMR 
SPECT-CT 
HMR50% 
Sensitivity  54% 
(15/28) 
57% 
(16/28) 
57% 
(16/28) 
54% 
(15/28) 
54% 
(15/28) 
54% 
(15/28) 
Specificity 78% 
(14/18) 
56% 
(10/18) 
56% 
(10/18) 
78% 
(14/18) 
83% 
(15/18) 
78% 
(14/18) 
Accuracy 63% 
(29/46) 
57% 
(26/46) 
57% 
(26/46) 
63% 
(29/46) 
65% 
(30/46) 
63% 
(29/46) 
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8.2.4 Discussion 
SPECT-CT HMR has theoretical advantages in improving the diagnostic accuracy of cardiac MIBG 
imaging as it potentially separates normal and abnormal uptake scans better than planar HMR due to 
improved contrast.  Our results show a tantalizingly good separation of the MCI-LB cases into two 
groups; following up the existing cohort will therefore be very helpful to establish whether the 
potential improvement is borne out in practice.  However, in our MCI dataset over half of the MCI-LB 
cases have scans that are normal, without any doubt.  There are also MCI-AD cases that are clearly 
abnormal.  This is reflected in the non-significant differences between mean HMR for the MCI dataset 
for all imaging methods.  We therefore didn’t see the improvement in accuracy with SPECT-CT in this 
particular dataset that we may have done if there had been more borderline images. 
Summed coronal CSPECT-CT appears to be an unsuitable technique for calculating HMR, both 
considering the histograms that show no clear difference between normal and low uptake and the 
specificity results. This technique was included because it should be a simple and reproducible way of 
analysing attenuation and scatter corrected SPECT images.  By summing the coronal slices, a “pseudo-
planar” image is generated, which can be analysed using the reproducible planar HMR methods 
introduced in section 7.1.  SPECT and SPECT-CT HMR is expected to be less repeatable as the operator 
needs to decide on the placement of the volumes in three dimensions.  We found that the placement 
of the mediastinum region in particular was quite arbitrary and hypothesised that the simple geometry 
of the CSPECT-CT images could provide the advantages of attenuation and scatter correction, without 
the increase in variation. 
The coefficient of variation is indeed lower for the CSPECT images than for SPECT, and is actually lower 
than that of the planar HMR.  This could be due to the lower matrix size of the SPECT images, which 
makes the summed coronal images look smoother than the true planar images or possibly related to 
the use of resolution modelling to reduced noise.  This can be seen in the example planar and summed 
coronal images displayed side by side in Figure 74 in section 8.1.  The mean CSPECT HMR should be 
the same as the mean planar HMR as this is the same geometry and neither are corrected for scatter 
and attenuation; but in fact the CSPECT HMR is consistently slightly higher (p <0.001). 
The greater separation between high and low uptake scans seen on the histogram data for SPECT-CT 
compared to CSPECT-CT (Figure 82) suggests that the increase in image contrast with SPECT is a bigger 
factor than attenuation and scatter correction.  However, attenuation and scatter correction does 
appear to increase separation for SPECT-CT HMR and led to one of the MCI-AD cases being designated 
as normal, whereas on planar imaging the patient had a low HMR.  This HMR values for this patient 
were 1.70 on delayed planar imaging (normal cut-off 1.86) and 5.75 on SPECT-CT (normal cut-off 4.87).  
The value on SPECT without corrections was 3.88, just below the cut-off of 3.96.   The planar and SPECT-
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CT images in Figure 86 show a clear difference in appearance of the heart, with very little uptake visible 
on planar and uptake clearly visible on SPECT-CT.  The BMI for this patient was 34.4, suggesting that 
the low HMR on the planar image may have been due to artefactual count reduction because of excess 
attenuation and scatter.   
 
 
Figure 86: Planar image and SPECT-CT central slice image for the MCI-AD patient with low uptake on the planar scan and 
uptake within normal limits on SPECT-CT. 
 
We expected to see more cases like the one above, given the BMI distribution in our dataset, with over 
half the patients classed as either overweight or obese (Figure 87) and given that several AD patients 
had unexpectedly low planar uptake.  However, when we look at the impact of CT attenuation and 
scatter correction on HMR for the whole dataset, there does not appear to be any link with BMI (Figure 
88).  On average, the HMR values are higher for SPECT-CT than SPECT, including for slim people, but 
there is a lot of variation.   This indicates that attenuation and scatter is not strongly dependent on 
BMI, which may help to explain why we did not see a significant difference in the slopes between 
SPECT HMR and BMI and SPECT-CT HMR and BMI for controls in the previous section. This is possibly 
because BMI is not a good surrogate for thickness of tissue overlying the heart. 
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Figure 87: BMI distribution for the MCI dataset 
 
 
Figure 88: Bland-Altman plot showing difference in HMR for SPECT-CT and SPECT, plotted against BMI.  The data point for the 
MCI-AD case discussed above is shown in green. 
 
8.2.5 Conclusion 
SPECT-CT improves the separation between normal and abnormal cardiac MIBG scans quite 
considerably, and may increase clinical confidence in scan interpretation.  However, the increased 
separation translates into only a small improvement in MCI diagnostic accuracy because many MCI-LB 
scans are clear-cut normal cardiac MIBG cases, and some MCI-AD are clear-cut abnormal.  In most 
cases planar imaging is more than sufficient to characterise the scans and SPECT-CT HMR doesn’t add 
useful information.   However, in clinical practice, SPECT-CT may be useful in borderline cases where 
the planar image result is unclear. 
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8.3 Absolute quantification of 123I-MIBG cardiac uptake using SPECT-CT imaging  
8.3.1 Introduction 
Previous sections have used various relative quantification methods to assess cardiac sympathetic 
innervation.  However, in theory a more direct absolute measure of specific uptake offers advantages 
and is the ultimate goal of nuclear medicine studies. Traditionally this has not been technically possible 
due to the very large uncertainty in scatter and attenuation effects.  Now with SPECT-CT and advances 
in reconstruction techniques there is the potential to provide a far more accurate measure of true 
activity within a given organ and hence measure absolute uptake in kBq/ml, as was explored for striatal 
uptake of FP-CIT in section 6.2.  In this section we report an investigation into the feasibility and 
accuracy of absolute quantification of cardiac MIBG in the diagnosis of Lewy body disease and compare 
this with previous relative methods.  Absolute quantification for cardiac MIBG imaging has not 
previously been investigated in the literature. 
In the previous section we showed that SPECT-CT relative quantification, via the volumetric heart-to-
mediastinum ratio on attenuation and scatter corrected SPECT images, could separate normal and 
abnormal cardiac MIBG scans better than planar imaging or SPECT without ACSC.  However a concern 
remained that these images could be subject to poor processing repeatability, due to the uncertainty 
in the placement of the mediastinum reference region.  The coefficient of variation of the SPECT-CT 
HMR between subjects was substantial at 25%, compared to 17% for delayed planar HMR.  By 
considering the absolute quantification of the activity concentration in the heart and mediastinum 
volumes of interest we will be able to show whether this was primarily due to variation in the cardiac 
VOI or mediastinum VOI. 
If the variation in mediastinum region is substantial, it may be that absolute quantification of cardiac 
MIBG uptake could offer advantages over SPECT-CT HMR by providing a result less affected by noise 
and more in keeping with the actual sympathetic innervation of the heart.  This has not been 
investigated before with CTACSC in the literature.  However, as discussed for FP-CIT in section 6.2, 
absolute quantification has practical challenges that introduce potential sources of error and 
uncertainty and which may outweigh any advantages that the removal of dependence on a noisy 
reference region brings.  These include the need to take height and weight measurements, accurately 
record the injected activity (including the residual activity in the syringe post-injection) and the time 
at which the activity was measured.  There is also a need for accurate gamma camera calibration (to 
allow detected signal to be converted to radioactivity concentration), with regular QC checks on this.  
All of the above involves extra staff time so it would not be justified to implement this technique in 
routine clinical practice without having demonstrated a clinically important benefit.  The scatter and 
attenuation correction method for torso studies requires CT imaging immediately after the SPECT, 
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increasing the radiation dose to the patient. This CT will always have at least some degree of mis-
registration relative to the SPECT due to breathing, the point in the cardiac cycle at which the CT was 
acquired and voluntary patient movement, all of which will affect the accuracy of the reconstructed 
images.  However this does also apply to the SPECT-CT HMR results, so is not a reason to prefer relative 
quantification (SPECT-CT HMR) over absolute cardiac uptake measurements.  Finally, the use of a 
scaling factor to take patient size and therefore tracer volume of distribution (VoD) into account is a 
further source of variation as it is known that VoD does not scale linearly with patient weight, which is 
often used as a surrogate in PET imaging [240]. For example, an overweight patient will have a higher 
weight than a slim patient of the same height, but the tracer VoD will not be increased by the same 
proportion.  However, some sort of adjustment for patient size is crucial, as smaller patients will have 
a lower tracer volume of distribution on average, with higher activity concentration in the heart (and 
in all other organs).  An alternative surrogate is lean body mass, which scales better with tracer VoD 
[241, 242].  However, lean body mass cannot be measured directly, adding an additional source of 
uncertainty.   LBM may be estimated from BMI and weight using the following sex-specific 
formulae[243], which have been validated for PET imaging [244]: 
LBM (males) = 9,270 × weight/(6,680 + 216 × BMI) 
LBM (females) = 9,270 × weight/(8,780 + 244 × BMI) 
The objectives of this section are as follows: 
• To assess whether patient weight or estimated lean body mass should be used for 
normalisation  
• To calculate and compare the coefficients of variation for absolute cardiac uptake and absolute 
mediastinum (background) uptake 
• To calculate normal cut-offs for absolute cardiac uptake and apply these to the cardiac uptake 
values in the MCI dataset 
• To compare the diagnostic accuracy of absolute cardiac uptake with that of SPECT-CT HMR 
 
8.3.2 Methods 
Subjects 
SPECT data is available for both the MIDAS and SUPErB subjects, but CT data for attenuation and 
scatter correction was only acquired for SUPErB.  Attenuation and scatter correction are a pre-requisite 
for accurate activity quantification, so we are only able to assess the potential benefits of absolute 
quantification in the SUPErB MCI cohort.  The SPECT-CT scans of the controls with normal planar 
imaging are used to assess the variation in absolute cardiac uptake, and to establish a normal cut-off.  
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One control was excluded due to the injected activity not being recorded, so 28 control scans were 
used in this section.   All the SUPErB MCI and control cases are included to assess the variation in 
mediastinum uptake, as this will be independent of cardiac innervation.  The SUPErB probable MCI-LB 
and MCI-AD cases are used to assess diagnostic accuracy, as in section 7.2.  As previously noted, one 
probable MCI-LB case was scanned on the wrong collimator but was clearly normal on planar and 
SPECT.  This case was excluded from this section. 
Absolute uptake calculation 
In order to obtain a meaningful uptake measurement, the detected signal needs to be corrected for 
the amount of activity injected and the size of the patient (as a surrogate for VoD).  In positron emission 
tomography (PET) this is usually achieved via the standardised uptake value (SUV), as applied to FP-CIT 
in section 6.2.  The SUV requires the measurement of the activity concentration in a volume of interest, 
obtained from the count density in the volume via a gamma camera calibration factor, CF.   
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐 (𝑘𝑘𝐵𝐵𝑞𝑞/𝑚𝑚𝑙𝑙) = 𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐴𝐴 𝑑𝑑𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 × 𝐶𝐶𝐶𝐶 
The activity concentration is normalised by the weight or LBM and by the activity administered to the 
patient to give the SUV:  
𝑆𝑆𝑆𝑆𝑆𝑆 =  𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐 (𝑘𝑘𝐵𝐵𝑞𝑞 𝑚𝑚𝑙𝑙⁄ )
𝐴𝐴𝑑𝑑𝑚𝑚𝐴𝐴𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑑𝑑 𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (𝑀𝑀𝐵𝐵𝑞𝑞) 𝑃𝑃𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴 𝑤𝑤𝑐𝑐𝐴𝐴𝑤𝑤ℎ𝐴𝐴 (𝑘𝑘𝑤𝑤)⁄  
Cardiac MIBG SUVs may be calculated by Hermes Medical Hybrid Recon software, as we did for FP-CIT, 
but using a specific calibration factor for MELP collimators and torso geometry.  This calibration factor 
has been obtained for MELP collimators.  However, because we had already reconstructed the cardiac 
MIBG data with standard SPECT-CT reconstructions without SUV information to use for relative 
quantification in the previous section, we manually calculated a quantity analogous to SUV, the 
normalised count density, from the existing reconstructed data.   
SUV can also be expressed as 
𝑆𝑆𝑆𝑆𝑆𝑆 =  𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐴𝐴 𝑑𝑑𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 × 𝐶𝐶𝐶𝐶
𝐴𝐴𝑑𝑑𝑚𝑚𝐴𝐴𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑑𝑑 𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (𝑀𝑀𝐵𝐵𝑞𝑞) 𝑃𝑃𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴 𝑤𝑤𝑐𝑐𝐴𝐴𝑤𝑤ℎ𝐴𝐴 (𝑘𝑘𝑤𝑤)⁄  
 
Assuming the calibration factor is unchanged between patients, SUV information is contained within a 
measurement of count density, normalised to injected activity and patient size.  We define the 
normalised count density (𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠) as the raw count density (mean number of counts per voxel) 
(𝐶𝐶𝐷𝐷𝑠𝑠𝑠𝑠𝑟𝑟) scaled to that of a standard sized person injected with 111 MBq 123I-MIBG, referenced to the 
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scan time.  We have defined 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠, which is simply a scaled version of SUV, as it can be calculated 
without requiring additional SUV reconstructions. 
A standard sized person weighs 70 kg and has a lean body mass (LBM) of 55 kg.  Either weight or LBM 
can be used to adjust the count density for patient size.  The size scaling factor (SSF) is the patient 
weight or LBM divided by the reference weight or LBM.  The activity scaling factor (ASF) is the decay 
corrected administered activity divided by the reference activity of 111 MBq. 
The raw count density is multiplied by these scaling factors to give the normalised count density: 
𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠 = 𝐶𝐶𝐷𝐷𝑠𝑠𝑠𝑠𝑟𝑟  × 𝐴𝐴𝑆𝑆𝐶𝐶 × 𝑆𝑆𝑆𝑆 
𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠_𝑟𝑟𝑠𝑠 =  𝐶𝐶𝐷𝐷𝑠𝑠𝑠𝑠𝑟𝑟  × 𝑃𝑃𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴 𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 111 𝑀𝑀𝐵𝐵𝑞𝑞⁄  × 𝑤𝑤𝑐𝑐𝐴𝐴𝑤𝑤ℎ𝐴𝐴 70 𝑘𝑘𝑤𝑤⁄  
𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠_𝐿𝐿𝐿𝐿𝐿𝐿 =  𝐶𝐶𝐷𝐷𝑠𝑠𝑠𝑠𝑟𝑟  × 𝑃𝑃𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴 𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 111 𝑀𝑀𝐵𝐵𝑞𝑞⁄  × 𝐿𝐿𝐵𝐵𝑀𝑀 55 𝑘𝑘𝑤𝑤⁄  
For example, one of our controls (BMI 29.7; weight 105 kg; LBM 75kg) was administered 118 MBq 123I-
MIBG at 12:00, with a residual activity of 6 MBq left in the syringe.  He was scanned 3.6 hours later, at 
which point the injected activity had decayed to 93 MBq, as the half-life of 123I is 13.2 hours.  The mean 
cardiac count density on the scan (CDraw), sampled using a 6cm diameter spherical VOI, was 292 counts 
per voxel.  The activity scaling factor (ASF) is 111/93 = 1.19.  The size scaling factor (SSF) is 105/70 = 
1.50 for weight scaling and 75/55 = 1.36 for LBM scaling.  The normalised count density is therefore 
𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠_𝑟𝑟𝑠𝑠 = 292 × 1.19 × 1.50 = 521 for weight scaling and 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠_𝐿𝐿𝐿𝐿𝐿𝐿 = 292 × 1.19 × 1.35 =469 for LBM scaling. 
This benefit of this normalised count density approach is that the VOIs used for relative quantification 
can be reused, avoiding introducing an additional source of uncertainty.  The method is valid because 
all our patients and controls were scanned using the same acquisition protocol on the same scanner.  
The scanner calibration factor that would have been required by Hybrid Recon software for SUV 
calculation is therefore just a scaling factor that is the same for all scans.   However, if the acquisition 
time had varied between patients, for example, or if some patients had been scanned with different 
collimators, the SUV software would have been the simplest method to account for these differences. 
Raw count density values were obtained for MCI patients and controls for the heart and mediastinum 
using the same spherical and threshold VOIs as in the previous section.  Both the body weight and LBM 
normalisation methods were used, resulting in four 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠 values for each subject (Table 65). 
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Table 65: Methods used to calculate normalised count density 
 Size normalisation method 
Weight LBM 
VOI 
method 
Sphere 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠_𝑟𝑟𝑠𝑠 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠_𝐿𝐿𝐿𝐿𝐿𝐿  
50% threshold 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠_𝑟𝑟𝑠𝑠_50% 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠_𝐿𝐿𝐿𝐿𝐿𝐿_50% 
 
Assessment of normalisation method 
The raw and normalised count densities for the mediastinum were plotted against the size scaling 
parameter used for normalisation (i.e. weight or LBM).  Mediastinum data for all MCI and control 
subjects were used.  We expected to see a drop in 𝐶𝐶𝐷𝐷𝑠𝑠𝑠𝑠𝑟𝑟 with increasing weight and LBM because the 
123I-MIBG is diluted over a larger volume of distribution.  If the normalisation method is effective we 
should see no drop in 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠 with patient size.  Similar plots were produced for the cardiac count 
densities, but this was restricted to only the 28 controls with normal cardiac uptake on planar imaging.   
The slopes of raw and normalised count densities against weight or LBM were calculated with 95% 
confidence intervals.  The standard errors were used to calculate whether the slopes were significantly 
closer to zero with the normalisation methods applied.  
The mean control 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠 values and the standard deviations were used to calculate coefficients of 
variation (CoV) for each normalisation method for both the heart and the mediastinum.  The CoV in 
this case is a measure of a combination of the variation between subjects and the uncertainty in VOI 
placement.  The absolute quantification CoV results were compared with the CoV for SPECT-CT HMR 
of 25%. 
Diagnostic accuracy of absolute cardiac uptake 
Normal cut-off values for 𝐶𝐶𝐷𝐷𝑏𝑏𝑐𝑐𝑠𝑠𝑠𝑠  were calculated from the control data, and defined as two standard 
deviations below the mean.   
MCI scans were dichotomised as normal or abnormal to calculate sensitivity and specificity using the 
threshold described above.  Sensitivity, specificity and accuracy was assessed for all four absolute 
uptake parameters listed in Table 65. 
8.3.3 Results 
Assessment of normalisation method 
The plots of mediastinal uptake in Figure 89 confirm that count density decreases with patient size.  
The slopes are both significantly different from zero (Table 66).  Both weight and LBM normalisation 
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have a statistically significant effect on the slopes, resulting in values that are not significantly different 
from zero.  Visually the normalisation to LBM appears more effective but the histograms are similar 
for both methods (Figure 90).  There is no cause identified for the obvious outlier – the image files 
have been checked and the correct collimator was used and the VOI placement was sensible.  This was 
an MCI-LB patient with low cardiac activity so the cardiac counts are unhelpful in determining the 
cause. 
The plots of the cardiac count density for the controls in Figure 91 again suggest that the LBM 
normalisation method may be slightly more effective than weight.  This is supported by the statistical 
analysis (Table 66), with the weight normalisation showing no statistically significant change in slope 
and the residual slope still negative.  The LBM normalisation method shows both a significant reduction 
in slope with normalisation applied and a resulting slope that is not significantly different from zero.  
 
Table 66: Slopes of CDraw and CDnorm_wt against weight and CDraw and CDnorm_LBM against LBM, for cardiac and 
mediastinal count density.  The 95% confidence intervals around the slope estimates are given as well as p-values for difference 
in slopes with and without normalisation applied. 
 
Cardiac counts 
against weight 
Cardiac counts 
against LBM 
Mediastinum 
counts against 
weight 
Mediastinum 
counts against 
LBM 
Slope (CDraw) -5.02 -7.19 -0.46 -0.59 
95% CI -6.57 to -3.46 -9.21 to -5.17 -0.60 to -0.32 -0.79 to -0.40 
Slope (CDnorm) -2.74 -2.00 -0.09 0.05 
95% CI -4.98 to -0.50 -4.88 to 0.87 -0.28 to 0.10 -0.21 to 0.31 
Difference in slope 
with normalisation 
2.27 5.18 0.37 0.64 
p-value for 
difference 
0.109 0.006 0.002 <0.001 
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Figure 89: Top: Mediastinal count density plotted against weight (left) and against LBM (right).  Bottom: Mediastinal CDnorm 
with weight normalisation (left) and LBM (right). 
  
Figure 90: Mediastinum count density histogram with weight normalisation (left) and LBM (right). 
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Figure 91: Top:Cardiac count density plotted against weight (left) and against LBM (right).  Bottom: Cardiac CDnorm with 
weight normalisation (left) and LBM (right). 
The coefficients of variation are shown in Table 67 and are similar for the mediastinum and heart VOIs, 
and in line with the SPECT-CT HMR CoV value of 25%, suggesting that uncertainty in mediastinum VOI 
placement is not contributing to the increased SPECT variation compared to planar, at least no more 
than the cardiac VOI.   
Histograms of cardiac count density for the entire MCI group are shown in Figure 92, with SPECT-CT 
histograms from section 8.2 as a comparison.  The separation between normal and abnormal scans 
seems similar for all cardiac CDnorm methods, and perhaps slightly less than for SPECT-CT HMR.  
However diagnostic accuracy is very similar to that of SPECT-CT HMR (Table 68). 
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Table 67: coefficients of variation in mediastinum uptake and cardiac uptake between controls subjects, showing similar 
variation for both VOIs and size normalisation methods. 
 Coefficient of variation 
 Mediastinum Heart (sphere VOI) Heart (50% 
threshold VOI) 
No normalisation 30% 35% 32% 
Activity only 31% 36% 33% 
Activity and weight 22% 25% 21% 
Activity and LBM 22% 24% 22% 
 
 
Table 68: Diagnostic accuracy of the absolute quantification methods, with planar and SPECT-CT HMR values reproduced for 
comparison. 
 
Sensitivity Specificity Accuracy 
Delayed planar 14/27 
52% 
14/18 
78% 
28/45 
62% 
SPECT-CT HMR 14/27 
52% 
15/18 
83% 
29/45 
64% 
CDnorm_wt 14/27 
52% 
15/18 
83% 
29/45 
64% 
CDnorm_wt_50% 14/27 
52% 
14/18 
78% 
28/45 
62% 
CDnorm_LBM 14/27 
52% 
14/18 
78% 
28/45 
62% 
CDnorm_LBM_50% 14/27 
52% 
14/18 
78% 
28/45 
62% 
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Figure 92: Histograms of normalised cardiac count density for the spherical mean counts and the 50% threshold mean.  The 
top row shows weight normalisation and the middle row LBM.  The SPECT-CT HMR histograms are shown in the bottom row 
for comparison.  Red categories are below the control derived cut-offs, green above, and orange borderline. 
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Figure 93:  Plots of cardiac count density for MCI-AD and MCI-LB cases, with SPECT-CT HMR plots for comparison. 
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8.3.4 Discussion 
VoD normalisation 
Both the body weight and lean body mass normalisation methods corrected for the effect of patient 
size reasonably well, but the LBM method was the better of the two, with no residual dependence on 
size for either cardiac or mediastinum counts.   We would therefore recommend this method over the 
weight based method.   However, the normalisation method did not affect diagnostic accuracy, 
possibly due to the large separation between groups discussed in section 8.2.  The accuracy with the 
50% threshold VOI was the same for both weight and LBM normalisation and the accuracy with the 
spherical VOI was actually slightly better for the weight normalisation due to the MCI-AD patient 
discussed in section 8.2 being normal with weight normalisation and abnormal with LBM. 
Comparison with SPECT-CT HMR  
There was no difference in accuracy compared with SPECT-CT HMR.  The histograms in Figure 92 and 
dot plots in Figure 93 suggest that the separation between normal and abnormal looking scans is 
slightly less than for SPECT-CT HMR, but the two methods are similar.  The coefficients of variation of 
the normalised count density in the cardiac and mediastinum VOIs were both similar to that of SPECT-
CT HMR.  This demonstrates that the noise in the SPECT-CT HMR data is contributed approximately 
equally by the cardiac and mediastinum regions, so the hypothesis that absolute quantification may 
benefit from removal of the variable mediastinum region appears incorrect.  Many of the factors that 
introduce uncertainty into absolute quantification, such as accurate activity measurements and 
correction for patient size, are cancelled out by use of relative quantification so SPECT-CT HMR is likely 
to be more reliable than cardiac CDnorm. 
8.3.5 Conclusion 
Based on this dataset, absolute quantification of cardiac MIBG uptake appears to offer no benefit over 
relative quantification with SPECT-CT HMR. The rationale for using absolute quantification over 
relative quantification so that uptake values are not dependent on a noisy reference region appears 
unfounded.   
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8.4 Regional cardiac 123I-MIBG uptake in dementia and healthy ageing 
8.4.1 Background 
Cardiac MIBG studies are typically quantified on planar images using the heart-to-mediastinum ratio 
as a diagnostic indicator, as in previous sections.  The HMR is an assessment of the overall cardiac 
uptake and does not take regional differences in uptake throughout the left ventricle into account.  
However, regional variation of uptake can be assessed using SPECT imaging.   
Published studies exploring the use of SPECT cardiac MIBG imaging for diagnosing Lewy body disease 
have suggested that regional assessment of cardiac uptake could improve sensitivity as regional 
defects may occur before global loss is apparent [56, 177, 179, 239, 245, 246].  However, we have 
noted that regional count reductions are sometimes seen in probable AD subjects who have normal 
planar scan appearances, suggesting that discrete areas of reduced regional counts may be non-
specific, e.g. due to unreported silent myocardial infarction, or artefactual, e.g. due to attenuation or 
the influence of extra-cardiac activity.   It has been reported in the literature that heterogeneous 
cardiac MIBG count distribution can occur in healthy controls, with relative reduction most commonly 
seen in the inferior wall [188, 216, 246-251].  This may be due to true physiological variation in 
sympathetic nerve distribution or artefacts caused by the imaging process – either from the signal 
being attenuated by the body or by interference from non-cardiac activity, predominantly the liver 
[252-254].  Although several groups investigating the diagnostic accuracy of cardiac 123I-MIBG for the 
diagnosis of Lewy body disease have acquired SPECT data alongside planar, often it is only the planar 
scans that have been used for analysis with the SPECT results not reported [55, 183, 236-238], 
suggesting that the added value of SPECT is unclear.  In their 2015 multicentre study, Yoshita et al. 
used SPECT for visual analysis but it was not clear on what basis the SPECT images were deemed normal 
or abnormal [53]. 
We reviewed cardiac MIBG SPECT image data from older adults with normal cognition from the SUPErB 
study and age matched DLB patients and Alzheimer’s disease patients from the MIDAS study in order 
to gain a better understanding of cardiac MIBG distribution in these groups and therefore how to 
interpret patient scans.  Our objective was to compare the distribution pattern of MIBG in the heart 
seen in these clinical groups.  The underlying hope was that we may be able to distinguish confounding 
regional reductions in cardiac uptake due to cardiac disease from pathological ones due to Lewy body 
disease by looking at heterogeneity, thereby improving specificity.  Sensitivity may also be improved if 
we were to find any characteristic patterns of reduction associated with Lewy body disease. The aim 
of this work was to carry out a pilot study to assess the patterns of regional uptake in controls, AD 
patients and DLB patients and determine whether this might have application in the diagnosis of Lewy 
body disease. 
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8.4.2 Methods 
Subjects 
Older people without cognitive impairment (controls): 
Thirty-one healthy adults aged over 60 years were recruited as part of the Newcastle SUPErB study.  A 
detailed medical history was taken, which later  enabled an estimate of cardiac risk to be made using 
the QRISK2 tool, recommended by NICE in Clinical Guideline 181 Cardiovascular disease: risk 
assessment and reduction [255].  QRISK2 uses the ratio of total cholesterol to high density lipoproteins 
as a risk factor, with a ratio of 4 used as default.  These parameters were not part of our original study 
design so were not available for most of the volunteers.  As the true ratios were not known, a ratio of 
6, which is regarded as the upper limit by Heart UK, was input for those with high cholesterol disclosed 
in their medical history and the default of 4 used for everyone else.  Two subjects had documented 
heart disease, making the QRISK2 score inappropriate - their risk scores were still calculated with this 
recorded as a limitation.  QRISK2 scores in controls were assessed for any correlation with cardiac 
uptake using linear regression. 
Older people with dementia: 
Seventeen patients meeting the clinical criteria for probable dementia with Lewy bodies and 15 
meeting criteria for dementia due to Alzheimer’s disease were recruited from memory clinics, as 
described in Chapter 2 and our previous publications [83, 190].  Cardiac risk was not calculated for the 
dementia patients since their cardiac uptake was expected to be affected by Lewy body disease in 
many cases.  However cardiac history was recorded to enable comparison with SPECT imaging results.  
We have previously showed no convincing evidence of lower cardiac MIBG uptake in patients with a 
previous MI, although this was a small subset [83]. 
Image acquisition 
Planar and SPECT images were acquired as described in sections 7.1 and 8.1 
Image processing 
All images were processed on a Hermes workstation.  Delayed anterior planar images were analysed 
to obtain the HMR as described in section 7.1.  SPECT images were processed in Hermes Hybrid recon 
using filtered back projection (FBP) with a Butterworth filter of 0.38 cycles per cm cut-off and order 8 
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applied.5 The images were reoriented during reconstruction to align with the horizontal and vertical 
long axes of the myocardium, as is standard for myocardial perfusion SPECT, with as much extra cardiac 
activity (e.g. liver and lung) masked out as possible.   
Image assessment 
Quantitative Perfusion SPECT (QPS) software (Hermes Medical Ltd, Stockholm) was used to display the 
short axis, vertical long axis and horizontal long axis slice images in rows for visual assessment of 
relative uptake.  Polar plots of relative uptake pattern were also reviewed.  These plots display the 
average relative uptake in the apex, anterior, lateral, inferior and septal walls as a percentage of the 
maximum pixel value.  The images and polar plots were reviewed blinded to the clinical groupings by 
a Consultant Clinical Scientist experienced in using the software for myocardial perfusion imaging (EJ).    
The overall degree of uniformity and the relative uptake for each of the left ventricle walls (anterior, 
inferior, septal, lateral and the apex) was recorded using the categories given in Table 69.    The ratings 
categories were developed by GR, EJ and JJL by reviewing cardiac MIBG images not included in the 
current study. 
Table 69: Rating categories for overall assessment of uptake pattern in the left ventricle and of uptake in each of the 
ventricular wall regions. 
Overall rating categories Uptake categories for 
each wall 
Interference categories 
• Not possible to score due to 
interference 
• Definitely uniform 
• Very slight heterogeneity 
• Patchy 
• Clear defect 
• Multiple clear defects 
• Other - see comment 
• Normal 
• Mildly reduced / 
patchy 
• Moderately 
reduced 
• Severely 
reduced 
• No uptake 
• No significant 
interference 
• Liver interference 
• Lung interference 
• Both liver and lung 
interference 
 
8.4.3 Results 
Controls with normal cognition 
Of the 31 controls recruited, 2 had to be excluded due to their image appearances (as for the planar 
analysis in Chapter 7).  The remaining 29 people included were aged between 62 and 94 years (mean 
                                                          
5 FBP was used as there was concern that resolution recovery used with the iterative OSEM method, when 
combined with MELP collimators and a non-circular autocontoured orbit may introduce artefactual non-
uniformity, based on scans of the anthropomorphic torso phantom.  
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75.2).  Most were male (22/29) and white (28/29).  Body mass indices (BMI) ranged from 22 to 38 
kg/m2, with the mean value of 27.2 in the overweight category.  Ten-year cardiac risk scores assessed 
with QRISK2 showed the group to be at high risk, as expected for older adults (Figure 94).  Most 
subjects were at higher risk than expected for age due to the inclusion of one or more cardiac risk 
factors in the calculation.  However, despite slight downward trends, there was no significant 
correlation between cardiac risk and either overall cardiac MIBG uptake as given by planar HMR 
(p=0.64) or minimum percentage relative uptake on SPECT (p = 0.08) (Figure 95). 
 
Figure 94: Plot of cardiac risk for our control subjects against subject age for males (blue data points) and females (orange 
data points. The two males with previous cardiac history are shown in open circles. The solid lines correspond to the mean 
QRISK2 database scores for white males and females with no cardiac risk factors.  The database is only available up to 84 
years. 
  
Figure 95:  Plots of HMR (left) and minimum relative uptake (right) against cardiac risk.  Controls with previous cardiac history 
are shown in open circles. 
Two controls had abnormally low uptake on planar imaging (below the normal threshold of 2.2 
suggested for medium energy collimators by the Japanese normal database of controls [188]) and no 
discernible uptake on SPECT imaging.  These individuals had no significant medical history and were 
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not taking any medications suspected of interfering with cardiac MIBG uptake, including those without 
strong clinical evidence of an effect [256].  Of the remaining 29 controls, three were not possible to 
assess due to a high degree of lung interference.  A further two with significant lung interference and 
two with liver interference were assessed but may be unreliable.  Overall, 62% of the controls had 
some degree of interference; lung interference in 11/29 cases (38%) and liver interference in 7/29 
(24%).  Almost all controls assessed (25/26) displayed at least one area of clearly reduced relative 
uptake, most often in the inferior wall, which was rated as normal or mildly reduced in only 4/26 cases 
(15%).  Some example images and ratings categories are shown in Figure 96. The results are 
summarised in Table 70 and Table 70 alongside those of the dementia patients.  
               
 
   
 
“Very slight heterogeneity” 
     
 
   
“multiple clear defects”   
 
   
  
“multiple clear defects”  
       
 
Figure 96: Top: QPS slice data and polar plot for the single control rated as within normal limits, showing almost perfectly 
uniform MIBG distribution, similar to that seen in normal Tc-99m myocardial perfusion images.  Middle: Slice data and polar 
plot for a more typical control, with reduced relative MIBG uptake inferiorly and at the apex.  Bottom: A very abnormal control 
but without prior known cardiac events. The sites of reduced relative count density are shown with white arrows. 
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People with dementia 
Of the 15 people with DLB who completed both planar and SPECT imaging, ten had HMR values below 
2.2.  Of these, there was one with visible cardiac uptake on SPECT images, but it was too unclear for a 
meaningful SPECT reconstruction to be obtained.  All five of the DLB subjects with normal planar 
cardiac uptake had uptake visible on SPECT, i.e. the normal HMRs were not caused by overlapping liver 
or lung.  There were therefore only five DLB SPECT scans included for SPECT regional analysis, those 
with normal planar imaging.  Of the 15 people with AD, three had HMR values below 2.2, however all 
15 AD patients had sufficient cardiac uptake to reconstruct clear SPECT images.   
The pattern of SPECT uptake was variable but overall similar to that seen in the controls for both AD 
and DLB (Table 70 and Table 71). 
Table 70: Frequency of regions showing reduced relative uptake for control, AD and DLB groups. 
 Apex Anterior wall Lateral wall Inferior wall Septal wall 
Controls 6/26 (23%) 0 2/26 (8%) 22/26 (85%) 4/26 (15%) 
AD 5/15 (33%) 0 2/15 (13%) 13/14 (93%) 4/15 (27%) 
DLB  1/5 (20%) 0 0 4/5 (80%) 1/5 (20%) 
 
Table 71:  Frequency of each overall rating category for control, AD and probable DLB groups. 
 
Control (n=29) AD (n=15) DLB (n=5) 
Interference present? 18 (62%) 10 (67%) 2 (40%) 
Not possible to score due to interference 7 (24%) 3 (20%) 1 (20%) 
Definitely uniform 0 0 0 
Very mild heterogeneity 1 (3%) 0 0 
Patchy 0 1 (7%) 0 
Clear defect 8 (28%) 3 (20%) 2 (40%) 
Multiple clear defects 13 (45%) 8 (53%) 2 (40%) 
 
Effect of myocardial infarction on planar and SPECT images 
One control, three of the AD patients and two of the DLB patients had had a previous MI.  Their images 
are displayed in Figure 97.  The control had a borderline HMR of 2.19 (assuming a normal range >2.20) 
despite a large area of apparently reduced uptake at the apex and inferiorly (lung interference 
anteriorly means this should be interpreted with caution).  Of the AD MI cases, one had a borderline 
HMR of 2.16 and two had normal uptake.  Of the DLB MI cases one had normal HMR (2.85) and one 
had no visible cardiac uptake and so was one of the cases excluded from SPECT regional analysis.  
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The cases with previous MI showed defects of varying magnitude and extent on SPECT and variable 
planar HMRs, none of which were abnormally low.  The number of cases is too low to establish a 
correlation between the extent of regional denervation and effect on global HMR but it seems likely 
that regional denervation would have to be widespread for planar HMR to be abnormally low.   
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Figure 97: Slice data and polar plots for cases with previous MI, with corresponding planar HMRs.  The sites of interference 
(top image) and relative reduced uptake are shown with arrows. 
 
8.4.4 Discussion 
The majority of the controls (25/26) and all the AD patients showed at least one region of reduced 
relative cardiac MIBG uptake, with 45% of controls and 53% of AD patients showing relative reduction 
in multiple regions.  This suggests that the presence of areas of reduced uptake on SPECT should not 
be used to diagnose Lewy body disease, as some authors have suggested, as this is likely to be highly 
non-specific.  Our controls were almost all at high risk of coronary events over the next 10 years, so 
cardiac disease as a cause for the relative reduction cannot be entirely excluded.  However we note 
the lack of correlation between QRISK2 score and non-uniformity index suggesting the most at risk 
individuals are not at significantly greater risk of cardiac sympathetic denervation. 
None of the control or dementia cases demonstrated reduced relative uptake in the anterior wall, 
which at first glance suggests that this region could be a useful target area in which to assess uptake 
in cases where the planar HMR is suspected of being affected by regional defects.  However, 11 of the 
29 control SPECT images were difficult to assess due to lung interference, three of whom were 
impossible to rate, making the anterior wall uptake unreliable. 
The strengths of this study include the inclusion of older people thoroughly assessed to have normal 
cognition but who also had other morbidities associated with ageing, including cardiac risk factors, 
making them a representative sample of older adults.  The patients with dementia had an expert panel 
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diagnostic review by three old-age psychiatrists, a method which has been validated against autopsy 
diagnosis and supported by regulatory authorities as a ‘gold standard’ [43, 207].  However, a limitation 
is the use of only one rater for the SPECT uniformity assessments.  This does however reflect clinical 
practice in radionuclide image reporting and the results are convincing even with a single rater.  A 
further limitation is the lack of detailed cardiac assessment and no myocardial perfusion imaging for 
correlation with cardiac MIBG.  However, Simula et al. have shown that myocardial perfusion imaging 
does not correlate with cardiac MIBG SPECT in asymptomatic high coronary risk cases with mild 
coronary artery stenosis [257].  They found a link between reduced uptake on cardiac MIBG SPECT and 
degree of stenosis for the left anterior descending artery (but not the left circumflex or right coronary 
artery) and suggest that CAD could be the cause of regional inhomogeneities on cardiac MIBG SPECT 
previously reported as normal variants [257].  However, on our SPECT scans the areas showing reduced 
uptake are the inferior wall and/or apex for the majority of controls (21/26), which is against cardiac 
disease being the main cause as this would be expected to affect any of the cardiac territories.  The 
pattern that we see suggests that either attenuation and scatter are causing this artefact, artefacts 
have been introduced in acquisition or reconstruction (e.g. due to high liver uptake), or there is a 
physiological reason for the apex and inferior wall to have reduced uptake.  
The literature on regional sympathetic innervation in healthy controls is quite mixed.  Most studies 
report a heterogeneous distribution within the left ventricle, although they do not agree on the sites 
of reduced uptake, perhaps related to small sample sizes and different age groups.   Early work by 
Sisson and colleagues in the 1980s on 20 men aged 20-62 years showed a relative reduction at the 
apex only [258].  The European guidelines on 123I-MIBG cardiac sympathetic imaging note that “normal 
cardiac MIBG distribution includes a relatively low uptake in the inferior wall, which is more 
pronounced in the elderly” referencing the 1993 study of Gill et al. [252] in seven young adults (29.4 ± 
7.5 years) and eight middle aged adults (aged 53 ± 5.1 years – by no means elderly!).  As well as the 
inferior reduction Gill et al. also reported septal reduction, with no difference between apex and base 
[252].  Tsuchimochi et al. studied 18 men and 11 women without cardiac diseases aged between 21 
and 79 years (mean 42 ± 17 years) and reported that the inferior uptake of MIBG decreased with age 
in healthy controls, especially in men [246].  This is important in the context of our study, as all 
participants were over 60 years of age and most of our controls were men. Image quality was however 
quite limited compared to modern gamma camera images for both this study published in 1995 and 
those of Sisson [258] and Gill [252]. 
Our results are similar to those of a more recent study published by Asghar et al. in 2017 [216] who 
reported reduced inferior wall uptake in all 14 healthy controls studied, and suggested that these 
effects are not predominantly caused by imaging artefacts.  However, all our control cases had normal 
anterior wall uptake, which was not the case in the Asghar study.  Interestingly, in their 2012 11C 
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Hydroxyephedrine PET study, Wong et al. showed that the lateral wall not the inferior wall shows 
reduced regional innervation in healthy controls, with relative sparing of anterior and septal walls 
[259].   
Post mortem tissue studies e.g. [260, 261] report non-uniform distribution of cardiac innervation, for 
example in the sinus node; but do not describe the relative distribution in the left ventricle so cannot 
be correlated with MIBG tracer uptake.  However, in their post-mortem study on the distribution of 
autonomic nerves in the human heart, Kawano et al. showed a small but statistically significant 
reduction in the sympathetic innervation of the inferior wall of the left ventricle compared to the 
anterior wall [262].  The reduction is only around 20%, making this unlikely to explain the substantial 
differences seen in 123I-MIBG uptake between the anterior and inferior wall in many controls. 
It has been hypothesised that due to its tracer kinetics, 123I-MIBG imaging is insensitive to substantial 
nerve losses in cardiac regions with mild to moderate levels of cardiac denervation and that regional 
nerve losses need to be relatively severe before a reduction in uptake becomes apparent [263].  If this 
is the case it makes the modest physiological differences seen by Kawano et al. [262] even less likely 
to explain the cardiac MIBG findings.  We note that 11C Hydroxyephedrine (HED) has similar kinetics to 
123I-MIBG, so this doesn’t explain the difference in relative uptake patterns. 
This leaves artefacts as a possible contributor to the apparent regional reductions in cardiac MIBG 
uptake.  In a study using an anthropomorphic chest phantom with uniform myocardium activity, the 
count density within the myocardium was inhomogeneous with both medium and low energy 
collimators [253]. There was an overestimation of the measured count density in both the anterior and 
the septal wall and an underestimation of count density in the inferior wall [253], which is in line with 
typical control studies and which the authors assumed was due to attenuation.  However, Gill 
considered attenuation artefacts an unlikely cause of the reduced inferior uptake in their control 
series, as myocardial perfusion imaging with thallium-201 did not show corresponding reductions 
[252].  We note that although we commonly see mildly reduced relative uptake in the inferior wall on 
clinical myocardial perfusion images obtained with 99mTc-tetrafosmin, these reductions are typically 
less obvious than those seen on the majority of our control 123I-MIBG images.   However both 99mTc 
and 201Tl have different physical properties to 123I, particularly in terms of high energy emissions and 
may not give the same apparent cardiac uptake patterns.   This discrepancy could be potentially be 
resolved with the use of SPECT-CT imaging to correct for attenuation and scatter of the gamma rays 
from the MIBG tracer within the body.   A recent phantom study by Shibutani et al. demonstrated an 
inferior artefact in a myocardium insert (scanned with a low-medium energy general purpose 
collimator), which resolved with Siemens Flash3D SPECT-CT reconstruction with ACSC [264].    
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Regarding our single control regarded as having uniform relative uptake, the following observations 
are of note. The planar HMR was 2.69, which is a typical value in line with the other controls (mean 
HMR 2.78 ± 0.46), rather than an outlier.  Similarly, the BMI of this individual was unremarkable at 28.6 
(mean 27.8 ± 4.2).  However, the relative uptake of the heart is similar to that of the liver, whereas in 
most of the controls the uptake is much higher in the liver than the heart (Figure 98).  In addition, the 
positioning of the dome of the liver is just inferior to the heart, which is not the case in many of the 
other controls.  This suggests that high liver uptake may be contributing to the apparent reduced 
inferior wall uptake seen in most of the controls.  One of the few studies to directly compare 11C 
Hydroxyephedrine PET with 123I-MIBG SPECT, in patients with heart failure and coronary heart disease, 
reported lower liver uptake on 11C Hydroxyephedrine PET than 123I-MIBG SPECT, with increased uptake 
in the inferior and septal regions [265], so this may explain the difference in relative distribution 
reported with the two tracers.   A study comparing both tracers in ten healthy young men with normal 
BMI showed lower relative uptake in the inferior wall and septum with 123I-MIBG SPECT compared with 
11C-HED [266].  This further suggests that liver uptake may be responsible for the inferior reduction, 
but we note that attenuation and scatter correction was used for the PET imaging but not the SPECT.  
To our knowledge, no other studies of 123I-MIBG and 11C-HED have been carried out in the same cohort 
of healthy controls and no studies at all with CT attenuation and scatter correction for 123I-MIBG.  
  
Figure 98: Left: coronal MIBG slice for the control subject with uniform relative cardiac uptake.  Right: a more typical control 
with high liver uptake relative to the heart.  Images are displayed scaled to the maximum voxel. 
Limitations  
As discussed above, a limitation of this study is the lack of definitive information on cardiac disease 
status of the participants.  The QRISK2 score gives an idea of the likelihood of future events, but it is 
impossible to exclude undiagnosed asymptomatic CAD.  The patients and controls were recruited to a 
dementia research study for which detailed cardiac assessment was not part of the study protocol; 
however an ECG and autonomic dysfunction tests were carried out.  A further limitation of this study 
is the lack of data from younger subjects as only those over 60 years of age were recruited.  SPECT-CT 
data for attenuation and scatter correction was not available for the patients so could not be assessed 
as part of this analysis. 
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8.4.5 Conclusion 
Areas of relatively reduced cardiac 123I-MIBG uptake on SPECT images are common, but not ubiquitous, 
in cognitively normal older adults and patients with dementia who have normal planar cardiac uptake.  
Uptake is often reduced in the inferior wall and sometimes in the septal wall, lateral wall and apex.  
Anterior wall uptake is often influenced by lung interference so appears unsuitable as a target region 
for uptake assessment, at least on images uncorrected for scatter and attenuation. 
Reduced regional cardiac MIBG uptake in the inferior wall of the left ventricle is common in older adults 
and most likely related to attenuation or liver uptake.  Reductions in other areas may also be 
artefactual or may be caused by mild underlying coronary artery disease.  The pattern of reduction is 
in any case non-specific and therefore unlikely to aid in the diagnosis of Lewy body disease in typical 
clinical settings.  
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8.5 Summary of chapter 8 
In section 8.1 we presented encouraging results in an anthropomorphic chest phantom, showing that 
increasing the amount of attenuating material had a notable impact on both the visual appearance 
and quantification of planar images, but that on SPECT-CT images the extra attenuation and scatter 
was compensated for accurately by the reconstruction algorithm.  We saw a statistically significant 
drop in planar HMR with patient size, which is in keeping with the limited literature on this topic 
published to date [218, 228].  On attenuation and scatter corrected SPECT-CT imaging, there was no 
evidence of a significant relationship between HMR and BMI.  However, when we looked at the 
difference between SPECT results (non-corrected) and SPECT-CT this was not significant, suggesting 
that in practice SPECT-CT ACSC may not be able to fully compensate for differences in patient size.    
In the next section we showed that the impact on diagnostic accuracy in MCI of SPECT and SPECT-CT 
was small, with one MCI-AD patient misdiagnosed as abnormal with planar imaging having uptake 
results within normal limits on SPECT-CT.  However, there was a considerably greater separation 
between normal uptake and low uptake scans with SPECT-CT than with either planar or non-corrected 
SPECT imaging, suggesting that SPECT-CT could have a role in cases that are borderline on planar 
imaging.  We will review this when the SUPErB cohort is complete and the full dataset has been 
processed.   The implication for clinical practice is that HMR ratios can be influenced by the size and 
shape of the patient, and borderline results in obese patients could be the result of attenuation and 
scatter, rather than early changes in innervation. 
 In section 8.3 we presented a method for quantifying the absolute uptake within cardiac regions of 
interest on SPECT-CT images, which has not been applied cardiac MIBG imaging before.   We found 
that cardiac signal should be normalised to lean body mass rather than patient weight.  We compared 
the accuracy of absolute quantification, using our controls to give normal cut-offs, with that of relative 
quantification with SPECT-CT and found no differences.  The distribution of the absolute quantification 
results, seen on dot plots and histograms, was similar to that of the SPECT-CT HMR results, suggesting 
that absolute quantification is not likely to improve the diagnosis of Lewy body disease.  In section 8.4 
we saw that reduced regional cardiac MIBG uptake is non-specific and therefore unlikely to aid in the 
diagnosis of Lewy body disease in typical clinical settings.  
To summarise, the work presented in this chapter provides evidence that SPECT-CT may be beneficial 
in research studies, where a more precise estimate of cardiac sympathetic innervation is desirable.  
SPECT-CT may also have a limited role in clinical practice, for example it may be indicated if early and 
delayed planar imaging has been carried out and the results are equivocal.  We would not recommend 
that SPECT-CT is routinely used in clinical practice as this would more than double the effective 
radiation dose to an individual with only a small chance of affecting the outcome of the test. 
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Chapter 9: FP-CIT and MIBG uptake in healthy 
ageing 
Published literature on the relationship between striatal FP-CIT uptake and age shows clear evidence 
that younger adults have higher uptake than older adults.  However, the mathematical model for the 
decline with age and whether this continues into old age is not clear.  Literature on cardiac MIBG 
uptake and age is mixed, with some studies demonstrating no significant change in uptake with age 
and some showing normal uptake is lower in old age.   In this chapter we investigate whether there is 
evidence of a relationship between uptake and age in older adults without evidence of Lewy body 
disease between the ages of 60 and 92 and discuss the implications for the diagnosis of Lewy body 
disease in this age group. 
Section 9.1 explores whether age-correction is needed for FP-CIT quantification in older adults and is 
adapted from our 2019 publication [267]. Section 9.2 applies similar methodology to planar and 
tomographic cardiac MIBG uptake measurements, using the SUPErB control group of older adults with 
normal cognition.  An overall chapter summary is given in section 9.3 
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 Do 123I-FP-CIT specific binding ratios decline with age in older adults? 
9.1.1 Introduction 
Studies in healthy controls over a wide range of ages have demonstrated that striatal uptake levels 
decrease with age, confirmed by Karrer et al. in their 2017 meta-analysis [200].  It is therefore 
important to interpret SBRs by comparing with age-matched healthy controls and Z scores are 
commonly age-adjusted for this purpose.  However, the exact form of the relationship between SBR 
and age is not clear, leading commercial software packages to implement different age correction 
models.  Patients referred for FP-CIT scans for dementia diagnosis are typically over 60 years of age 
and often much older.  It is therefore vital to ensure that age-correction is appropriate for this age 
group.   
Some dopamine transporter availability studies report a linear decline in SBR with age, for example 
the ENC-DAT study [152].  This is a large European initiative led by the European Association of Nuclear 
Medicine (EANM), which included FP-CIT scans of 139 adults aged between 20 and 83 years and found 
slopes (absolute change in SBR per year) of −0.015 (95% confidence interval: −0.021 to -0.009) for men 
and −0.018 (−0.025 to –0.011), which they state corresponds to a 4 to 7% decline in SBR per decade 
depending on the striatal region assessed [152].  Prior to this, a large single-centre study of 186 adults 
found a loss of 46% over 18-88 years, on average 6.6% per decade, also applying a linear model [268].    
A recent publication studying 256 healthy individuals in Japan aged between 30 and 83 [269] 
demonstrated a linear fit for both males and females, reporting an average decline of 6.3% per decade.  
However, a study using a Tc-99m ligand similar to FP-CIT [270] concluded that an exponential or bi-
linear function of SBR with age is a better model, with the decline tailing off in older age.  The meta-
analysis by Karrer et al. [200], which combined data on a variety of PET and SPECT dopamine 
transporter ligands, concluded that while there is some suggestive evidence for steeper decline in 
young adults, a linear relationship describes the decrease in function with age as well as an exponential 
function (coefficient of determination (R2) values of 38.6% for linear fit and 37.1% for log-linear fit).  
However, most subjects were not scanned with 123I-FP-CIT, with only 5 such studies included within 
the 33 studies on dopamine transporter availability.  In addition, the majority of the 289 123I-FP-CIT 
scans included appear to come from two studies published by the ENC-DAT team [142, 271] suggesting 
that double counting may have occurred.  The relationship in older subjects alone was not studied, as 
this was not the focus of the meta-analysis, so it was not demonstrated that a significant age-
dependency exists in this age group.   
Two commercial software packages were used in the current study: DaTQUANT and BRASS.  The 
DaTQUANT normal database consists of 119 healthy control subjects (aged 30 - 84 years) taken from 
the Parkinson’s Progression Marker Initiative study (PPMI https://www.ppmi-info.org [272]).  A bi-
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linear model with different slopes for individuals under 55 and over 68, with a transition region in 
between is implemented.  This was generated by the DaTQUANT developers by splitting the control 
SBRs into two clusters with different linear fits, since it was noticed that the SBR does not change as 
rapidly in older age (Personal communication, GE Healthcare).    This was done separately for the left 
and right striata and for each sub-region resulting in small differences between regions and sides.  The 
slopes implemented for the whole striatum (i.e. absolute change in SBR per year) are -0.025 for both 
striata under 55 years of age and -0.012 and -0.007 for the left and right striata respectively over 68 
years (Personal communication, GE Healthcare).  The DaTQUANT SBR intercepts (i.e. projected SBR at 
age zero) are 3.5 (left striatum) and 3.4 (right) for the younger cluster and 2.7 (left) and 2.3 (right) for 
the older cluster.  These slopes and SBR intercept values apply to images reconstructed with OSEM 
iterative reconstruction without attenuation correction, and correspond to decreases in SBR of 0.25 
(10%) between 40 and 50 years, 0.12 (7%) between 70 and 80 years for the left striatum and 0.07 (4%) 
between 70 and 80 years for the right striatum.   A bi-linear model can also be implemented within 
BRASS, but we used the default model, which is a linear fit to 103 of the controls from the ENC-DAT 
study aged between 21 and 83 years, used as the healthy control database in BRASS.   
Our experience with both software packages has been that SBRs for the oldest adults can be quite low 
and the scans can have abnormal visual appearances, yet the age-corrected Z scores can be within the 
normal range.  This raises the possibility that the age correction required for older people may be 
overestimated.  Published data showing SBR against age for the healthy controls from the ENC-DAT 
study [152], which applied a single linear fit to all ages, shows little evidence of a clear continuing 
decrease in SBR with age in adults over 60 years old, substantial variation between subjects and 
relatively few data points for subjects over 75 years.  The DaTQUANT database also shows no 
convincing decline in SBR with age for subjects over 60 (SBR data accessed within the software).  
We recruited healthy older adults and older adults with cognitive impairment but no signs of Lewy 
body disease to determine whether there is evidence of age-dependency of SBR in adults over 60 years 
of age.  We also used a separate independent test group of individuals over 60 with and without Lewy 
body disease to test our findings concerning age correction. 
9.1.2 Methods 
Subject selection 
Healthy older adults, adults with mild cognitive impairment (MCI) and adults with dementia were taken 
from the SUPErB, LewyPro and MIDAS studies.  The healthy older adults and the MCI-AD individuals 
from one of the studies were combined to give a large group of controls (i.e. older people without 
evidence of Lewy body disease).  An independent group of individuals with MCI and individuals with 
dementia was used to test the effects of age correction.  For both the control and test groups, MRI 
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brain scans and CT scans (where available) were reviewed by a radiologist to exclude other causes of 
cognitive impairment. 
Control group: MCI-AD and healthy older adults 
Twenty-six individuals meeting the NIA-AA clinical criteria for MCI due to Alzheimer’s disease (MCI-AD) 
[273] were recruited from memory clinics, specialist dementia services, elderly medicine clinics and 
neurology clinics in the North East of England. Potential subjects had been diagnosed with MCI in these 
services and were approached to take part in the Newcastle University LewyPro study [37].  Diagnoses 
were confirmed as MCI-AD by an expert consensus clinical panel of old-age psychiatrists.  As Lewy body 
disease may be misdiagnosed as MCI-AD, we excluded any MCI-AD individual with an abnormal FP-CIT 
scan from our control group.  An abnormal FP-CIT scan was defined by an abnormal consensus visual 
rating, given by a panel of five experts, as described in section 6.5.  Three of the 26 MCI-AD individuals 
(aged 72, 76 and 79) were thus excluded because their FP-CIT scans were rated as abnormal.   
Thirty-one healthy controls were taken from the SUPErB study.  Incidental Lewy body disease is 
common in older people [274] so we excluded any healthy older adults with an abnormal rated FP-CIT 
scan from our control group to ensure that our data reflected age-related changes in adults without 
any evidence of Lewy body disease.  Two of the 31 healthy older adults (aged 63 and 73) were thus 
excluded because their FP-CIT scans had been rated as abnormal by the expert panel (see section 6.1). 
Test group: individuals with dementia and MCI 
Sixteen individuals over 60 years of age with probable DLB, 17 with probable AD, 20 with MCI due to 
probable Lewy body disease (MCI-LB) and 18 with MCI due to probable AD (MCI-AD) were included to 
study the effect of age correction on FP-CIT results in older patients.  Those with dementia were 
recruited as part of the MIDAS study [83].  Those with MCI were recruited as part of an ongoing 
Newcastle University follow up study to the LewyPro study [37].  Note the MCI-AD individuals included 
here are not included in the above control group.  Baseline diagnoses were used for these groups as 
one year follow up diagnoses were not available.   
Image processing and SBR calculation 
FP-CIT images were acquired as described previously in chapters 4 and 6.  SBRs were calculated with 
BRASS and DaTQUANT.  Age corrected Z scores and Z scores without age-correction were recorded 
from BRASS.  It is not possible to turn off age-correction when using the DaTQUANT normal database 
so only age-corrected Z scores were recorded from DaTQUANT.   Sub-regions such as the caudate, 
putamen and posterior putamen can be evaluated by both packages but we chose to focus on whole 
striatum results to reduce the effects of random noise due to small, possibly mis-registered volumes 
of interest in our data.   
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Analysis 
A linear mixed effects model [275] (IBM SPSS v.24) was used to test for age dependency and any effect 
of gender, side (left vs right striatum) and dataset (MCI-AD vs adults with no cognitive impairment).  
Age, gender, side and dataset were input as fixed effects in the model and study ID input as a random 
effect. A mixed effects approach was used so that data from both striata could be included to give 104 
SBR measurements; the random effect of study ID accounts for the fact that the SBR in the left and 
right striatum of an individual are likely to be correlated.  The model was run for DaTQUANT and BRASS 
data separately, with both SBR and corrected Z score used as the dependent variable.  P-values of less 
than 0.05 were taken to indicate effects significantly different from zero. The rate of change in SBR 
and corrected Z score with age and 95% confidence limits were recorded. 
9.1.3 Results 
Subject characteristics 
The age and sex of the individuals included and proportion of women in each group is given in Table 
72. 
Table 72: Ages and gender balance of the individuals with MCI due to AD, the healthy older adults, the two groups taken 
together as a control group and the test individuals with DLB. , AD, MCI-LB and MCI-AD.  
  Number included Mean age (SD) Proportion 
female 
Controls Probable MCI-AD  23 77.7 (8.3) 0.61 (14/23) 
Healthy older 
adults 
29 74.5 (7.6) 0.28 (8/29) 
Total controls 52 75.9 (8.0) 0.42 (22/52) 
Test group Probable DLB 16 77.2 (7.5) 0.06 (1/16) 
Probable AD 17 77.2 (6.5) 0.24 (4/17) 
Probable MCI-LB 20 73.6 (6.8) 0.10 (2/20) 
Probable MCI-AD 
(test group) 
18 73.8 (6.9) 0.44 (8/18) 
Total test group 71 n/a n/a 
 
SBR age-dependency in the control group 
The mixed effects model showed that the effect of age, gender, striatum side or dataset (MCI-AD vs 
healthy adults) on SBR was not significant for either DaTQUANT or BRASS (Table 73).  The only 
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significant effect on age-corrected Z score was striatum side, which applied to DaTQUANT only, likely 
due to different slopes implemented in the software for right and left.  
Table 73: Estimate of fixed effects from SPSS mixed effects model for DaTQUANT and BRASS for dependent variables SBR and 
Z score. 
  Specific binding ratio (SBR) SBR Z score 
Co-variate  DaTQUANT BRASS DaTQUANT BRASS 
Age Estimate -0.041 -0.066 0.170 0.015 
T statistic -0.947 -1.048 1.328 1.142 
95% CI -0.013 to 
+0.005 
-0.019 to 
+0.006 
-0.009 to 
0.427 
-0.011 to 
+0.041 
p-value 0.348 0.300 0.190 0.259 
Gender Estimate 0.136 0.149 0.396 0.309 
T statistic 1.868 1.419 1.865 1.443 
95% CI -0.010 to 
+0.283 
-0.062 to 
+0.361 
-0.310 to 
+0.824 
-0.121 to 
+0.739 
p-value 0.068 0.162 0.068 0.155 
Control dataset Estimate 0.090 0.205 0.251 0.430 
T statistic 1.238 1.951 1.185 2.018 
95% CI -0.056 to 
+0.237 
-0.006 to 
+0.416  
-0.175 to 
+0.678 
+0.001 to 
+0.859 
p-value 0.222 0.057 0.242 0.049 
Striatum side Estimate 0.006 0.022 0.159 0.002 
T statistic 0.429 1.152 3.372 0.049 
95% CI -0.022 to 
+0.034 
-0.016 to 
+0.060 
+0.064 to 
+0.254 
-0.077 to 
+0.0810 
p-value 0.669 0.255 0.001 0.961 
 
 
Plots of SBR against age for the 52 controls are shown in Figure 99.  Visually, there is no clear evidence 
of age-dependency in this age group.   
226 
 
 
Figure 99: Mean striatum SBR values plotted against age for DaTQUANT (left) and BRASS (right). 
 
The slopes of the linear fits to the DaTQUANT and BRASS SBR data as a function of age for controls 
from the mixed effects model are given in Table 74.   The SBR slopes are negative but not significantly 
different from zero.  The corrected Z score slopes are larger and positive, however these are also not 
significantly different from zero. 
Table 74: Rate of change in SBR and age corrected Z score per year for Newcastle control subjects over 60 years of age 
calculated with DaTQUANT and BRASS 
 
 
SBR Age-corrected Z score 
 Slope 95% confidence 
interval 
p-value  Slope 95% confidence 
interval 
p-value  
DaTQUANT -0.004 
 
-0.013 to 0.005 0.35 0.017 -0.009 to 0.043 0.19 
BRASS -0.007 
 
-0.019 to 0.006 0.30 0.015 -0.011 to 0.041 0.26 
 
Z score results for our controls with age correction applied are shown plotted against age in Figure 100 
(a) and (b) for BRASS and DaTQUANT. Both appear to show an increase in corrected Z score with age, 
although the mixed effects model above showed that this was not statistically significant.  Control Z 
scores with the age correction function switched off in BRASS are plotted in Figure 100 (c).  These Z 
scores result from comparing to the mean SBR taken over the entire ENC-DAT database age range.  It 
is not possible to switch off age correction in DaTQUANT when using the factory installed PPMI 
database so we have not compared Z scores with and without age correction for DaTQUANT. 
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Figure 100: (a) BRASS age corrected Z scores for controls, (b) DaTQUANT age corrected Z scores and (c) BRASS Z scores without 
age correction.  The average values of the right and left striatum SBRs are used. 
 
Age correction in the test groups 
Figure 101 shows BRASS Z scores with and without age correction for probable DLB, AD, MCI-LB and 
MCI-AD (the test group).  The lowest of the scores for the right and left striata have been taken, rather 
than one side or an average as this reflects clinical practice.  The number of images correctly classified 
based on BRASS Z score values with and without age correction is shown in Table 75.  
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Figure 101: BRASS Z scores (lowest of left and right striatum) with and without age correction for probable DLB (a) probable 
AD (b), probable MCI-LB (c) and probable MCI-AD (d).  
 
Table 75: Number of individuals with BRASS age corrected and non-corrected Z scores above and below our threshold of -2SD. 
 BRASS age correction on BRASS age correction off 
 Z below 
-2 
Z above 
-2 
% with expected Z 
score 
Z below -
2 
Z above 
-2 
% with expected Z 
score 
Controls 4 48 92% 4 48 92% 
Prob DLB 13 3 81% 14 2 88% 
Prob AD 0 17 100% 2 15 88% 
Prob MCI-LB 10 10 50% 13 7 65% 
Prob MCI-AD 2 16 89% 5 13 72% 
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9.1.4 Discussion 
Our results show that any decrease in the SBR of older adults with age appears to be very small, which 
suggests that a single linear fit over the entire adult age range may be inappropriate for older adults.  
The 95% confidence intervals for our linear fits (absolute SBR change per year) are -0.013 to +0.005 
with DaTQUANT and -0.019 to +0.006 with BRASS.  These correspond to percentage changes in SBR 
per decade in the control group of -7 to +3% with DaTQUANT and -7 to +2% with BRASS, taken over 
the range 70-80 years.  The confidence intervals encompass zero, and the linear mixed effects model 
showed no significant difference from zero in any measured slope, so our results do not support age-
dependency in this age range.  The current default SBR decreases modelled in the software correspond 
to approximately -5% between 70 and 80 years for BRASS and -4 to -7% for DaTQUANT, depending on 
striatal region.  The slope between age and standardised uptake measurement (absolute change per 
year) reported in the 2017 meta-analysis was -0.032 [200], which was stated to correspond to a -8.9% 
change per decade.  This is an average over all decades so the percentage change per decade would 
be smaller for younger adults and greater for older adults, giving values much greater than our small 
estimates.  We note that the 2007 study by Koch et al. concluding that the decline in dopamine 
transporter availability tails off in older age [270] was not included in the meta-analysis.  This study 
reported an average decline of 9.5% per decade under 48 years of age and 6.3 % on average over 48 
years.  This is evidence against a linear model, where the percentage effect would be expected to 
increase in magnitude with age.  As was the case with the meta-analysis [200], Koch et al. [270] also 
reported similar R2 values for logarithmic and linear regression, suggesting that an exponential 
relationship is equally plausible.  Yamamoto et al. [276] studied 30 healthy controls aged 50 to 86 years 
and reported a linear relationship between SBR and age (parameters not specified).  However, they 
found that the percentage change in SBR per decade was lowest (2.4%) for those over 70 years, which 
is not in keeping with a linear model. 
We cannot exclude a small decrease in SBR with age, or indeed an increase, based on our dataset of 
52 controls.  However we note that the databases used by the manufacturers included similar numbers 
of participants over 60 years of age to our study (68 PPMI participants for DaTQUANT and around 55 
ENC-DAT participants for BRASS).  To our knowledge, no publications reporting a decrease in SBR with 
age have demonstrated that a statistically significant decrease also exists for older adults (>60 years), 
including the meta-analysis.  A strength of our study lies in the focus on the age group most relevant 
to clinical practice.   
Reviewing DaTQUANT database participants aged over 60 years within the software shows results 
similar to our controls, with no clear continuing decline in SBR in this age group.  Visual review of 
published ENC-DAT control data also shows no definite decline in SBR with age beyond 60 years of age.  
230 
 
However, the largest published dataset is the Japanese multicentre database [269], which does appear 
to show a continuing decline in SBR in older age.  The SBR calculation method used in this study was 
the Southampton method [277], which unlike the commercial software does not attempt automated 
registration to a template.  The Southampton method places large VOIs around each striatum to 
reduce partial volume effects and calculates SBRs based on an assumed striatal volume which is either 
kept the same for all patients or fixed values assigned depending on gender [144].  As the authors 
discussed, any loss of striatal volume with age will cause SBR to be underestimated with this method, 
possibly exaggerating the rate of decline with age [269].  Although it is possible to calculate SBR values 
for sub-striatal regions such as the caudate and putamen separately, we chose to consider only the 
whole striatum for this study.  Since the caudate and putamen can usually not be fully distinguished 
on an FP-CIT scan, both BRASS and DaTQUANT have to use a somewhat arbitrary dividing line between 
them.  In our experience, even when the putamen shows clearly reduced uptake visually it may have 
a normal SBR, due to counts from the caudate nucleus.  In addition, with smaller regions, uncertainty 
due to lower counts is greater.  The limitation of this is that the whole striatum analysis will be less 
sensitive to any losses occurring only in individual regions.  It is known that putaminal uptake is often 
affected first in Lewy body disease and Nobili et al. [142] showed that for the ENC-DAT normal 
database the putamen to caudate ratio dropped with age.  However, their generalised linear model 
analysis showed no statistically significant difference between regions, so we conclude that any such 
effect is small and unlikely to explain our findings. 
As with all such studies recruiting healthy controls, it is possible that the sample recruited is 
misrepresentative of the general population.  This issue is likely to increase with age as a smaller 
proportion of older people may be able and willing to undergo the travel, tests and scans required to 
participate.  We do not know whether older adults with above average general health are likely to 
have above average dopaminergic function but we cannot exclude this as a source of bias both for our 
study and the databases used in BRASS and DaTQUANT.   Although we achieved a good gender balance 
within our control group, consisting of 44% women and 56% men, this was not the case for the MCI 
and dementia groups, predominantly due to the higher prevalence of Lewy body disease in males. 
For the oldest adults (over 80 years of age) a drop in BRASS Z score of around one standard deviation 
is seen with age correction switched off.  In our DLB dataset this would have changed the interpretation 
of the result from normal to abnormal in one case (from Z = -1.42 with age correction to -2.27 without).  
In our MCI-LB dataset there are more borderline results and interpretation would have changed from 
normal to abnormal in three of the 20 cases.  However, as our AD and MCI-AD Z scores are slightly 
lower than expected with age correction applied, removing the age correction shifts 2 AD and three 
MCI-AD cases below Z scores of -2.  We note that turning age correction off in BRASS means that 
images are compared against the whole database, (mean age of 52), which exaggerates the effect 
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somewhat as it is clear that an age-dependency exists in younger adults. Ideally, we would compare 
our data against a subset of older database subjects only.  Unfortunately it is not possible to recalculate 
a mean SBR using only the older ENC-DAT subjects as this data is not published or available within the 
software – only the mean and standard deviation values for the whole dataset are used within BRASS.   
It is also not possible to adjust the DaTQUANT database to include only subjects over 60 as the original 
scans are required for creating a new database.   At present, the only way of comparing SBRs against 
an older database without age correction is to set up a local control database. 
9.1.5 Conclusion 
We found that the rate of change in SBR with age for control subjects over 60 was not significantly 
different from zero, suggesting that any decline in SBR with age in healthy older adults is likely to be 
lower than previously thought.  Both BRASS and DaTQUANT apply slopes that are greater than our 
estimates, leading to potentially large differences between the software age-adjusted SBR and 
individual values for the oldest patients.  With BRASS, Z scores are around 1SD lower with age 
correction switched off for subjects over 80 years of age.  Use of current age correction methods in 
older people being assessed for DLB and MCI-LB could contribute to false negative reporting and 
misdiagnosis and therefore caution is suggested in clinical practice and research applications. 
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 Does cardiac 123I-MIBG uptake decrease with age in healthy older adults? 
9.2.1 Introduction 
So far in this thesis we have assumed that cardiac uptake, as measured by either planar or SPECT 
methods, does not depend on age.  This was the conclusion of a relatively large study of 94 healthy 
controls aged between 29 and 82 enrolled in the US ADMIRE-HF study [181] but other publications in 
the literature are conflicting.  The ADMIRE-HF study, published by Jacobson et al., used both planar 
and SPECT HMR measurements and found no statistically significant relationship between age and 
HMR for any of the methods [181].   Prior to this, a smaller Spanish study of 38 patients aged between 
16 to 75 and enrolled in a cancer drug trial had reported a significant decrease in planar HMR with age 
(r = -0.6264; p < 0.001) [278].  However as Jacobson et al. pointed out [181], a relatively small number 
of patients were used to span a wide age range, with only 6 patients aged between 40 and 60 and 10 
aged over 60.  Tsuchimochi found no correlation between HMR and age, but included only 29 subjects 
covering an age range of 21 to 79 years [279].  Sakata et al. studied 300 adults in Japan with normal 
coronary angiography results, aged between 40 and 79 years [280].  They found a significant increase 
in MIBG washout rate with age on SPECT images, but unfortunately did not perform planar imaging or 
calculate SPECT HMR.  Unfortunately it is therefore impossible to compare their results, which suggest 
a change with age, with those of the ADMIRE-HF study, which do not.  Rengo et al. used multivariate 
analysis in a group of 180 middle aged and elderly heart failure patients in Italy to show that age was 
an independent predictor of cardiac MIBG uptake [281], with lower uptake in older patients.   
The most recent evidence on cardiac MIBG and ageing comes from the Japanese Society of Nuclear 
Medicine working group normal database and is presented by Nakajima et al. [221].  The database 
consists of 62 patients aged between 20 and 84 years, mean 57 ± 19 years.  A small, yet significant 
effect of ageing was seen for delayed HMR (a decline of approximately 0.2 in units of HMR between 
the ages of 50 and 80).  Interestingly the decrease was only significant after the data, acquired with a 
range of collimators, were corrected to give results consistent with medium energy collimators.  The 
subjects included are patients with normal scans, rather than healthy controls and only those with a 
low likelihood of cardiac disease were included.   
Interestingly, in the ADMIRE-HR control study it was noted that activity-normalised cardiac uptake 
measurements (counts per pixel/voxel per MBq administered) actually increased with age, but so did 
mediastinal counts, producing no significant effect overall.  This was the case for both planar and SPECT 
imaging, with both cardiac and mediastinal regions showing a statistically significant correlation.  With 
SPECT the HMR also appeared to increase slightly with age but this wasn’t statistically significant.  This 
study did not include CT data for scatter and attenuation correction for the SPECT images and used 
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LEHR collimators [181], which may be unsuitable for measuring absolute uptake in torso studies, 
although a point spread function based correction for septal penetration was made. 
As both ACSC and non-corrected SPECT data can be reconstructed for SUPErB study participants, 
including both relative and absolute quantification results, the SUPErB control dataset is suitable for 
assessing these effects further.  The use of medium energy collimators means that the results should 
be less dependent on source to detector distance than those of Jacobson et al.  Although there are 
only 31 subjects, the age range of interest (60 years +) is relatively narrow.  In addition, the entire 
dataset of SUPErB subjects can be used to assess any variation in mediastinal region uptake with age, 
which will of course affect HMR.  If cardiac uptake does decrease with age then correcting for this may 
give improved accuracy in diagnosis of DLB. The aim of this study was therefore to measure the change 
in cardiac uptake with age in cognitively normal control subjects. 
9.2.2 Methods 
Subjects and imaging 
Cognitively normal controls from the SUPErB study, with normal visual planar imaging appearances are 
included in this section; 2 of the 31 controls were excluded.  One further control was excluded as the 
administered activity was not recorded, so 28 individuals were included in total for cardiac uptake 
assessment.  We obtained HMR from early and delayed planar imaging as described in chapter 7, SPECT 
and SPECT-CT HMRs as detailed in section 8.1 and 8.2 and normalised cardiac and mediastinal count 
density as described in section 8.3.  The 6 cm diameter spherical VOI results were used for the SPECT 
images, rather than the threshold results as the two were shown to give similar results in section 8.2.  
Lean body mass normalisation was used for the absolute quantification results as we showed this to 
be more effective than weight normalization in section 8.3.   
In addition, we studied the mediastinum VOI uptake on SPECT imaging in all 83 SUPErB subjects (MCI 
plus controls), since we assume that the mediastinum uptake is not affected by the Lewy body disease 
process and this allows a larger sample to be studied.  The absolute quantification results from section 
8.3 were used to assess the relationship between mediastinal uptake and age. 
Analysis 
A similar method to that used for striatal uptake in the previous section was adopted.  Linear mixed 
effects models [275] (IBM SPSS v.24) were used to test for dependence of the different cardiac and 
mediastinal uptake measures on various covariates.  Age, gender, BMI, weight and lean body mass 
were input as fixed effects in the model.  Age was combined with weight, BMI and LBM to check for 
possible interactions.  With planar HMR, the mixed effects approach allowed with study ID to be input 
as a random effect so that data from both early and delayed planar imaging could be grouped to give 
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56 HMR measurements; the random effect of study ID accounts for the fact that the early and delayed 
planar HMRs of an individual are likely to be correlated.  P-values of less than 0.05 were taken to 
indicate effects significantly different from zero. Scatter plots of uptake against age were produced for 
early HMR, delayed HMR, SPECT HMR, SPECT-CT HMR in order to visualise the relationships. 
9.2.3 Results 
Plots of cardiac uptake against age are shown in Figure 102 for early and delayed planar HMR, SPECT 
HMR, SPECT-CT HMR and normalised cardiac count density measured on SPECT and SPECT-CT images.  
All except early HMR show a trend towards lower cardiac uptake with age, but this is only statistically 
significant for SPECT-CT HMR.  The results are presented in more detail below. 
Planar imaging 
The results of the multivariate analysis are given in Table 76 for planar (early and delayed combined 
with mixed effect model).  The planar HMR results show weak evidence of relationships with both age 
and measures of patient size (p values between 0.07 and 0.11), however with age and size variables 
combined the relationship becomes significant, with a p-value for LBM*age of 0.09, suggesting an 
interaction between these parameters.  Gender is important for both planar cardiac and planar 
mediastinum counts, but appears to completely cancel out with planar HMR.  Only the data for early 
and delayed planar HMR combined is shown, but delayed planar HMR alone did not show any 
statistically significant covariates. 
 
Table 76: HMR and count density results of linear mixed effects model for planar images in normal controls (early and delayed 
data combined in model). P values for covariates with a significant effect on uptake are shown in bold italics. 
 Planar HMR 
(early and delayed 
combined) 
Planar cardiac count 
density (activity 
normalised) 
Planar mediastinal count 
density (activity 
normalised) 
 Wald Chi-
Square 
P value Wald Chi-
Square 
P value Wald Chi-
Square 
P value 
Weight 3.242 .072 8.614 .003 3.109 .078 
BMI 2.587 .108 7.145 .008 2.338 .126 
LBM 3.227 .072 10.015 .002 4.274 .039 
Gender .330 .566 4.904 .027 9.277 .002 
Age 2.567 .109 .294 .588 1.041 .308 
Time point .684 .408 .025 .873 .157 .692 
LBM * Age 6.792 .009 5.571 .018 .208 .648 
BMI * Age 3.197 .074 4.387 .036 .447 .504 
Weight * 
Age 
5.156 .023 6.241 .012 .733 .392 
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Figure 102: Cardiac uptake in cognitively normal controls plotted against age for early and delayed planar HMR, SPECT HMR, 
SPECT-CT HMR and normalised cardiac count density measured SPECT and SPECT-CT images  
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SPECT and SPECT-CT 
SPECT imaging without attenuation and scatter correction results show no significant covariates for 
either HMR or normalised count density (Table 77). For SPECT-CT HMR the only significant variable is 
age (p=0.04) with all other covariates showing p values >0.5.   SPECT-CT cardiac count density is not 
dependent on age (p=0.26) indicating that it is variation in the mediastinum counts which have a major 
contribution to the HMR age relationship.  SPECT-CT HMR is related to patient size, even after LBM 
normalisation.    
 
Table 77: Results of linear mixed effects model for SPECT image uptake measurements in controls.  P values for covariates 
with a significant effect on uptake are shown in bold italic font. 
 SPECT HMR SPECT-CT HMR SPECT cardiac 
count density  
SPECT-CT 
cardiac count 
density  
 
Χ2 P  Χ2 P  Χ2 P  Χ2 P  
Weight .206 .320 .044 .704 .883 .348 7.390 .007 
BMI .608 .650 .050 .834 .954 .329 5.484 .019 
LBM .254 .435 .366 .823 .518 .472 5.519 .019 
Gender .004 .614 4.359 .545 .349 .555 .468 .494 
Age 1.242 .949 .193 .037 .349 .555 1.254 .263 
BMI * Age .498 .265 .185 .661 1.034 .309 5.908 .015 
Weight * 
Age 
.171 .480 .335 .667 1.558 .212 9.520 .002 
LBM * Age .273 .679 .357 .563 1.521 .217 9.689 .002 
 
 
Mediastinum uptake (plotted for both MCI and control subjects in Figure 103) appears on SPECT and 
SPECT-CT images appears to show a slight increase with age even with activity and LBM normalization, 
but there is substantial variation between subjects and the effect does not come close to being 
statistically significant.  Plots of LBM normalised SPECT and SPECT-CT mediastinum uptake are shown 
in Figure 103.   None of the covariates included in the linear mixed effects model had a significant 
effect on mediastinal uptake (Table 78). 
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Figure 103: Top: activity-normalised mediastinal count density for all subjects on SPECT and SPECT-CT images.  Bottom: 
activity and lean body mass normalised mediastinal count density on SPECT and SPECT-CT images. 
 
Table 78: Results of linear mixed effects model for mediastinum uptake, showing no variation with age or any of the covariates 
tested. 
 SPECT 
mediastinal count 
density (activity 
normalised) 
SPECT-CT 
mediastinal count 
density (activity 
normalised) 
SPECT mediastinal 
count density 
(activity and LBM 
normalised) 
SPECT –CT 
mediastinal count 
density (activity and 
LBM normalised) 
 Chi-
Square 
P 
value 
Chi-
Square 
P 
value 
Chi-
Square 
P 
value 
Chi-
Square 
P 
value 
Age .615 .433 .001 .972 .179 .672 .077 .782 
Weight .001 .975 .560 .454 .002 .964 .278 .598 
BMI .011 .916 1.050 .306 .031 .861 .347 .556 
Gender .085 .770 .016 .900 .828 .363 .154 .694 
LBM .000 .998 .322 .571 .003 .956 .188 .664 
Age*Weight  .023 .879 .248 .618 .005 .944 .225 .635 
Age*BMI .062 .804 .471 .493 .096 .757 .160 .689 
Age*LBM .105 .746 .018 .894 .058 .810 .267 .605 
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9.2.4 Discussion 
Our planar results are in keeping with the findings of the ADMIRE-HF study, with both our dataset and 
the ADMIRE-HF controls showing no evidence of a relationship between early HMR and age, and both 
showing a suggestion of a decline in delayed planar HMR with age, which is not statistically significant.  
It is possible that with a larger sample size or wider age range we would have seen a significant effect, 
especially given the positive result with SPECT-CT HMR and the small significant decline in delayed 
HMR with age seen in the Japanese database, also with medium energy collimators [221].   
In our planar HMR dataset, the combination of age with LBM had a significant effect on HMR, even 
though these covariates separately did not show strong evidence for a relationship ( 
Table 76).   This suggests that there is an interaction between LBM and age, although we note that 
there is not an obvious linear correlation between them. 
Our tomographic results are quite different from those in the ADMIRE-HF study, where a statistically 
significant increase in SPECT cardiac and mediastinal count density was seen with age and a trend 
towards higher SPECT HMR [181].  Our results show a trend towards lower SPECT HMR with age, which 
becomes statistically significant with attenuation and scatter correction applied.   The SPECT 
mediastinal count density without LBM correction, which is the value most similar to that measured 
by Jacobson et al., does show a suggestion of increasing uptake with age, but this is removed when 
corrected for patient size with LBM normalisation.   The cardiac count density does appear to decrease 
with age, but the slope is not significant.  However, the slope of SPECT-CT HMR against age is 
significant, even though there is no corresponding increase in mediastinum count density with age to 
increase the effect.  This suggests that the relationship between cardiac count density and age may be 
masked by inter-subject variation, and taking the ratio to obtain HMR may cancel out some of this 
variation between patients.  This would also support the use of SPECT-CT HMR over absolute 
quantification for cardiac MIBG imaging. 
On delayed planar imaging and non-corrected SPECT imaging, HMR does appears to decline with age, 
although this is not statistically significant.    Our results with SPECT-CT indicate that this is a real effect 
and that the planar relationship is likely masked by variation between subjects due to other factors 
such as physiological variation and patient size.   The effect of ageing on delayed planar HMR appears 
to account for a non-trivial amount of the variation seen between subjects, an average decrease of 
around 0.4 HMR points in the range 60-90 years, compared to a total variation of around ±1 HMR point 
(SD=0.46).   Accounting for age has the potential to improve the diagnosis of Lewy body disease, by 
reducing the variation between normal subjects.  A larger sample of normal SPECT-CT scans would be 
required to characterize the relationship between HMR and age more comprehensively, which could 
be obtained from the MCI-AD dataset after follow up to confirm the subjects are unlikely to have Lewy 
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body disease.  This would be similar to our approach in the previous section on FP-CIT uptake and 
ageing, where MCI-AD cases from the LewyPro study with several years clinical follow up were used as 
controls. 
9.2.5 Conclusion 
In cognitively normal controls, our results show a significant decline in HMR with age on attenuation 
and scatter corrected SPECT-CT images.  This suggests that correcting for age could be important for 
improving the diagnosis of Lewy body disease, including on delayed planar images.  Further work with 
a larger dataset is indicated to characterize the relationship and the correction required. 
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 Summary of chapter 9 
In section 9.1 we showed that visually there appeared to be no decline in striatal SBR with age in people 
over 60 years of age without Lewy body disease.  On inspection of the control data used by the 
software manufacturers there also appeared to be no clear drop with age in this age group.  Our mixed 
methods analysis showed no dependence on age.  Although these results are convincing, our sample 
size was too small to be able to exclude a small decrease, or indeed increase, in uptake with age.  Our 
95% confidence intervals overlapped with the slopes used by BRASS and DaTQUANT even though our 
estimated slope was smaller.  We speculate that an exponential relationship between striatal uptake 
and age may be a better model of the biological effect, as this would account for both the large effects 
seen in young adults and the negligible effect in old age.   Further work with larger samples over a 
wider age range would be necessary to fully characterise the relationship between striatal uptake and 
age. 
In section 9.2 we showed that unlike striatal FP-CIT uptake, HMR results do appear to decrease in old 
age, with the results obtained on scatter and attenuation corrected SPECT-CT images of cognitively 
normal older adults showing a statistically significant inverse linear relationship with age.  One possible 
reason for the discrepancy between cardiac sympathetic innervation and dopaminergic innervation in 
older adults may be the interaction with cardiac disease, which would of course not affect the striata.  
The majority of our controls did not have a history of cardiac problems, but the risk of asymptomatic 
cardiac disease increases with age and it is possible that this could account for the observed decline in 
cardiac MIBG uptake.  Nevertheless, the results suggest that, on average, a correction for age could 
reduce the variation in cardiac MIBG uptake between subjects – regardless of the physiological reasons 
for the variation. 
The strengths of the work presented in this chapter include the recruitment of elderly subjects with 
normal cognition, representing the ages of people typically presenting for memory and cognition 
assessment in the NHS.  This makes the results more relevant to clinical practice than studies covering 
the whole adult age range, where typically few adults over the age of 70 are included.  A further 
strength is the prospective recruitment of volunteers, rather than the retrospective selection of 
patients with normal imaging from clinical databases.  The main limitation is the sample sizes, which 
are rather too small to definitively confirm the relationships in question. 
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Chapter 10: Discussion and conclusions 
This thesis focussed on the optimisation and quantification of two scintigraphic biomarkers for the 
diagnosis of DLB: 123I-FP-CIT (DaTSCAN™) and cardiac 123I-MIBG.   Both scans have technical limitations 
that suggest that, whilst very accurate in distinguishing between Lewy body disease and other 
conditions at the dementia stage, their performance may not be ideal for detecting early 
neurodegenerative change with current methods used in clinical practice.   In this thesis these issues 
were addressed using a range of novel state-of-the-art approaches.  Throughout the thesis these novel 
techniques were compared with the standard techniques to evaluate their potential benefit.   The 
application of both biomarkers was studied in advanced anthropomorphic phantom models, cohorts 
of highly characterised dementia and MCI subjects and older adults with normal cognition recruited as 
age matched controls. 
This chapter presents an overview of the main findings presented in the thesis and the novel 
contributions to the field.  The use of both biomarkers in clinical practice and research is then discussed 
in light of the findings and the limitations of the work and future directions are summarised. 
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 Overview of main findings and novel contributions 
10.1.1 FP-CIT summary 
Software comparison 
We showed that 123I-FP-CIT specific binding ratios (SBRs) calculated by BRASS and DaTQUANT software 
packages are systematically different, although give similar diagnostic accuracy.  These have not been 
compared directly in the literature. The SBRs are affected by the reconstruction method used and by 
factors such as image registration that affect the SBR calculation.  The associated Z scores output by 
the software also depend on the normal database used for comparison and the method used for age-
correction.  Quantification results obtained with different methods are therefore not directly 
comparable and a consistent reconstruction method and software package should be used.  For the 
SUPErB study the BRASS software package was chosen based on technical advantages over 
DaTQUANT.  
Factors affecting BRASS quantification 
Phantom experiments and reprocessing of scans from the LewyPro study showed that pixel size, repeat 
scanning and reorientation during processing had small random effects on BRASS quantification of less 
than 10%.  
Visual rating and BRASS quantification 
The reconstruction method required for comparison with the BRASS normal database, denoted 
RRACSC_Uniform in this thesis, was adopted for both the standard quantification method and for 
visual assessment.  The visual rating of FP-CIT scans by a consensus panel of raters was compared to 
BRASS quantification using the standard RRACSC_Uniform reconstruction method applied in SUPErB, 
selecting only probable MCI-AD and MCI-LB cases for analysis.  The sensitivity of visual assessment of 
FP-CIT scans by raters with access to BRASS quantification was 48% (95% CI: 29 to 68%) and specificity 
88% (62 to 98%).  The sensitivity and specificity of BRASS quantification alone was 44% (25 to 65%) and 
100% (79 to 100%).  There were three cases where there was discordance between the panel and 
BRASS quantification but the overall accuracy of the visual ratings method and quantification alone 
was very similar. Long term follow up, including repeat FP-CIT scans, is ongoing and will help to clarify 
the status of the considerable number of cases assumed to be early Lewy body disease but with normal 
FP-CIT scans, as well as that of the cases where there was discordance between the panel and BRASS. 
Advanced FP-CIT reconstruction methods 
Standard BRASS SBR quantification results were compared with absolute quantification with SUV-
SPECT.  Preliminary results suggest that SUV-SPECT using either the mean striatal SUV or the SUVpeak 
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separates normal and abnormal subjects less well than semi-quantification, with more variation seen 
among normal subjects.  We recommend that SBRs continue to be used for quantification rather than 
SUV.  This is in line with the results of recent publications on this topic from Japan [196, 197].  However, 
the scaling of the images to the absolute value rather than relative to the maximum voxel for visual 
rating could be a more robust way of detecting subtle balanced loss and further investigation is 
warranted as this has not been investigated in the literature. 
It was found that advanced FP-CIT reconstruction methods using SPECT-CT and collimator modelling 
affected specific binding ratio values, but the overall interpretation of the scans with respect to the 
SBRs of the age-matched SUPErB control database reconstructed with the same method was not 
affected.  It was therefore not recommended to use SPECT-CT for calculating SBRs in FP-CIT in clinical 
practice.   The lack of improved diagnostic accuracy with CT attenuation and scatter correction is in 
keeping with the literature on this topic [102, 162, 198], but there have been no published studies 
applying full collimator modelling to FP-CIT. 
Test-retest variation 
The repeatability of visual rating and BRASS quantification was assessed using baseline and follow up 
scans in cognitively normal controls.  Two of the 20 controls with repeat visual ratings were assessed 
as abnormal at baseline but normal at one year follow up and overall concordance was 75% for our 
modified and extended Benamer ratings scale and 90% for binary abnormal-normal categorisation.  
SBR results on several of the baseline and repeat scans differed by more than 20% and the mean of 
the absolute test-retest difference was 12%, similar to the coefficient of variation among subjects at 
baseline and in keeping with previous work at Newcastle [204], but higher than early work on FP-CIT 
repeatability [201].  The causes of the intra and inter-subject variation are unknown, but the results 
suggest that a drop in SBR of less than around 20% in repeat scans should not be regarded as 
significant.  
Striatal uptake of FP-CIT in healthy ageing 
The scan data for controls with normal cognition was used to explore ageing effects.  Multivariate 
analysis using linear mixed effects models was performed to determine whether there is an association 
between uptake and ageing between 60 and 90 years of age.  We found that SBR does not continue to 
decrease with age in older adults, as was previously assumed to be the case, indicating potential 
misdiagnosis if linear age correction is applied.  This novel finding was published in the Annals of 
Nuclear Medicine journal [267] and presented at international conferences.  Linear age corrections are 
currently applied in BRASS and DaTQUANT, although a meta-analysis found that an exponential model 
fits the data equally well [200]. 
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In clinical practice this potential problem is difficult to avoid as it requires the use of a local age-
matched database for older adults rather than the default age-corrected software databases.  
Switching off age correction is not possible with some commercial software packages, and would be 
inappropriate for a database made up of a wide range of ages as there is clear evidence of a 
relationship between SBR and age in younger adults.  As turning off age correction in commercial 
software is unhelpful and determining a local age-matched normal range is not a practical solution for 
most clinical centres, we investigated the practical clinical implications of using quantification software 
with the default age correction applied. To do this we compared the accuracy of BRASS quantification 
in the SUPErB study using our local control database with the accuracy of BRASS using the ENC-DAT 
database with age correction.  There was no change in clinical interpretation of the scans, indicating 
that the linear age correction method used in BRASS, did not lead to misdiagnosis in this dataset.  It is 
likely therefore that the effect of age correction is not large.  Nevertheless, possible overcorrection in 
subjects over 80 years should be borne in mind, particularly in borderline cases.  In research studies 
aiming to identify subtle changes, it may be more important to use a more appropriate model. 
10.1.2 Cardiac MIBG summary 
Preliminary work 
Anthropomorphic phantom scans established that, as expected from the literature, medium energy 
collimators give better image contrast than low energy due to reduced septal penetration of high 
energy gamma rays and confirmed their use for the SUPErB study.  A method for normalising HMR 
results obtained with different acquisition settings using simple phantom scans was presented.  We 
found that an administered activity of 111 MBq with planar scan duration of ten minutes (the protocol 
used in Japan [185]) provides adequate counting statistics for heart to mediastinum ratio (HMR) 
calculations to be accurate to within 2%, suggesting that the recommendation of 370 MBq in UK ARSAC 
guidelines is excessive.  Phantom scans showed that large changes in count density due to increasing 
scan time or administered MIBG activity did not affect HMR.   
Processing methods for planar HMR calculation 
Using data from the MIDAS study we found that different methods of planar MIBG analysis are 
operator dependent and give systematically different results. We also explored the use of visual rating 
and found that semi-quantification gave higher specificity, provided an appropriate normal HMR cut-
off is used.  We recommended the use of a 6 cm circular cardiac ROI for calculating HMR as this method 
reduced inter-operator variation when compared to a region tailored to the patient, without changing 
accuracy and is in line with the method used in the Japanese literature [173, 219].  These results have 
been published in Nuclear Medicine Communications [190] and disseminated to the local nuclear 
medicine community at regional meetings. 
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Normal HMR cut-off values 
We found that previously published HMR cut-off values in Japan and the USA may not be valid in a UK 
population and proposed suitable alternatives based on the SUPErB control dataset for both early and 
delayed images.  These cut-offs are 2.10 for early imaging and 1.86 for delayed imaging, suitable for 
use with medium energy collimators and Siemens cameras only. 
This work was accepted for publication in the Journal of Nuclear Cardiology in August 2019 and will be 
published with an accompanying editorial piece by Prof Nakajima of Kanazawa University, Japan with 
whom we collaborated to compare Japanese and UK data directly.  Previous publications have 
addressed the need to account for technical factors in HMR thresholds [165, 167, 168] – this work 
shows that population differences also affect interpretation. 
Early vs delayed imaging 
We acquired early and delayed images in both the MIDAS and SUPErB studies and found that HMR 
values obtained on the standard delayed images gave marginally superior accuracy to early images.  
Greater separation in uptake between normal and abnormal scans on delayed images both in the 
SUPErB and MIDAS studies was found, in keeping with that reported in the literature [235].  In research, 
there are benefits in the maintaining the standard delayed method. 
In our series 78% of cases gave a clear non-equivocal result on early imaging and the early and delayed 
result differed in only 4% of cases. This finding suggests that in clinical practice an alternative protocol 
could be adopted in which only an equivocal early HMR result would lead to patients having the 
delayed scan.  This protocol could save time in the majority of cases so would be more convenient for 
patients and save NHS staff and scanner time.   
We brought all the planar cardiac MIBG data together to propose an accurate and practical evidence-
based cardiac MIBG protocol for image acquisition and analysis.  This protocol could be used in clinical 
practice within the NHS and in research studies requiring a binary normal/abnormal sympathetic 
innervation result.  We suggested that patients should be administered 111 MBq and a planar anterior 
image of the chest acquired around 20 minutes later, using medium energy collimators.  If the HMR, 
calculated using our 6 cm circle ROI method, is below 1.6 or above 2.5 the patient should be informed 
that the test is complete.  If the HMR at 20 minutes is equivocal the patient should be asked to return 
for a repeat scan to be carried out 3-4 hours after injection.    
Effect of patient size on cardiac MIBG uptake results 
The effect of patient size on apparent uptake was assessed with an anthropomorphic torso phantom 
and using the SUPErB controls. This was performed for both planar and SPECT acquisitions; for the 
latter the effect of using advanced image reconstruction methods with CT attenuation and scatter 
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corrections compared to conventional processing was explored.  In the phantom, increasing the size 
reduced apparent cardiac uptake by 39% on planar images and 33% on non-corrected SPECT images 
but with SPECT-CT images with attenuation and scatter correction applied the reduction was only 3%.  
For the control subjects, planar cardiac 123I-MIBG images show a significant inverse relationship 
between cardiac uptake ratios and subject BMI.   SPECT images with CT attenuation and scatter 
correction applied showed no statistically significant drop in cardiac uptake with BMI, suggesting that 
the corrections are effective in patients.  However, there was considerable inter-subject variation, 
which may explain why there is no statistically significant difference between the slopes of HMR 
against BMI for non-corrected and ACSC SPECT.  This work suggests that ACSC SPECT has the potential 
to improve cardiac 123I-MIBG quantification, particularly in borderline planar cases.  This has not been 
explored in the literature and larger studies would be needed to confirm our findings.  
This work is currently under peer review for publication in Biomedical Physics and Engineering express. 
Use of SPECT-CT for quantification of cardiac MIBG uptake  
The diagnostic accuracy and the separation of normal and abnormal scans into clusters was compared 
for planar, SPECT-CT relative quantification and SPECT-CT absolute quantification.  We saw that the 
separation between normal and abnormal cardiac MIBG scans on planar imaging is around 1.5 HMR 
points, increasing to around 5 points with SPECT and around 7 points with SPECT-CT. This is a novel 
finding as SPECT with CT ACSC has not previously been used in the literature for cardiac MIBG imaging.  
However this very promising finding translates into only a small improvement in MCI diagnostic 
accuracy because in most cases planar imaging is sufficient to characterise the scans as normal or 
abnormal.   Application in routine clinical practice may be limited, but results here suggest potential 
value in research for the measurement of serial change over time and correlation of uptake with 
clinical symptoms, for example. 
Preliminary exploration of cardiac 123I-MIBG regional uptake patterns 
The uniformity pattern of MIBG uptake within the myocardium was assessed for controls and dementia 
patients, as a feasibility study to see if this might be useful for diagnosing Lewy body disease in patients 
with global uptake within the normal range.  Studies in the literature had been mixed, with some 
suggesting that assessment of regional reductions improves diagnosis [56, 177, 179, 239, 245, 246] 
and some that this is not specific [188, 216, 246-251]. 
We found that areas of relatively reduced cardiac 123I-MIBG uptake on SPECT images are very common 
in cognitively normal older adults and patients with dementia who have normal planar cardiac uptake.  
Reduced regional cardiac MIBG uptake in the inferior wall of the left ventricle is the most common 
defect and likely related to attenuation or liver uptake.  Reductions in other areas may also be 
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artefactual or may be caused by mild underlying coronary artery disease.  The pattern of reduction is 
in any case non-specific and therefore unlikely to aid in the diagnosis of Lewy body disease in typical 
clinical settings.   This work is currently under review with the Journal of Nuclear Cardiology. 
Cardiac MIBG uptake in healthy ageing 
In cognitively normal controls, we saw a small but significant decline in HMR with age on attenuation 
and scatter corrected SPECT-CT images, of around 0.5 HMR points on SPECT-CT per decade (around 
5%).  On planar and non-corrected SPECT imaging HMR also appears to declines with age but this is 
not statistically significant.  This was in contrast to FP-CIT, where no evidence of any relationship 
between striatal uptake and age was seen in our cohort of individuals without Lewy body disease over 
60 years of age.  Estimates in the literature for the relationship between FP-CIT uptake and age are 
around 7% per decade and these are accounted for in quantification software packages.   Previous 
literature on the relationship between cardiac MIBG and age is mixed, with a large US study showing 
no relationship and the Japanese normal patient database showing slightly lower mean HMR in over 
60s compared to under 60s.  Neither study used SPECT-CT however.  Although the effect of ageing on 
sympathetic innervation appears small compared to the overall variation seen between subjects, 
correction could reduce this variation and help to improve diagnostic accuracy. 
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 Comparison between FP-CIT and cardiac MIBG 
A common finding throughout this thesis is that many individuals with probable MCI-LB diagnosed 
based on clinical features have clear normal image appearances and quantification results on FP-CIT 
and/or cardiac MIBG scans, with the specific reconstruction and processing method making little 
difference to the binary interpretation of the scans.  In cardiac MIBG we saw a greater separation of 
scan data into two distinct groups with SPECT-CT than with planar imaging or with FP-CIT, but this did 
not translate into greater sensitivity with respect to the clinical diagnoses.  If Lewy body disease is not 
present in the relevant tissue the imaging technique will always have limited sensitivity, even with 
technical improvements.  Longer term follow up of these patients and eventual autopsy will help to 
clarify the utility of both scans, and it will be of particular interest to see whether probable MCI-LB 
patients with both normal FP-CIT and MIBG scans do go onto develop DLB.   
We know that Lewy body disease is found throughout the nervous system [81] and does not appear 
to have a consistent pattern of spread [1] so it is not surprising that some scans in probable MCI-LB 
cases are normal, particularly as this is early stage disease.  Our results add to the body of evidence 
contradicting the Braak hypothesis that the progression of Lewy body pathology follows “an ascending 
course with little interindividual variation” [282], for example, some MCI-LB patients had normal 
cardiac MIBG and abnormal FP-CIT.  It has been shown in an autopsy study at Newcastle that 10% of 
people diagnosed with DLB who meet pathologic criteria for Lewy body disease had normal FP-CIT 
imaging in life [48] suggesting that it is possible for the striatum to be spared even in advanced disease.      
The concordance between planar MIBG HMR and visual rating of FP-CIT scans with access to 
quantification results was around 80%: 82% for probable MCI-LB, categorised using clinical symptoms 
only, 67% for MCI-AD and 88% for the controls.  Two controls were rated abnormal on each of the 
scans, different individuals for each scan.  The overall diagnostic accuracy results presented in this 
thesis are similar for both techniques, showing that sometimes the FP-CIT result is more in line with 
the clinical picture and sometimes the cardiac MIBG result.  The diagnoses with respect to clinical 
symptom count only (0=AD, 2+=MCI-LB) allow us to compare the scans directly.  The sensitivity with 
respect to clinical symptoms is 59% for both scans.  The specificity is 81% for FP-CIT and 85% for MIBG 
(the difference due to just one patient with no clinical features of Lewy body disease having a normal 
MIBG scan and abnormal FP-CIT).  Our results from SUPErB so far suggest that around half of people 
with MCI-LB develop pathology affecting both dopaminergic function and sympathetic function at an 
early stage, around a third have no signs of significant disease in either the heart or substantia nigra 
and the rest have either only the dopaminergic nerves affected early on or signs of cardiac denervation 
only, around one in 12 (8%) for each case. The level of concordance is similar to that reported by 
Tiraboschi et al. who compared cardiac MIBG and FP-CIT DLB and AD in the only other prospective 
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study in the literature [67] and found the results to be concordant in 51 of the 59 patients (86%).   The 
numbers are too low to come to firm conclusions, especially without autopsy data but the relatively 
high concordance in SUPErB suggests it would require a very large study to detect any difference in 
diagnostic accuracy with certainty. 
There were no controls or MCI-AD cases with both biomarkers abnormal, suggesting that the use of 
both may be justified in situations where high specificity is required, for example in selecting people 
with AD without evidence of additional Lewy body disease.  The combined sensitivity would be reduced 
but only from 59% to 50%, so it may be feasible to use both biomarkers to select MCI-LB cases with 
more certainty for clinical trials of new disease modifying therapies. 
Currently lack of knowledge on how to interpret cardiac MIBG scans is a significant barrier to their use 
in routine clinical practice in the UK, despite the inclusion of cardiac MIBG as an alternative to FP-CIT 
in the 2018 NICE dementia guidelines.  This could be addressed with UK wide standardisation of 
imaging protocols and scanner calibration (see section 10.4 below). 
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 Strengths and limitations 
Clinical diagnoses 
A key strength of this work is the use of well-characterised dementia and MCI cohorts and age-matched 
controls with normal cognition recruited into research studies.  These subjects underwent a wide range 
of cognitive and neuropsychology tests, more comprehensive than those carried out in a clinical 
setting, and their results were reviewed by a panel of expert old-age psychiatrists with particular 
interest and expertise in prodromal diagnosis before coming to a consensus diagnosis.  MCI-LB subjects 
with only one core clinical feature of Lewy body disease or positive biomarker were excluded from 
analysis, as were MCI-AD cases with one positive biomarker6.  We are therefore as certain as possible 
that the diagnoses are accurate but this can only be confirmed by future neuropathology at autopsy, 
included as part of the study.  With the MCI studies, such autopsy confirmation is not likely to be 
received for several years for the majority of patients and will therefore not be fully representative of 
the pathology present at recruitment.   A limitation is that tests for detecting Alzheimer’s disease 
pathology, such as amyloid or tau PET scanning, were not performed so we are not able to tell on a 
biomarker level, whether the profile of the MCI-LB cases is likely to have a contribution from AD 
pathology.  This however, is in keeping with the NIA-AA framework [24], in which a clinical diagnosis 
of AD is made via the exclusion of other causes rather than via confirmation of AD pathology.   
We used the 2017 international DLB consortium criteria for DLB diagnosis [1] to categorise the MCI-LB 
cases into possible and probable categories, applying the same criteria at the MCI stage as used at the 
dementia stage, including the use of MIBG and FP-CIT results for assigning possible and probable 
groups.  The possible MCI-LB cases were then excluded from analysis within this thesis.  In the FP-CIT 
section MIBG was used as a biomarker and in the MIBG section FP-CIT was used.  Flow charts showing 
the decision making process based on core clinical symptoms at one year and baseline biomarker 
results were given in the clinical background chapter in section 2.3.3.   
There was non-concordance between cardiac MIBG and FP-CIT results in the SUPErB study in around 
20% of cases, leading to slight differences in the diagnostic groupings in the FP-CIT and cardiac MIBG 
sections of this thesis.  An alternative approach would have been to use only the core clinical features, 
resulting in the same clinical groups for both the FP-CIT and MIBG work, making it easier to compare 
the scans.  However, many MCI-LB participants had only one core clinical feature, even with one or 
both scans abnormal, and would have been excluded with this approach.  In this thesis, only the 
baseline biomarkers were used for diagnosis, even though follow-up FP-CIT scans were available in the 
                                                          
6 No MCI-AD cases had both FP-CIT and MIBG abnormal but if so they would have been excluded rather than 
moved into the probable MCI-LB category as this requires at least one core clinical feature of Lewy body disease. 
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majority of cases included.  This was because we have not acquired repeat cardiac MIBG scans and 
because baseline biomarker results are more in keeping with clinical practice, where a patient’s 
diagnosis will be revised following changes in symptoms but it is less common to request a repeat FP-
CIT scan. 
Quantification work 
Strengths of the work on FP-CIT and cardiac MIBG quantification presented in this thesis include the 
following advantages not generally available in routine clinical practice: 
• Access to two of the most widely used FP-CIT quantification packages, BRASS and DaTQUANT 
(typically NHS departments will have one or the other or an in-house method) 
• Access to an advanced FP-CIT reconstruction method not yet released by the developer for 
clinical use 
• Visual FP-CIT results from a consensus ratings panel of five experts, rather than a single clinical 
reporter 
• Use of ENC-DAT FP-CIT normal database (purchased for Fellowship)  
• Data from controls from the SUPErB study with normal cognition 
• Use of well-characterised MCI and dementia research cases with follow up (as discussed 
above) 
• Use of sophisticated anthropomorphic phantoms (purchased for Fellowship) 
• Calibration of gamma camera for planar cardiac MIBG imaging with help from colleagues in 
Japan and the Netherlands.  This has not been done in any other UK centre 
A limitation of the work on advanced FP-CIT analysis methods was the lack of a suitable method for 
SUV-SPECT analysis for the FP-CIT data that would produce results that can be compared to SBR 
methods.  If the manufacturer of BRASS (Hermes Medical Ltd) were to agree to make changes to the 
SBR calculation method in future releases of BRASS, such that the results could be used for absolute 
quantification, this would be ideal.  The evidence presented in this thesis and in a limited number of 
small published studies suggests that SUV-SPECT is slightly less accurate than SBR, but this could not 
be concluded with as much certainty as we would have liked. 
Time factors were a major limitation in all the work involving phantom scans.  The availability of the 
gamma camera was limited to weekday evenings after clinical scans had been completed.  Lengthy 
scans were required to mimic patient count rates so only a few scans could be acquired in each session, 
as often complex manipulations of activity distribution in the phantom were required between each 
scan. Weekend work was not thought to be feasible as 123I can only be delivered on weekday mornings 
and has a half-life of 13.2 hours making it at least twice as expensive to order sufficient activity, 
however in hindsight this would probably have been worthwhile.  Much of the phantom work would 
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have benefitted from access to the equipment for whole day rather than sessions of a few hours as 
multiple scans of the exact same activity distribution could have been achieved. 
Although the sample sizes of the control and MCI groups were reasonable for an imaging study they 
remain too small for us to be able to detect small effects with certainty, for example the lack of decline 
in FP-CIT uptake with age in older adults and the relationship between SPECT-CT cardiac uptake and 
patient size.  Many of the results in this thesis should therefore be regarded as preliminary findings, 
requiring larger multi-centre studies for confirmation. 
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 Future directions 
10.4.1 Ongoing work with SUPErB study 
As the SUPErB study is ongoing, with recruitment only finishing in August 2019, only a subset of the 
data was considered in this thesis (59 MCI subjects recruited up until January 2018).  This was so that 
one year follow up diagnoses could be used to determine the clinical groups to be used in the thesis 
and to allow time for analysis.  I will be starting a part time post-doctoral position at Newcastle 
University following the fellowship to enable some of the work presented here to be extended to the 
full SUPErB dataset of around 100 MCI subjects.  We plan to publish much of the work presented in 
this thesis after re-analysis with the complete dataset. 
10.4.2 UK wide calibration of gamma cameras for cardiac MIBG imaging 
The results of the MIDAS pilot study into the use of cardiac MIBG imaging for dementia diagnosis in a 
UK setting were encouraging and we have been approached several times by interested clinicians and 
clinical scientists in other UK centres for advice on implementing a cardiac MIBG service.  The results 
in section 7.2 on HMR thresholds suggest that for other UK centres would be better off applying our 
results than other values in the literature from other countries; however to do so would require 
calibration of the gamma cameras, using similar methods as those presented in section 5.2.  We are 
therefore planning to apply for funding for a UK wide calibration project.  In this project we would 
manufacture similar planar phantoms in house, constructed to give known activity concentration ratios 
and take or send them to different centres.  We would use the results to convert our results to HMR 
cut-off values appropriate for other centres to use and develop national guidelines. 
10.4.3 Simulation work using Monte Carlo modelling  
Simulating scans using Monte Carlo methods enables investigation of the effects of patient factors in 
a more flexible and controlled manner than can be obtained with physical anthropomorphic phantoms, 
overcoming difficulties of gold standards with patient studies.  In addition to the large amount of work 
presented here I also carried out some preliminary work on developing a Monte Carlo model of our 
gamma camera (see Appendix G) which will form the basis for future work.  
10.4.4 Multicentre clinical study 
We plan to apply for funding in future to conduct a large multi-centre study into the use of FP-CIT and 
cardiac MIBG in the diagnosis of Lewy body disease in the UK.  This will enable our findings to be 
replicated in different settings and will increase the power of the study, clarifying some of the findings 
in this thesis that appear promising but are hampered by small clinical groups. 
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 Concluding remarks 
This thesis presented an in-depth and comprehensive study of technical aspects of nuclear medicine 
biomarker quantification using 123I labelled radiopharmaceuticals for the diagnosis of Lewy body 
disease. This provides a solid foundation for clinical and research application of these techniques in 
both early and established disease.  Proposals are made for further work to advance these studies via 
a larger multicentre study and phantom calibration. 
Appendices 
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Appendix A: Key technical and practical differences between DaTQUANT and BRASS 
  DaTQUANT BRASS 
Te
ch
ni
ca
l c
on
sid
er
at
io
ns
 
Image 
reconstruction 
Accepts raw and transaxial data - but 
internal reconstruction of raw data 
recommended to ensure consistency 
with normal database.   
Iterative reconstruction (OSEM) or FBP 
with or without uniform attenuation 
correction available.  Scatter correction 
and CTAC not supported. 
Accepts reconstructed transaxial data 
only, which must have been 
reconstructed within Hermes using 
recommended settings (OSEM with 
resolution recovery, scatter and 
attenuation correction) for normal 
database comparison to be valid. 
Normal 
database 
116 healthy control studies from 20 
centres scanned as part of Parkinson’s 
Progression Markers Initiative.  31 to 84 
years old (mean 60.5). 
103 healthy control studies from 
European Association of Nuclear 
Medicine ENC-DAT database (10 
different centres, mean age 51 years) 
Image 
registration 
Deformable registration of subject 
image to fit normal template   
Deformable registration of normal 
template image to subject image.  Two 
hemispheres registered separately. 
Adjustment of 
regions 
Whole striatum VOIs can be moved 
individually but sub-regions (caudate 
etc…) cannot be adjusted.  The occipital 
background region cannot be adjusted. 
The entire subject image can be shifted, 
rotated or scaled to fit the template. The 
template is fixed so no individual regions 
can be adjusted.   
Camera 
correction 
Not used SBR results can be adjusted for 
differences between cameras.  
Calibration scans using a striatal 
phantom are required. 
Z scores and 
age correction 
Calculated with respect to SBR 
interpolated from normal controls.  Non-
linear fit used for interpolation. 
Z = (SBR – control mean for age)/SD 
Same SD used for all values of SBR. 
Calculated as a linear function of age. 
((SBR+((Age-51.5631)*0.0138))-
3.3334)/0.5004)   
 
Pr
ac
tic
al
 co
ns
id
er
at
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ns
  
Saving results Results can be saved as pdf and added to 
a .csv file containing all studies 
processed – however .csv file does not 
store Z scores 
Results can be saved within Hermes 
database and exported as an 
individual .csv file. 
Not possible to process in batches or 
save multiple results to a file 
Display of 
results 
Subject SBRs are displayed with age-
matched control means and SDs and Z 
scores. 
A plot of normal control SBRs against age 
is displayed with the subject result 
highlighted. 
Subject SBRs are displayed with Z scores.  
No plot. 
Access to 
normal 
database 
results 
No access to PPMI scans 
Results are available indirectly by 
reading results from plots of SBR vs age. 
No access to any control data 
Local normal 
databases 
Easy to create local databases and swap 
between them 
Possible to create and implement local 
databases with support from Hermes 
Published 
work 
None as of September 2016 Development work published and used 
in several published studies  
Cost and 
accessibility 
Much less expensive than BRASS 
(<£1000 for single computer licence) and 
available as a standalone package for 
any PC.   
Only available on Hermes workstations.  
Much more expensive than DaTQUANT 
(>£10,000).  However can be made 
available on multiple workstations. 
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Appendix B: Factors affecting FP-CIT Z scores 
This appendix details possible reasons for the differences seen between BRASS and DaTQUANT Z 
scores in Chapter 4. 
Camera correction 
The DaTQUANT PPMI normal database SBR values were used to determine whether there is a 
significant difference between controls acquired with different cameras and therefore whether lack of 
calibration might explain the difference between our local normal patients and the PPMI controls.  The 
SBR data for PPMI controls is not freely available in the literature or from GE Healthcare but was 
instead obtained by recording SBR results from the normal database plot within DaTQUANT.  The 
camera used to scan each PPMI control was recorded (if given) and results were divided into three 
groups: Siemens (i.e. same manufacturer as the Newcastle cameras), other manufacturers and 
unknown (Figure 104).  The subject ages ranged from 30 to 85.  A comparison between the Siemens 
results (59 subjects) and the results for other known cameras (40 subjects) showed that Siemens SBRs 
were on average lower than other manufacturers by 0.15 (p=0.02).  Sixteen subjects with unknown 
camera were excluded.  However, for older subjects only (over 60) the difference was 0.09 and was 
not statistically significant.  Furthermore, since the local normal patients were scanned with Siemens 
cameras, the SBR results with DaTQUANT would be expected to be lower than average rather than 
higher.  It is therefore highly unlikely that a lack of camera correction accounts for the high Z scores 
for the local normal patients with DaTQUANT.   
The ENC-DAT database used by BRASS is not available within the software and publications have not 
supplied the full dataset with the camera used for each subject.  This makes it difficult to comment on 
whether there is a significant difference between cameras.  The original work on phantom calibration 
for the database provided a range of different calibration factors for each camera model [158], 
(although the SBRs were not compared to test for significant differences).  However, a recent 
publication by members of the ENC-DAT group [283] suggested that correcting for camera differences 
has very little impact on diagnostic accuracy.  However this study was limited to clinical patients with 
three year’s follow up, rather than research subjects and therefore it is likely that the original FP-CIT 
scan report influenced the diagnosis.  It is also difficult to reconcile this lack of camera effect with the 
+15% SBR correction factor we are applying to make our results compatible with the normal database.  
Without this correction our normal patients would have low SBRs on BRASS compared to the ENC-DAT 
database. 
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Figure 104: DaTQUANT SBRs for PPMI normal database for Siemens, other manufacturer and unknown scanners.  Visually 
there does not appear to be any systematic difference between Siemens camera results and other cameras for subjects over 
60 years and this is supported by a non-significant t-test result. 
 
Age correction differences 
By default, BRASS applies a Z score age correction formula that is linear across all ages, resulting in a 
large adjustment of Z scores upwards for older subjects.  The ENC-DAT healthy control database used 
by BRASS is not available within the software for inspection but the data has been published by Varrone 
et al.[111], where plots of SBR against age are given (SBRs calculated with an older version of BRASS 
without resolution recovery so not directly comparable to our local results).   The linear age correction 
formula in BRASS is derived from this work (Figure 105).  Note that although Varrone et al. showed a 
small but significant difference between SBRs for men and women (higher for women) [111], gender 
is not taken into account within BRASS (nor within DaTQUANT).  
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Figure 105: ENC-DAT (left) and PPMI SBR data (right) for healthy controls as a function of age.  The ENC-DAT plot is taken from 
[111] showing a linear fit with age and the PPMI plot is a screenshot from the DaTQUANT program showing a non-linear fit 
that drops off less steeply with age.  Visually, despite the different fits displayed, the distribution of data points is similar and 
there does not seem to be a big difference in the relationship between SBR and age. 
 
The age correction in DaTQUANT works quite differently.  A non-linear fit of SBR as a function of age is 
performed and the interpolated SBR for the patient is used for calculating patient Z scores.  In the PPMI 
dataset the decline in SBR with age occurs at a lower rate for subjects over 60 than for younger 
subjects.    However this does not account for the higher Z scores with DaTQUANT at all.  The opposite 
effect would be expected since DaTQUANT takes account of SBRs being higher for older subjects than 
would be expected from a linear relationship between SBR and age.   The need for age correction in 
older adults is discussed in much more detail in section 9.1, and in our publication based on this work 
[267]. 
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Appendix C: Effect of scan reorientation and zoom on FP-CIT quantification with BRASS 
Introduction 
Clinical 123I-FP-CIT scans are usually manually reorientated in three planes during image reconstruction 
to correct for variation in patient positioning and give a standard output for visual reporting.  The 
transverse slices are adjusted for head rotation, the coronal slices for sideways head tilt and the sagittal 
slices are adjusted for “up-down” tilt.  Because the patient is scanned with their head back in a 
headrest, the sagittal slices often need rotating forward to bring the brain in line with the plane of the 
anterior and posterior commissure (AC-PC line) as shown in Figure 106.  It is straightforward to rotate 
the transverse and coronal planes so that the striata are symmetrical but the AC-PC plane is more 
difficult to judge on an FP-CIT scan as anatomical features are less obvious. 
                         
Figure 106: Illustration of the AC-PC line orientation, taken from Radiopaedia.org (https://radiopaedia.org/articles/ac-pc-line-
1) 
The BRASS software application (Hermes Medical Solutions Ltd) automatically registers the FP-CIT scan 
to a standard template (as illustrated in Figure 107), so manual reorientation during reconstruction is 
not necessary - as long as the images are only intended to be used for quantification and not for not 
visual assessment.  In fact, Hermes warn the user not to adjust the images prior to processing with 
BRASS: “In order to obtain the most accurate and reproducible results when reconstructing studies 
which will be evaluated using the HybridViewer BRASS application for DaTScan with the EARL database, 
the following guidance should be followed: 
• The ENCDAT reconstruction protocol provided by Hermes should be used  
• The Chang attenuation outlines should not be adjusted  
• The reconstructed images should not be aligned manually  
• The reconstructed images should not be zoomed” [284] 
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This is because rotation and zooming require interpolation, which reduces image resolution [284].  
BRASS was validated at the RVI using a set of local normal patient scans with clinical follow up that 
were retrieved and reconstructed as recommended by Hermes.  Following the above guidance, these 
were not reorientated during reconstruction.   
 
 
Figure 107: Top: Example study input into BRASS before registration (left).  The normal FP-CIT template is shown in the centre 
and the MRI anatomical template for reference on the right.  Bottom: The images after registration to the template. 
Previously, visual reporting of FP-CIT scans at the Newcastle Royal Victoria Infirmary (RVI) was done 
using data reconstructed with the filtered back projection algorithm without attenuation and scatter 
correction (FBP).  BRASS (v2.6) quantification requires a different reconstruction method, which uses 
the OSEM iterative algorithm with corrections for resolution, attenuation and scatter (OSEM_RRACSC).  
Given that the visual appearance of the OSEM_RRACSC images is superior to the FBP_NC images in 
terms of image noise, resolution and contrast we decided to implement the former for the SUPErB 
research study.  It was decided that a gradual switch to clinical reporting with OSEM_RRACSC would 
be made within NuTH, with the non-corrected FBP images also generated at first.  These would also 
act as a quality control step to ensure no artefacts were introduced by applying resolution modelling, 
attenuation or scatter correction. 
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To use the OSEM_RRACSC images for visual reporting they need to be reorientated, which as discussed 
above has not been done for quantification.  In order to make the image display as close as possible to 
the previous processing it is also necessary to add an additional zoom of 200% (2x) in the 
reconstruction.   Finally, because the OSEM_RRACSC algorithm takes several minutes to complete on 
the full field of view raw projection images it is beneficial to crop the raw images both superiorly and 
inferiorly so that just the brain is included and not the space above the head or the jaw and salivary 
glands (Figure 108).  Usually over half the image can be removed in this way without affecting the 
appearance of the reconstructed images.    
 
It would be much simpler to use the same reconstructed images for reporting and quantification with 
BRASS and theoretically these changes should not make much difference to the automated 
registration.  However a conference talk from a colleague at the Royal Free hospital (British Nuclear 
Medicine Society 2013) suggested adjusting scans for tilt did affect BRASS quantification.  This work 
was done using an older version of BRASS rather than the current Hybrid Viewer version (v2.6).  We 
were unable to find any literature published on this topic (Spring 2017). 
The purpose of this piece of work was to assess whether reorientation, image cropping and zoom have 
a significant effect on BRASS quantification results and therefore whether it is necessary to process a 
separate reconstruction using the full raw dataset with original orientation and zoom for use with 
BRASS.   
  
Figure 108: Raw FP-CIT projection data showing full field of view (left), superior cropping (middle) and cropping of the salivary 
glands inferiorly (right – different patient). 
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Method 
Thirty FP-CIT scans7 taken from the LewyPro study were reconstructed using the OSEM_RRACSC 
method within Hermes HybridRecon (Neurology) in the following four ways: 
1. Using the full field of view raw dataset with no reorientation or zoom. 
2. Using the full field of view raw dataset and applying reorientation as required in all three 
planes – angles of rotation recorded.  
3. Cropping the raw dataset - no reorientation or zoom. 
4. Using the same cropped dataset with no reorientation as above but with an additional 2x 
zoom. 
Figure 109 shows the reconstructed images before and after reorientation for an example scan.  The 
120 resulting scans were processed with BRASS and the striatal to background ratios with camera 
correction for the left and right striatum and left and right caudate and putamen recorded.  The Z-
scores, which compare the SBR results to the Hermes normal database, were also recorded for each 
of the six regions.   
The differences in SBR values between each of the following reconstruction methods were calculated: 
• Datasets 1 and 2 (effect of reorientation on SBR values) 
• Datasets 1 and 3 (effect of cropping raw projection dataset) 
• Datasets 3 and 4 (effect of 2x zoom) 
The mean difference in SBR for each region was recorded.  Paired t-tests were used to test for any 
significant differences in SBR values. 
In clinical practice age corrected Z-scores are often used to judge whether an SBR value is below the 
normal range expected for a healthy individual of the same age, with a Z-score of -2 taken to indicate 
a significantly reduced SBR.   We therefore used Z-score discrepancies to assess whether any 
differences in SBR value between reconstruction methods were clinically significant.  The frequency of 
a mis-match between the Z-scores of the two reconstructions in question was recorded.  For example, 
if the Z-score for one reconstruction was lower than -2 (i.e. abnormal quantification, more than 2 SD 
from the normal mean) and for the other it was higher, or vice versa, then it was considered a clinically 
significant mismatch.   E.g. if the right Z-score was -1.9 for one recon and -2.1 for the other it would be 
clinically significant, assuming -2SD is used as threshold.  As there are 30 scans used in this sample, 
each with six regions, the total number of Z-score matches / mismatched for each reconstruction 
method being compared is 120.   
                                                          
7 The first thirty scans were selected from the LewyPro dataset of 74 scans as the reprocessing required is time 
consuming and thirty was considered an adequate sample. 
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 Transverse plane Coronal plane Sagittal plane 
Original images 
without rotation 
   
Images after rotation 
   
Angle rotated + 8 + 8 - 10 
Figure 109: Example images displayed in HybridRecon before and after reorientation in all three planes, with the angles of 
rotation applied for this study.  This is LewyP001, used as an example throughout this document. 
 
 
 
 
 
Figure 110: Example image reconstructed using the four methods discussed in the text. Top to bottom: 1) Original images with 
no reorientation or cropping; 2) reorientated images; 3) cropped images, 4) cropped and zoomed images. 
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Results and discussion 
The mean striatal to background (SBR) values for the 30 scans reconstructed without reorientation, 
cropping or zoom is shown at the top of Table 79. The mean changes in SBR values given by 
reorientation, cropping and zoom are shown in bold.  The p-value result from the paired t-test to check 
for statistical significance is shown in the middle row.  P values of less than 0.05 indicate that it is very 
unlikely that the difference seen is due to chance.  Finally, the number of mismatched Z-scores (out of 
a possible 30 for each region) is given in the bottom row. 
  Right 
striatum 
Left 
striatum 
Right 
caudate  
Left 
caudate  
Right 
putamen  
Left 
putamen  
Mean SBR values for 
original images 
2.50 2.53 2.64 2.72 2.33 2.31 
Reorientation 
(Dataset 2 – 
Dataset 1) 
Mean SBR 
difference 
-0.07 -0.07 -0.05 -0.07 -0.08 -0.08 
p-value 0.002 0.002 0.123 0.013 0.008 0.011 
Z-score 
matches 
29 30 30 29 30 30 
Cropping 
(Dataset 3 – 
Dataset 1) 
Mean SBR 
difference 
0.01 0.01 -0.01 0.01 0.03 0.00 
p-value 0.613 0.378 0.609 0.591 0.275 0.983 
Z-score 
matches 
30 30 30 29 30 30 
Zoom 
(Dataset 4 – 
Dataset 3) 
Mean SBR 
difference 
0.02 0.02 0.03 0.02 0.01 0.03 
p-value 0.010 0.010 0.111 0.518 0.566 0.379 
Z-score 
matches 
30 30 30 30 30 30 
Table 79: Differences in mean SBR values for the reconstruction methods compared.  For each effect (reorientation, cropping 
and zoom) the mean change in SBR values is shown in bold on the top row, the p-value for the paired t-tests in the middle row 
and the number of Z-score matches (out of 30) in the bottom row. 
Effect of reorientation 
The average angle of rotation was -1.8 degrees in the transverse plane, -1.5 degrees in the coronal 
plane and -8.51 in the sagittal plane.   On average the SBR values and Z-scores for all regions were 
lower for the reoriented / adjusted reconstructions than the original ones.  Using paired t-tests to test 
for significance only the right caudate showed no significant difference (mean SBR difference = -0.05, 
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p = 0.12).  For all other regions the average SBR differences were -0.07 or -0.08, p<0.05.  However, 
these mean differences are quite small, less than 5% drop in SBR. 
A Z-score mismatch between the original orientation and reorientated images occurred just twice in 
the whole dataset of 180 Z-scores (6 x 30), each for different patients.  So of the 30 patients, two had 
one Z-score of a possible six that was not consistent between the two reconstructions.    None had 
more than one Z-score mis-match.  Example BRASS output for original and reoriented images is shown 
in Figure 111. 
 
                         
Figure 111: Example BRASS output for original orientation scan (left) and reorientated images (right).  This is the same example 
subject as shown above.  Note that on average the SBR values were lower for the reorientated images; here they are slightly 
higher. 
Effect of cropping the projection data 
The root mean squared change in SBR values resulting from cropping the raw images prior to 
reconstruction was very small and not statistically significant.  One Z-score (of a possible 120) showed 
a mismatch between the full field of view and cropped reconstructions.  Example BRASS output for the 
same example patient used throughout is shown in Figure 112. 
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Figure 112: BRASS output for the example patient without cropping (left) and with cropping (right). 
Effect of 2x zoom 
On average all the regions (and Z-scores) were very slightly higher for the zoomed reconstructed 
images than the original ones, but the difference was even smaller than for reorientation.  The mean 
SBR differences were between +0.01 and +0.03, which is approximately a 1% increase on 
average.   Paired t-tests indicated that the whole striatum SBR increases were statistically significant 
but the individual caudate and putamen increases were not.  This is likely to be because there is more 
random variation between results for the small regions so such a small increase would be difficult to 
demonstrate.  There were no instances of Z-score mismatch between original scale and zoomed 
images.   Example BRASS output for original and 2x zoomed images is shown in Figure 113. 
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Figure 113: BRASS output for example original scale and 2x zoomed images. 
 
Conclusion 
Cropping the dataset to include only the brain has no significant effect on the results.  Reorientation 
and zoom both have a small statistically significant effect on the BRASS quantification results but these 
are both clinically insignificant and furthermore act in opposite directions. We can therefore proceed 
to include the OSEM_RRACSC reconstruction used in research studies alongside the FBP reconstruction 
used clinically and eventually move to using the same images for reporting and quantification in clinical 
practice. 
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Appendix D: The effect of pixel size on the quantification of FP-CIT images 
Introduction 
123I-FP-CIT quantification with BRASS software (Hermes Medical Ltd, Stockholm) is used extensively 
throughout this thesis.  Hermes states that a FP-CIT image pixel size of between 2 and 3 mm should be 
used for quantification with BRASS, as this is used in the ENC-DAT project from which the BRASS normal 
database is taken [111] and is recommended by the European Association of Nuclear Medicine [113] 
in order to achieve a pixel size “one-third to one-half of the expected resolution”.  However the current 
pixel size used at the RVI for both NHS scans and ongoing University studies is 3.9mm, which is 
recommended for quantification with DaTQUANT.  This value was set by GE Healthcare, the 
manufacturer of both FP-CIT and DaTQUANT in accordance with the US Society of Nuclear Medicine 
guidelines, which state that “experimental studies with a striatal phantom suggest that optimal images 
are obtained when the selected matrix size and zoom factors give a pixel size of 3.5–4.5 mm” [112].  
Other than the society guidelines, we could not find any published data to support either approach to 
pixel size.  Using a larger or smaller pixel size than recommended could potentially affect how well the 
BRASS and DaTQUANT automated registration algorithms can register the scan to the template 
defining the striatal regions, which could affect the results.   
The pixel size could be reduced to fulfil BRASS requirements by increasing the zoom applied when 
acquiring the images, as this means the same number of pixels would cover a smaller area.  However 
a zoom of x1.23 is already applied in our standard clinical FP-CIT protocol.  Increasing the zoom would 
make it more difficult to set up the patient within the field of view correctly, so is not a change to 
implement without evidence that it would be beneficial.   Of course, reducing the pixel size in line with 
BRASS recommendations would mean a move away from the pixel size recommended for DaTQUANT. 
The purpose of this work is to use an anthropomorphic striatal phantom to acquire images with the 
current 3.9mm pixel size used in clinical practice and with pixel sizes within the recommended 2-3 mm 
range and to use this data to determine whether there is a difference in BRASS and DaTQUANT results 
with pixel size.  This information will help us decide whether reducing the pixel size is necessary for the 
SUPErB study, which we would prefer not to do.  It is likely that there will be normal random variation 
between subsequent scans even under the same conditions so repeated scans of the phantom scanned 
with the same zoom will be used to quantify this. 
Objectives 
• To investigate the effect of pixel size on FP-CIT quantification with BRASS and DaTQUANT using 
phantom images. 
• To acquire phantom images with SPECT-CT with a range of striatal to background activity ratios 
and known activity concentrations. 
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Methods 
Image acquisition 
The striatal phantom (RSD Radiology Support Devices, Long Beach, CA, USA) was filled with 123I activity 
concentrations intended to give normal striatal to background ratios on quantification (~15:1 and 
~10:1).  Figure 17 in section 4.1 shows the phantom being filled and assembled.  The exact activity 
ratios were later verified using samples of solution analysed in a gamma counter.  The phantom was 
scanned three times using the current RVI imaging protocol which uses a zoom of 1.23.  The phantom 
was repositioned between each repeat acquisition to mimic repeat scans of a patient and allow an 
estimation of random variation between repeat scans to be made.   Without repositioning, the 
phantom was then scanned with the three zooms available on the scanner calculated to give pixel sizes 
between 2 and 3 mm (1.78x, 2x and 2.29x). This resulted in four scans taken with the phantom in the 
exact same position with pixel sizes of 3.9 mm, 2.7 mm, 2.4 mm and 2.1 mm.  The phantom was 
deliberately not moved between these acquisitions so that the effect of zoom could be separated from 
the effect of differences in positioning.  Note however that there will still be a random element in the 
imaging due to the stochastic nature of radionuclide imaging with limited counts. 
The phantom background activity concentration was then approximately doubled to give striatal to 
background ratios intended to give borderline results on quantification (~7:1 and ~5:1).  Again, the 
exact ratios were later verified using samples analysed with a gamma counter.  The phantom was 
scanned using the current zoom of 1.23, with the time per projection reduced from 25 seconds to 12 
seconds to compensate for the increased activity. No adjustment for decay was made. Without 
repositioning the phantom, the images were repeated using a zoom of 2.  There was insufficient time 
available on the scanner to scan with all three increased zooms so the middle value was chosen.   
Finally, the background activity concentration in the phantom was approximately doubled again to 
give striatal to background ratios of ~3.5:1 and 2.5:1 and the phantom scanned with zooms of 1.23 and 
2, again halving the time per projection to compensate for the increased activity.   This resulted in scan 
data for six different striatal to background ratios ranging from very normal to very abnormal, with at 
least two different pixel sizes for each.  All acquisitions included a CT scan for attenuation and scatter 
correction. 
Determining activity ratios and absolute activities 
The absolute activities in the striata and background compartments (and striatal to background activity 
concentration ratios) were determined using 1 ml sample solutions from each compartment counted 
in a gamma counter alongside a standard solution with known activity concentration.   
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Two solutions of approximately 40 kBq/ml and 50 kBq/ml were prepared and used to fill the striata.  
The volume solution in each striatum was measured by weighing the container of solution before and 
after filling. The volume of the background compartment was estimated by measuring the amount of 
distilled water required to fill it.  This volume information was used to calculate the activities needed 
to give the different striatal to background ratios required.   
After each acquisition, before increasing the background activity, sample counting tubes were filled 
with background solution samples.  The two striatal concentrations were unchanged throughout so 
only needed to be sampled once after all acquisitions were completed.  Three samples were taken 
from each compartment and the sample tubes were weighed before and after the solution was added 
so that an exact volume could be determined for each sample.    
A standard 123I solution of known activity concentration was prepared using a syringe of 123I measured 
as 5.23 MBq in the radionuclide calibrator at reference time of 11:00.  This was diluted to exactly 1 
litre in a calibrated flask to give a known concentration of 5.23 kBq / ml.  Three samples of 
approximately 1 ml were taken from this to count alongside the phantom samples so that the absolute 
activities in the phantom could be determined.  Again the sample tubes were weighed to determine 
the exact volume of each sample. 
The samples from the three background concentrations, two striatal concentrations and the standard 
solution were counted in the gamma counter for 120 seconds each, alongside 1ml samples of water 
used to correct for environmental background counts.  The timestamp for each measurement was 
used to decay correct the counts to the reference time of 11:00.  The counts were also normalised to 
the volume of the solution in each tube to give the counts per ml.  The mean counts per ml measured 
from the three standard solution samples was used to determine the activity concentration for each 
of the samples from the phantom. 
Image processing 
BRASS: 
Each image was first reconstructed using Hermes HybridRecon(Neurology).  An iterative ordered 
subsets expectation maximum (OSEM) algorithm was applied with resolution modelling for the specific 
collimator used, Monte Carlo derived scatter correction and attenuation correction.  Both uniform 
(geometrical) based attenuation and scatter correction and CT data driven methods were used.  The 
resultant images were loaded into BRASS and the SBRs with camera correction were recorded for the 
right and left whole striata, caudate and putamen. 
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DaTQUANT: 
The raw data for each image was exported from a Hermes workstation and loaded onto a desktop PC 
with DaTQUANT installed.  A dicom directory was set up to import the raw data into DaTQUANT.  The 
images were reconstructed within DaTQUANT using the built in GE Xeleris OSEM algorithm but without 
correcting for attenuation or scatter8.  The SBRs were recorded for the right and left whole striata, 
caudate and putamen.  The Hermes uniform AC and CTAC reconstructed images were also exported 
and analysed with DaTQUANT to allow direct comparison between the two software packages with 
the same input data. 
Analysis 
The range (max-min) of SBR values for each region over the three repeated normal uptake scans was 
calculated and expressed as a percentage of the average SBR.  The percentage variation for each region 
was then averaged to give a mean SBR variation with repositioning for a normal uptake scan.  This was 
done for BRASS and DaTQUANT results for all reconstructions tested.  The variation between the four 
normal uptake scans with different zooms was calculated in the same way.  The percentage variation 
for repositioning was compared with the percentage variation with zoom for a normal uptake scan.   
The percentage differences in SBR values for zooms of 1.23 and 2.0 were compared for the six striatal 
to background activity ratios given from the normal, borderline and abnormal uptake phantom scans. 
Results 
The activity concentrations and absolute amount of 123I activity in the left and right striatal 
compartments and background section of the phantom are shown in Table 80.   
Table 80: Activity concentrations measured for each phantom compartment with reference to a standard solution. 
 Activity concentration 
/ kBq/ml 
Compartment volume 
/ mls 
Total activities at 
reference time / MBq 
Right striatum 58.5 10.4 0.61 
Left striatum 38.5 10.6 0.41 
Background 1 4.0 1295 5.1 
Background 2 8.8 1295 11.5 
Background 3 19.0 1295 24.6 
 
                                                          
8 Scatter correction and CTAC are unavailable within DaTQUANT and we found the DaTQUANT uniform 
attenuation correction to be unreliable using the default thresholding values. 
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For quantification, striatal to background ratios are defined as (striatal counts – background 
counts)/background counts.  This means that the SBRs measured from the samples are the ratio of 
striatal and background activity concentration measurements, minus 1.   These measured values are 
given in Table 81 with the SBR results from BRASS and DaTQUANT alongside.  The SBRs are 
underestimated by both software packages, suggesting that the partial volume effect is large.  
However, it is the change in SBR with pixel size that is assessed here, rather than the absolute error.    
Table 81: Activity ratios and measured SBRs shown alongside BRASS and DaTQUANT SBR results for the standard 1.23x zoom. 
 Measured 
activity 
concentration 
ratio 
Measured 
SBR (ratio 
– 1) 
BRASS 
SBR 
(Chang 
AC) 
BRASS 
SBR 
(CTAC) 
DaTQUANT 
SBR 
(NC) 
DaTQUANT 
SBR 
(Hermes 
Chang AC) 
DaTQUANT 
SBR 
(Hermes 
CTAC) 
Normal 
uptake 
Right 
striatum 
14.7 13.7 5.65 6.06 5.17 4.58 5.95 
Left 
striatum 
9.7 8.7 3.25 
 
3.44 
 
2.98 2.63 3.51 
Borderline 
uptake 
Right 
striatum 
6.6 5.6 2.32 
 
2.33 
 
1.95 
 
1.69 2.36 
Left 
striatum 
4.4 3.4 1.28 
 
1.21 
 
1.04 0.92 1.23 
Low 
uptake 
Right 
striatum 
3.1 2.1 1.05 0.78 0.63 0.59 0.87 
Left 
striatum 
2.0 1.0 0.52 0.27 0.28 0.24 0.49 
 
Images of the phantom with normal striatal to background ratio for each pixel size / zoom are given in 
Figure 114, with the images from BRASS and DaTQUANT with striatal regions overlaid shown below. 
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Zoom 1.23   
Pixel size 3.9mm 
Zoom 1.78 
Pixel size 2.7 mm 
Zoom 2.00  
Pixel size 2.4 mm 
Zoom 2.29 
Pixel size 2.1 mm 
    
  
  
    
Figure 114: Top: Phantom images with normal filling ratios with increasing zoom, illustrating the images becoming less 
“pixelated” at higher zoom.  Middle: BRASS images for each zoom with striatal contours (occipital background not shown).  
BRASS registers the template to the subject image so the image size displayed increases with zoom. Bottom: DaTQUANT 
images for each zoom with caudate, putamen and background contours shown.  DaTQUANT registers the subject image to a 
template, so the images are resized to match the template. 
The percentage variation in SBR values over three repeat scans, averaged over all regions, was 7.0% 
and 7.5% with the BRASS uniform AC and CTAC reconstructions respectively (Table 82).  The 
percentage variation with the four pixel sizes / zooms was 8.3% and 7.2% respectively.  With scans 
reconstructed in DaTQUANT (no AC) the percentage variation for the repeat scans was 8.9% and was 
13.6% for the scans with different pixel zooms.  Plots of SBR value against zoom factor for BRASS and 
DaTQUANT (Figure 115) suggest that there is no systematic variation for BRASS but SBRs appear lower 
for higher zooms with DaTQUANT.  The results for zooms of 1.23 and 2.0 for normal uptake, borderline 
and low uptake are given in Table 83.  There is generally much more variation between the scans with 
different zooms with lower uptake.  Table 82 and Table 83 also show results for the same reconstructed 
data (Hermes uniform AC and Hermes CTAC) processed with BRASS and DaTQUANT.  There is more 
variation in the DaTQUANT results than the BRASS results particularly at low uptake. 
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Table 82: The variation in quantification results seen with repeat scanning with the same zoom (top rows) and with increasing 
zoom (bottom rows). 
 BRASS 
Uniform AC 
BRASS CTAC DaTQUANT 
NC  
DaTQUANT 
Hermes 
Uniform AC  
DaTQUANT 
Hermes 
CTAC  
Variation in 
quantification 
with repeat 
scanning 
Average SBR 
difference (all 
regions) 
0.28 0.35 0.32 0.25 0.29 
Percentage 
difference 
7.0% 7.5% 8.9% 6.0% 8.3% 
Variation in 
quantification 
with zoom 
Average SBR 
difference (all 
regions) 
0.29 0.33 0.47 0.52 0.50 
Percentage 
difference 
8.3% 7.2% 13.6% 12.3% 13.3% 
 
 
Figure 115: Plots of SBR against zoom factor for BRASS (with uniform AC) and DaTQUANT (no AC). 
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Table 83: Variation in SBR values between zooms of 1.23 and 2.0 for normal, borderline and low uptake ratios 
 BRASS 
Uniform 
ACSC 
BRASS  
CT ACSC 
DaTQUANT 
NC  
DaTQUANT 
Hermes 
Uniform 
ACSC 
DaTQUANT 
Hermes CT 
ACSC 
Normal 
uptake ratios 
Average SBR 
difference (all 
regions) 
0.20 0.05 0.15 0.18 0.26 
Percentage 
difference 
5.5% 1.1% 4.0% 4.7% 6.9% 
Borderline 
uptake ratios 
Average SBR 
difference (all 
regions) 
0.13 0.09 0.07 0.23 0.19 
Percentage 
difference 
6.9% 4.4% 5.5% 13.0% 11.7% 
Low uptake 
ratios 
Average SBR 
difference (all 
regions) 
0.07 0.08 0.05 0.17 0.14 
Percentage 
difference 
8.0% 14.7% 9.6% 19.1% 23.6% 
 
Discussion 
The data here show that changing the zoom has a similar effect on quantification results with BRASS 
as repeating the scan with the phantom repositioned.  This suggests that the variation is random and 
could be due to slight changes in the input image.  There is therefore no definite evidence to support 
changing the zoom to give a pixel size closer to that used with the Hermes normal database in BRASS.  
Changing the zoom just for research studies would be confusing for staff acquiring and processing the 
data, and changing the zoom for all studies would mean making changes to the way clinical images are 
presented for reporting, since the slice thickness would also change.   
For DaTQUANT these results show that changing the zoom does appear to have a greater effect on the 
SBR results than repositioning, and the plot in Figure 115 suggests that SBR results decrease with zoom, 
or increase with pixel size.  The same reconstructed input image data analysed with DaTQUANT and 
BRASS also showed more variation with zoom with DaTQUANT than with BRASS.  Since the current 
zoom factor of 1.23 is recommended by GE Healthcare it would be sensible to stick with this factor 
given that it seems to be more important for DaTQUANT than BRASS. 
DaTQUANT and BRASS register the images in different ways, which is one reason why there might be 
the discrepancies between them for the same input data.  DaTQUANT “warps” the study image to fit 
the normal template image, whereas BRASS adjusts the normal template to the study image, and does 
a separate registration for each hemisphere of the brain. 
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This amount of data in this study is limited due to unavoidable time constraints.  Each acquisition took 
around 40 minutes in total and all were carried out in the same imaging session so that the same 
phantom striatal activity could be used.  Ideally repeat scans with the same zoom would have been 
carried out for all striatal activity ratios, not just the normal uptake scan.  If time permitted it would 
also have been better to have taken images for all zooms each time the phantom was repositioned, 
rather than only the standard 1.23 zoom.  It would also have been useful to collect data for repeat 
scans with the same parameters without any movement of the phantom to explore the effect of 
statistical variation in image counts on the quantification results as it is impossible to separate this 
from the effects of zoom.  The phantom was filled with activity designed to give count rates similar to 
patient studies.  If higher activities had been used, the acquisition time could have been reduced, but 
we wanted the count rates to match clinical scanning as closely as possible.   
Conclusion 
Although the results are limited and insufficient for statistical analysis, the results obtained support 
keeping the current zoom factor of 1.23 for both BRASS and DaTQUANT processing.
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Appendix E: Cardiac MIBG imaging protocol details from the literature 
Paper evaluating MIBG for DLB 
vs AD or other dementias (date 
order) 
Country; 
setting 
Subjects 
included 
Activity / 
MBq;  
 Image 
duration 
Post-
injection 
delay 
HMR 
normal cut-
off; origin 
Camera and 
collimator 
Sensitivity 
and 
specificity  
 
Yoshita et al. PLOS 2015 Mar 
20;10(3) [53] 
 
Japan; 
multicentre 
87 DLB; 46 
AD 111 MBq; 
not 
stated 
20-30 
mins &   
3-4 hours 
2.10 (both 
time points); 
ROC 
analysis 
Mixed 
(multicentre) 
results scaled to 
MEGP 
Sens 69% 
Spec: 89% 
(both time 
points) 
Lebasnier et al. 
Eur J Nucl Med Mol Imaging. 2015 
Jan 28. [56] 
France; 
single 
centre 
45 with Lewy 
body disease; 
19 without 
<60 kg 
148 MBq, 
60–90 kg 
222 MBq, 
>90 kg 
296 MBq; 
 
10 
minutes 4 hours 
1.47; 
ROC 
analysis 
Siemens Symbia 
T2; LEHR 
Sens: 82% 
Spec: 84% 
 
Slaets et al. Int J Geriatr Psychiatry. 
2014 Nov 3. [59] 
 
Belgium; 
single 
cente 
20 possible 
DLB at 
baseline with 
6+ months 
follow up 
74 MBq not stated 4 hours 
1.68; 
Yoshita et 
al. 2006 
Phillips XCT or 
GE Varicam; 
LEHR 
Sens: 100% 
(16/16) 
Spec: 75% 
(3/4) 
 
Inui et al. 
Ann Nucl Med. 2014 
Oct;28(8):796-804. [236] 
 
Japan; 
single 
centre 
35 prob DLB; 
34 prob AD 111 MBq 6 mins 4 hours 
1.7; 
ROC 
analysis 
ADAC Vertex-
Plus, HITACHI; 
LEGP 
Sens: 97%; 
Spec: 100% 
Sakamoto et al. 
Ann Nucl Med. 2014 
Apr;28(3):203-11. [285] 
 
Japan; 
single 
centre 
24 prob DLB; 
76 without 
DLB inc PD 
 
111 MBq 5 mins 15 mins 
2.2; 
ROC 
analysis in 
independent 
group 
Millennium VG, 
GE; MEGP 
Sens: 83% 
Spec: 85% 
Fukui et al. 
Dement Geriatr Cogn Dis Extra. 
2013 May 18;3(1):148-60 [286] 
Japan; 
single 
centre 
53 DLB 
(MIBG not 
done in AD) 
Not stated Not stated 
20 mins 
&   4 
hours 
Not clear Not stated Not assessed 
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Paper evaluating MIBG for DLB 
vs AD or other dementias (date 
order) 
Country; 
setting 
Subjects 
included 
Activity / 
MBq;  
 Image 
duration 
Post-
injection 
delay 
HMR 
normal cut-
off; origin 
Camera and 
collimator 
Sensitivity 
and 
specificity  
 
Treglia et al. J Neuroimaging. 2014 
Mar-Apr;24(2):149-54.  [68] 
 
Italy; 
single 
centre 
20 DLB; 11 
other 
dementia; 20 
control 
subjects 
111 MBq 5 mins 15 mins & 4 hours 
1.55; 2SD 
below 
control mean 
 
“Imaged 
according to 
EANM 
guidelines” 
Control mean 
1.89; probably 
low energy 
Sens: 90% 
Spec: 91% 
Camacho et al. 
Q J Nucl Med Mol Imaging. 2011 
Aug;55(4):476-83. [287] 
 
Spain; 
single 
centre 
28 DLB Not in abstract; article not accessible 
1.56; not 
accessible 
Not accessible; 
HMR cut-off in 
abstract suggests 
low energy 
Sens: 82% 
(23/28) 
Novellino et al. Neurobiology of 
Aging. 2010 Nov;31(11):1903-11. 
[184] 
Italy; 
single 
centre 
9 DLB; 6 
FTD; 16 
controls 
111 MBq Not stated 
10 mins 
& 4 hours 
3SD below 
control 
mean. 
1.91 ±0.17 = 
1.40 at 10 
mins; 1.99 
±0.19 = 1.42 
at 4 hours 
Axis, Picker; 
collimator not 
stated 
Sens: 100% 
(9/9) 
Spec: 100% 
(6/6) 
(both time 
points) 
Estorch et al. 
Eur J Nucl Med Mol Imaging. 2008 
Sep;35(9):1636-41. [54] 
 
Spain; 
single 
centre 
19 DLB; 12 
AD; 13 other 
non LBD 
370 MBq Not stated 
15 mins 
& 4 hours 
1.56 (local 
database 
over 60 
years); 1.36 
ROC 
analysis on 4 
hour images 
GE 
Millenium 
Hawkeye V3; 
LEGP 
Sens 94% 
Spec: 96% 
(using ROC 
cut-off) 
Wada-Isoe et al. 
J Neurol Sci. 2007 Sep 15;260(1-
2):33-7. [237] 
 
Japan; 
single 
centre 
20 DLB; 32 
AD; 29 
controls 
111 MBq Not stated 
30 mins 
& 3.5 
hours 
1.81 (30 
mins); 1.82 
(3.5 hours); 
Not given 
30 mins: 
Sens 85%; 
Spec 100% 
3.5 hours: 
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Paper evaluating MIBG for DLB 
vs AD or other dementias (date 
order) 
Country; 
setting 
Subjects 
included 
Activity / 
MBq;  
 Image 
duration 
Post-
injection 
delay 
HMR 
normal cut-
off; origin 
Camera and 
collimator 
Sensitivity 
and 
specificity  
ROC 
analysis 
Sens 100%; 
Spec 91% 
Hanyu et al. Dement Geriatr Cogn 
Disord. 2006;22(5-6):379-84. [55] 
 
Japan; 
single 
centre 
32 DLB; 9 
PDD; 40 AD 111 MBq 5 mins 4 hours 
1.73 
2SD below 
control mean 
2.37 ± 0.32 
PRISM 2000VP, 
Picker; 
LEHR 
Sens 95% 
Spec 87% 
Yoshita et al. 
Neurology. 2006 Jun 
27;66(12):1850-4. [58] 
 
Japan; 
multi 
centre 
37 DLB; 42 
AD; 10 
controls 
111 MBq 5 mins 20 mins & 3 hours 
1.61 (20 
mins), 1.68 
(3 hours); 
ROC 
analysis 
PRISM 2000XP, 
Shimadzu or 
9300A, Toshiba 
LEHR 
20 
mins:Sens 
97% Spec 
100% 
3 
hours:Sens 
100% Spec 
100% 
Oide et al. 
Intern Med. 2003 Aug;42(8):686-
90. 
 
Japan; 
single 
centre 
10 DLB, 10 
AD 148 MBq 2 mins 
15 mins 
& 4 hours Not stated 
(ZLC-7500, 
Siemens); 
LEHR 
Not stated 
but around 
1.8 from 
plot 
Yoshita et al. 
J Neurol Neurosurg Psychiatry. 
2001 Nov;71(5):583-8. 
 
Japan; 
single 
centre 
14 DLB; 14 
AD 111 MBq 2 mins 
20 mins 
& 3 hours Not stated 
GCA9300A/HG, 
Toshiba; LEHR 
Not stated 
but around 
1.7 from 
plot 
Watanabe et al. 
J Neurol Neurosurg Psychiatry. 
2001 Jun;70(6):781-3. 
 
Japan; 
single 
centre 
11 DLB; 10 
AD; 11 
controls 
111 MBq 5 mins 30 mins & 4 hours Not stated Not stated 
Not stated 
but around 
1.8 from 
plots 
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Appendix F: Consistency of FP-CIT processing for semi-quantification 
This appendix explores whether careful reprocessing of baseline and repeat FP-CIT scans by the same 
operator gives more consistent quantification results. 
Three subjects were noted to have very different baseline and repeat SBR results with BRASS.  The 
orientation of the reconstructed images, including the extent of the reconstructed data inferiorly, 
differed between the baseline and repeat images.   An example is shown in Figure 116.   However, 
careful reprocessing of the scans, using the CT data as a guide, did not result in more consistent SBR 
results (Table 84).  The changes in SBR between baseline and repeat for the three scans with original 
processing were -23%, +43% and +32%; after reprocessing the changes were -25%, +43% and +27%.   
The rest of the scans were therefore not reprocessed and the original results used. 
  
Figure 116: Baseline (left) and repeat (right) coronal and showing quite different inferior scan extent and different 
reorientation on the sagittal views.  The CT data is shown to aid visualisation, but was not used in the reconstruction. 
 
Table 84: Baseline and repeat SBRs and Z scores for the regions with greatest change for the three controls noted to have 
different results.  The differences with both the original processing and following careful reprocessing by the same operator 
are shown. 
  
Example 1 Example 2 Example 3 
Or
ig
in
al
 in
de
pe
nd
en
t 
pr
oc
es
sin
g 
Region with greatest change Right caudate Right caudate Left caudate 
Baseline SBR (Z score) 3.06 (-0.06) 2.69 (-1.21) 2.93 (-0.54) 
Repeat SBR (Z score) 2.36 (-1.37) 3.84 (1.05) 3.86 (1.31) 
% SBR change (Z score change) -23% (-1.31) +43% (+2.26) +32% (+1.85) 
Re
-p
ro
ce
ss
in
g 
ba
se
lin
e 
an
d 
re
pe
at
 
Region with greatest change Right caudate Left caudate Left caudate 
Baseline SBR (Z score) 3.13 (0.08) 2.77 (-0.92) 3.08 (-0.24) 
Repeat SBR (Z score) 2.36 (-1.36) 3.96 (1.37) 3.91 (1.40) 
% SBR change (Z score change) -25% (-1.44) +43% (+2.29) +27% (+1.64) 
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Appendix G: Simulation work using Monte Carlo modelling  
This Appendix details preliminary work on developing a Monte Carlo model of the Siemens Intevo 
gamma camera, which will form the basis for future work. 
Monte Carlo methods are statistical techniques used to model repetitive processes containing a 
random element, such as the interaction of radiation with matter [288].  They enable investigation of 
the effects of patient factors in a more flexible and controlled manner than can be obtained with 
physical anthropomorphic phantoms, and overcome difficulties of gold standards with patient studies. 
A typical calculation uses a probability distribution and a random number generator to determine an 
outcome for an event – this is then repeated many times for subsequent events to build up an overall 
representation of the system being modelled [289].   To use an example relevant to nuclear medicine, 
we might wish to model the interaction of gamma rays with material of a certain density.  In a Monte 
Carlo simulation of a nuclear medicine scan, for each gamma ray photon emitted from the patient a 
random number is generated and this determines the outcome for that individual photon.  The random 
numbers are assigned to the outcomes according to the interaction cross-section (probability) of each 
outcome (absorption, scatter, no interaction…) occurring – so the most likely will have the most 
numbers assigned to it.  This means that if a high number of interactions is simulated the results will 
be a close match to the predefined probability distribution, but no two simulations will give identical 
results.  
In nuclear medicine, using a Monte Carlo method to simulate a scan has significant advantages over 
physical experiments [289].  It is more straightforward to change parameters and run a new simulation 
than it is to modify a physical set up.  Data from Monte Carlo simulations could be used to investigate 
the effect of differences in size and shape of internal organs on semi-quantification, which would be 
impossible to achieve with human studies and difficult with physical phantom models.  In addition, 
with simulations it is possible to study the underlying physical processes, such as the amount of 
attenuation and scatter.  This is not possible with a physical experiment as we can’t separate out the 
primary and scattered components with certainty.   
I have completed some key tasks related to Monte Carlo modelling during the Fellowship – completion 
of a basic gamma camera model (Figure 117), acquisition of energy spectrum data from point sources 
and phantoms with which to test the model, export of raw simulated data and reconstruction within 
Hermes HybridRecon (Figure 118) and the purchase of the commercial XCAT anatomical CT dataset 
with which I can create activity distributions in MATLAB (examples shown in Figure 119). 
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Figure 117: Visualisation of model of dual headed gamma 
camera showing collimators, NaI crystal and backscatter 
component, with uniform phantom on couch 
 
 
 
 Figure 118: Top: raw simulation data and sinogram in 
Hermes Hybrid Recon program.  Bottom: axial, coronal and 
sagittal planes through reconstructed images of simulated 
phantom. 
  
Figure 119: Slice data generated using XCAT virtual phantom showing CT Hounsfield units (left) and activity distribution 
in bone, lung, heart and background (right). 
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